<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Vitamin D and vitamin D analogues for preventing fractures in post‐menopausal women and older men - Avenell, A - 2014 | Cochrane Library</title> <meta content="Vitamin D and vitamin D analogues for preventing fractures in post‐menopausal women and older men - Avenell, A - 2014 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD000227.pub4/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Vitamin D and vitamin D analogues for preventing fractures in post‐menopausal women and older men - Avenell, A - 2014 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD000227.pub4/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD000227.pub4" name="dc.identifier" scheme="DOI"/> <meta content="Vitamin D and vitamin D analogues for preventing fractures in post‐menopausal women and older men" name="citation_title"/> <meta content="Alison Avenell" name="citation_author"/> <meta content="University of Aberdeen" name="citation_author_institution"/> <meta content="a.avenell@abdn.ac.uk" name="citation_author_email"/> <meta content="Jenson CS Mak" name="citation_author"/> <meta content="Gosford Hospital" name="citation_author_institution"/> <meta content="Dianne L O'Connell" name="citation_author"/> <meta content="Cancer Council NSW" name="citation_author_institution"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="4" name="citation_issue"/> <meta content="10.1002/14651858.CD000227.pub4" name="citation_doi"/> <meta content="2014" name="citation_date"/> <meta content="2014/04/14" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD000227.pub4/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD000227.pub4/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD000227.pub4/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Bone Density Conservation Agents [*therapeutic use]; Calcitriol [therapeutic use]; Dietary Supplements; Fractures, Spontaneous [etiology, *prevention &amp; control]; Frail Elderly; Hydroxycholecalciferols [therapeutic use]; Osteoporosis [complications, *drug therapy]; Osteoporosis, Postmenopausal [prevention &amp; control]; Randomized Controlled Trials as Topic; Vitamin D [analogs &amp; derivatives, *therapeutic use]; Vitamins [*therapeutic use]" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000227.pub4&amp;doi=10.1002/14651858.CD000227.pub4&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000227.pub4&amp;doi=10.1002/14651858.CD000227.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000227.pub4&amp;doi=10.1002/14651858.CD000227.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000227.pub4&amp;doi=10.1002/14651858.CD000227.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000227.pub4&amp;doi=10.1002/14651858.CD000227.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000227.pub4&amp;doi=10.1002/14651858.CD000227.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000227.pub4&amp;doi=10.1002/14651858.CD000227.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000227.pub4&amp;doi=10.1002/14651858.CD000227.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000227.pub4&amp;doi=10.1002/14651858.CD000227.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000227.pub4&amp;doi=10.1002/14651858.CD000227.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000227.pub4&amp;doi=10.1002/14651858.CD000227.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000227.pub4&amp;doi=10.1002/14651858.CD000227.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000227.pub4&amp;doi=10.1002/14651858.CD000227.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000227.pub4&amp;doi=10.1002/14651858.CD000227.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000227.pub4&amp;doi=10.1002/14651858.CD000227.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000227.pub4&amp;doi=10.1002/14651858.CD000227.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000227.pub4&amp;doi=10.1002/14651858.CD000227.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000227.pub4&amp;doi=10.1002/14651858.CD000227.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000227.pub4&amp;doi=10.1002/14651858.CD000227.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000227.pub4&amp;doi=10.1002/14651858.CD000227.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000227.pub4&amp;doi=10.1002/14651858.CD000227.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000227.pub4&amp;doi=10.1002/14651858.CD000227.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000227.pub4&amp;doi=10.1002/14651858.CD000227.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772874000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772901000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000"}};Liferay.authToken="z6k50IFd";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD000227\x2epub4\x26doi\x3d10\x2e1002\x2f14651858\x2eCD000227\x2epub4\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD000227\x2epub4\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD000227\x2epub4\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1513679709000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","de","zh_HANS","zh_HANT","ru","ko","ms","ja","hr","fa","pl","ta"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD000227.pub4",title:"Vitamin D and vitamin D analogues for preventing fractures in post\\u2010menopausal women and older men",firstPublishedDate:"Apr 14, 2014 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Bone, Joint and Muscle Trauma Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738734064000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=z6k50IFd&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD000227.pub4&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD000227.pub4';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD000227.pub4/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD000227.pub4/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD000227.pub4%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD000227.pub4/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD000227.pub4/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD000227.pub4/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD000227.pub4/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD000227.PUB4" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;ja&quot;,&quot;title&quot;:&quot;アブストラクト&quot;},{&quot;language&quot;:&quot;ko&quot;,&quot;title&quot;:&quot;초록&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;摘要&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;de&quot;,&quot;title&quot;:&quot;Zusammenfassung in einfacher Sprache&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;hr&quot;,&quot;title&quot;:&quot;Laički sažetak&quot;},{&quot;language&quot;:&quot;ja&quot;,&quot;title&quot;:&quot;一般語訳&quot;},{&quot;language&quot;:&quot;ko&quot;,&quot;title&quot;:&quot;쉬운 말 요약&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;},{&quot;language&quot;:&quot;pl&quot;,&quot;title&quot;:&quot;Streszczenie prostym językiem&quot;},{&quot;language&quot;:&quot;ru&quot;,&quot;title&quot;:&quot;Резюме на простом языке&quot;},{&quot;language&quot;:&quot;ta&quot;,&quot;title&quot;:&quot;எளியமொழிச் சுருக்கம்&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;简语概要&quot;},{&quot;language&quot;:&quot;zh_HANT&quot;,&quot;title&quot;:&quot;淺顯易懂的口語結論&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]},{&quot;param&quot;: &quot;comments&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Comments&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD000227.pub4/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD000227.PUB4" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD000227.pub4/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD000227.pub4/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>22107 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD000227.pub4" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD000227.pub4/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD000227.pub4/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD000227.pub4/full#CD000227-abs-0002"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD000227.pub4/full#CD000227-sec-0090"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD000227.pub4/full#CD000227-sec-0008"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD000227.pub4/full#CD000227-sec-0009"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD000227.pub4/full#CD000227-sec-0014"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD000227.pub4/full#CD000227-sec-0015"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD000227.pub4/full#CD000227-sec-0039"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD000227.pub4/full#CD000227-sec-0077"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD000227.pub4/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD000227.pub4/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD000227.pub4/appendices#CD000227-sec-0095"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD000227.pub4/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD000227.pub4/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD000227.pub4/media/CDSR/CD000227/table_n/CD000227StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD000227.pub4/media/CDSR/CD000227/table_n/CD000227StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD000227.pub4/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD000227.pub4/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD000227.pub4/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD000227.pub4/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD000227.pub4/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD000227.pub4/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2014 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD000227.pub4/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Vitamin D and vitamin D analogues for preventing fractures in post‐menopausal women and older men </h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD000227.pub4/information#CD000227-cr-0004"><i class="icon corresponding-author fa fa-envelope"></i>Alison Avenell</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD000227.pub4/information#CD000227-cr-0005">Jenson CS Mak</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD000227.pub4/information#CD000227-cr-0006">Dianne L O'Connell</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD000227.pub4/information/en#CD000227-sec-0117">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 14 April 2014 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD000227.pub4/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD000227.pub4">https://doi.org/10.1002/14651858.CD000227.pub4</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD000227-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD000227-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD000227-abs-0018">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD000227-abs-0014">فارسی</a> </li> <li class="section-language"> <a class="" href="full/ja#CD000227-abs-0011">日本語</a> </li> <li class="section-language"> <a class="" href="full/ko#CD000227-abs-0008">한국어</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD000227-abs-0004">简体中文</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD000227-abs-0001" lang="en"> <section id="CD000227-sec-0001"> <h3 class="title" id="CD000227-sec-0001">Background</h3> <p>Vitamin D and related compounds have been used to prevent osteoporotic fractures in older people. This is the third update of a Cochrane review first published in 1996. </p> </section> <section id="CD000227-sec-0002"> <h3 class="title" id="CD000227-sec-0002">Objectives</h3> <p>To determine the effects of vitamin D or related compounds, with or without calcium, for preventing fractures in post‐menopausal women and older men. </p> </section> <section id="CD000227-sec-0003"> <h3 class="title" id="CD000227-sec-0003">Search methods</h3> <p>We searched the Cochrane Bone, Joint and Muscle Trauma Group Specialised Register (to December 2012), the Cochrane Central Register of Controlled Trials (2012, Issue 12), MEDLINE (1966 to November Week 3 2012), EMBASE (1980 to 2012 Week 50), CINAHL (1982 to December 2012), BIOSIS (1985 to 3 January 2013), Current Controlled Trials (December 2012) and reference lists of articles. </p> </section> <section id="CD000227-sec-0004"> <h3 class="title" id="CD000227-sec-0004">Selection criteria</h3> <p>Randomised or quasi‐randomised trials that compared vitamin D or related compounds, alone or with calcium, against placebo, no intervention or calcium alone, and that reported fracture outcomes in older people. The primary outcome was hip fracture. </p> </section> <section id="CD000227-sec-0005"> <h3 class="title" id="CD000227-sec-0005">Data collection and analysis</h3> <p>Two authors independently assessed trial risk of selection bias and aspects of methodological quality, and extracted data. Data were pooled, where possible, using the fixed‐effect model, or the random‐effects model when heterogeneity between studies appeared substantial. </p> </section> <section id="CD000227-sec-0006"> <h3 class="title" id="CD000227-sec-0006">Main results</h3> <p>We included 53 trials with a total of 91,791 participants. Thirty‐one trials, with sample sizes ranging from 70 to 36,282 participants, examined vitamin D (including 25‐hydroxy vitamin D) with or without calcium in the prevention of fractures in community, nursing home or hospital inpatient populations. Twelve of these 31 trials had participants with a mean or median age of 80 years or over. </p> <p>Another group of 22 smaller trials examined calcitriol or alfacalcidol (1‐alphahydroxyvitamin D3), mostly with participants who had established osteoporosis. These trials were carried out in the setting of institutional referral clinics or hospitals. </p> <p>In the assessment of risk of bias for random sequence generation, 21 trials (40%) were deemed to be at low risk, 28 trials (53%) at unclear risk and four trials at high risk (8%). For allocation concealment, 22 trials were at low risk (42%), 29 trials were at unclear risk (55%) and two trials were at high risk (4%). </p> <p>There is high quality evidence that vitamin D alone, in the formats and doses tested, is unlikely to be effective in preventing hip fracture (11 trials, 27,693 participants; risk ratio (RR) 1.12, 95% confidence intervals (CI) 0.98 to 1.29) or any new fracture (15 trials, 28,271 participants; RR 1.03, 95% CI 0.96 to 1.11). </p> <p>There is high quality evidence that vitamin D plus calcium results in a small reduction in hip fracture risk (nine trials, 49,853 participants; RR 0.84, 95% confidence interval (CI) 0.74 to 0.96; P value 0.01). In low‐risk populations (residents in the community: with an estimated eight hip fractures per 1000 per year), this equates to one fewer hip fracture per 1000 older adults per year (95% CI 0 to 2). In high risk populations (residents in institutions: with an estimated 54 hip fractures per 1000 per year), this equates to nine fewer hip fractures per 1000 older adults per year (95% CI 2 to 14).  </p> <p>There is high quality evidence that vitamin D plus calcium is associated with a statistically significant reduction in incidence of new non‐vertebral fractures. However, there is only moderate quality evidence of an absence of a statistically significant preventive effect on clinical vertebral fractures. There is high quality evidence that vitamin D plus calcium reduces the risk of any type of fracture (10 trials, 49,976 participants; RR 0.95, 95% CI 0.90 to 0.99). </p> <p>In terms of the results for adverse effects: mortality was not adversely affected by either vitamin D or vitamin D plus calcium supplementation (29 trials, 71,032 participants, RR 0.97, 95% CI 0.93 to 1.01). Hypercalcaemia, which was usually mild (2.6 to 2.8 mmol/L), was more common in people receiving vitamin D or an analogue, with or without calcium (21 trials, 17,124 participants, RR 2.28, 95% CI 1.57 to 3.31), especially for calcitriol (four trials, 988 participants, RR 4.41, 95% CI 2.14 to 9.09), than in people receiving placebo or control. There was also a small increased risk of gastrointestinal symptoms (15 trials, 47,761 participants, RR 1.04, 95% CI 1.00 to 1.08), especially for calcium plus vitamin D (four trials, 40,524 participants, RR 1.05, 95% CI 1.01 to 1.09), and a significant increase in renal disease (11 trials, 46,548 participants, RR 1.16, 95% CI 1.02 to 1.33). Other systematic reviews have found an increased association of myocardial infarction with supplemental calcium; and evidence of increased myocardial infarction and stroke, but decreased cancer, with supplemental calcium plus vitamin D, without an overall effect on mortality. </p> </section> <section id="CD000227-sec-0007"> <h3 class="title" id="CD000227-sec-0007">Authors' conclusions</h3> <p>Vitamin D alone is unlikely to prevent fractures in the doses and formulations tested so far in older people. Supplements of vitamin D and calcium may prevent hip or any type of fracture. There was a small but significant increase in gastrointestinal symptoms and renal disease associated with vitamin D and calcium. This review found that there was no increased risk of death from taking calcium and vitamin D. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD000227-abs-0002" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD000227-abs-0002">English</a> </li> <li class="section-language"> <a class="" href="full/de#CD000227-abs-0003">Deutsch</a> </li> <li class="section-language"> <a class="" href="full/es#CD000227-abs-0019">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD000227-abs-0015">فارسی</a> </li> <li class="section-language"> <a class="" href="full/hr#CD000227-abs-0013">Hrvatski</a> </li> <li class="section-language"> <a class="" href="full/ja#CD000227-abs-0012">日本語</a> </li> <li class="section-language"> <a class="" href="full/ko#CD000227-abs-0009">한국어</a> </li> <li class="section-language"> <a class="" href="full/ms#CD000227-abs-0010">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="full/pl#CD000227-abs-0016">Polski</a> </li> <li class="section-language"> <a class="" href="full/ru#CD000227-abs-0007">Русский</a> </li> <li class="section-language"> <a class="" href="full/ta#CD000227-abs-0017">தமிழ்</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD000227-abs-0005">简体中文</a> </li> <li class="section-language"> <a class="" href="full/zh_HANT#CD000227-abs-0006">繁體中文</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD000227-abs-0002" lang="en"> <h3>Vitamin D and related vitamin D compounds for preventing fractures resulting from osteoporosis in older people </h3> <p><b>Why do older people suffer bone fractures?</b> </p> <p>Hip fractures and several other types of fractures are very common in post‐menopausal women and older men due to age‐related weakening of their bones (osteoporosis). </p> <p><b>What is the impact of bone fractures in older people?</b> </p> <p>Fractures due to osteoporosis often occur in the hip, wrist or spine and can lead to considerable disability or even death. Those who survive often have reduced mobility and may require greater social and nursing care. </p> <p><b>Why might vitamin D help?</b> </p> <p>Vitamin D is necessary for building strong bone. Older people often have low vitamin D levels because of lack of exposure to sunlight and low consumption of vitamin D in their diet. Therefore, it has been suggested that taking additional vitamin D in the form of supplements may help to reduce the risk of fractures of the hip and other bones. </p> <p><b>Purpose of this review</b> </p> <p>To investigate the effects of vitamin D or vitamin D‐related supplements, taken with or without calcium supplements, for preventing fractures in post‐menopausal women and older men. </p> <p><b>Conduct of this review</b> </p> <p>The review authors searched the medical literature up to December 2012, and identified 53 relevant medical trials, with a total of 91,791 people taking part. The trials reported fracture outcomes in postmenopausal women or men aged over 65 years from community, hospital and nursing‐home settings. These trials compared vitamin D or related supplements with – or without ‐ calcium supplements, against fake supplements (placebo), no supplement or calcium supplements alone. </p> <p><b>Findings of this review</b> </p> <p>The review found reliable evidence that taking vitamin D only, in the forms tested in the trials, is unlikely to prevent fractures. However, reliable evidence showed that vitamin D taken with additional calcium supplements slightly reduces the likelihood of hip fractures and other types of fracture. The review found that there was no increased risk of death from taking vitamin D and calcium. </p> <p>Although the risk of harmful effects (such as gastrointestinal (stomach) symptoms and kidney disease) from taking vitamin D and calcium is small, some people, particularly with kidney stones, kidney disease, high blood calcium levels, gastrointestinal disease or who are at risk of heart disease should seek medical advice before taking these supplements. </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD000227-sec-0090" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD000227-sec-0090"></div> <h3 class="title" id="CD000227-sec-0091">Implications for practice</h3> <section id="CD000227-sec-0091"> <p>Vitamin D plus calcium can help prevent hip fracture or any type of fracture. The benefits need to be balanced against the risk of kidney stones, kidney disease, gastrointestinal disease or heart disease (<a href="./references#CD000227-bbs2-0144" title="BollandMJ , AvenellA , BaronJA , GreyA , MacLennanGS , GambleGD , et al. Effect of calcium supplementation on the risk of myocardial infarction and cardiovascular events: a meta-analysis. BMJ2010;341:c3691.">Bolland 2010</a>; <a href="./references#CD000227-bbs2-0145" title="BollandMJ , GreyA , AvenellA , GambleGD , ReidIR . Calcium supplements with or without vitamin D and risk of cardiovascular events: reanalysis of the Women's Health Initiative limited access dataset and meta-analysis. BMJ2011;342:d2040.">Bolland 2011a</a>). Vitamin D and calcium together are not associated with an increased risk of dying. </p> <p>Vitamin D alone, in the doses and formulations that have been used, appears unlikely to be effective in fracture prevention in older people. </p> <p>Alphacalcidol may protect against vertebral fractures.</p> <p>Calcitriol appears to be associated with an increased incidence of adverse effects such as hypercalcaemia. </p> </section> <h3 class="title" id="CD000227-sec-0092">Implications for research</h3> <section id="CD000227-sec-0092"> <p>Newer vitamin D dosing strategies to achieve better long‐term compliance and at least a 25(OH)D level of 75 nmol/L, should be tested in institutional settings for fracture prevention. As the generalisability of the trials from French nursing homes is still unclear, and calcium and vitamin D have more adverse effects and require daily dosing, a third calcium and vitamin D arm could be added to a trial of vitamin D compared to placebo or control intervention. </p> <p>The design and reporting of any future trials should conform to the CONSORT statement (<a href="./references#CD000227-bbs2-0190" title="SchulzKF , AltmanDG , MoherD , for the CONSORT Group. CONSORT 2010 Statement: updated guidelines for reporting parallel group randomised trials. BMJ2010;340:c332.">Schulz 2010</a>), or any future development of it. Trials using cluster randomisation should perform appropriate analyses and include sufficient information in trial reports to aid interpretation by readers and users of such trials (<a href="./references#CD000227-bbs2-0148" title="CampbellMK , PiaggioG , ElbourneDR , AltmanDG , for the CONSORT Group. Consort 2010 statement: extension to cluster randomised trials. BMJ2012;345:e5661.">Campbell 2012</a>). </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD000227-sec-0008" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD000227-sec-0008"></div> <div class="table" id="CD000227-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Vitamin D [D2, D3 or 25(OH)D] plus calcium compared with control or placebo for preventing fractures in older people</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Vitamin D (D2, D3 or 25(OH)D) plus calcium compared with control or placebo for preventing fractures in older people</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> post‐menopausal women and older people at risk of osteoporotic fractures </p> <p><b>Settings:</b> community or institutional </p> <p><b>Intervention:</b> vitamin D (D2, D3 or 25(OH)D) plus calcium </p> <p><b>Comparison:</b> control or placebo </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>No of Participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Quality of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Comments</b> </p> <p><b>Notes on assessment of the quality</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Assumed risk</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Corresponding risk</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>No vitamin D plus calcium</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Vitamin D plus calcium</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Persons sustaining new hip fracture</b> </p> <p>(1 year estimate)<sup>1</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Lower risk population</b><sup>2</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 0.84</b> (0.74 to 0.96) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>49,853 participants<br/>(9 trials) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊕⊕<br/><b>high</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>8 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>7 per 1000</b><br/>(6 to 8) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>High risk population</b><sup>3</sup> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>54 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>45 per 1000</b><br/>(40 to 52) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Persons sustaining new non‐vertebral fracture</b> </p> <p>(1 year estimate)<sup>1</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Overall population</b><sup>4</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR</b> <b>0.86</b> </p> <p>(0.78 to 0.96)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>10,380 participants</p> <p>(8 trials)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊕<br/><b>high</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>39 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>34 per 1000</b><br/>(30 to 37) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Persons sustaining new vertebral fracture or deformity</b> </p> <p>(1 year estimate)<sup>1</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Overall population</b><sup>5</sup> (see notes) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR</b> <b>0.89</b> </p> <p>(0.74 to 1.09)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>42,185 participants</p> <p>(4 trials)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/><b>moderate</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Variation and difficulties in the diagnosis and definition of vertebral fractures means that estimates of control risk are likely to be very provisional (and probably underestimates). This also reduces the quality of this evidence, downgraded to moderate evidence </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>2 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>2 per 1000</b><br/>(1 to 2) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Persons sustaining any new fracture</b> </p> <p>(1 year estimate)<sup>1</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Lower risk population</b><sup>6</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 0.95</b> </p> <p>(0.90 to 0.99)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>49,976</p> <p>participants</p> <p>(10 trials)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊕⊕<br/><b>high</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>26 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>25 per 1000</b><br/>(23 to 26) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>High risk population</b><sup>7</sup> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>75 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>71 per 1000</b><br/>(68 to 74) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Persons with hypercalcaemia ‐ Vitamin D (D2, D3 or 25(OH)D) plus calcium</b> </p> <p>(1 year estimate)<sup>1</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Overall population</b><sup>8</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 3.29</b> </p> <p>(0.37 to 29.14)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>3853 participants</p> <p>(2 trials)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/><b>low</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Downgraded for imprecision: confidence interval (0.37 to 29.14) crosses line of no effect </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>4 per 10,000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>13 per 10,000</b> </p> <p>(1 to 117)</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Persons with renal disease (calculi or insufficiency) ‐ Vitamin D (D2, D3 or 25(OH)D) plus calcium</b> </p> <p>(1 year estimate)<sup>1</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Overall population</b><sup>9</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 1.17</b> </p> <p>(1.03 to 1.34)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>39,552 participants<br/>(2 trials) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊕<br/><b>high</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>These data are dominated by the WHI 2006 trial, which had a 7 year follow‐up. As noted, the risk of some complications are unlikely to be uniform over time </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>8 per 10,000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>9 per 10,000</b><br/>(8 to 11) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Deaths ‐ Vitamin D (D2, D3, 25(OH)D) plus calcium</b> </p> <p>(1 year estimate)<sup>1</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Overall population</b><sup>10</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 0.94</b><br/>(0.87 to 1.02) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>46,794 participants<br/>(6 trials) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊕<br/><b>high</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>A similar overall result was found when data were pooled from 29 trials</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>57 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>54 per 1000</b><br/>(50 to 58) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in the footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><b>CI:</b> Confidence interval; <b>RR:</b> Risk Ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/><b>High quality:</b> further research is very unlikely to change our confidence in the estimate of effect<br/><b>Moderate quality:</b> further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate<br/><b>Low quality:</b> further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate<br/><b>Very low quality:</b> we are very uncertain about the estimate </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p>1. The included studies had different follow‐ups. All estimates are calculated for 1 year follow‐up. However, the risk of some outcomes may not be uniform over time </p> <p>2. Control group risk derived from median control group data across community residence studies testing vitamin D [D2, D3 or 25(OH)D] plus calcium; plus data from community studies reported in the Gillespie 2010 Cochrane review: Gillespie WJ, Gillespie LD, Parker MJ. Hip protectors for preventing hip fractures in older people. Cochrane Database of Systematic Reviews 2010, Issue 10. Art. No.: CD001255. DOI: 10.1002/14651858.CD001255.pub4 </p> <p>3. Control group risk derived from median control group data across institutional residence studies testing vitamin D [D2, D3 or 25(OH)D] plus calcium; plus data from institutional studies reported in Gillespie 2010 </p> <p>4. Control group risk derived from median control group across studies testing vitamin D [D2, D3 or 25(OH)D] alone and trials testing vitamin D [D2, D3 or 25(OH)D] plus calcium </p> <p>5. Control group risk derived from median control group across studies testing vitamin D [D2, D3 or 25(OH)D] plus calcium </p> <p>6. Control group risk derived from median control group data across community residence studies testing vitamin D [D2, D3 or 25(OH)D] plus calcium </p> <p>7. Control group risk derived from median control group data across institutional residence studies testing vitamin D [D2, D3 or 25(OH)D] plus calcium </p> <p>8. Control group risk derived from median control group across studies testing vitamin D [D2, D3 or 25(OH)D] alone. Five of 10 trials in this group and the two trials (Chapuy 1992 and Chapuy 2002) reporting on hypercalcaemia, reported no events in the control group </p> <p>9. Control group risk derived from median control group across studies testing vitamin D [D2, D3 or 25(OH)D] alone and trials testing vitamin D [D2, D3 or 25(OH)D] plus calcium </p> <p>10. Control group risk derived from median control group across studies testing vitamin D [D2, D3 or 25(OH)D] alone and trials testing vitamin D [D2, D3 or 25(OH)D] plus calcium </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD000227-sec-0009" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD000227-sec-0009"></div> <section id="CD000227-sec-0010"> <h3 class="title" id="CD000227-sec-0010">Description of the condition</h3> <p>Osteoporosis, a gradual loss of bone mass, is a complex, chronic, multifactorial process, which is a normal part of ageing. It derives its public health importance from its association with the development of characteristic fractures late in life, and because of the increasing number of people living longer, particularly in industrialised societies. Both men and women are affected, but the main burden of disease is in post‐menopausal women. Osteoporotic fractures include those of the hip, wrist and spinal vertebrae, and can lead to considerable disability. Incidence rates for hip fracture vary by a factor of more than ten worldwide, with age‐standardised incidence rates highest in Scandinavia and lowest in Africa and South America (<a href="./references#CD000227-bbs2-0172" title="KanisJA , OdenA , McCloskeyEV , JohanssonH , WahlDA , CooperC . A systematic review of hip fracture incidence and probability of fracture worldwide. Osteoporosis International2012;23:2239-56.">Kanis 2012</a>). Many patients with hip fractures have other medical conditions, but the hip fracture itself may account for 17% to 32% of deaths in patients with hip fracture, and 1.5% of all deaths in people aged 50 years or older (<a href="./references#CD000227-bbs2-0171" title="KanisJA , OdenA , JohnellO , De LaetC , JonssonB , OglesbyAK . The components of excess mortality after hip fracture. Bone2003;32:468-73.">Kanis 2003</a>). Survivors of hip fracture are often disabled by reduced mobility and may require greater social and nursing care (<a href="./references#CD000227-bbs2-0169" title="JohnellO , KanisJA . An estimate of the worldwide prevalence, mortality and disability associated with hip fracture. Osteoporosis International2004;15:897-902.">Johnell 2004</a>). </p> <p>A high proportion of vertebral fractures do not come to clinical attention and may not cause symptoms, but undiagnosed vertebral fractures may be associated with increased back pain and functional limitation (<a href="./references#CD000227-bbs2-0182" title="NevittMC , EttingerB , BlackDM , StoneK , JamalSA , EnsrudK , et al. The association of radiographically detected vertebral fractures with back pain and function: a prospective study. Annals of Internal Medicine1998;128(10):793-800.">Nevitt 1998</a>). The criteria used to define vertebral fractures in radiographs may differ, but studies suggest that up to half of women over the age of 75 years in Europe and North America have vertebral fractures (<a href="./references#CD000227-bbs2-0154" title="CummingsSR , Melton LJIII . Epidemiology and outcomes of osteoporotic fractures. Lancet2002;359:1761-7.">Cummings 2002</a>). </p> <p>Between 1988 and 1998, in England and Wales, the estimated lifetime risk of hip fracture for a woman aged 50 years was 11.4%, and for a man aged 50 years was 3.1% (<a href="./references#CD000227-bbs2-0193" title="Van StaaTP , DennisonEM , LeufkensHG , CooperC . Epidemiology of fractures in England and Wales. Bone2001;29(6):517-22.">Van Staa 2001</a>). Similarly, the lifetime risk for a woman aged 50 years for a distal forearm fracture was 16.6% and for a clinically evident vertebral fracture, 3.1%; for a man aged 50 years these risks were 2.9% and 1.2% respectively (<a href="./references#CD000227-bbs2-0193" title="Van StaaTP , DennisonEM , LeufkensHG , CooperC . Epidemiology of fractures in England and Wales. Bone2001;29(6):517-22.">Van Staa 2001</a>). In the last 20 years hip fracture rates have tended to stabilise ‐ or even fall ‐ in Europe, North America, Australia and New Zealand, but rates may be rising in Asia (<a href="./references#CD000227-bbs2-0151" title="CooperC , ColeZA , HolroydCR , EarlSC , HarveyNC , DennisonEM , et al. Secular trends in the incidence of hip and other osteoporotic fractures. Osteoporosis International2011;22:1277-88.">Cooper 2011</a>). </p> </section> <section id="CD000227-sec-0011"> <h3 class="title" id="CD000227-sec-0011">Description of the intervention</h3> <p>The primary goal of the various interventions, such as vitamin D, that have been proposed for osteoporosis is the prevention of fractures. While slowing progressive bone loss plausibly reduces fracture rates, other factors, particularly the fall rate in older people, are clearly involved (<a href="./references#CD000227-bbs2-0153" title="CummingsSR , NevittMC , BrownerWS , StoneK , FoxKM , EnsrudKE , et al. Risk factors for hip fracture in white women. Study of Osteoporotic Fractures Research Group. New England Journal of Medicine1995;332:767-73.">Cummings 1995</a>). Effective strategies may require prophylactic measures many years before fractures are likely to occur. The conduct of randomised controlled trials of effectiveness in this context is difficult. Financial, academic and commercial pressures have favoured the selection of short‐term intermediate outcomes, such as changes in bone mineral density (BMD), as evidence of efficacy, but the effectiveness of interventions is best measured using fracture outcomes. </p> </section> <section id="CD000227-sec-0012"> <h3 class="title" id="CD000227-sec-0012">How the intervention might work</h3> <p>Vitamin D is one of a number of agents with known biological effects on mineral homeostasis, acting mainly upon the intestine, kidneys and bone. Intestinal calcium absorption is stimulated and bone mass protected (<a href="./references#CD000227-bbs2-0183" title="NormanAW , HenryHL . Vitamin D: metabolism and mechanism of action. In: FavusMJ , editors(s). Primer on the metabolic bone diseases and disorders of mineral metabolism. 2nd edition. New York: Raven Press, 1993:63-70.">Norman 1993</a>), although the benefit may be largely lost within two years of discontinuation of the supplement (<a href="./references#CD000227-bbs2-0155" title="Dawson-HughesB , HarrissSS , KrallEA , DallalGE . Effect of withdrawal of calcium and vitamin D supplements on bone-mass in elderly men and women. American Journal of Clinical Nutrition2000;72(3):745-50.">Dawson‐Hughes 2000</a>). Vitamin D is mostly derived from exposure of the skin to ultraviolet sunlight. Although there are a few dietary sources, such as oily fish, these contribute relatively little vitamin D (known as D3, cholecalciferol), except in people who consume oily fish several times a week. Synthetic vitamin D (known as D2, ergocalciferol) is frequently the form provided in supplements, but this may not be equivalent to vitamin D3 (<a href="./references#CD000227-bbs2-0165" title="HoughtonLA , ViethR . The case against ergocalciferol (vitamin D2) as a vitamin supplement. American Journal of Clinical Nutrition2006;84(4):694-7.">Houghton 2006</a>). </p> <p>Administration of vitamin D, and particularly its derivatives (analogues) (see <a href="#CD000227-tbl-0002">Table 1</a> for details of nomenclature, synonyms and abbreviations of vitamin D), may carry a risk of hypercalcaemia and hypercalciuria (high levels of calcium in the blood and urine, respectively). There is a winter decline in circulating vitamin D concentrations in older people living at high latitudes that may be correctable by a single injection of cholecalciferol (<a href="./references#CD000227-bbs2-0173" title="Khaw K-T, ScraggR , MurphyS . Single dose cholecalciferol suppresses the winter increase in parathyroid hormone concentrations in healthy older men and women: a randomized trial. American Journal of Clinical Nutrition1994;59:1040-4.">Khaw 1994</a>). However, the bioavailability of intramuscular vitamin D is variable, and may be very poor; thus intermittent high‐dose oral supplementation may be more reliable (<a href="./references#CD000227-bbs2-0189" title="RomagnoliE , MasciaML , CiprianiC , FassinoV , MazzeiF , D'ErasmoE , et al. Short and long-term variations in serum calciotropic hormones after a single very large dose of ergocalciferol (vitamin D2) or cholecalciferol (vitamin D3) in the elderly. Journal of Clinical Endocrinology and Metabolism2008;93(8):3015-20.">Romagnoli 2008</a>). The rates of hip fracture vary annually with a winter peak in both Northern and Southern hemispheres (<a href="./references#CD000227-bbs2-0168" title="JacobsenSJ , GoldbergJ , MilesTP , BrodyJA , StiersW , RimmAA . Regional variation in the incidence of hip fracture. US white women aged 65 years and older. Journal of the American Medical Association1990;264:500-2.">Jacobsen 1990</a>; <a href="./references#CD000227-bbs2-0175" title="LauEMC , GillespieWJ , ValentiL , O'ConnellDL . The seasonality of hip fracture and its relationship with weather conditions in New South Wales. Australian Journal of Public Health1995;19:76-80.">Lau 1995</a>). Inadequate vitamin D levels have been demonstrated in patients with osteoporosis (<a href="./references#CD000227-bbs2-0178" title="LipsP , HoskingD , LippunerK , NorquistJM , WehrenL , MaaloufG , et al. The prevalence of vitamin D inadequacy amongst women with osteoporosis: an international epidemiological investigation. [erratum appears in J Intern Med. 2007 Apr;261(4):408]. Journal of Internal Medicine2006;260(3):245-54.">Lips 2006</a>) ‐ especially those with hip fracture ‐ in many countries, although low levels may be influenced by the fracture itself (<a href="./references#CD000227-bbs2-0186" title="PieperCF , Colon-EmericC , CaminisJ , BetchykK , ZhangJ , JanningC , et al. Distribution and correlates of serum 25-hydroxyvitamin D levels in a sample of patients with hip fracture. American Journal of Geriatric Pharmacotherapy2007;5(4):335-40.">Pieper 2007</a>). Adequate calcium intake may also protect bone mass (<a href="./references#CD000227-bbs2-0152" title="CummingRG . Calcium intake and bone mass. A quantitative review of the evidence. Calcified Tissue International1990;47:194-201.">Cumming 1990</a>), but calcium supplements may provoke gastrointestinal symptoms. </p> <div class="table" id="CD000227-tbl-0002"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Vitamin D nomenclature, synonyms and abbreviations</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Vitamin D</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Synonyms</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Graph abbreviations</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Vitamin D: two forms are vitamin D2 and vitamin D3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Vitamin D2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Ergocalciferol</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>D2</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Vitamin D3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Cholecalciferol</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>D3</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>25‐hydroxy vitamin D: vitamin D with one hydroxyl group added equivalent to liver activation </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Calcidiol</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>25(OH)D</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1‐alphahydroxyvitamin D3*: vitamin D with one hydroxyl group added equivalent to renal activation </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Alfacalcidol</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1‐alpha(OH)D3</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1,25‐dihydroxyvitamin D3*: vitamin D with two hydroxyl groups added equivalent to both liver and renal activation </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Calcitriol</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1,25(OH)<sub>2</sub>D3 </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>24R,25(OH)<sub>2</sub> vitamin D3*: vitamin D with two hydroxyl groups added equivalent to both liver and renal activation </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> </tbody> </table> <div class="table-footnote"> <p>* denotes analogues/derivatives<br/>Ca: abbreviation for calcium in graphs </p> </div> </div> </section> <section id="CD000227-sec-0013"> <h3 class="title" id="CD000227-sec-0013">Why it is important to do this review</h3> <p>Vitamin D is an attractive candidate agent for use in public health interventions, particularly if it can be given intermittently in high dosage. A randomised trial widely quoted as supporting the effectiveness of vitamin D evaluated co‐administration of daily oral vitamin D3 and calcium supplements (<a href="./references#CD000227-bbs2-0008" title="ChapuyMC , ArlotM , et al. Prevention of non vertebral fractures and cortical bone loss in elderly women: a prospective controlled trial using calcium and vitamin D3 supplements [abstract]. Osteoporosis International1993;3 Suppl 1:258. ChapuyMC , ArlotME , DelmasPD , MeunierPJ . Effect of calcium and cholecalciferol treatment for three years on hip fractures in elderly women. BMJ1994;308:1081-2. ChapuyMC , ArlotME , DuboeufF , BrunJ , CrouzetB , ArnaudS , et al. Vitamin D3 and calcium to prevent hip fractures in elderly women. New England Journal of Medicine1992;327:1637-42. MeunierPJ , PamphileR , ChapuyMC , SchultenJ , ArlotM , LilluH . A calcium-vitamin D3 combined supplementation is cost-saving for preventing hip fractures in institutionalised elderly women: an economic evaluation from the perspective of seven European countries (Belgium, France, Germany, The Netherlands, Spain, Sweden, United Kingdom). Osteoporosis International2002;13(Suppl 1):S14. ">Chapuy 1992</a>). Calcium co‐supplementation requires tablets to be taken daily, which may influence compliance; furthermore, calcium may be associated with gastrointestinal side‐effects (<a href="./references#CD000227-bbs2-0044" title="AndersonFH , GrantAM , AvenellA , CampbellMK , CooperC , DonaldsonC , et al. The RECORD Trial: an evaluation of calcium and/or vitamin D in the secondary prevention of osteoporotic fractures. Bone2005;36(Suppl 2):S122-3. FrancisRM , Grant AM and the RECORD trial group. The RECORD trial: a randomised double-blind study of calcium and/or vitamin D in the secondary prevention of low trauma fractures. Age Ageing2005;34(Suppl 2):ii15. GrantA , on behalf of the RECORD Trial Group. Prevention of low-trauma fractures in older people [author reply]. Lancet2005;366(9485):543-4. GrantAM , AndersonFH , for the RECORD Trial Group. The Medical Research Council RECORD Trial: an evaluation of calcium and/or vitamin D in the secondary prevention of osteoporotic fractures. Osteoporosis International2004;15(Suppl 2):S13. GrantAM , AndersonFH . The RECORD trial: an evaluation of calcium and/or vitamin D in the secondary prevention of osteoporotic fractures. Osteoporosis International2005;16(Suppl 3):S4-5. GrantAM , AvenellA , CampbellMK , McDonaldAM , MacLennanGS , McPhersonGC , et al. Oral vitamin D3 and calcium for secondary prevention of low-trauma fractures in elderly people (Randomised Evaluation of Calcium Or vitamin D, RECORD): a randomised placebo-controlled trial [comment in: Lancet 2005;366(9485):543]. Lancet2005;365(9471):1621-8. GrantAM . Personal communication 11 March 2004. ">RECORD 2005</a>). A systematic review of current evidence to assess for effectiveness of vitamin D analogues, with and without calcium, in fracture prevention in older people should inform practice and research. This is an update of a Cochrane review first published in 1996, and previously updated in 2009 (<a href="./references#CD000227-bbs2-0134" title="AvenellA , GillespieWJ , GillespieLD , O'ConnellD . Vitamin D and vitamin D analogues for preventing fractures associated with involutional and post-menopausal osteoporosis. Cochrane Database of Systematic Reviews2009, Issue 2. Art. No: CD000227. [DOI: 10.1002/14651858.CD000227.pub3]">Avenell 2009a</a>). </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD000227-sec-0014" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD000227-sec-0014"></div> <p>To determine the effects of vitamin D or related compounds, with or without calcium, for preventing fractures in post‐menopausal women and older men. </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD000227-sec-0015" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD000227-sec-0015"></div> <section id="CD000227-sec-0016"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD000227-sec-0017"> <h4 class="title">Types of studies</h4> <p>Any randomised trial or quasi‐randomised (method of allocating participants to a treatment that is not strictly random, e.g. by date of birth, hospital record number, alternation) trial meeting the criteria for participants, interventions or outcomes listed below. </p> </section> <section id="CD000227-sec-0018"> <h4 class="title">Types of participants</h4> <p>Trials with post‐menopausal women or older men (mean or median population age over 65 years), or both. We included trials whose participants had neurological disease impairing mobility (for example, after stroke or in Parkinson's disease), but excluded studies focused on participants on corticosteroid therapy, which is the subject of another Cochrane review (<a href="./references#CD000227-bbs2-0164" title="HomikJ , Suarez-AlmazorME , SheaB , CranneyA , WellsGA , TugwellP . Calcium and vitamin D for corticosteroid-induced osteoporosis. Cochrane Database of Systematic Reviews1998, Issue 2. Art. No: CD000952. [DOI: 10.1002/14651858.CD000952]">Homik 1998</a>), and studies where vitamin D was given to patients selected on the basis of renal failure. </p> </section> <section id="CD000227-sec-0019"> <h4 class="title">Types of interventions</h4> <p>Administration of a vitamin D or a vitamin D‐related compound, either alone or in combination with calcium supplementation, compared with a placebo, no intervention, or the administration of calcium supplements (see <a href="#CD000227-tbl-0002">Table 1</a> for details of nomenclature, synonyms and abbreviations of the vitamin D preparations considered here). Interventions incorporating treatments other than vitamin D and calcium were not considered, e.g. vitamin D and hormone replacement therapy (HRT) compared with HRT alone. Interventions examining eldecalcitol (ED‐71, 1alpha,25‐dihydroxy‐2beta‐(3‐hydroxypropoxy) vitamin D3) were also not included. </p> <p>In defining a comparison, advice only on dietary modification to increase calcium intake was not considered as supplementation. </p> </section> <section id="CD000227-sec-0020"> <h4 class="title">Types of outcome measures</h4> <section id="CD000227-sec-0021"> <h5 class="title">Primary outcomes</h5> <p> <ol id="CD000227-list-0001"> <li> <p>Hip fracture</p> </li> </ol> </p> </section> <section id="CD000227-sec-0022"> <h5 class="title">Secondary outcomes</h5> <p> <ol id="CD000227-list-0002"> <li> <p>Any non‐vertebral fracture. Non‐vertebral fractures were defined as all fractures except those of the vertebrae, but including hip fractures. </p> </li> <li> <p>Vertebral fracture (two outcomes were sought: clinical fracture events, and new vertebral deformity identified by radiological morphometry or semi‐quantitative reading by a radiologist, using routine radiographs, according to a defined experimental protocol. Either of these methods appear to provide a valid approach to defining vertebral deformity (<a href="./references#CD000227-bbs2-0143" title="BlackBM , PalermoL , NevittMC , GenantHK , EpsteinR , San-ValentinR , et al. Comparison of methods for defining prevalent vertebral deformities: the study of osteoporotic fractures. Journal of Bone and Mineral Research1995;10:890-902.">Black 1995</a>)) </p> </li> <li> <p>Any new fracture. In previous versions of the review, the category 'any new fracture' was classified as fractures not covered by hip, vertebral or non‐vertebral categories, or where the site of fracture was unclear. This meant that some of the very large community trials were not analysed together, because they chose to report 'non‐vertebral fractures' or 'hip fractures' or 'vertebral fractures' but not 'all fractures' and these numbers were not available or could not be calculated from the data without risk of double counting. As a new feature in this version of the review for Analyses 1 to 4 (comparisons involving vitamin D), the category 'all fractures' includes data from non‐vertebral fractures (or hip or vertebral fractures if not given), if the data for 'all fractures' are not available (see <a href="#CD000227-sec-0121">Differences between protocol and review</a>). </p> </li> <li> <p>Adverse effects (hypercalcaemia, renal disease, gastrointestinal symptoms, all as defined by the investigators; death) </p> </li> </ol> </p> </section> </section> </section> <section id="CD000227-sec-0023"> <h3 class="title">Search methods for identification of studies</h3> <section id="CD000227-sec-0024"> <h4 class="title">Electronic searches</h4> <p>We searched the Cochrane Bone, Joint and Muscle Trauma Group Specialised Register (to December 2012), the Cochrane Central Register of Controlled Trials (2012 Issue 12), MEDLINE (1966 to November Week 3 2012), EMBASE (1980 to 2012 Week 50), CINAHL (Cumulative Index to Nursing and Allied Health Literature) (1982 to December 2012) and BIOSIS (1985 to 3 January 2013). </p> <p>In MEDLINE (OVID Web), we combined subject specific terms with the sensitivity‐maximising version of the Cochrane Highly Sensitive Search Strategy for identifying randomised trials (<a href="./references#CD000227-bbs2-0176" title="LefebvreC , ManheimerE , GlanvilleJ . Chapter 6: Searching for studies. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.">Lefebvre 2011</a>), and modified for use in other databases (see <a href="http://archie.cochrane.org/sections/documents/view?version=71827887219093363861100813161057&amp;format=REVMAN#APP-01" target="_blank">Appendix 1</a>). For this update, the search results were limited to 2007 onwards. Details of the previous search strategies can be found in past versions of the review, most recently <a href="./references#CD000227-bbs2-0196" title="AvenellA , GillespieWJ , GillespieLD , O'ConnellD . Vitamin D and vitamin D analogues for preventing fractures associated with involutional and post-menopausal osteoporosis. Cochrane Database of Systematic Reviews2009, Issue 2. Art. No: CD000227. [DOI: 10.1002/14651858.CD000227.pub3]">Avenell 2009b</a>. </p> <p>We identified ongoing studies by searching all registers in <a href="http://www.controlled-trials.com/" target="_blank">Current Controlled Trials</a> (December 2012). </p> </section> <section id="CD000227-sec-0025"> <h4 class="title">Searching other resources</h4> <p>We also checked reference lists of articles and contacted active researchers in the field. We handsearched abstracts published in the <i>Journal of Bone and Mineral Research</i> (1986 to 2012 volume 27), <i>Bone</i> (1998 to December 2012), <i>Calcified Tissue International</i> (1998 to December 2012) and <i>Osteoporosis International</i> (1998 to December 2012). </p> <p>We placed no restrictions on the language of publication.</p> </section> </section> <section id="CD000227-sec-0026"> <h3 class="title" id="CD000227-sec-0026">Data collection and analysis</h3> <section id="CD000227-sec-0027"> <h4 class="title">Selection of studies</h4> <p>After initial screening by one person, the citations of potentially eligible studies were entered into Review Manager software (<a href="./references#CD000227-bbs2-0188" title="The Nordic Cochrane Centre, The Cochrane CollaborationReview Manager (RevMan). Version 5.2. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2012.">RevMan 2012</a>). Full text copies of these references were retrieved and at least two authors independently sorted them into included and excluded studies on the basis of the criteria above. </p> </section> <section id="CD000227-sec-0028"> <h4 class="title">Data extraction and management</h4> <p>Two review authors extracted data independently using a data extraction form developed for previous versions of this review. Any unresolved disagreement between authors was adjudicated by a third author. One author entered qualitative details and published data describing study population, interventions and outcomes into RevMan, and another author checked data entry for outcomes. </p> </section> <section id="CD000227-sec-0029"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>Two review authors independently assessed the risk of bias for the two domains of randomisation sequence generation and allocation concealment, according to the Cochrane Collaboration 'Risk of bias' tool (<a href="./references#CD000227-bbs2-0162" title="HigginsJPT , Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.">Higgins 2011</a>). For the remaining assessment of risk of bias, two review authors independently assessed methodological quality using a scoring schedule and a coding instruction manual, which was used in previous versions of this review. The assessment protocol scored each item between 0 and 2 (see <a href="#CD000227-tbl-0003">Table 2</a> for the quality assessment items, B to J, and possible scores). Disagreement between review authors was adjudicated by a third author. </p> <div class="table" id="CD000227-tbl-0003"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Quality assessment items and possible scores</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Items</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Scores</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Item B</b><br/>Were the outcomes of participants who withdrew or were excluded after allocation described and included in an "intention‐to‐treat" analysis? </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Score 2</b> if adequate detail of withdrawals and exclusions after randomisation exists, and an intention‐to‐treat analysis has been, or can be carried out<br/><br/><b>Score 1</b> if number and reasons for withdrawal are mentioned but intention to treat analysis is not possible<br/><br/><b>Score 0</b> if inadequate detail exists to allow the author to check or carry out an intention to treat analysis, or obvious differences with no adjustment </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Item C</b><br/>Were the outcome assessors blind to assignment status? </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Score 2</b> if blinding of all possible outcome assessors is clearly established<br/><br/><b>Score 1</b> if there is a small or moderate chance of unblinding of assessors, or some but not other assessors who could have been blinded were blinded<br/><br/><b>Score 0</b> if no attempt to blind assessors to the assignment of treatment is reported </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Item D</b><br/>Were the treatment and control group comparable at entry? </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Score 2</b> if groups are demonstrably comparable in respect of potential confounding factors on inspection of the characteristics on entry (means with some expression of the variation e.g. SD, SE, confidence intervals are required), or differences between groups adjusted for in the analysis (stratification, Mantel‐Haenszel technique, logistic regression, multiple regression, multivariable techniques)<br/><br/><b>Score 1</b> if confounding appears small: although noted, adjustment has not been made<br/><br/><b>Score 0</b> if description of the treatment groups at baseline, either in text or table, is inadequate to confirm comparability for all plausibly important confounders, or statistically significant differences between the groups are present but no adjustment has been made in the analysis </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Item E</b><br/>Were the subjects blind to assignment status following allocation? </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Score 2</b> if effective action has been taken to blind participants to assignment<br/><br/><b>Score 1</b> if in a drug study, or in a study comparing a physical modality with a control, it is unclear whether participants were made aware, or could have become aware, of their assignment prior to measurement of outcomes, or the nature of the trial intervention is such that it is unlikely that they will have effects which allow identification of assignment (e.g. calcium supplements versus placebo)<br/><br/><b>Score 0</b> if in a drug study, no treatment rather than a placebo is used, or in a placebo‐controlled drug study or in a study of comparable physical modalities, participants became aware of their allocation before outcome assessment and analysis </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Item F</b><br/>Were the providers of care blind to assignment status? </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Score 2</b> if the study is clearly double or triple blind<br/><br/><b>Score 1</b> if it is unclear whether the treatment providers were blinded to the allocation<br/><br/><b>Score 0</b> if in a placebo controlled drug trial, the providers of care were informed of the treatment allocation before outcome assessment and analysis, or a physical modality was used in one or more arms of the trial </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Item G</b><br/>Were the care programmes, other than the trial options, identical? </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Score 2</b> if it is clear that the care programmes other than the trial interventions were identical<br/><br/><b>Score 1</b> if differences between the programmes are trivial </p> <p><b>Score 0</b> if the nature of the care programmes other than the trial interventions is unclear, or there are important differences between the programmes offered, other than the trial interventions </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Item H</b><br/>Were the inclusion and exclusion criteria for entry clearly defined? </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Score 2</b> if the inclusion and exclusion criteria are clearly defined and indicate that individuals currently exposed to a trial intervention were excluded e.g. vitamin D analogue, hormone replacement therapy<br/><br/><b>Score 1</b> if the inclusion and exclusion criteria as described allow the possibility that individuals may have entered the study currently exposed to a trial intervention, or description of the inclusion and exclusion criteria is inadequate to determine how the sample was made up<br/><br/><b>Score 0</b> if no description, other than age and gender, of inclusion and exclusion criteria was provided </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Item J</b><br/>Was the ascertainment of fractures and other outcomes active and of clinically appropriate duration? </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Score 2</b> if some form of concurrent collection of data about fracture e.g. subjects given postcards to mail back etc., with confirmation by interview, and by radiograph if positive, or, for vertebral fracture, routine confirmation by radiograph<br/><br/><b>Score 1</b> if contact was made on a regular basis e.g. 6‐monthly phone call to establish if fracture had occurred or not, with confirmation by radiograph if positive<br/><br/><b>Score 0</b> if fracture was registered as an outcome without confirmation by radiograph </p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>Item A, which considered allocation concealment, was removed as this now forms part of the risk of bias assessment </p> </div> </div> </section> <section id="CD000227-sec-0030"> <h4 class="title">Measures of treatment effect</h4> <p>We calculated risk ratios (RR) and 95% confidence intervals (95% CI) for dichotomous outcomes. For fracture outcomes we used the number, or proportion, of participants with at least one new fracture at the end of the observation period to calculate the RR and 95% CI. </p> </section> <section id="CD000227-sec-0031"> <h4 class="title">Unit of analysis issues</h4> <p>For meta‐analyses including the cluster‐randomised trial by <a href="./references#CD000227-bbs2-0028" title="LawM , MorrisJ , WithersH . Cholecalciferol, not ergocalciferol, should be used for vitamin D supplementation [author reply]. Age and Ageing2006;35(6):645. [MEDLINE: 16982666]LawM , MorrisJ , WithersH . Vitamin D supplementation and the prevention of fractures and falls. Reply. Age and Ageing2007;36(2):233. LawM , MorrisJ , WithersH . Vitamin D supplementation and the prevention of fractures and falls [author reply]. Age and Ageing2007;36(2):233. [MEDLINE: 17255084]LawM , WithersH , MorrisJ , AndersonF . Vitamin D supplementation and the prevention of fractures and falls: results of a randomised trial in elderly people in residential accommodation [comment in: Age and Ageing 2006;35(6):645 and Age and Ageing 2007;36(2):232-3]. Age and Ageing2006;35(5):482-6. ">Law 2006</a>, the review authors made adjustments to the number of participants with outcomes and the denominators in <a href="./references#CD000227-bbs2-0028" title="LawM , MorrisJ , WithersH . Cholecalciferol, not ergocalciferol, should be used for vitamin D supplementation [author reply]. Age and Ageing2006;35(6):645. [MEDLINE: 16982666]LawM , MorrisJ , WithersH . Vitamin D supplementation and the prevention of fractures and falls. Reply. Age and Ageing2007;36(2):233. LawM , MorrisJ , WithersH . Vitamin D supplementation and the prevention of fractures and falls [author reply]. Age and Ageing2007;36(2):233. [MEDLINE: 17255084]LawM , WithersH , MorrisJ , AndersonF . Vitamin D supplementation and the prevention of fractures and falls: results of a randomised trial in elderly people in residential accommodation [comment in: Age and Ageing 2006;35(6):645 and Age and Ageing 2007;36(2):232-3]. Age and Ageing2006;35(5):482-6. ">Law 2006</a> using an intraclass correlation coefficient of 0.026 (derived from <a href="./references#CD000227-bbs2-0158" title="DyerCA , TaylorGJ , ReedM , DyerCA , RobertsonDR , HarringtonR . Falls prevention in residential care homes: a randomised controlled trial. Age and Ageing2004;33:596-602.">Dyer 2004</a>), using methods described in <a href="./references#CD000227-bbs2-0163" title="HigginsJPT , GreenS , editors. Example of incorporating a cluster-randomized trial. Cochrane handbook for Systematic Review of Interventions 5.1.0 [updated March 2011].Section 16.3.5. In: The Cochrane Library, Issue 1, 2014. Chichester, UK: John Wiley &amp; Sons, Ltd.">Higgins 2011a</a>. This means that the numbers of participants with outcomes and denominators in the meta‐analyses in which this trial is included do not reflect the total number actually randomised and having events. </p> </section> <section id="CD000227-sec-0032"> <h4 class="title">Dealing with missing data</h4> <p>Denominators used in calculating the incidence of outcomes for each group in each study were all participants randomised to that group (intention‐to‐treat analysis), unless that information was unavailable from the published reports or after contact with investigators, in which case we used the denominator in the published report. </p> </section> <section id="CD000227-sec-0033"> <h4 class="title">Assessment of heterogeneity</h4> <p>Heterogeneity was assessed using the I<sup>2</sup> test (<a href="./references#CD000227-bbs2-0161" title="HigginsJP , ThompsonSG , DeeksJJ , AltmanDG . Measuring inconsistency in meta-analysis. BMJ2003;327:557-60.">Higgins 2003</a>), in conjunction with the P value from the Chi<sup>2</sup> test and visual inspection. </p> </section> <section id="CD000227-sec-0034"> <h4 class="title">Assessment of reporting biases</h4> <p>Where there were at least 10 trials in a meta‐analysis, the possibility of publication bias was assessed via visual inspection of funnel plots. </p> </section> <section id="CD000227-sec-0035"> <h4 class="title">Data synthesis</h4> <p>Where it was possible and appropriate to pool data, the resulting pooled risk ratio was calculated with 95% CIs. The fixed‐effect model was used to pool data unless substantial heterogeneity was present, in which case we used the random‐effects model. </p> <p>Some trials, such as the <a href="./references#CD000227-bbs2-0044" title="AndersonFH , GrantAM , AvenellA , CampbellMK , CooperC , DonaldsonC , et al. The RECORD Trial: an evaluation of calcium and/or vitamin D in the secondary prevention of osteoporotic fractures. Bone2005;36(Suppl 2):S122-3. FrancisRM , Grant AM and the RECORD trial group. The RECORD trial: a randomised double-blind study of calcium and/or vitamin D in the secondary prevention of low trauma fractures. Age Ageing2005;34(Suppl 2):ii15. GrantA , on behalf of the RECORD Trial Group. Prevention of low-trauma fractures in older people [author reply]. Lancet2005;366(9485):543-4. GrantAM , AndersonFH , for the RECORD Trial Group. The Medical Research Council RECORD Trial: an evaluation of calcium and/or vitamin D in the secondary prevention of osteoporotic fractures. Osteoporosis International2004;15(Suppl 2):S13. GrantAM , AndersonFH . The RECORD trial: an evaluation of calcium and/or vitamin D in the secondary prevention of osteoporotic fractures. Osteoporosis International2005;16(Suppl 3):S4-5. GrantAM , AvenellA , CampbellMK , McDonaldAM , MacLennanGS , McPhersonGC , et al. Oral vitamin D3 and calcium for secondary prevention of low-trauma fractures in elderly people (Randomised Evaluation of Calcium Or vitamin D, RECORD): a randomised placebo-controlled trial [comment in: Lancet 2005;366(9485):543]. Lancet2005;365(9471):1621-8. GrantAM . Personal communication 11 March 2004. ">RECORD 2005</a> trial, had a factorial design, e.g. calcium and vitamin D supplementation (group 1) and vitamin D supplementation (group 2) compared with calcium supplementation (group 3) and placebo (group 4). In such cases the data in the meta‐analyses of fractures refer only to the individual groups of the study (group 1 versus group 3, or group 2 versus group 4), and do not make use of the factorial design to explore the full range of combinations of supplements because of the potential interaction of vitamin D and calcium, with the exception of the adverse events meta‐analyses. </p> </section> <section id="CD000227-sec-0036"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>In previous versions of the review, we set out two secondary hypotheses that anticipated an effect or a greater effect of supplementation with vitamin D or a vitamin D‐related compound, either alone, or in combination with calcium, on the incidence of hip, non‐vertebral, vertebral or any new fracture in a) older people with a history of previous osteoporotic fracture, and b) older people who are more likely to be frail, which we defined as residents in institutions such as nursing homes or residential care homes. Subgroup analyses were undertaken to explore these two secondary hypotheses; i.e. by history of osteoporotic fracture and by residential status. </p> <p>We investigated whether the results of subgroups were significantly different by inspecting the overlap of CIs and by performing the test for subgroup differences available in RevMan (<a href="./references#CD000227-bbs2-0188" title="The Nordic Cochrane Centre, The Cochrane CollaborationReview Manager (RevMan). Version 5.2. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2012.">RevMan 2012</a>). </p> </section> <section id="CD000227-sec-0037"> <h4 class="title">Sensitivity analysis</h4> <p>We undertook a post hoc sensitivity analysis for vitamin D alone versus placebo or no treatment comparison. We examined the results for meta‐analyses with and without three trials (<a href="./references#CD000227-bbs2-0028" title="LawM , MorrisJ , WithersH . Cholecalciferol, not ergocalciferol, should be used for vitamin D supplementation [author reply]. Age and Ageing2006;35(6):645. [MEDLINE: 16982666]LawM , MorrisJ , WithersH . Vitamin D supplementation and the prevention of fractures and falls. Reply. Age and Ageing2007;36(2):233. LawM , MorrisJ , WithersH . Vitamin D supplementation and the prevention of fractures and falls [author reply]. Age and Ageing2007;36(2):233. [MEDLINE: 17255084]LawM , WithersH , MorrisJ , AndersonF . Vitamin D supplementation and the prevention of fractures and falls: results of a randomised trial in elderly people in residential accommodation [comment in: Age and Ageing 2006;35(6):645 and Age and Ageing 2007;36(2):232-3]. Age and Ageing2006;35(5):482-6. ">Law 2006</a>; <a href="./references#CD000227-bbs2-0046" title="AndersonFH , SmithHE , RaphaelHM , CooperC . Intramuscular vitamin D increased serum 1,25-dihydroxycholecalciferol but did not affect 25-hydroxy-cholecalciferol levels in health older adults [abstract]. Journal of Bone and Mineral Research2000;15(Suppl 1):S315. AndersonFH , SmithHE , RaphaelHM , CrozierSR , CooperC . Effect of annual intramuscular vitamin D3 supplementation on fracture risk in 9440 community-living older people: the Wessex fracture prevention trial [abstract]. Journal of Bone and Mineral Research2004;19(Suppl 1):S57. ArdenNK , CrozierS , SmithH , AndersonF , EdwardsC , RaphaelH , et al. Knee pain, knee osteoarthritis, and the risk of fracture. Arthritis and Rheumatism2006;55(4):610-5. CooperC , CrozierS . Personal communication 23 February 2005. RaphaelH , SmithH , AndersonF , CooperC . Tackling the problems of trial management in primary care - experience from the Wessex research network fracture prevention study of annual vitamin D injection in older people [abstract]. Osteoporosis International2000;11(Suppl 1):S63-4. SmithH , AndersonF , RaphaelH , CooperC . The Wessex research network fracture prevention study - a large pragmatic trial of annual vitamin D injection in older people [abstract]. Osteoporosis International2000;11(Suppl 1):S64. SmithH , AndersonF , RaphaelH , CrozierS , CooperC . Effect of annual intramuscular vitamin D supplementation on fracture risk: population-based, randomised, double-blind, placebo-controlled trial [abstract]. Osteoporosis International2004;15(Suppl 1):S8. SmithH , AndersonF , RaphaelH , MaslinP , CrozierS , CooperC . Effect of annual intramuscular vitamin D on fracture risk in elderly men and women--a population-based, randomized, double-blind, placebo-controlled trial. Rheumatology2007;46(12):1852-7. ">Smith 2007</a>; <a href="./references#CD000227-bbs2-0050" title="SandersK , DuqueG , EbelingP , McCorquodaleT , HerrmannM , Shore-LorentiC , et al. The efficacy of high-does oral vitamin D3 administered once a year: increased fracture risk is associated with 1,25 vitamin D level at 3-months post dose. In: ASBMR Annual Meeting; 2012 Oct 12-15; Minneapolis, Minnesota. http://www.asbmr.org/Meetings/AnnualMeeting/AbstractDetail.aspx?aid=6beb2500-4b8e-472b-8b38-d881cadb80e3. 2012. SandersK , StuartA , WilliamsonE , SimpsonJ , KotowiczM , NicholsonG . The efficacy of high-dose oral vitamin D3 administered once a year: a randomised, double-blind, placebo-controlled trial (Vital D study) for falls and fractures in older women. Osteoporosis International2011;22(Suppl 1):S104-5. SandersKM , DuqueG , McCorquodaleT , StuartAL , WilliamsonEJ , KotowiczMA , et al. Annual high-dose oral vitamin D3: is the increased risk of falls attributable to changes in muscle strength?Osteoporosis International2011;22(Suppl 4):S552. SandersKM , EbelingPR , StuartAL , WilliamsonEJ , KotowiczMA , NicholsonGC . Annual high-dose oral vitamin D3: is increased risk of fractures attributable to changes in bone turnover markers?Osteoporosis International2011;22(Suppl 4):S589. SandersKM , HaylesAL , KotowiczMA , NicholsonGC . Does vitamin D explain the lower fracture rate in rural communities?Bone2007;40(6 Suppl 2):S195. SandersKM , HaylesAL , KotowiczMA , NicholsonGC . The possible role of vitamin D and falls in relation to lower fracture rates in rural communities. Osteoporosis International2007;18(Suppl 1):S120-1. SandersKM , StuartAL , KotowiczMA , NicholsonGC . Annual feedback is an effective tool for a sustained increase in calcium intake among older women. Nutrients2010;2:1018-25. SandersKM , StuartAL , MerrimanEN , ReadML , KotowiczMA , YoungD , et al. Trials and tribulations of recruiting 2,000 older women onto a clinical trial investigating falls and fractures: Vital D study. BMC Medical Research Methodology2009;9:78. SandersKM , StuartAL , NicholsonGC . High-dose oral vitamin D supplementation and risk of falls in older women. JAMA2010;304(8):856-7. SandersKM , StuartAL , WilliamsonEJ , JackaFN , DoddS , NicholsonG , et al. Annual high-dose vitamin D3 and mental well-being: randomised controlled trial. British Journal of Psychiatry2011;198:357-64. SandersKM , StuartAL , WilliamsonEJ , SimpsonJA , KotowiczMA , NicholsonGC . Annual high-dose oral vitamin D for falls and fractures in elderly women: a randomised, double-blind, placebo-controlled trial (Vital D study). Osteoporosis International2010;21(Suppl 1):S30. SandersKM , StuartAL , WilliamsonEJ , SimpsonJA , KotowiczMA , YoungD , et al. Annual high-dose oral vitamin D and falls and fractures in older women. A randomized controlled trial. JAMA2010;303(18):1815-22. Sanders KM et al. Incorrect data. JAMA2010;303(23):2357. ">Vital D</a>); this was because in <a href="./references#CD000227-bbs2-0028" title="LawM , MorrisJ , WithersH . Cholecalciferol, not ergocalciferol, should be used for vitamin D supplementation [author reply]. Age and Ageing2006;35(6):645. [MEDLINE: 16982666]LawM , MorrisJ , WithersH . Vitamin D supplementation and the prevention of fractures and falls. Reply. Age and Ageing2007;36(2):233. LawM , MorrisJ , WithersH . Vitamin D supplementation and the prevention of fractures and falls [author reply]. Age and Ageing2007;36(2):233. [MEDLINE: 17255084]LawM , WithersH , MorrisJ , AndersonF . Vitamin D supplementation and the prevention of fractures and falls: results of a randomised trial in elderly people in residential accommodation [comment in: Age and Ageing 2006;35(6):645 and Age and Ageing 2007;36(2):232-3]. Age and Ageing2006;35(5):482-6. ">Law 2006</a>, the effect of clustering might not have been adequately controlled in our meta‐analyses; and in <a href="./references#CD000227-bbs2-0046" title="AndersonFH , SmithHE , RaphaelHM , CooperC . Intramuscular vitamin D increased serum 1,25-dihydroxycholecalciferol but did not affect 25-hydroxy-cholecalciferol levels in health older adults [abstract]. Journal of Bone and Mineral Research2000;15(Suppl 1):S315. AndersonFH , SmithHE , RaphaelHM , CrozierSR , CooperC . Effect of annual intramuscular vitamin D3 supplementation on fracture risk in 9440 community-living older people: the Wessex fracture prevention trial [abstract]. Journal of Bone and Mineral Research2004;19(Suppl 1):S57. ArdenNK , CrozierS , SmithH , AndersonF , EdwardsC , RaphaelH , et al. Knee pain, knee osteoarthritis, and the risk of fracture. Arthritis and Rheumatism2006;55(4):610-5. CooperC , CrozierS . Personal communication 23 February 2005. RaphaelH , SmithH , AndersonF , CooperC . Tackling the problems of trial management in primary care - experience from the Wessex research network fracture prevention study of annual vitamin D injection in older people [abstract]. Osteoporosis International2000;11(Suppl 1):S63-4. SmithH , AndersonF , RaphaelH , CooperC . The Wessex research network fracture prevention study - a large pragmatic trial of annual vitamin D injection in older people [abstract]. Osteoporosis International2000;11(Suppl 1):S64. SmithH , AndersonF , RaphaelH , CrozierS , CooperC . Effect of annual intramuscular vitamin D supplementation on fracture risk: population-based, randomised, double-blind, placebo-controlled trial [abstract]. Osteoporosis International2004;15(Suppl 1):S8. SmithH , AndersonF , RaphaelH , MaslinP , CrozierS , CooperC . Effect of annual intramuscular vitamin D on fracture risk in elderly men and women--a population-based, randomized, double-blind, placebo-controlled trial. Rheumatology2007;46(12):1852-7. ">Smith 2007</a> and <a href="./references#CD000227-bbs2-0050" title="SandersK , DuqueG , EbelingP , McCorquodaleT , HerrmannM , Shore-LorentiC , et al. The efficacy of high-does oral vitamin D3 administered once a year: increased fracture risk is associated with 1,25 vitamin D level at 3-months post dose. In: ASBMR Annual Meeting; 2012 Oct 12-15; Minneapolis, Minnesota. http://www.asbmr.org/Meetings/AnnualMeeting/AbstractDetail.aspx?aid=6beb2500-4b8e-472b-8b38-d881cadb80e3. 2012. SandersK , StuartA , WilliamsonE , SimpsonJ , KotowiczM , NicholsonG . The efficacy of high-dose oral vitamin D3 administered once a year: a randomised, double-blind, placebo-controlled trial (Vital D study) for falls and fractures in older women. Osteoporosis International2011;22(Suppl 1):S104-5. SandersKM , DuqueG , McCorquodaleT , StuartAL , WilliamsonEJ , KotowiczMA , et al. Annual high-dose oral vitamin D3: is the increased risk of falls attributable to changes in muscle strength?Osteoporosis International2011;22(Suppl 4):S552. SandersKM , EbelingPR , StuartAL , WilliamsonEJ , KotowiczMA , NicholsonGC . Annual high-dose oral vitamin D3: is increased risk of fractures attributable to changes in bone turnover markers?Osteoporosis International2011;22(Suppl 4):S589. SandersKM , HaylesAL , KotowiczMA , NicholsonGC . Does vitamin D explain the lower fracture rate in rural communities?Bone2007;40(6 Suppl 2):S195. SandersKM , HaylesAL , KotowiczMA , NicholsonGC . The possible role of vitamin D and falls in relation to lower fracture rates in rural communities. Osteoporosis International2007;18(Suppl 1):S120-1. SandersKM , StuartAL , KotowiczMA , NicholsonGC . Annual feedback is an effective tool for a sustained increase in calcium intake among older women. Nutrients2010;2:1018-25. SandersKM , StuartAL , MerrimanEN , ReadML , KotowiczMA , YoungD , et al. Trials and tribulations of recruiting 2,000 older women onto a clinical trial investigating falls and fractures: Vital D study. BMC Medical Research Methodology2009;9:78. SandersKM , StuartAL , NicholsonGC . High-dose oral vitamin D supplementation and risk of falls in older women. JAMA2010;304(8):856-7. SandersKM , StuartAL , WilliamsonEJ , JackaFN , DoddS , NicholsonG , et al. Annual high-dose vitamin D3 and mental well-being: randomised controlled trial. British Journal of Psychiatry2011;198:357-64. SandersKM , StuartAL , WilliamsonEJ , SimpsonJA , KotowiczMA , NicholsonGC . Annual high-dose oral vitamin D for falls and fractures in elderly women: a randomised, double-blind, placebo-controlled trial (Vital D study). Osteoporosis International2010;21(Suppl 1):S30. SandersKM , StuartAL , WilliamsonEJ , SimpsonJA , KotowiczMA , YoungD , et al. Annual high-dose oral vitamin D and falls and fractures in older women. A randomized controlled trial. JAMA2010;303(18):1815-22. Sanders KM et al. Incorrect data. JAMA2010;303(23):2357. ">Vital D</a>, there may have been supratherapeutic dosing (<a href="./references#CD000227-bbs2-0156" title="Dawson-HughesB , HarrisSS . High-dose vitamin D supplementation. Too much of a good thing?JAMA2010;303:1861-2.">Dawson‐Hughes 2010</a>). </p> </section> <section id="CD000227-sec-0038"> <h4 class="title">'Summary of findings' tables</h4> <p>We have presented the main results of the comparison for vitamin D plus calcium versus placebo or no treatment in a 'Summary of findings' (SoF) table. We graded the evidence as 'very low', 'low', 'moderate' or 'high' in accordance with the GRADE working group criteria. </p> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD000227-sec-0039" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD000227-sec-0039"></div> <section id="CD000227-sec-0040"> <h3 class="title">Description of studies</h3> <section id="CD000227-sec-0041"> <h4 class="title">Results of the search</h4> <p>The search was updated from August 2007 to December 2012. We screened a total of 4028 records from the following databases: Cochrane Bone, Joint and Muscle Trauma Group Specialised Register (31), the Cochrane Central Register of Controlled Trials (372), MEDLINE (901), EMBASE (1398), CINAHL (362), BIOSIS (729), and Current Controlled Trials (235). </p> <p>Twenty‐one studies were identified. We included twelve of these: seven new trials (<a href="./references#CD000227-bbs2-0006" title="BurleighE , McCollJ , PotterJ . Does vitamin D stop inpatients falling? A randomised controlled trial. Age and Ageing2007;36(5):507-13. ">Burleigh 2007</a>; <a href="./references#CD000227-bbs2-0020" title="GlendenningP , ZhuK , InderjeethC , HowatP , LewisJR , PrinceRL . Effects of three-monthly oral 150,000 IU cholecalciferol supplementation on falls, mobility, and muscle strength in older postmenopausal women: a randomized controlled trial. Journal of Bone and Mineral Research2012;27(1):170-6. ">Glendenning 2012</a>; <a href="./references#CD000227-bbs2-0026" title="JanssenHC , SamsonMM , VerhaarHJ . Muscle strength and mobility in vitamin D-insufficient female geriatric patients: a randomized controlled trial on vitamin D and calcium supplementation. Aging Clinical and Experimental Research2010;22(1):78-84. ">Janssen 2010</a>; <a href="./references#CD000227-bbs2-0033" title="MitriJ , Dawson-HughesB , HuFB , PittasAG . Effects of vitamin D and calcium supplementation on pancreatic β cell function, insulin sensitivity, and glycemia in adults at high risk of diabetes: the Calcium and Vitamin D for Diabetes Mellitus (CaDDM) randomized controlled trial. American Journal of Clinical Nutrition2011;94:486-94. ">Mitri 2011</a>; <a href="./references#CD000227-bbs2-0035" title="OnesK , SchachtE , DukasL , CaglarN . Effects of combined treatment with alendronate and alfacalcidol on bone mineral density and bone turnover in postmenopausal osteoporosis: a two-years, randomized, multiarm, controlled trial. Internet Journal of Epidemiology2007;4(1):DOI: 10.5580/1523. ">Ones 2007</a>; <a href="./references#CD000227-bbs2-0052" title="WithamMD , CrightonLJ , GillespieND , StruthersAD , McMurdoME . The effects of vitamin D supplementation on physical function and quality of life in older patients with heart failure. A randomized controlled trial. Circulation: Heart Failure2010;3:195-201. ">Witham 2010</a>; <a href="./references#CD000227-bbs2-0053" title="WithamM . Can high-dose vitamin D supplementation reduce blood pressure and markers of cardiovascular risk in older people with isolated systolic hypertension? A randomised, double-blind, parallel group placebo controlled trial. http://www.controlled-trials.com/ISRCTN92186858/ (accessed 3 December 2013). WithamMD , PriceRJ , StruthersAD , DonnanPT , MessowM , FordI , et al. Vitamin D supplementation to reduce blood pressure in older patients with isolated systolic hypertension (VitDISH) - a randomised controlled trial. Personal communication ahead of publication 15 January 2013. ">Witham 2013</a>); one study that had been ongoing at the time of the previous update of this review (<a href="./references#CD000227-bbs2-0050" title="SandersK , DuqueG , EbelingP , McCorquodaleT , HerrmannM , Shore-LorentiC , et al. The efficacy of high-does oral vitamin D3 administered once a year: increased fracture risk is associated with 1,25 vitamin D level at 3-months post dose. In: ASBMR Annual Meeting; 2012 Oct 12-15; Minneapolis, Minnesota. http://www.asbmr.org/Meetings/AnnualMeeting/AbstractDetail.aspx?aid=6beb2500-4b8e-472b-8b38-d881cadb80e3. 2012. SandersK , StuartA , WilliamsonE , SimpsonJ , KotowiczM , NicholsonG . The efficacy of high-dose oral vitamin D3 administered once a year: a randomised, double-blind, placebo-controlled trial (Vital D study) for falls and fractures in older women. Osteoporosis International2011;22(Suppl 1):S104-5. SandersKM , DuqueG , McCorquodaleT , StuartAL , WilliamsonEJ , KotowiczMA , et al. Annual high-dose oral vitamin D3: is the increased risk of falls attributable to changes in muscle strength?Osteoporosis International2011;22(Suppl 4):S552. SandersKM , EbelingPR , StuartAL , WilliamsonEJ , KotowiczMA , NicholsonGC . Annual high-dose oral vitamin D3: is increased risk of fractures attributable to changes in bone turnover markers?Osteoporosis International2011;22(Suppl 4):S589. SandersKM , HaylesAL , KotowiczMA , NicholsonGC . Does vitamin D explain the lower fracture rate in rural communities?Bone2007;40(6 Suppl 2):S195. SandersKM , HaylesAL , KotowiczMA , NicholsonGC . The possible role of vitamin D and falls in relation to lower fracture rates in rural communities. Osteoporosis International2007;18(Suppl 1):S120-1. SandersKM , StuartAL , KotowiczMA , NicholsonGC . Annual feedback is an effective tool for a sustained increase in calcium intake among older women. Nutrients2010;2:1018-25. SandersKM , StuartAL , MerrimanEN , ReadML , KotowiczMA , YoungD , et al. Trials and tribulations of recruiting 2,000 older women onto a clinical trial investigating falls and fractures: Vital D study. BMC Medical Research Methodology2009;9:78. SandersKM , StuartAL , NicholsonGC . High-dose oral vitamin D supplementation and risk of falls in older women. JAMA2010;304(8):856-7. SandersKM , StuartAL , WilliamsonEJ , JackaFN , DoddS , NicholsonG , et al. Annual high-dose vitamin D3 and mental well-being: randomised controlled trial. British Journal of Psychiatry2011;198:357-64. SandersKM , StuartAL , WilliamsonEJ , SimpsonJA , KotowiczMA , NicholsonGC . Annual high-dose oral vitamin D for falls and fractures in elderly women: a randomised, double-blind, placebo-controlled trial (Vital D study). Osteoporosis International2010;21(Suppl 1):S30. SandersKM , StuartAL , WilliamsonEJ , SimpsonJA , KotowiczMA , YoungD , et al. Annual high-dose oral vitamin D and falls and fractures in older women. A randomized controlled trial. JAMA2010;303(18):1815-22. Sanders KM et al. Incorrect data. JAMA2010;303(23):2357. ">Vital D</a>); and four studies had previously been awaiting assessment (<a href="./references#CD000227-bbs2-0023" title="HayashiY , FujitaT , InoueT . A multi-center study on efficacy of 1 alpha-hydroxy vitamin D3 in preventing spinal fracture of patients with osteoporosis (abstract). Journal of Bone and Mineral Research1989;4 Suppl 1:Si84. HayashiY , FujitaT , InoueT . Decrease of vertebral fracture in osteoporotics by administration of 1alpha-hydroxy-vitamin D3. Journal of Bone and Mineral Metabolism1992;10(2):50-4. ">Hayashi 1992</a>; <a href="./references#CD000227-bbs2-0034" title="NakatsukaK , InabaM , ArataniH , IbaK , SatoT , KoikeT , et al. Effects of long-term administration of alfacalcidol on bone mass and bone metabolism in patients with primary osteoporosis - comparison with calcium preparations [Japanese]. Nippon Ronen Igakkai Zasshi - Japanese Journal of Geriatrics1997;34(7):569-76. ">Nakatsuka 1997</a>; <a href="./references#CD000227-bbs2-0037" title="KarkkainenM , TuppurainenM , RikkonenT , SalovaaraK , SirolaJ , HonkanenR , et al. Vitamin-D 800IU/day + calcium 1000mg supplementation decreases the risk of recurrent falling among postmenopausal ambulatory women - a population-based, randomized, 3-year study (OSTPRE-FPS). Osteoporosis International2008;19(Suppl 1):S17-18. KarkkainenM , TuppurainenM , RikkonenT , SalovaaraK , SirolaJ , HonkanenR , et al. Vitamin-D 800IU/day + calcium supplementation decreases the risk of falling among postmenopausal ambulatory women - a population-based, randomized 3-year study (OSTPRE-FPS) [abstract]. Journal of Bone and Mineral Research2007;22(Suppl 1):S131. KarkkainenM , TuppurainenM , SalovaaraK , SandiniL , RikkonenT , SirolaJ , et al. Effect of calcium and vitamin D supplementation on bone mineral density in women aged 65-71 years: a 3-year randomized population-based trial (OSTPRE-FPS). Osteoporosis International2010;21:2047-55. KarkkainenMK , TuppurainenM , SalovaaraM , SandiniL , RikkonenT , SirolaJ , et al. Does daily vitamin D 800 IU and calcium 1000 mg supplementation decrease the risk of falling in ambulatory women aged 65-71 years? A 3-year randomized population-based trial (OSTPRE-FPS). Maturitas2010;65:359-65. KrogerHP , TuppurainenM . OSTPRE-FPS Prevention of Fractures and Falls in Postmenopausal Women With Calcium and Vitamin-D Supplementation - a Randomised Study. http://www.controlled-trials.com/mrct/trial/405493/OSTPRE. SalovaaraK , TuppurainenM , KarkkainenM , RikkonenT , SandiniL , SirolaJ , et al. Effect of vitamin D3 and calcium on fracture risk in 65- to 71-year-old women: a population-based 3-year randomized, controlled trial - the OSTPRE-FPS. Journal of Bone and Mineral Research2010;25(7):1487-95. SalovaaraKT , TuppurainenM , RikkonenT , KarkkainenM , SirolaJ , HonkanenR , et al. Effect of vitamin-D3 and calcium on fracture risk in 65-71 year old women in a 3-year randomized clinical trial - preliminary results from the OSTPRE-Fracture Prevention Study. Calcified Tissue International2008;82:545-6. SalovaaraKT , TuppurainenM , RikkonenT , KarkkainenM , SirolaJ , HonkanenR , et al. Effect of vitamin-D3 and calcium on fracture risk in 65-71 year old women in a 3-year randomized clinical trial - preliminary results of the OSTPRE-Fracture Prevention Study. Journal of Bone and Mineral Research2007;22(Suppl 1):S76. ">OSTPRE‐FPS 2007</a>; <a href="./references#CD000227-bbs2-0041" title="BollandMJ , GreyA . Different outcomes of meta-analyses and data inconsistency:response to comments by Pfeifer. Archives of Osteoporosis2015;10:43. BollandMJ , GreyA . Inconsistent data in text and tables. Osteoporosis International2015;26:2713. MinneHW , DobnigH , PfeiferM , SuppanK . Effects of vitamin D and calcium supplementation on falls and parameters of muscle function: a prospective, randomized, double-blind multicenter study [abstract]. Osteoporosis International2006;17(Suppl 2):S212. MinneHW , DobnigH , PfeiferM , SuppanK . Effects of vitamin D and calcium supplementation on falls and parameters of muscle-function - a prospective, randomized, double-blind multi-center study [abstract]. Osteoporosis International2006;17(Suppl 1):S21. PfeiferM , BegerowB , MinneHW , SuppanK , Fahrleitner-PammerA , DobnigH . Effects of a long-term vitamin D and calcium supplementation on falls and parameters of muscle function in community-dwelling older individuals. Osteoporosis International2009;20:315-22. PfeiferM , DobnigH , BegerowB , SuppanK . Effects of vitamin D and calcium supplementation on falls and parameters of muscle function: a prospective randomized, double-blind multi-centre study [abstract]. Journal of Bone and Mineral Research2004;19(Suppl 1):S58. PfeiferM , DobnigH , MinneHW , SuppanK . Effects of vitamin D and calcium supplementation on falls and parameters of muscle function - a prospective, randomized, double-blind multi-center study [abstract]. Osteoporosis International2005;16(Suppl 3):S45. PfeiferM . Different outcomes of meta-analyses and data inconsistency. Osteoporosis International2015;26:2715–2716. PfeiferM . Randomized controlled clinical trials and meta-analyses. Archives of Osteoporosis2015;10:42. ">Pfeifer 2009</a>). One study was excluded (<a href="./references#CD000227-bbs2-0102" title="OrimoH , NakamuraT , FukunagaM , OhtaH , HosoiT , UemuraY , et al. Effects of alendronate plus alfacalcidol in osteoporosis patients with a high risk of fracture: the Japanese Osteoporosis Intervention Trial (JOINT) - 02. Current Medical Research and Opinion2011;27(6):1273-84. ">Orimo 2011</a>), two were placed in <a href="./references#CD000227-bbs1-0004" title="">Ongoing studies</a> (<a href="./references#CD000227-bbs2-0130" title="Lopez-Torres HidalgoJ , ANVITAD Group. Prevention of falls and fractures in old people by administration of calcium and vitamin D. Randomized clinical trial. BMC Public Health2011;11:910. ">ANVITAD</a>; <a href="./references#CD000227-bbs2-0131" title="MakJ . Replenishment of Vitamin D in Hip fractured Patients (REVITAHIP) Trial. http://apps.who.int/trialsearch/trial.aspx?trialid=ACTRN12610000392066 (accessed 27 March 2012). MakJC , CameronID , MasonRS , KleinL , SoongM , OhnK . Improving mobility and reducing disability in older people through early high-dose vitamin D replacement following hip fracture (the REVITAHIP trial): preliminary results. Osteoporosis International2011;22(Suppl 4):S586-7. ">REVITAHIP</a>) and six await classification (<a href="./references#CD000227-bbs2-0117" title="Bischoff-FerrariHA , Dawson-HughesB , PlatzA , OravEJ , StahelinHB , WillettWC , et al. Effect of high-dosage cholecalciferol and extended physiotherapy on complications after hip fracture. A randomized controlled trial. Archives of Internal Medicine2010;170(9):813-20. ">Bischoff‐Ferrari 2010a</a>; <a href="./references#CD000227-bbs2-0121" title="PapaioannouA , KennedyCC , GiangregorioL , IoannidisG , PritchardJ , HanleyDA , et al. A randomized controlled trial of vitamin D dosing strategies after acute hip fracture: no advantage of loading doses over daily supplementation. BMC Muscloskeletal Disorders2011;12:135. ">Papaioannou 2011</a>; <a href="./references#CD000227-bbs2-0122" title="PetkakovM , PopovicV , MilicD , DamjanovicS , ManojlovicD , MicicJ . Treatment of postmenopausal osteoporosis with 1-alpha(OH)D3 [Lecenje postmenopauzne osteoporoze sintetskim analogom vitamina de-tri]. Srpski Arhiv za Celokupno Lekarstvo1995;123(7-8):171-3. ">Petkakov 1995</a>; <a href="./references#CD000227-bbs2-0127" title="The TIDE trial investigators. Design, history and results of the Thiazolidinedione Intervention with vitamin D Evaluation (TIDE). Diabetologia2012;55:36-45. ">TIDE 2012</a>; <a href="./references#CD000227-bbs2-0128" title="WoodAD , SecombesKR , ThiesF , AucottL , BlackAJ , MavroeidiA , et al. Vitamin D3 supplementation has no effect on conventional cardiovascular risk factors: a parallel-group, double-blind, placebo-controlled RCT. Journal of Clinical Endocrinology and Metabolism2012;97:3557-68. ">Wood 2012</a>; <a href="./references#CD000227-bbs2-0129" title="Xia W-B, Zhang Z-L, Wang H-F, Meng X-W, ZhangY , Zhu G-Y, et al. The efficacy and safety of calcitriol and/or Caltrate D in elderly Chinese women with low bone mass. Acta Pharmacologica Sinica2009;30(3):372-8. ">Xia 2009</a>). </p> <p>One previously included trial is now awaiting classification (<a href="./references#CD000227-bbs2-0119" title="NutiR , BianchiG , BrandiML , CaudarellaR , D'ErasmoE , FioreC , et al. Efficacy and safety of alfacalcidol compared to vitamin D plus calcium in post menopausal osteoporosis [abstract]. Osteoporosis International2005;16(Suppl 3):S75-6. NutiR , BianchiG , BrandiML , CaudarellaR , D'ErasmoE , FioreC , et al. Superiority of alfacalcidol compared to vitamin D plus calcium in lumbar bone mineral density in postmenopausal osteoporosis. Rheumatology International2006;26(5):445-53. ">Nuti 2006</a>), as both trial arms included forms of vitamin D. Three previously included studies have been moved to <a href="./references#CD000227-bbs1-0003" title="">Studies awaiting classification</a>, whilst clarification is awaited for data queries (<a href="./references#CD000227-bbs2-0123" title="SatoY , MaruokaH , OizumiK . Amelioration of hemiplegia-associated stroke osteopenia more than four years after stroke by 1-alpha-hydroxyvitamin D3 and calcium supplementation. Stroke1997;28:736-9. ">Sato 1997</a>; <a href="./references#CD000227-bbs2-0124" title="SatoY , ManabeS , KunoH , OizumiK . Amelioration of osteopenia and hypovitaminosis D by 1-alpha-hydroxyvitamin D3 in elderly patients with Parkinson's disease. Journal of Neurology, Neurosurgery and Psychiatry1999;66:64-8. ">Sato 1999a</a>; <a href="./references#CD000227-bbs2-0125" title="SatoS , KunoH , KajiM , SaruwatariN , OizumiK . Effect of ipriflavone on bone in elderly hemiplegic stroke patients with hypovitaminosis D. American Journal of Physical Medicine and Rehabilitation1999;78:457-63. ">Sato 1999b</a>). </p> <p>Overall, this review now has a total of 53 included trials, 63 excluded studies, two ongoing trials and 13 studies awaiting classification. See <a href="#CD000227-fig-0001">Figure 1</a> for study flow diagram. </p> <div class="figure" id="CD000227-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="tudy flow diagram for the updated search (December 2012)" data-id="CD000227-fig-0001" src="/cdsr/doi/10.1002/14651858.CD000227.pub4/media/CDSR/CD000227/image_n/nCD000227-FIG-01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>tudy flow diagram for the updated search (December 2012)</p> </div> </div> </div> </section> <section id="CD000227-sec-0042"> <h4 class="title">Included studies</h4> <p>Fifty‐three trials were included in this review: 49 were individually randomised controlled trials (RCTs), one was a cluster‐randomised trial (<a href="./references#CD000227-bbs2-0028" title="LawM , MorrisJ , WithersH . Cholecalciferol, not ergocalciferol, should be used for vitamin D supplementation [author reply]. Age and Ageing2006;35(6):645. [MEDLINE: 16982666]LawM , MorrisJ , WithersH . Vitamin D supplementation and the prevention of fractures and falls. Reply. Age and Ageing2007;36(2):233. LawM , MorrisJ , WithersH . Vitamin D supplementation and the prevention of fractures and falls [author reply]. Age and Ageing2007;36(2):233. [MEDLINE: 17255084]LawM , WithersH , MorrisJ , AndersonF . Vitamin D supplementation and the prevention of fractures and falls: results of a randomised trial in elderly people in residential accommodation [comment in: Age and Ageing 2006;35(6):645 and Age and Ageing 2007;36(2):232-3]. Age and Ageing2006;35(5):482-6. ">Law 2006</a>), and three were quasi‐randomised (<a href="./references#CD000227-bbs2-0023" title="HayashiY , FujitaT , InoueT . A multi-center study on efficacy of 1 alpha-hydroxy vitamin D3 in preventing spinal fracture of patients with osteoporosis (abstract). Journal of Bone and Mineral Research1989;4 Suppl 1:Si84. HayashiY , FujitaT , InoueT . Decrease of vertebral fracture in osteoporotics by administration of 1alpha-hydroxy-vitamin D3. Journal of Bone and Mineral Metabolism1992;10(2):50-4. ">Hayashi 1992</a>; <a href="./references#CD000227-bbs2-0024" title="InkovaaraJ , GothoniG , HalttulaR , HeikinheimoR , TokolaO . Calcium, vitamin D and anabolic steroids in treatment of aged bones: double-blind placebo-controlled long-term clinical trial. Age and Ageing1983;12:124-30. ">Inkovaara 1983</a>; <a href="./references#CD000227-bbs2-0032" title="MeyerHE , FalchJA , KvaavikE , SmedshaugGB , TverdalA , PedersenJI . Can vitamin D supplementation reduce the risk of fracture in the elderly? A randomised controlled trial. Osteoporosis International2000;11(Suppl 2):S114-5. MeyerHE , SmedshaugGB , KvaavikE , FalchJA , TverdalA , PedersenJI . Can vitamin D supplementation reduce the risk of fracture in the elderly? A randomized controlled trial. Journal of Bone and Mineral Research2002;17(4):709-15. SmedshaugGB , PedersenJI , MeyerHE . Can vitamin D supplementation improve grip strength in elderly nursing home residents? A double-blinded controlled trial. Scandinavian Journal of Food and Nutrition2007;51(2):74-8. ">Meyer 2002</a>) (see '<a href="./references#CD000227-sec-0124" title="">Characteristics of included studies</a>' table for full descriptions). There was a total of 91,791 participants in the 53 trials. </p> <p>Broadly, the included trials fall into two main groups.</p> <section id="CD000227-sec-0043"> <h5 class="title">Trials with cholecalciferol, ergocalciferol or 25‐hydroxy vitamin D</h5> <p>In this first group, there were 31 trials; the number of participants ranged from 70 to 36,282. These trials were set in Australasia, Europe, and North America; there were none from the Far East. They examined the use of vitamin D (including 25‐hydroxy vitamin D) with or without calcium in the prevention of fractures (see <a href="#CD000227-tbl-0004">Table 3</a> for further details of studies included in comparisons 1 to 4). These trials were set in community, nursing home or hospital inpatient populations, and generally had older participants than in the second group of trials described below. Twelve trials had participants with a mean or median age of 80 years or over (<a href="./references#CD000227-bbs2-0004" title="Bischoff-FerrariHA , ConzelmannM , StahelinHB , DickW , CarpenterMG , AdkinAL , et al. Is fall prevention by vitamin D mediated by a change in postural or dynamic balance?Osteoporosis International2006;17(5):656-63. BischoffHA , StahelinHB , DickW , AkosR , KnechtM , SalisC , et al. Effects of vitamin D and calcium supplementation on falls: a randomized controlled trial. Journal of Bone and Mineral Research2003;18(2):343-51. [MEDLINE: 12568412]BischoffHA . Personal communication 13 July 2003. BischoffHA . Vitamin D deficiency in the elderly. Journal of Bone and Mineral Research2003;18(7):1343. [MEDLINE: 12854846]HeaneyR . Vitamin D depletion and effective calcium absorption. Journal of Bone and Mineral Research2003;18(7):1342. ">Bischoff 2003</a>; <a href="./references#CD000227-bbs2-0006" title="BurleighE , McCollJ , PotterJ . Does vitamin D stop inpatients falling? A randomised controlled trial. Age and Ageing2007;36(5):507-13. ">Burleigh 2007</a>; <a href="./references#CD000227-bbs2-0008" title="ChapuyMC , ArlotM , et al. Prevention of non vertebral fractures and cortical bone loss in elderly women: a prospective controlled trial using calcium and vitamin D3 supplements [abstract]. Osteoporosis International1993;3 Suppl 1:258. ChapuyMC , ArlotME , DelmasPD , MeunierPJ . Effect of calcium and cholecalciferol treatment for three years on hip fractures in elderly women. BMJ1994;308:1081-2. ChapuyMC , ArlotME , DuboeufF , BrunJ , CrouzetB , ArnaudS , et al. Vitamin D3 and calcium to prevent hip fractures in elderly women. New England Journal of Medicine1992;327:1637-42. MeunierPJ , PamphileR , ChapuyMC , SchultenJ , ArlotM , LilluH . A calcium-vitamin D3 combined supplementation is cost-saving for preventing hip fractures in institutionalised elderly women: an economic evaluation from the perspective of seven European countries (Belgium, France, Germany, The Netherlands, Spain, Sweden, United Kingdom). Osteoporosis International2002;13(Suppl 1):S14. ">Chapuy 1992</a>; <a href="./references#CD000227-bbs2-0009" title="BosworthC , deBoerIH , TargherG , KendrickJ , SmitsG , ChoncholM . The effect of combined calcium and cholecalciferol supplementation on bone mineral density in elderly women with moderate chronic kidney disease. Clinical Nephrology2012;77(5):358-65. ChapuyMC , PamphileR , ParisE , KempfC , SchlichtingM , ArnaudS , et al. Combined calcium and vitamin D3 supplementation in elderly women: confirmation of reversal of secondary hyperparathyroidism and hip fracture risk: the Decalyos II study. Osteoporosis International2002;13(3):257-64. [MEDLINE: 11991447]ChapuyMC , PamphileR , ParisE , KempfC , SchlichtingM , ArnaudS , et al. Combined calcium and vitamin D3 supplementation to prevent hip fracture in elderly women. A confirmatory study: Decalyos II. Osteoporosis International2002;13(Suppl 1):S25. MeunierPJ . Personal communication 28 February 2005. ">Chapuy 2002</a>; <a href="./references#CD000227-bbs2-0014" title="FlickerL , MacInnisR , SteinM , SchererS , MeadK , NowsonC , et al. Should all older people in residential care receive vitamin D to prevent falls? Results of a randomised trial [abstract]. Journal of Bone and Mineral Research2004;19(Suppl 1):S99. FlickerL , MacInnisRJ , SteinMS , SchererSC , MeadKE , et al. Response letter to Dr. Gau et al. Journal of the American Geriatrics Society2006;54:1021-2. FlickerL , MacInnisRJ , SteinMS , SchererSC , MeadKE , NowsonCA , et al. Erratum. Journal of the American Geriatrics Society2012;60:1599. FlickerL , MacInnisRJ , SteinMS , SchererSC , MeadKE , NowsonCA , et al. Should older people in residential care receive vitamin D to prevent falls? Results of a randomized trial. Journal of the American Geriatrics Society2005;53(11):1881-8. FlickerL , MacInnisRJ , SteinMS , SchererSC , MeadKE , NowsonCA . Should all older people in residential care receive vitamin D to prevent falls? Results of a randomised trial. Journal of Bone and Mineral Research2004;19(Suppl 1):S99. FlickerL . Personal communication 7 January 2008. ">Flicker 2005</a>; <a href="./references#CD000227-bbs2-0022" title="HarwoodRH , SahotaO , GaynorK , MasudT , HoskingD . A randomised, controlled comparison of different calcium and vitamin D supplementation regimens in elderly women after hip fracture: The Nottingham Neck of Femur (NoNOF) Study. Age and Ageing2004;33:45-51. [14695863]HarwoodRW . Personal communication 24 January 2003. SahotaO , HarwoodRH , GaynorK , MasudT , HoskingDJ . A randomised, controlled comparison of different calcium and vitamin D regimes: the NoNOF (Nottingham Neck of Femur) study. Osteoporosis International2003;14(Suppl 4):S10-11. ">Harwood 2004</a>; <a href="./references#CD000227-bbs2-0026" title="JanssenHC , SamsonMM , VerhaarHJ . Muscle strength and mobility in vitamin D-insufficient female geriatric patients: a randomized controlled trial on vitamin D and calcium supplementation. Aging Clinical and Experimental Research2010;22(1):78-84. ">Janssen 2010</a>; <a href="./references#CD000227-bbs2-0028" title="LawM , MorrisJ , WithersH . Cholecalciferol, not ergocalciferol, should be used for vitamin D supplementation [author reply]. Age and Ageing2006;35(6):645. [MEDLINE: 16982666]LawM , MorrisJ , WithersH . Vitamin D supplementation and the prevention of fractures and falls. Reply. Age and Ageing2007;36(2):233. LawM , MorrisJ , WithersH . Vitamin D supplementation and the prevention of fractures and falls [author reply]. Age and Ageing2007;36(2):233. [MEDLINE: 17255084]LawM , WithersH , MorrisJ , AndersonF . Vitamin D supplementation and the prevention of fractures and falls: results of a randomised trial in elderly people in residential accommodation [comment in: Age and Ageing 2006;35(6):645 and Age and Ageing 2007;36(2):232-3]. Age and Ageing2006;35(5):482-6. ">Law 2006</a>; <a href="./references#CD000227-bbs2-0029" title="GraafmansWC , OomsME , HofsteeHMA , BezemerPD , BouterLM , LipsP . Falls in the elderly: a prospective study of risk factors and risk profiles. American Journal of Epidemiology1996;143(11):1129-36. LipsP , GraafmansWC , OomsME , BezemerPD , BouterLM . The effect of vitamin D supplementation on the incidence of hip fractures in elderly people. Journal of Bone and Mineral Research1994;9 Suppl 1:S148. LipsP , GraafmansWC , OomsME , BezemerPD , BouterLM . Vitamin D supplementation and fracture incidence in elderly persons. Annals of Internal Medicine1996;124:400-6. [MEDLINE: 1996151943]">Lips 1996</a>; <a href="./references#CD000227-bbs2-0030" title="JohansenA , LyonsRA , StoneM , BrophyS , NewcombeRG , PhillipsCJ , et al. Preventing fractures among older people living in institutional care: a randomised double blind placebo controlled trial of vitamin D supplementation [abstract]. Age and Ageing2006;35(Suppl 3):i41. LyonsRA , JohansenA , BrophyS , NewcombeRG , PhillipsCJ , LervyB , et al. Preventing fractures among older people living in institutional care: a pragmatic randomised double blind placebo controlled trial of vitamin D supplementation. Osteoporosis International2007;18(6):811-8. LyonsRA , JohansenA , StoneMD , BrophyS , NewcombeRG , PhilipsCJ , et al. Preventing fractures among older people living in institutional care: a randomised double blind placebo controlled trial of vitamin D supplementation [abstract]. Osteoporosis International2006;17(Suppl 3):372. ">Lyons 2007</a>; <a href="./references#CD000227-bbs2-0032" title="MeyerHE , FalchJA , KvaavikE , SmedshaugGB , TverdalA , PedersenJI . Can vitamin D supplementation reduce the risk of fracture in the elderly? A randomised controlled trial. Osteoporosis International2000;11(Suppl 2):S114-5. MeyerHE , SmedshaugGB , KvaavikE , FalchJA , TverdalA , PedersenJI . Can vitamin D supplementation reduce the risk of fracture in the elderly? A randomized controlled trial. Journal of Bone and Mineral Research2002;17(4):709-15. SmedshaugGB , PedersenJI , MeyerHE . Can vitamin D supplementation improve grip strength in elderly nursing home residents? A double-blinded controlled trial. Scandinavian Journal of Food and Nutrition2007;51(2):74-8. ">Meyer 2002</a>; <a href="./references#CD000227-bbs2-0052" title="WithamMD , CrightonLJ , GillespieND , StruthersAD , McMurdoME . The effects of vitamin D supplementation on physical function and quality of life in older patients with heart failure. A randomized controlled trial. Circulation: Heart Failure2010;3:195-201. ">Witham 2010</a>). Fifteen trials included women only; none included men only (see <a href="#CD000227-tbl-0004">Table 3</a>). Only three trials specifically recruited participants who had had a previous fracture (<a href="./references#CD000227-bbs2-0003" title="AvenellA , GrantAM , McGeeM , McPhersonG , CampbellMK , McGee MA for the RECORD Trial Management Group. The effects of an open design on trial participant recruitment, compliance and retention - a randomized controlled trial comparison with a blinded, placebo-controlled design. Clinical Trials Journal2004;1:490-8. AvenellA . Personal communication2005. ">Avenell 2004</a>; <a href="./references#CD000227-bbs2-0022" title="HarwoodRH , SahotaO , GaynorK , MasudT , HoskingD . A randomised, controlled comparison of different calcium and vitamin D supplementation regimens in elderly women after hip fracture: The Nottingham Neck of Femur (NoNOF) Study. Age and Ageing2004;33:45-51. [14695863]HarwoodRW . Personal communication 24 January 2003. SahotaO , HarwoodRH , GaynorK , MasudT , HoskingDJ . A randomised, controlled comparison of different calcium and vitamin D regimes: the NoNOF (Nottingham Neck of Femur) study. Osteoporosis International2003;14(Suppl 4):S10-11. ">Harwood 2004</a>; <a href="./references#CD000227-bbs2-0044" title="AndersonFH , GrantAM , AvenellA , CampbellMK , CooperC , DonaldsonC , et al. The RECORD Trial: an evaluation of calcium and/or vitamin D in the secondary prevention of osteoporotic fractures. Bone2005;36(Suppl 2):S122-3. FrancisRM , Grant AM and the RECORD trial group. The RECORD trial: a randomised double-blind study of calcium and/or vitamin D in the secondary prevention of low trauma fractures. Age Ageing2005;34(Suppl 2):ii15. GrantA , on behalf of the RECORD Trial Group. Prevention of low-trauma fractures in older people [author reply]. Lancet2005;366(9485):543-4. GrantAM , AndersonFH , for the RECORD Trial Group. The Medical Research Council RECORD Trial: an evaluation of calcium and/or vitamin D in the secondary prevention of osteoporotic fractures. Osteoporosis International2004;15(Suppl 2):S13. GrantAM , AndersonFH . The RECORD trial: an evaluation of calcium and/or vitamin D in the secondary prevention of osteoporotic fractures. Osteoporosis International2005;16(Suppl 3):S4-5. GrantAM , AvenellA , CampbellMK , McDonaldAM , MacLennanGS , McPhersonGC , et al. Oral vitamin D3 and calcium for secondary prevention of low-trauma fractures in elderly people (Randomised Evaluation of Calcium Or vitamin D, RECORD): a randomised placebo-controlled trial [comment in: Lancet 2005;366(9485):543]. Lancet2005;365(9471):1621-8. GrantAM . Personal communication 11 March 2004. ">RECORD 2005</a>). Thirteen trials had more than 1000 participants (<a href="./references#CD000227-bbs2-0008" title="ChapuyMC , ArlotM , et al. Prevention of non vertebral fractures and cortical bone loss in elderly women: a prospective controlled trial using calcium and vitamin D3 supplements [abstract]. Osteoporosis International1993;3 Suppl 1:258. ChapuyMC , ArlotME , DelmasPD , MeunierPJ . Effect of calcium and cholecalciferol treatment for three years on hip fractures in elderly women. BMJ1994;308:1081-2. ChapuyMC , ArlotME , DuboeufF , BrunJ , CrouzetB , ArnaudS , et al. Vitamin D3 and calcium to prevent hip fractures in elderly women. New England Journal of Medicine1992;327:1637-42. MeunierPJ , PamphileR , ChapuyMC , SchultenJ , ArlotM , LilluH . A calcium-vitamin D3 combined supplementation is cost-saving for preventing hip fractures in institutionalised elderly women: an economic evaluation from the perspective of seven European countries (Belgium, France, Germany, The Netherlands, Spain, Sweden, United Kingdom). Osteoporosis International2002;13(Suppl 1):S14. ">Chapuy 1992</a>; <a href="./references#CD000227-bbs2-0018" title="Garay LilloJ , ParrenoJ , GonzálezY , GonzálezJA . Geminis: a prospective, multicentric, randomised study to evaluate the effect of tricalcium phosphate versus tricalcium phosphate plus 25(OH) Vitamin D on the risk of fractures in older women [Géminis: Estudio prospectivo, multicéntrico y aleatori para valorar el efecto del Fosfato Tricálcico versus Fosfato Tricálcico + 25(OH) Vitamina D sobre el riesgo de fracturas en mujerioes ancianas.]. Geriátrika1997;13(6):24-8. ">Garay Lillo 1997</a>; <a href="./references#CD000227-bbs2-0028" title="LawM , MorrisJ , WithersH . Cholecalciferol, not ergocalciferol, should be used for vitamin D supplementation [author reply]. Age and Ageing2006;35(6):645. [MEDLINE: 16982666]LawM , MorrisJ , WithersH . Vitamin D supplementation and the prevention of fractures and falls. Reply. Age and Ageing2007;36(2):233. LawM , MorrisJ , WithersH . Vitamin D supplementation and the prevention of fractures and falls [author reply]. Age and Ageing2007;36(2):233. [MEDLINE: 17255084]LawM , WithersH , MorrisJ , AndersonF . Vitamin D supplementation and the prevention of fractures and falls: results of a randomised trial in elderly people in residential accommodation [comment in: Age and Ageing 2006;35(6):645 and Age and Ageing 2007;36(2):232-3]. Age and Ageing2006;35(5):482-6. ">Law 2006</a>; <a href="./references#CD000227-bbs2-0029" title="GraafmansWC , OomsME , HofsteeHMA , BezemerPD , BouterLM , LipsP . Falls in the elderly: a prospective study of risk factors and risk profiles. American Journal of Epidemiology1996;143(11):1129-36. LipsP , GraafmansWC , OomsME , BezemerPD , BouterLM . The effect of vitamin D supplementation on the incidence of hip fractures in elderly people. Journal of Bone and Mineral Research1994;9 Suppl 1:S148. LipsP , GraafmansWC , OomsME , BezemerPD , BouterLM . Vitamin D supplementation and fracture incidence in elderly persons. Annals of Internal Medicine1996;124:400-6. [MEDLINE: 1996151943]">Lips 1996</a>; <a href="./references#CD000227-bbs2-0030" title="JohansenA , LyonsRA , StoneM , BrophyS , NewcombeRG , PhillipsCJ , et al. Preventing fractures among older people living in institutional care: a randomised double blind placebo controlled trial of vitamin D supplementation [abstract]. Age and Ageing2006;35(Suppl 3):i41. LyonsRA , JohansenA , BrophyS , NewcombeRG , PhillipsCJ , LervyB , et al. Preventing fractures among older people living in institutional care: a pragmatic randomised double blind placebo controlled trial of vitamin D supplementation. Osteoporosis International2007;18(6):811-8. LyonsRA , JohansenA , StoneMD , BrophyS , NewcombeRG , PhilipsCJ , et al. Preventing fractures among older people living in institutional care: a randomised double blind placebo controlled trial of vitamin D supplementation [abstract]. Osteoporosis International2006;17(Suppl 3):372. ">Lyons 2007</a>; <a href="./references#CD000227-bbs2-0032" title="MeyerHE , FalchJA , KvaavikE , SmedshaugGB , TverdalA , PedersenJI . Can vitamin D supplementation reduce the risk of fracture in the elderly? A randomised controlled trial. Osteoporosis International2000;11(Suppl 2):S114-5. MeyerHE , SmedshaugGB , KvaavikE , FalchJA , TverdalA , PedersenJI . Can vitamin D supplementation reduce the risk of fracture in the elderly? A randomized controlled trial. Journal of Bone and Mineral Research2002;17(4):709-15. SmedshaugGB , PedersenJI , MeyerHE . Can vitamin D supplementation improve grip strength in elderly nursing home residents? A double-blinded controlled trial. Scandinavian Journal of Food and Nutrition2007;51(2):74-8. ">Meyer 2002</a>; <a href="./references#CD000227-bbs2-0037" title="KarkkainenM , TuppurainenM , RikkonenT , SalovaaraK , SirolaJ , HonkanenR , et al. Vitamin-D 800IU/day + calcium 1000mg supplementation decreases the risk of recurrent falling among postmenopausal ambulatory women - a population-based, randomized, 3-year study (OSTPRE-FPS). Osteoporosis International2008;19(Suppl 1):S17-18. KarkkainenM , TuppurainenM , RikkonenT , SalovaaraK , SirolaJ , HonkanenR , et al. Vitamin-D 800IU/day + calcium supplementation decreases the risk of falling among postmenopausal ambulatory women - a population-based, randomized 3-year study (OSTPRE-FPS) [abstract]. Journal of Bone and Mineral Research2007;22(Suppl 1):S131. KarkkainenM , TuppurainenM , SalovaaraK , SandiniL , RikkonenT , SirolaJ , et al. Effect of calcium and vitamin D supplementation on bone mineral density in women aged 65-71 years: a 3-year randomized population-based trial (OSTPRE-FPS). Osteoporosis International2010;21:2047-55. KarkkainenMK , TuppurainenM , SalovaaraM , SandiniL , RikkonenT , SirolaJ , et al. Does daily vitamin D 800 IU and calcium 1000 mg supplementation decrease the risk of falling in ambulatory women aged 65-71 years? A 3-year randomized population-based trial (OSTPRE-FPS). Maturitas2010;65:359-65. KrogerHP , TuppurainenM . OSTPRE-FPS Prevention of Fractures and Falls in Postmenopausal Women With Calcium and Vitamin-D Supplementation - a Randomised Study. http://www.controlled-trials.com/mrct/trial/405493/OSTPRE. SalovaaraK , TuppurainenM , KarkkainenM , RikkonenT , SandiniL , SirolaJ , et al. Effect of vitamin D3 and calcium on fracture risk in 65- to 71-year-old women: a population-based 3-year randomized, controlled trial - the OSTPRE-FPS. Journal of Bone and Mineral Research2010;25(7):1487-95. SalovaaraKT , TuppurainenM , RikkonenT , KarkkainenM , SirolaJ , HonkanenR , et al. Effect of vitamin-D3 and calcium on fracture risk in 65-71 year old women in a 3-year randomized clinical trial - preliminary results from the OSTPRE-Fracture Prevention Study. Calcified Tissue International2008;82:545-6. SalovaaraKT , TuppurainenM , RikkonenT , KarkkainenM , SirolaJ , HonkanenR , et al. Effect of vitamin-D3 and calcium on fracture risk in 65-71 year old women in a 3-year randomized clinical trial - preliminary results of the OSTPRE-Fracture Prevention Study. Journal of Bone and Mineral Research2007;22(Suppl 1):S76. ">OSTPRE‐FPS 2007</a>; <a href="./references#CD000227-bbs2-0042" title="DumvilleJC , MilesJN , PorthouseJ , CockayneES , SaxonL , KingC , et al. Can vitamin D supplementation prevent seasonal affective disorder? A randomised trial among older women. Osteoporosis International2004;15:S42-3. PorthouseJ , CockayneS , KingC , SaxonL , SteeleE , AsprayT , et al. Randomised controlled trial of calcium and supplementation with cholecalciferol (vitamin D3) for prevention of fractures in primary care. BMJ2005;330(7498):1003-6. PorthouseJ , CockayneS , KingC , SaxonL , SteeleE , AsprayT , et al. Randomised controlled trial of calcium and vitamin D supplementation for fracture prevention in primary care. Osteoporosis International2004;15(Suppl 2):S13. PorthouseJ , CockayneS , KingC , SaxonL , SteeleE , AsprayT , et al. Randomised controlled trial of calcium and vitamin D supplementation for fracture prevention in primary care. Osteoporosis International2005;16:S27. PufferS . Calcium and vitamin D in primary care: adherence results from a randomised controlled trial [abstract 6.9.3]. In: RCN International Nursing Conference; 2004 Mar 21-31; Cambridge (UK). London: Royal College of Nursing, 2004. S Puffer, on behalf of the Calcium and Vitamin D Trial. Calcium and vitamin D in primary care. Compliance results from a randomised controlled trial. Osteoporosis International2003;14(Suppl 4):S8. TorgersonD , on behalf of the trial group. Calcium and vitamin D in preventing fractures [author reply]. BMJ2005;331(7508):109. TorgersonDJ . Personal communication 9-16 February 2005. ">Porthouse 2005</a>; <a href="./references#CD000227-bbs2-0044" title="AndersonFH , GrantAM , AvenellA , CampbellMK , CooperC , DonaldsonC , et al. The RECORD Trial: an evaluation of calcium and/or vitamin D in the secondary prevention of osteoporotic fractures. Bone2005;36(Suppl 2):S122-3. FrancisRM , Grant AM and the RECORD trial group. The RECORD trial: a randomised double-blind study of calcium and/or vitamin D in the secondary prevention of low trauma fractures. Age Ageing2005;34(Suppl 2):ii15. GrantA , on behalf of the RECORD Trial Group. Prevention of low-trauma fractures in older people [author reply]. Lancet2005;366(9485):543-4. GrantAM , AndersonFH , for the RECORD Trial Group. The Medical Research Council RECORD Trial: an evaluation of calcium and/or vitamin D in the secondary prevention of osteoporotic fractures. Osteoporosis International2004;15(Suppl 2):S13. GrantAM , AndersonFH . The RECORD trial: an evaluation of calcium and/or vitamin D in the secondary prevention of osteoporotic fractures. Osteoporosis International2005;16(Suppl 3):S4-5. GrantAM , AvenellA , CampbellMK , McDonaldAM , MacLennanGS , McPhersonGC , et al. Oral vitamin D3 and calcium for secondary prevention of low-trauma fractures in elderly people (Randomised Evaluation of Calcium Or vitamin D, RECORD): a randomised placebo-controlled trial [comment in: Lancet 2005;366(9485):543]. Lancet2005;365(9471):1621-8. GrantAM . Personal communication 11 March 2004. ">RECORD 2005</a>; <a href="./references#CD000227-bbs2-0046" title="AndersonFH , SmithHE , RaphaelHM , CooperC . Intramuscular vitamin D increased serum 1,25-dihydroxycholecalciferol but did not affect 25-hydroxy-cholecalciferol levels in health older adults [abstract]. Journal of Bone and Mineral Research2000;15(Suppl 1):S315. AndersonFH , SmithHE , RaphaelHM , CrozierSR , CooperC . Effect of annual intramuscular vitamin D3 supplementation on fracture risk in 9440 community-living older people: the Wessex fracture prevention trial [abstract]. Journal of Bone and Mineral Research2004;19(Suppl 1):S57. ArdenNK , CrozierS , SmithH , AndersonF , EdwardsC , RaphaelH , et al. Knee pain, knee osteoarthritis, and the risk of fracture. Arthritis and Rheumatism2006;55(4):610-5. CooperC , CrozierS . Personal communication 23 February 2005. RaphaelH , SmithH , AndersonF , CooperC . Tackling the problems of trial management in primary care - experience from the Wessex research network fracture prevention study of annual vitamin D injection in older people [abstract]. Osteoporosis International2000;11(Suppl 1):S63-4. SmithH , AndersonF , RaphaelH , CooperC . The Wessex research network fracture prevention study - a large pragmatic trial of annual vitamin D injection in older people [abstract]. Osteoporosis International2000;11(Suppl 1):S64. SmithH , AndersonF , RaphaelH , CrozierS , CooperC . Effect of annual intramuscular vitamin D supplementation on fracture risk: population-based, randomised, double-blind, placebo-controlled trial [abstract]. Osteoporosis International2004;15(Suppl 1):S8. SmithH , AndersonF , RaphaelH , MaslinP , CrozierS , CooperC . Effect of annual intramuscular vitamin D on fracture risk in elderly men and women--a population-based, randomized, double-blind, placebo-controlled trial. Rheumatology2007;46(12):1852-7. ">Smith 2007</a>; <a href="./references#CD000227-bbs2-0048" title="TrivediDP , DollR , KhawKT . Effect of four monthly oral vitamin D3 (cholecalciferol) supplementation on fractures and mortality in men and women living in the community: randomised double blind controlled trial. BMJ2003;326:469. ">Trivedi 2003</a>; <a href="./references#CD000227-bbs2-0050" title="SandersK , DuqueG , EbelingP , McCorquodaleT , HerrmannM , Shore-LorentiC , et al. The efficacy of high-does oral vitamin D3 administered once a year: increased fracture risk is associated with 1,25 vitamin D level at 3-months post dose. In: ASBMR Annual Meeting; 2012 Oct 12-15; Minneapolis, Minnesota. http://www.asbmr.org/Meetings/AnnualMeeting/AbstractDetail.aspx?aid=6beb2500-4b8e-472b-8b38-d881cadb80e3. 2012. SandersK , StuartA , WilliamsonE , SimpsonJ , KotowiczM , NicholsonG . The efficacy of high-dose oral vitamin D3 administered once a year: a randomised, double-blind, placebo-controlled trial (Vital D study) for falls and fractures in older women. Osteoporosis International2011;22(Suppl 1):S104-5. SandersKM , DuqueG , McCorquodaleT , StuartAL , WilliamsonEJ , KotowiczMA , et al. Annual high-dose oral vitamin D3: is the increased risk of falls attributable to changes in muscle strength?Osteoporosis International2011;22(Suppl 4):S552. SandersKM , EbelingPR , StuartAL , WilliamsonEJ , KotowiczMA , NicholsonGC . Annual high-dose oral vitamin D3: is increased risk of fractures attributable to changes in bone turnover markers?Osteoporosis International2011;22(Suppl 4):S589. SandersKM , HaylesAL , KotowiczMA , NicholsonGC . Does vitamin D explain the lower fracture rate in rural communities?Bone2007;40(6 Suppl 2):S195. SandersKM , HaylesAL , KotowiczMA , NicholsonGC . The possible role of vitamin D and falls in relation to lower fracture rates in rural communities. Osteoporosis International2007;18(Suppl 1):S120-1. SandersKM , StuartAL , KotowiczMA , NicholsonGC . Annual feedback is an effective tool for a sustained increase in calcium intake among older women. Nutrients2010;2:1018-25. SandersKM , StuartAL , MerrimanEN , ReadML , KotowiczMA , YoungD , et al. Trials and tribulations of recruiting 2,000 older women onto a clinical trial investigating falls and fractures: Vital D study. BMC Medical Research Methodology2009;9:78. SandersKM , StuartAL , NicholsonGC . High-dose oral vitamin D supplementation and risk of falls in older women. JAMA2010;304(8):856-7. SandersKM , StuartAL , WilliamsonEJ , JackaFN , DoddS , NicholsonG , et al. Annual high-dose vitamin D3 and mental well-being: randomised controlled trial. British Journal of Psychiatry2011;198:357-64. SandersKM , StuartAL , WilliamsonEJ , SimpsonJA , KotowiczMA , NicholsonGC . Annual high-dose oral vitamin D for falls and fractures in elderly women: a randomised, double-blind, placebo-controlled trial (Vital D study). Osteoporosis International2010;21(Suppl 1):S30. SandersKM , StuartAL , WilliamsonEJ , SimpsonJA , KotowiczMA , YoungD , et al. Annual high-dose oral vitamin D and falls and fractures in older women. A randomized controlled trial. JAMA2010;303(18):1815-22. Sanders KM et al. Incorrect data. JAMA2010;303(23):2357. ">Vital D</a>; <a href="./references#CD000227-bbs2-0051" title="CauleyJ , Wactawski-WendeJ , RobbinsJ , RodaboughR , ChenZ , JohnsonK , et al. The Women's Health Initiative (WHI) calcium and vitamin D supplementation trial: health outcomes 5 years after trial completion. ASBMR Annual Meeting; 2012 Oct 12-15; Minneapolis, Minnesota. http://www.asbmr.org/Meetings/AnnualMeeting/AbstractDetail.aspx?aid=6450bf3e-c670-4dc0-814c-8842e23cd80e (accessed 27 December 2012). CauleyJA , LaCroixA , WuL , LeeJ , HorowitzM , BauerD , et al. Serum 25 hydroxy vitamin D 25(OH) and the risk of hip fracture: the Women's Health Initiative (WHI). Journal of Bone and Mineral Research2007;22(Suppl 1):S57. ChenZ , BeckTJ , WrightNC , LaCroixAZ , CauleyJA , LewisCE , et al. The effect of calcium plus vitamin D supplement on hip geometric structures: results from the Women's Health Initiative CaD trial. Journal of Bone and Mineral Research2007;22(Suppl 1):S59. JacksonRD , LaCroixAZ , CauleyJA , McGowanJ . The Women's Health Initiative Calcium-Vitamin D Trial: overview and baseline characteristics of participants. Annals of Epidemiology2003;13:S98-106. JacksonRD , LaCroixAZ , GassM , WallaceRB , RobbinsJ , LewisCE , et al. Calcium plus vitamin D supplementation and the risk of fractures [erratum appears in New England Journal of Medicine 9 March 2006;354(10):1102]. New England Journal of Medicine2006;354(7):669-83. JacksonRD , WrightNC , BeckTJ , SherrillD , CauleyJA , LewisCE , et al. Calcium plus vitamin D supplementation has limited effects on femoral geometric strength in older postmenopausal women: the Women's Health Initiative. Calcified Tissue International2011;88:198-208. McGowanJA , JacksonRD , CauleyJA , LaCroixAZ . Calcium and vitamin D in the prevention of hip and other fractures: an update on the Women's Health Initiative CaD Trial. Journal of Bone and Mineral Research2002;17(Suppl 1):S477. The Women's Health Initiative Study Group. Design of the Women's Health Initiative clinical trial and observational study. Controlled Clinical Trials1998;19(1):61-109. ">WHI 2006</a>). </p> <div class="table" id="CD000227-tbl-0004"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Characteristics of studies in comparisons 1 to 4</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Comparison 1: Vitamin D [D2, D3 or 25(OH)D] versus control or placebo</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Trial name in decreasing order of size</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Number recruited</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Setting</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Previous fracture Y/N</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Male or female?</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Mean/median age</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD000227-bbs2-0046" title="AndersonFH , SmithHE , RaphaelHM , CooperC . Intramuscular vitamin D increased serum 1,25-dihydroxycholecalciferol but did not affect 25-hydroxy-cholecalciferol levels in health older adults [abstract]. Journal of Bone and Mineral Research2000;15(Suppl 1):S315. AndersonFH , SmithHE , RaphaelHM , CrozierSR , CooperC . Effect of annual intramuscular vitamin D3 supplementation on fracture risk in 9440 community-living older people: the Wessex fracture prevention trial [abstract]. Journal of Bone and Mineral Research2004;19(Suppl 1):S57. ArdenNK , CrozierS , SmithH , AndersonF , EdwardsC , RaphaelH , et al. Knee pain, knee osteoarthritis, and the risk of fracture. Arthritis and Rheumatism2006;55(4):610-5. CooperC , CrozierS . Personal communication 23 February 2005. RaphaelH , SmithH , AndersonF , CooperC . Tackling the problems of trial management in primary care - experience from the Wessex research network fracture prevention study of annual vitamin D injection in older people [abstract]. Osteoporosis International2000;11(Suppl 1):S63-4. SmithH , AndersonF , RaphaelH , CooperC . The Wessex research network fracture prevention study - a large pragmatic trial of annual vitamin D injection in older people [abstract]. Osteoporosis International2000;11(Suppl 1):S64. SmithH , AndersonF , RaphaelH , CrozierS , CooperC . Effect of annual intramuscular vitamin D supplementation on fracture risk: population-based, randomised, double-blind, placebo-controlled trial [abstract]. Osteoporosis International2004;15(Suppl 1):S8. SmithH , AndersonF , RaphaelH , MaslinP , CrozierS , CooperC . Effect of annual intramuscular vitamin D on fracture risk in elderly men and women--a population-based, randomized, double-blind, placebo-controlled trial. Rheumatology2007;46(12):1852-7. ">Smith 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9440</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Multicentre general practice study in 111 sites, UK</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N</p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Both (4354 women, 5086 men)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>79</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000227-bbs2-0044" title="AndersonFH , GrantAM , AvenellA , CampbellMK , CooperC , DonaldsonC , et al. The RECORD Trial: an evaluation of calcium and/or vitamin D in the secondary prevention of osteoporotic fractures. Bone2005;36(Suppl 2):S122-3. FrancisRM , Grant AM and the RECORD trial group. The RECORD trial: a randomised double-blind study of calcium and/or vitamin D in the secondary prevention of low trauma fractures. Age Ageing2005;34(Suppl 2):ii15. GrantA , on behalf of the RECORD Trial Group. Prevention of low-trauma fractures in older people [author reply]. Lancet2005;366(9485):543-4. GrantAM , AndersonFH , for the RECORD Trial Group. The Medical Research Council RECORD Trial: an evaluation of calcium and/or vitamin D in the secondary prevention of osteoporotic fractures. Osteoporosis International2004;15(Suppl 2):S13. GrantAM , AndersonFH . The RECORD trial: an evaluation of calcium and/or vitamin D in the secondary prevention of osteoporotic fractures. Osteoporosis International2005;16(Suppl 3):S4-5. GrantAM , AvenellA , CampbellMK , McDonaldAM , MacLennanGS , McPhersonGC , et al. Oral vitamin D3 and calcium for secondary prevention of low-trauma fractures in elderly people (Randomised Evaluation of Calcium Or vitamin D, RECORD): a randomised placebo-controlled trial [comment in: Lancet 2005;366(9485):543]. Lancet2005;365(9471):1621-8. GrantAM . Personal communication 11 March 2004. ">RECORD 2005</a> </p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5292</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Community‐based study, UK</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p>Both (4481 women, 811 men)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>77</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD000227-bbs2-0028" title="LawM , MorrisJ , WithersH . Cholecalciferol, not ergocalciferol, should be used for vitamin D supplementation [author reply]. Age and Ageing2006;35(6):645. [MEDLINE: 16982666]LawM , MorrisJ , WithersH . Vitamin D supplementation and the prevention of fractures and falls. Reply. Age and Ageing2007;36(2):233. LawM , MorrisJ , WithersH . Vitamin D supplementation and the prevention of fractures and falls [author reply]. Age and Ageing2007;36(2):233. [MEDLINE: 17255084]LawM , WithersH , MorrisJ , AndersonF . Vitamin D supplementation and the prevention of fractures and falls: results of a randomised trial in elderly people in residential accommodation [comment in: Age and Ageing 2006;35(6):645 and Age and Ageing 2007;36(2):232-3]. Age and Ageing2006;35(5):482-6. ">Law 2006</a> </p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3717</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Clusters of participants in 30 bedded units in care homes or entire care home if small, UK </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N</p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Both (2825 women, 892 men)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>85</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD000227-bbs2-0030" title="JohansenA , LyonsRA , StoneM , BrophyS , NewcombeRG , PhillipsCJ , et al. Preventing fractures among older people living in institutional care: a randomised double blind placebo controlled trial of vitamin D supplementation [abstract]. Age and Ageing2006;35(Suppl 3):i41. LyonsRA , JohansenA , BrophyS , NewcombeRG , PhillipsCJ , LervyB , et al. Preventing fractures among older people living in institutional care: a pragmatic randomised double blind placebo controlled trial of vitamin D supplementation. Osteoporosis International2007;18(6):811-8. LyonsRA , JohansenA , StoneMD , BrophyS , NewcombeRG , PhilipsCJ , et al. Preventing fractures among older people living in institutional care: a randomised double blind placebo controlled trial of vitamin D supplementation [abstract]. Osteoporosis International2006;17(Suppl 3):372. ">Lyons 2007</a> </p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3440</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Residential homes (38%), nursing or dual‐registered home (55%), sheltered accommodation (7%), Wales </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N</p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Both (2624 women, 816 men)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>84</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD000227-bbs2-0048" title="TrivediDP , DollR , KhawKT . Effect of four monthly oral vitamin D3 (cholecalciferol) supplementation on fractures and mortality in men and women living in the community: randomised double blind controlled trial. BMJ2003;326:469. ">Trivedi 2003</a> </p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2686</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Community‐based study, UK</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N</p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Both (2037 men and 649 women)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>75</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD000227-bbs2-0029" title="GraafmansWC , OomsME , HofsteeHMA , BezemerPD , BouterLM , LipsP . Falls in the elderly: a prospective study of risk factors and risk profiles. American Journal of Epidemiology1996;143(11):1129-36. LipsP , GraafmansWC , OomsME , BezemerPD , BouterLM . The effect of vitamin D supplementation on the incidence of hip fractures in elderly people. Journal of Bone and Mineral Research1994;9 Suppl 1:S148. LipsP , GraafmansWC , OomsME , BezemerPD , BouterLM . Vitamin D supplementation and fracture incidence in elderly persons. Annals of Internal Medicine1996;124:400-6. [MEDLINE: 1996151943]">Lips 1996</a> </p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2578</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Community‐based study, The Netherlands</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N</p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Both (1916 women and 662 men)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>80</p> <p> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD000227-bbs2-0050" title="SandersK , DuqueG , EbelingP , McCorquodaleT , HerrmannM , Shore-LorentiC , et al. The efficacy of high-does oral vitamin D3 administered once a year: increased fracture risk is associated with 1,25 vitamin D level at 3-months post dose. In: ASBMR Annual Meeting; 2012 Oct 12-15; Minneapolis, Minnesota. http://www.asbmr.org/Meetings/AnnualMeeting/AbstractDetail.aspx?aid=6beb2500-4b8e-472b-8b38-d881cadb80e3. 2012. SandersK , StuartA , WilliamsonE , SimpsonJ , KotowiczM , NicholsonG . The efficacy of high-dose oral vitamin D3 administered once a year: a randomised, double-blind, placebo-controlled trial (Vital D study) for falls and fractures in older women. Osteoporosis International2011;22(Suppl 1):S104-5. SandersKM , DuqueG , McCorquodaleT , StuartAL , WilliamsonEJ , KotowiczMA , et al. Annual high-dose oral vitamin D3: is the increased risk of falls attributable to changes in muscle strength?Osteoporosis International2011;22(Suppl 4):S552. SandersKM , EbelingPR , StuartAL , WilliamsonEJ , KotowiczMA , NicholsonGC . Annual high-dose oral vitamin D3: is increased risk of fractures attributable to changes in bone turnover markers?Osteoporosis International2011;22(Suppl 4):S589. SandersKM , HaylesAL , KotowiczMA , NicholsonGC . Does vitamin D explain the lower fracture rate in rural communities?Bone2007;40(6 Suppl 2):S195. SandersKM , HaylesAL , KotowiczMA , NicholsonGC . The possible role of vitamin D and falls in relation to lower fracture rates in rural communities. Osteoporosis International2007;18(Suppl 1):S120-1. SandersKM , StuartAL , KotowiczMA , NicholsonGC . Annual feedback is an effective tool for a sustained increase in calcium intake among older women. Nutrients2010;2:1018-25. SandersKM , StuartAL , MerrimanEN , ReadML , KotowiczMA , YoungD , et al. Trials and tribulations of recruiting 2,000 older women onto a clinical trial investigating falls and fractures: Vital D study. BMC Medical Research Methodology2009;9:78. SandersKM , StuartAL , NicholsonGC . High-dose oral vitamin D supplementation and risk of falls in older women. JAMA2010;304(8):856-7. SandersKM , StuartAL , WilliamsonEJ , JackaFN , DoddS , NicholsonG , et al. Annual high-dose vitamin D3 and mental well-being: randomised controlled trial. British Journal of Psychiatry2011;198:357-64. SandersKM , StuartAL , WilliamsonEJ , SimpsonJA , KotowiczMA , NicholsonGC . Annual high-dose oral vitamin D for falls and fractures in elderly women: a randomised, double-blind, placebo-controlled trial (Vital D study). Osteoporosis International2010;21(Suppl 1):S30. SandersKM , StuartAL , WilliamsonEJ , SimpsonJA , KotowiczMA , YoungD , et al. Annual high-dose oral vitamin D and falls and fractures in older women. A randomized controlled trial. JAMA2010;303(18):1815-22. Sanders KM et al. Incorrect data. JAMA2010;303(23):2357. ">Vital D</a> </p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2258</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Community‐dwelling women in southern Victoria, Australia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Some</p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Women only</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>76</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD000227-bbs2-0032" title="MeyerHE , FalchJA , KvaavikE , SmedshaugGB , TverdalA , PedersenJI . Can vitamin D supplementation reduce the risk of fracture in the elderly? A randomised controlled trial. Osteoporosis International2000;11(Suppl 2):S114-5. MeyerHE , SmedshaugGB , KvaavikE , FalchJA , TverdalA , PedersenJI . Can vitamin D supplementation reduce the risk of fracture in the elderly? A randomized controlled trial. Journal of Bone and Mineral Research2002;17(4):709-15. SmedshaugGB , PedersenJI , MeyerHE . Can vitamin D supplementation improve grip strength in elderly nursing home residents? A double-blinded controlled trial. Scandinavian Journal of Food and Nutrition2007;51(2):74-8. ">Meyer 2002</a> </p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1144</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Nursing homes, Norway</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N</p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Both (868 women, 276 men)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>85</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD000227-bbs2-0020" title="GlendenningP , ZhuK , InderjeethC , HowatP , LewisJR , PrinceRL . Effects of three-monthly oral 150,000 IU cholecalciferol supplementation on falls, mobility, and muscle strength in older postmenopausal women: a randomized controlled trial. Journal of Bone and Mineral Research2012;27(1):170-6. ">Glendenning 2012</a> </p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>686</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Community living (from general practice or electoral role), Perth, Australia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N</p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Women only</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>77</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD000227-bbs2-0039" title="PeacockM , LiuG , CareyM , McClintockR , AmbrosiusW , HuiS , et al. Effect of calcium or 25OH vitamin D3 dietary supplementation on bone loss at the hip in men and women over the age of 60. Journal of Clinical Endocrinology and Metabolism2000;85:3011-9. ">Peacock 2000</a> </p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>438</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Community study, USA</p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N</p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Both (316 women, 122 men)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean age women 74 years, men 76 years</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD000227-bbs2-0053" title="WithamM . Can high-dose vitamin D supplementation reduce blood pressure and markers of cardiovascular risk in older people with isolated systolic hypertension? A randomised, double-blind, parallel group placebo controlled trial. http://www.controlled-trials.com/ISRCTN92186858/ (accessed 3 December 2013). WithamMD , PriceRJ , StruthersAD , DonnanPT , MessowM , FordI , et al. Vitamin D supplementation to reduce blood pressure in older patients with isolated systolic hypertension (VitDISH) - a randomised controlled trial. Personal communication ahead of publication 15 January 2013. ">Witham 2013</a> </p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>159</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Participants recruited from primary care, secondary care and the press, Scotland, UK </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N</p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Both (82 men, 77 women)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>77</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD000227-bbs2-0022" title="HarwoodRH , SahotaO , GaynorK , MasudT , HoskingD . A randomised, controlled comparison of different calcium and vitamin D supplementation regimens in elderly women after hip fracture: The Nottingham Neck of Femur (NoNOF) Study. Age and Ageing2004;33:45-51. [14695863]HarwoodRW . Personal communication 24 January 2003. SahotaO , HarwoodRH , GaynorK , MasudT , HoskingDJ . A randomised, controlled comparison of different calcium and vitamin D regimes: the NoNOF (Nottingham Neck of Femur) study. Osteoporosis International2003;14(Suppl 4):S10-11. ">Harwood 2004</a> </p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>150</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Community‐based study, UK</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Women only</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>81</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD000227-bbs2-0003" title="AvenellA , GrantAM , McGeeM , McPhersonG , CampbellMK , McGee MA for the RECORD Trial Management Group. The effects of an open design on trial participant recruitment, compliance and retention - a randomized controlled trial comparison with a blinded, placebo-controlled design. Clinical Trials Journal2004;1:490-8. AvenellA . Personal communication2005. ">Avenell 2004</a> </p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>134</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Community‐based study, UK</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Both (111 women, 23 men)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>78</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD000227-bbs2-0052" title="WithamMD , CrightonLJ , GillespieND , StruthersAD , McMurdoME . The effects of vitamin D supplementation on physical function and quality of life in older patients with heart failure. A randomized controlled trial. Circulation: Heart Failure2010;3:195-201. ">Witham 2010</a> </p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>105</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Participants recruited from primary and secondary care, Scotland, UK</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N</p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Both (69 men, 36 women)</p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>80</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD000227-bbs2-0033" title="MitriJ , Dawson-HughesB , HuFB , PittasAG . Effects of vitamin D and calcium supplementation on pancreatic β cell function, insulin sensitivity, and glycemia in adults at high risk of diabetes: the Calcium and Vitamin D for Diabetes Mellitus (CaDDM) randomized controlled trial. American Journal of Clinical Nutrition2011;94:486-94. ">Mitri 2011</a> </p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>92</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Community recruitment, Boston, USA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N</p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Both (47 women, 45 men)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>57</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Comparison 2: Vitamin D [D2, D3 or 25(OH)D] and calcium versus calcium</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Trial name in decreasing order of size</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Number recruited</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Setting</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Previous fracture Y/N</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Male or female?</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Mean/median age</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD000227-bbs2-0018" title="Garay LilloJ , ParrenoJ , GonzálezY , GonzálezJA . Geminis: a prospective, multicentric, randomised study to evaluate the effect of tricalcium phosphate versus tricalcium phosphate plus 25(OH) Vitamin D on the risk of fractures in older women [Géminis: Estudio prospectivo, multicéntrico y aleatori para valorar el efecto del Fosfato Tricálcico versus Fosfato Tricálcico + 25(OH) Vitamina D sobre el riesgo de fracturas en mujerioes ancianas.]. Geriátrika1997;13(6):24-8. ">Garay Lillo 1997</a> </p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6945</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Community‐based study, Spain</p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>N</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Women only</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not available</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD000227-bbs2-0044" title="AndersonFH , GrantAM , AvenellA , CampbellMK , CooperC , DonaldsonC , et al. The RECORD Trial: an evaluation of calcium and/or vitamin D in the secondary prevention of osteoporotic fractures. Bone2005;36(Suppl 2):S122-3. FrancisRM , Grant AM and the RECORD trial group. The RECORD trial: a randomised double-blind study of calcium and/or vitamin D in the secondary prevention of low trauma fractures. Age Ageing2005;34(Suppl 2):ii15. GrantA , on behalf of the RECORD Trial Group. Prevention of low-trauma fractures in older people [author reply]. Lancet2005;366(9485):543-4. GrantAM , AndersonFH , for the RECORD Trial Group. The Medical Research Council RECORD Trial: an evaluation of calcium and/or vitamin D in the secondary prevention of osteoporotic fractures. Osteoporosis International2004;15(Suppl 2):S13. GrantAM , AndersonFH . The RECORD trial: an evaluation of calcium and/or vitamin D in the secondary prevention of osteoporotic fractures. Osteoporosis International2005;16(Suppl 3):S4-5. GrantAM , AvenellA , CampbellMK , McDonaldAM , MacLennanGS , McPhersonGC , et al. Oral vitamin D3 and calcium for secondary prevention of low-trauma fractures in elderly people (Randomised Evaluation of Calcium Or vitamin D, RECORD): a randomised placebo-controlled trial [comment in: Lancet 2005;366(9485):543]. Lancet2005;365(9471):1621-8. GrantAM . Personal communication 11 March 2004. ">RECORD 2005</a> </p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5292</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Community‐based study, UK</p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Both (4481 women, 811 men)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>77</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD000227-bbs2-0014" title="FlickerL , MacInnisR , SteinM , SchererS , MeadK , NowsonC , et al. Should all older people in residential care receive vitamin D to prevent falls? Results of a randomised trial [abstract]. Journal of Bone and Mineral Research2004;19(Suppl 1):S99. FlickerL , MacInnisRJ , SteinMS , SchererSC , MeadKE , et al. Response letter to Dr. Gau et al. Journal of the American Geriatrics Society2006;54:1021-2. FlickerL , MacInnisRJ , SteinMS , SchererSC , MeadKE , NowsonCA , et al. Erratum. Journal of the American Geriatrics Society2012;60:1599. FlickerL , MacInnisRJ , SteinMS , SchererSC , MeadKE , NowsonCA , et al. Should older people in residential care receive vitamin D to prevent falls? Results of a randomized trial. Journal of the American Geriatrics Society2005;53(11):1881-8. FlickerL , MacInnisRJ , SteinMS , SchererSC , MeadKE , NowsonCA . Should all older people in residential care receive vitamin D to prevent falls? Results of a randomised trial. Journal of Bone and Mineral Research2004;19(Suppl 1):S99. FlickerL . Personal communication 7 January 2008. ">Flicker 2005</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>693</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>60 assisted living facilities and 89 nursing homes, Australia</p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>N</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Both (594 women, 31 men)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>83</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD000227-bbs2-0043" title="PrinceRL , AustinN , DevineA , DickIM , BruceD , ZhuK . Effects of ergocalciferol added to calcium on the risk of falls in elderly high-risk women. Archives of Internal Medicine2008;168(1):103-8. ZhuK , BruceD , AustinN , DevineA , EbelingPR , PrinceRL . Randomized controlled trial of the effects of calcium with or without vitamin D on bone structure and bone-related chemistry in elderly women with vitamin D insufficiency. Journal of Bone and Mineral Research2008;23(8):1343-8. ZhuK , DevineA , DickIM , WilsonSG , PrinceRL . Effects of calcium and vitamin D supplementation on hip bone mineral density and calcium-related analytes in elderly ambulatory Australian women: a five-year randomized controlled trial. Journal of Clinical Endocrinology and Metabolism2008;93(3):743-9. ">Prince 2008</a> </p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>302</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Community‐based study, Australia</p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>N</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Women only</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>77</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD000227-bbs2-0041" title="BollandMJ , GreyA . Different outcomes of meta-analyses and data inconsistency:response to comments by Pfeifer. Archives of Osteoporosis2015;10:43. BollandMJ , GreyA . Inconsistent data in text and tables. Osteoporosis International2015;26:2713. MinneHW , DobnigH , PfeiferM , SuppanK . Effects of vitamin D and calcium supplementation on falls and parameters of muscle function: a prospective, randomized, double-blind multicenter study [abstract]. Osteoporosis International2006;17(Suppl 2):S212. MinneHW , DobnigH , PfeiferM , SuppanK . Effects of vitamin D and calcium supplementation on falls and parameters of muscle-function - a prospective, randomized, double-blind multi-center study [abstract]. Osteoporosis International2006;17(Suppl 1):S21. PfeiferM , BegerowB , MinneHW , SuppanK , Fahrleitner-PammerA , DobnigH . Effects of a long-term vitamin D and calcium supplementation on falls and parameters of muscle function in community-dwelling older individuals. Osteoporosis International2009;20:315-22. PfeiferM , DobnigH , BegerowB , SuppanK . Effects of vitamin D and calcium supplementation on falls and parameters of muscle function: a prospective randomized, double-blind multi-centre study [abstract]. Journal of Bone and Mineral Research2004;19(Suppl 1):S58. PfeiferM , DobnigH , MinneHW , SuppanK . Effects of vitamin D and calcium supplementation on falls and parameters of muscle function - a prospective, randomized, double-blind multi-center study [abstract]. Osteoporosis International2005;16(Suppl 3):S45. PfeiferM . Different outcomes of meta-analyses and data inconsistency. Osteoporosis International2015;26:2715–2716. PfeiferM . Randomized controlled clinical trials and meta-analyses. Archives of Osteoporosis2015;10:42. ">Pfeifer 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>242</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Community‐based study, Austria and Germany</p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>N</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Both (181 women, 61 men)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>77</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD000227-bbs2-0006" title="BurleighE , McCollJ , PotterJ . Does vitamin D stop inpatients falling? A randomised controlled trial. Age and Ageing2007;36(5):507-13. ">Burleigh 2007</a> </p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>205</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Acute geriatric unit, Glasgow, Scotland, UK</p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>N</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Both (121 women, 84 men)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>83</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD000227-bbs2-0027" title="KomulainenM , KrogerH , TuppurainenMT , HeikkinenAM , AlhavaE , HonkanenR , et al. Prevention of femoral and lumbar bone loss with hormone replacement therapy and Vitamin D3 in early postmenopausal women: a population based 5-year randomized trial. Journal of Clinical Endocrinology and Metabolism1999;84(2):546-52. KomulainenM , KrogerH , TuppurainenMT , Keikkinen A-M, HonkanenR , SaarikoskiS , et al. Identification of early postmenopausal women with no bone response to HRT: results of a five-year clinical trial. Osteoporosis International2000;11:211-8. KomulainenMH , KrogerH , TuppurainenMT , Heikkinen A-M, AlhavaE , HonkanenR , et al. HRT and Vit D in prevention of non-vertebral fractures in postmenopausal women; a 5 year randomized trial. Maturitas1998;31(1):45-54. KomulainenMH . Personal communication 11 November 2004. ">Komulainen 1998</a> </p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>232</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Community‐based study, Finland</p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>N</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Women only</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>53</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD000227-bbs2-0040" title="MinneHW , PfeiferM , BegerowB , NachtigallD , HansenC . Vitamin D and calcium supplementation reduces falls in elderly women via improvement of body sway and normalisation of blood pressure; a prospective, randomized, and double-blind study. Osteoporosis International2000;11(Suppl 2):S115. PfeiferM , BegerowB , MinneHW , AbramsC , NachtigallD , HansenC . Effects of a short-term vitamin D and calcium supplementation on body sway and secondary hyperparathyroidism in elderly women. Journal of Bone and Mineral Research2000;15(6):1113-8. PfeiferM , BegerowB , NachtigallD , HansenC . Prevention of falls-related fractures: vitamin D reduces body sway in the elderly - a prospective, randomized, double blind study [abstract]. Bone1998;23(5 Suppl 1):1110. ">Pfeifer 2000</a> </p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>148</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Osteology clinic, Germany</p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>N</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Women only</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>75</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD000227-bbs2-0003" title="AvenellA , GrantAM , McGeeM , McPhersonG , CampbellMK , McGee MA for the RECORD Trial Management Group. The effects of an open design on trial participant recruitment, compliance and retention - a randomized controlled trial comparison with a blinded, placebo-controlled design. Clinical Trials Journal2004;1:490-8. AvenellA . Personal communication2005. ">Avenell 2004</a> </p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>134</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Community‐based study, UK</p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Both (111 women, 23 men)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>78</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD000227-bbs2-0004" title="Bischoff-FerrariHA , ConzelmannM , StahelinHB , DickW , CarpenterMG , AdkinAL , et al. Is fall prevention by vitamin D mediated by a change in postural or dynamic balance?Osteoporosis International2006;17(5):656-63. BischoffHA , StahelinHB , DickW , AkosR , KnechtM , SalisC , et al. Effects of vitamin D and calcium supplementation on falls: a randomized controlled trial. Journal of Bone and Mineral Research2003;18(2):343-51. [MEDLINE: 12568412]BischoffHA . Personal communication 13 July 2003. BischoffHA . Vitamin D deficiency in the elderly. Journal of Bone and Mineral Research2003;18(7):1343. [MEDLINE: 12854846]HeaneyR . Vitamin D depletion and effective calcium absorption. Journal of Bone and Mineral Research2003;18(7):1342. ">Bischoff 2003</a> </p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>122</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Two long‐stay geriatric care units, Switzerland</p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>N</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Women only</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>85</p> <p> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD000227-bbs2-0026" title="JanssenHC , SamsonMM , VerhaarHJ . Muscle strength and mobility in vitamin D-insufficient female geriatric patients: a randomized controlled trial on vitamin D and calcium supplementation. Aging Clinical and Experimental Research2010;22(1):78-84. ">Janssen 2010</a> </p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>70</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Outpatient clinic of the Department of Geriatric Medicine at the University Medical Centre, Utrecht, The Netherlands </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>N</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Women only</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>81</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Comparison 3: Vitamin D [D2, D3 or 25(OH)D] versus calcium</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Trial name in decreasing order of size</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Number recruited</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Setting</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Previous fracture Y/N</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Male or female?</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Mean/median age</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD000227-bbs2-0044" title="AndersonFH , GrantAM , AvenellA , CampbellMK , CooperC , DonaldsonC , et al. The RECORD Trial: an evaluation of calcium and/or vitamin D in the secondary prevention of osteoporotic fractures. Bone2005;36(Suppl 2):S122-3. FrancisRM , Grant AM and the RECORD trial group. The RECORD trial: a randomised double-blind study of calcium and/or vitamin D in the secondary prevention of low trauma fractures. Age Ageing2005;34(Suppl 2):ii15. GrantA , on behalf of the RECORD Trial Group. Prevention of low-trauma fractures in older people [author reply]. Lancet2005;366(9485):543-4. GrantAM , AndersonFH , for the RECORD Trial Group. The Medical Research Council RECORD Trial: an evaluation of calcium and/or vitamin D in the secondary prevention of osteoporotic fractures. Osteoporosis International2004;15(Suppl 2):S13. GrantAM , AndersonFH . The RECORD trial: an evaluation of calcium and/or vitamin D in the secondary prevention of osteoporotic fractures. Osteoporosis International2005;16(Suppl 3):S4-5. GrantAM , AvenellA , CampbellMK , McDonaldAM , MacLennanGS , McPhersonGC , et al. Oral vitamin D3 and calcium for secondary prevention of low-trauma fractures in elderly people (Randomised Evaluation of Calcium Or vitamin D, RECORD): a randomised placebo-controlled trial [comment in: Lancet 2005;366(9485):543]. Lancet2005;365(9471):1621-8. GrantAM . Personal communication 11 March 2004. ">RECORD 2005</a> </p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5292</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Community‐based study, UK</p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Both (4481 women, 811 men)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>77</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD000227-bbs2-0039" title="PeacockM , LiuG , CareyM , McClintockR , AmbrosiusW , HuiS , et al. Effect of calcium or 25OH vitamin D3 dietary supplementation on bone loss at the hip in men and women over the age of 60. Journal of Clinical Endocrinology and Metabolism2000;85:3011-9. ">Peacock 2000</a> </p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>438</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Community‐based study, USA</p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>N</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Both (316 women, 122 men)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean age women 74 years, men 76 years</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD000227-bbs2-0003" title="AvenellA , GrantAM , McGeeM , McPhersonG , CampbellMK , McGee MA for the RECORD Trial Management Group. The effects of an open design on trial participant recruitment, compliance and retention - a randomized controlled trial comparison with a blinded, placebo-controlled design. Clinical Trials Journal2004;1:490-8. AvenellA . Personal communication2005. ">Avenell 2004</a> </p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>134</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Community‐based study, UK</p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Both (111 women, 23 men)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>78</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD000227-bbs2-0033" title="MitriJ , Dawson-HughesB , HuFB , PittasAG . Effects of vitamin D and calcium supplementation on pancreatic β cell function, insulin sensitivity, and glycemia in adults at high risk of diabetes: the Calcium and Vitamin D for Diabetes Mellitus (CaDDM) randomized controlled trial. American Journal of Clinical Nutrition2011;94:486-94. ">Mitri 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>92</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Community‐based study, USA</p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>N</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Both (47 women, 45 men)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>57</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Comparison 4: Vitamin D [D2, D3 or 25(OH)D] and calcium versus control or placebo</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Trial name in decreasing order of size</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Number recruited</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Setting</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Previous fracture Y/N</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Male or female?</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Mean/median age</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD000227-bbs2-0051" title="CauleyJ , Wactawski-WendeJ , RobbinsJ , RodaboughR , ChenZ , JohnsonK , et al. The Women's Health Initiative (WHI) calcium and vitamin D supplementation trial: health outcomes 5 years after trial completion. ASBMR Annual Meeting; 2012 Oct 12-15; Minneapolis, Minnesota. http://www.asbmr.org/Meetings/AnnualMeeting/AbstractDetail.aspx?aid=6450bf3e-c670-4dc0-814c-8842e23cd80e (accessed 27 December 2012). CauleyJA , LaCroixA , WuL , LeeJ , HorowitzM , BauerD , et al. Serum 25 hydroxy vitamin D 25(OH) and the risk of hip fracture: the Women's Health Initiative (WHI). Journal of Bone and Mineral Research2007;22(Suppl 1):S57. ChenZ , BeckTJ , WrightNC , LaCroixAZ , CauleyJA , LewisCE , et al. The effect of calcium plus vitamin D supplement on hip geometric structures: results from the Women's Health Initiative CaD trial. Journal of Bone and Mineral Research2007;22(Suppl 1):S59. JacksonRD , LaCroixAZ , CauleyJA , McGowanJ . The Women's Health Initiative Calcium-Vitamin D Trial: overview and baseline characteristics of participants. Annals of Epidemiology2003;13:S98-106. JacksonRD , LaCroixAZ , GassM , WallaceRB , RobbinsJ , LewisCE , et al. Calcium plus vitamin D supplementation and the risk of fractures [erratum appears in New England Journal of Medicine 9 March 2006;354(10):1102]. New England Journal of Medicine2006;354(7):669-83. JacksonRD , WrightNC , BeckTJ , SherrillD , CauleyJA , LewisCE , et al. Calcium plus vitamin D supplementation has limited effects on femoral geometric strength in older postmenopausal women: the Women's Health Initiative. Calcified Tissue International2011;88:198-208. McGowanJA , JacksonRD , CauleyJA , LaCroixAZ . Calcium and vitamin D in the prevention of hip and other fractures: an update on the Women's Health Initiative CaD Trial. Journal of Bone and Mineral Research2002;17(Suppl 1):S477. The Women's Health Initiative Study Group. Design of the Women's Health Initiative clinical trial and observational study. Controlled Clinical Trials1998;19(1):61-109. ">WHI 2006</a> </p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>36,282</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Community based women, USA</p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>N</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Women only</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>62</p> <p> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000227-bbs2-0044" title="AndersonFH , GrantAM , AvenellA , CampbellMK , CooperC , DonaldsonC , et al. The RECORD Trial: an evaluation of calcium and/or vitamin D in the secondary prevention of osteoporotic fractures. Bone2005;36(Suppl 2):S122-3. FrancisRM , Grant AM and the RECORD trial group. The RECORD trial: a randomised double-blind study of calcium and/or vitamin D in the secondary prevention of low trauma fractures. Age Ageing2005;34(Suppl 2):ii15. GrantA , on behalf of the RECORD Trial Group. Prevention of low-trauma fractures in older people [author reply]. Lancet2005;366(9485):543-4. GrantAM , AndersonFH , for the RECORD Trial Group. The Medical Research Council RECORD Trial: an evaluation of calcium and/or vitamin D in the secondary prevention of osteoporotic fractures. Osteoporosis International2004;15(Suppl 2):S13. GrantAM , AndersonFH . The RECORD trial: an evaluation of calcium and/or vitamin D in the secondary prevention of osteoporotic fractures. Osteoporosis International2005;16(Suppl 3):S4-5. GrantAM , AvenellA , CampbellMK , McDonaldAM , MacLennanGS , McPhersonGC , et al. Oral vitamin D3 and calcium for secondary prevention of low-trauma fractures in elderly people (Randomised Evaluation of Calcium Or vitamin D, RECORD): a randomised placebo-controlled trial [comment in: Lancet 2005;366(9485):543]. Lancet2005;365(9471):1621-8. GrantAM . Personal communication 11 March 2004. ">RECORD 2005</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5292</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Community‐based study, UK</p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Both (4481 women, 811 men)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>77</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD000227-bbs2-0037" title="KarkkainenM , TuppurainenM , RikkonenT , SalovaaraK , SirolaJ , HonkanenR , et al. Vitamin-D 800IU/day + calcium 1000mg supplementation decreases the risk of recurrent falling among postmenopausal ambulatory women - a population-based, randomized, 3-year study (OSTPRE-FPS). Osteoporosis International2008;19(Suppl 1):S17-18. KarkkainenM , TuppurainenM , RikkonenT , SalovaaraK , SirolaJ , HonkanenR , et al. Vitamin-D 800IU/day + calcium supplementation decreases the risk of falling among postmenopausal ambulatory women - a population-based, randomized 3-year study (OSTPRE-FPS) [abstract]. Journal of Bone and Mineral Research2007;22(Suppl 1):S131. KarkkainenM , TuppurainenM , SalovaaraK , SandiniL , RikkonenT , SirolaJ , et al. Effect of calcium and vitamin D supplementation on bone mineral density in women aged 65-71 years: a 3-year randomized population-based trial (OSTPRE-FPS). Osteoporosis International2010;21:2047-55. KarkkainenMK , TuppurainenM , SalovaaraM , SandiniL , RikkonenT , SirolaJ , et al. Does daily vitamin D 800 IU and calcium 1000 mg supplementation decrease the risk of falling in ambulatory women aged 65-71 years? A 3-year randomized population-based trial (OSTPRE-FPS). Maturitas2010;65:359-65. KrogerHP , TuppurainenM . OSTPRE-FPS Prevention of Fractures and Falls in Postmenopausal Women With Calcium and Vitamin-D Supplementation - a Randomised Study. http://www.controlled-trials.com/mrct/trial/405493/OSTPRE. SalovaaraK , TuppurainenM , KarkkainenM , RikkonenT , SandiniL , SirolaJ , et al. Effect of vitamin D3 and calcium on fracture risk in 65- to 71-year-old women: a population-based 3-year randomized, controlled trial - the OSTPRE-FPS. Journal of Bone and Mineral Research2010;25(7):1487-95. SalovaaraKT , TuppurainenM , RikkonenT , KarkkainenM , SirolaJ , HonkanenR , et al. Effect of vitamin-D3 and calcium on fracture risk in 65-71 year old women in a 3-year randomized clinical trial - preliminary results from the OSTPRE-Fracture Prevention Study. Calcified Tissue International2008;82:545-6. SalovaaraKT , TuppurainenM , RikkonenT , KarkkainenM , SirolaJ , HonkanenR , et al. Effect of vitamin-D3 and calcium on fracture risk in 65-71 year old women in a 3-year randomized clinical trial - preliminary results of the OSTPRE-Fracture Prevention Study. Journal of Bone and Mineral Research2007;22(Suppl 1):S76. ">OSTPRE‐FPS 2007</a> </p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3195</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Population‐based sample, recruited by post, northern Savonia, Finland</p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>N</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Women only</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>67</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD000227-bbs2-0042" title="DumvilleJC , MilesJN , PorthouseJ , CockayneES , SaxonL , KingC , et al. Can vitamin D supplementation prevent seasonal affective disorder? A randomised trial among older women. Osteoporosis International2004;15:S42-3. PorthouseJ , CockayneS , KingC , SaxonL , SteeleE , AsprayT , et al. Randomised controlled trial of calcium and supplementation with cholecalciferol (vitamin D3) for prevention of fractures in primary care. BMJ2005;330(7498):1003-6. PorthouseJ , CockayneS , KingC , SaxonL , SteeleE , AsprayT , et al. Randomised controlled trial of calcium and vitamin D supplementation for fracture prevention in primary care. Osteoporosis International2004;15(Suppl 2):S13. PorthouseJ , CockayneS , KingC , SaxonL , SteeleE , AsprayT , et al. Randomised controlled trial of calcium and vitamin D supplementation for fracture prevention in primary care. Osteoporosis International2005;16:S27. PufferS . Calcium and vitamin D in primary care: adherence results from a randomised controlled trial [abstract 6.9.3]. In: RCN International Nursing Conference; 2004 Mar 21-31; Cambridge (UK). London: Royal College of Nursing, 2004. S Puffer, on behalf of the Calcium and Vitamin D Trial. Calcium and vitamin D in primary care. Compliance results from a randomised controlled trial. Osteoporosis International2003;14(Suppl 4):S8. TorgersonD , on behalf of the trial group. Calcium and vitamin D in preventing fractures [author reply]. BMJ2005;331(7508):109. TorgersonDJ . Personal communication 9-16 February 2005. ">Porthouse 2005</a> </p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3314</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Multicentre general practice study, UK</p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Some</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Women only</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>77</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD000227-bbs2-0008" title="ChapuyMC , ArlotM , et al. Prevention of non vertebral fractures and cortical bone loss in elderly women: a prospective controlled trial using calcium and vitamin D3 supplements [abstract]. Osteoporosis International1993;3 Suppl 1:258. ChapuyMC , ArlotME , DelmasPD , MeunierPJ . Effect of calcium and cholecalciferol treatment for three years on hip fractures in elderly women. BMJ1994;308:1081-2. ChapuyMC , ArlotME , DuboeufF , BrunJ , CrouzetB , ArnaudS , et al. Vitamin D3 and calcium to prevent hip fractures in elderly women. New England Journal of Medicine1992;327:1637-42. MeunierPJ , PamphileR , ChapuyMC , SchultenJ , ArlotM , LilluH . A calcium-vitamin D3 combined supplementation is cost-saving for preventing hip fractures in institutionalised elderly women: an economic evaluation from the perspective of seven European countries (Belgium, France, Germany, The Netherlands, Spain, Sweden, United Kingdom). Osteoporosis International2002;13(Suppl 1):S14. ">Chapuy 1992</a> </p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3270</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Residents of nursing homes or apartment houses for elderly people, France</p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>N</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Women only</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>84</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD000227-bbs2-0009" title="BosworthC , deBoerIH , TargherG , KendrickJ , SmitsG , ChoncholM . The effect of combined calcium and cholecalciferol supplementation on bone mineral density in elderly women with moderate chronic kidney disease. Clinical Nephrology2012;77(5):358-65. ChapuyMC , PamphileR , ParisE , KempfC , SchlichtingM , ArnaudS , et al. Combined calcium and vitamin D3 supplementation in elderly women: confirmation of reversal of secondary hyperparathyroidism and hip fracture risk: the Decalyos II study. Osteoporosis International2002;13(3):257-64. [MEDLINE: 11991447]ChapuyMC , PamphileR , ParisE , KempfC , SchlichtingM , ArnaudS , et al. Combined calcium and vitamin D3 supplementation to prevent hip fracture in elderly women. A confirmatory study: Decalyos II. Osteoporosis International2002;13(Suppl 1):S25. MeunierPJ . Personal communication 28 February 2005. ">Chapuy 2002</a> </p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>583</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Residents of 55 apartment houses for elderly people, France</p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>N</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Women only</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>85</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD000227-bbs2-0010" title="Bischoff-FerrariHA , OravEJ , Dawson-HughesB . Additive effect of higher testosterone levels and vitamin D plus calcium supplementation in regard to fall risk reduction among older men and women. Osteoporosis International2008;19:1307-14. Bischoff-FerrariHA , OravEJ , Dawson-HughesB . Effect of cholecalciferol plus calcium on falling in ambulatory older men and women: a 3-year randomized controlled trial. Archives of Internal Medicine2006;166(4):424-30. Bischoff-FerrariHA , OravEJ , Dawson-HughesB . Effect of vitamin D3 plus calcium on fall risk in older men and women: a 3-year randomized controlled trial. Journal of Bone and Mineral Research2004;19(Suppl 1):S57. Dawson-HughesB , HarrisSS , KrallEA , DallalGE . Effect of calcium and vitamin D supplementation on bone density in men and women 65 years of age or older. New England Journal of Medicine1997;337(10):670-6. Dawson-HughesB , HarrisSS , KrallEA , DallalGE . Effect of withdrawal of calcium and vitamin D supplements on bone mass in elderly men and women. American Journal of Clinical Nutrition2000;72(3):745-50. Dawson-HughesB , HarrisSS . Calcium intake influences the association of protein intake with rates of bone loss in elderly men and women. American Journal of Clinical Nutrition2002;75(4):773-9. KrallEA , RandallC , HarrisSS , GarciaRI , Dawson-HughesB . Calcium and vitamin D supplements reduce tooth loss in the elderly. Journal of Bone and Mineral Research2000;15(Suppl 1):S191. KrallEA , WehlerC , GarciaRI , HarrisSS , Dawson-HughesB . Calcium and vitamin D supplements reduce tooth loss in the elderly. American Journal of Medicine2001;111(6):452-6. NiramitmahapanyaS , HarrisSS , Dawson-HughesB . Type of dietary fat is associated with the 25-hydroxyvitamin D3 increment in response to vitamin D supplementation. Journal of Clinical Endocrinology and Metabolism2011;96(10):3170-4. ">Dawson‐Hughes 1997</a> </p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>445</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Community‐based study, USA</p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>N</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Both (199 men, 246 women</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>71</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD000227-bbs2-0022" title="HarwoodRH , SahotaO , GaynorK , MasudT , HoskingD . A randomised, controlled comparison of different calcium and vitamin D supplementation regimens in elderly women after hip fracture: The Nottingham Neck of Femur (NoNOF) Study. Age and Ageing2004;33:45-51. [14695863]HarwoodRW . Personal communication 24 January 2003. SahotaO , HarwoodRH , GaynorK , MasudT , HoskingDJ . A randomised, controlled comparison of different calcium and vitamin D regimes: the NoNOF (Nottingham Neck of Femur) study. Osteoporosis International2003;14(Suppl 4):S10-11. ">Harwood 2004</a> </p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>150</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Community‐based study, UK</p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Women only</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>81</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD000227-bbs2-0003" title="AvenellA , GrantAM , McGeeM , McPhersonG , CampbellMK , McGee MA for the RECORD Trial Management Group. The effects of an open design on trial participant recruitment, compliance and retention - a randomized controlled trial comparison with a blinded, placebo-controlled design. Clinical Trials Journal2004;1:490-8. AvenellA . Personal communication2005. ">Avenell 2004</a> </p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>134</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Community‐based study, UK</p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Both (111 women, 23 men)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>78</p> </td> </tr> </tbody> </table> </div> <p><a href="./references#CD000227-bbs2-0003" title="AvenellA , GrantAM , McGeeM , McPhersonG , CampbellMK , McGee MA for the RECORD Trial Management Group. The effects of an open design on trial participant recruitment, compliance and retention - a randomized controlled trial comparison with a blinded, placebo-controlled design. Clinical Trials Journal2004;1:490-8. AvenellA . Personal communication2005. ">Avenell 2004</a> was a small open design study, which was conducted in parallel to <a href="./references#CD000227-bbs2-0044" title="AndersonFH , GrantAM , AvenellA , CampbellMK , CooperC , DonaldsonC , et al. The RECORD Trial: an evaluation of calcium and/or vitamin D in the secondary prevention of osteoporotic fractures. Bone2005;36(Suppl 2):S122-3. FrancisRM , Grant AM and the RECORD trial group. The RECORD trial: a randomised double-blind study of calcium and/or vitamin D in the secondary prevention of low trauma fractures. Age Ageing2005;34(Suppl 2):ii15. GrantA , on behalf of the RECORD Trial Group. Prevention of low-trauma fractures in older people [author reply]. Lancet2005;366(9485):543-4. GrantAM , AndersonFH , for the RECORD Trial Group. The Medical Research Council RECORD Trial: an evaluation of calcium and/or vitamin D in the secondary prevention of osteoporotic fractures. Osteoporosis International2004;15(Suppl 2):S13. GrantAM , AndersonFH . The RECORD trial: an evaluation of calcium and/or vitamin D in the secondary prevention of osteoporotic fractures. Osteoporosis International2005;16(Suppl 3):S4-5. GrantAM , AvenellA , CampbellMK , McDonaldAM , MacLennanGS , McPhersonGC , et al. Oral vitamin D3 and calcium for secondary prevention of low-trauma fractures in elderly people (Randomised Evaluation of Calcium Or vitamin D, RECORD): a randomised placebo-controlled trial [comment in: Lancet 2005;366(9485):543]. Lancet2005;365(9471):1621-8. GrantAM . Personal communication 11 March 2004. ">RECORD 2005</a>. <a href="./references#CD000227-bbs2-0028" title="LawM , MorrisJ , WithersH . Cholecalciferol, not ergocalciferol, should be used for vitamin D supplementation [author reply]. Age and Ageing2006;35(6):645. [MEDLINE: 16982666]LawM , MorrisJ , WithersH . Vitamin D supplementation and the prevention of fractures and falls. Reply. Age and Ageing2007;36(2):233. LawM , MorrisJ , WithersH . Vitamin D supplementation and the prevention of fractures and falls [author reply]. Age and Ageing2007;36(2):233. [MEDLINE: 17255084]LawM , WithersH , MorrisJ , AndersonF . Vitamin D supplementation and the prevention of fractures and falls: results of a randomised trial in elderly people in residential accommodation [comment in: Age and Ageing 2006;35(6):645 and Age and Ageing 2007;36(2):232-3]. Age and Ageing2006;35(5):482-6. ">Law 2006</a> examined three‐monthly vitamin D2 versus no treatment and was the only cluster‐randomised trial; it involved 223 residential units in 118 homes for older people. </p> <p>The 15 trials comparing vitamin D versus placebo or control, ranged in size from 92 to 9440 participants. The 11 trials comparing vitamin D and calcium versus calcium alone, ranged in size from 70 to 6945 participants. Four trials compared vitamin D versus calcium; these ranged in size from 92 to 5292 participants. The nine trials comparing calcium and vitamin D versus placebo or control, ranged in size from 134 to 36,282 participants. </p> </section> <section id="CD000227-sec-0044"> <h5 class="title">Trials with calcitriol or alfacalcidol (1‐alphahydroxyvitamin D3)</h5> <p>In this second group, 22 smaller trials contributed data on calcitriol or alfacalcidol (1‐alphahydroxyvitamin D3). Seven of these trials were set in Japan (<a href="./references#CD000227-bbs2-0021" title="GoraiI , ChakiO , TaguchiY , NakayamaM , OsadaH , SuzukiN , et al. Early postmenopausal bone loss is prevented by estrogen and partially by 1alpha-OH-vitamin D3: therapeutic effects of estrogen and/or 1alpha-OH-vitamin D3. Calcified Tissue International1999;65:16-22. ">Gorai 1999</a>; <a href="./references#CD000227-bbs2-0023" title="HayashiY , FujitaT , InoueT . A multi-center study on efficacy of 1 alpha-hydroxy vitamin D3 in preventing spinal fracture of patients with osteoporosis (abstract). Journal of Bone and Mineral Research1989;4 Suppl 1:Si84. HayashiY , FujitaT , InoueT . Decrease of vertebral fracture in osteoporotics by administration of 1alpha-hydroxy-vitamin D3. Journal of Bone and Mineral Metabolism1992;10(2):50-4. ">Hayashi 1992</a>; <a href="./references#CD000227-bbs2-0025" title="AlpertJS . Concerns about the integrity of Ishida Y, Kawai S. Am J Med. 2004;117:549-555: the reply. American Journal of Medicine2020;133:e315. AvenellA , GreyA , GambleGD , BollandMJ . Concerns about the integrity of the Yamaguchi Osteoporosis Prevention Study (YOPS) report, Am J Med. 2004;117:549-555. American Journal of Medicine2020;133:e311-4. IshidaY , KawaiS . A two-year randomized controlled trial of hormone replacement therapy, etidronate, calcitonin, vitamin D, or vitamin K, in women with postmenopausal osteoporosis. Journal of Bone and Mineral Research2002;17(Suppl 1):S478. IshidaY , KawaiS . Comparative efficacy of hormone replacement therapy, bisphosphonates, calcitonin, vitamin D and vitamin K in postmenopausal women with osteoporosis. Journal of Bone and Mineral Research2003;18(Suppl 2):S158. IshidaY , KawaiS . Comparative efficacy of hormone replacement therapy, etidronate, calcitonin, alfacalcidol, and vitamin K in postmenopausal women with osteoporosis: the Yamaguchi osteoporosis prevention study. American Journal of Medicine2004;117:549-55. IshidaY , KawaiS . Comparative efficacy of hormone replacement therapy, etidronate, calcitonin, vitamin D and vitamin K in postmenopausal osteoporosis. Bone2003;33(5 Suppl1):S220. IshidaY , SohH , OgawaS , KawaharaS , MurataH . A one-year randomized controlled trial of hormone replacement therapy, bisphosphonate, calcitonin, vitamin D, and vitamin K, in women with postmenopausal osteoporosis. Journal of Bone and Mineral Research2000;15(Suppl 1):S310. IshidaY , SohH , TsuchidaS , KawaharaS , MurataH , KawaiS . Effectiveness of hormone replacement therapy, etidronate, calcitonin, vitamin D, and vitamin K in postmenopausal women with osteoporosis [abstract]. Bone2002;30(3 Suppl 1):50S. IshidaY . Personal communication 21 February 2005. ">Ishida 2004 (retracted)</a>; <a href="./references#CD000227-bbs2-0034" title="NakatsukaK , InabaM , ArataniH , IbaK , SatoT , KoikeT , et al. Effects of long-term administration of alfacalcidol on bone mass and bone metabolism in patients with primary osteoporosis - comparison with calcium preparations [Japanese]. Nippon Ronen Igakkai Zasshi - Japanese Journal of Geriatrics1997;34(7):569-76. ">Nakatsuka 1997</a>; <a href="./references#CD000227-bbs2-0036" title="OrimoH , ShirakiM , HayashiY , HoshinoT , OnayaT , MiyazakiS , et al. Effects of 1-alpha-hydroxyvitamin D3 on lumbar bone mineral density and vertebral fractures in patients with postmenopausal osteoporosis. Calcified Tissue International1994;54:370-6. ">Orimo 1994</a>; <a href="./references#CD000227-bbs2-0045" title="ShirakiM , KushidaK , YamazakiK , NagaiT , InoueT , OrimoH . Effects of 2 years' treatment of osteoporosis with 1alpha-hydroxy vitamin D3 on bone mineral density and incidence of fracture: a placebo-controlled, double-blind prospective study. Endocrine Journal1996;43(2):211-20. ">Shiraki 1996</a>; <a href="./references#CD000227-bbs2-0049" title="UshiroyamaT , IkedaA , SakaiM , HigashiyamaT , UekiM . Effects of the combined use of calcitonin and 1alpha-hydroxycholecalciferol on vertebral bone loss and bone turnover in women with postmenopausal osteopenia and osteoporosis: a prospective study of long-term and continuous administration with low dose calcitonin. Maturitas2001;40:229-38. ">Ushiroyama 2001</a>), with the rest being located in Australasia, Europe, Israel and North America. Almost all recruited from referral populations with established osteoporosis or other diseases thought to relate to vitamin D deficiency and were carried out in the setting of outpatient or research clinics. In the majority, osteoporosis had been formally diagnosed, and often the presence of one or more deformed vertebrae on an initial radiograph was required for inclusion in the trial. Most participants underwent bone density measurements, or extensive biochemical analyses of blood and urine, or assessment of musculoskeletal function. Radiological vertebral deformity or changes in bone mineral density were often the principal outcomes, although other fracture data were sometimes available. None of this group of trials had participants with a group mean or median age of 80 years or more. One trial included men only (<a href="./references#CD000227-bbs2-0012" title="EbelingPR , WarkJD , YeungS , PoonC , SalehiN , NicholsonGC , et al. Effects of calcitriol or calcium on bone mineral density, bone turnover, and fractures in men with primary osteoporosis: a two-year randomized, double-blind, double placebo study. Journal of Clinical Endocrinology and Metabolism2001;86(9):4098-103. EbelingPR . Personal communication 15 February 2005. ">Ebeling 2001</a>), and three had men and women (<a href="./references#CD000227-bbs2-0011" title="DukasL , BischoffHA , LindpaintnerLS , SchachtE , Birkner-BinderD , DammTN , et al. Alfacalcidol reduces the number of fallers in a community-dwelling elderly population with a minimum calcium intake of more than 500 mg daily. Journal of the American Geriatrics Society2004;52(2):230-6. DukasL , BischoffHA , LindpaintnerLS , SchachtE , Birkner-BinderD , ThalmanB , et al. Alfacalcidol reduces the number of fallers and falls in community-dwelling elderly provided a minimum total daily intake of 500mg calcium [abstract]. Calcified Tissue International2003;72:371. DukasL , SchachtE , MazorZ , StahelinHB . Treatment with alfacalcidol in elderly people significantly decreases the high risk of falls associated with a low creatinine clearance of &lt;65 ml/min. Osteoporosis International2005;16(2):198-203. DukasL , SchachtE , StahelinHB . A significant independent new risk factor for falls in the elderly: a low creatinine clearance of less than 65ml/min. Osteoporosis International2003;14(Suppl 7):S33. DukasL , SchachtE , StahelinHB . High risk of falls related to low D-hormone syndrome and its treatment with alfacalcidol. Osteoporosis International2004;15(Suppl 1):S8-9. DukasL , SchachtE , StahelinHB . Reduction of falls and fallers in high risk patients by D-hormone analogs. Osteoporosis International2004;15(Suppl 1):S144-5. DukasL , SchachtE , StahelinHB . Treatment with alfacalcidol significantly decreases the high incidence of fallers and the high risk of falls associated with low creatinine clearance (&lt;65ml/min) in elderly community-dwelling men and women. Osteoporosis International2003;14(Suppl 7):S33. DukasL , SchachtE . Reduction of falls and fallers using D-hormone analogs. Osteoporosis International2006;17(Suppl 1):S122-3. DukasLC , SchachtE , MazorZ , StahelinHB . The low creatinine clearance associated high risk of falls can significantly be treated with alfacalcidol. Journal of Bone and Mineral Research2004;19(Suppl 1):S95. DukasLC . Personal communication 19 July 2004. ">Dukas 2004</a>, <a href="./references#CD000227-bbs2-0019" title="GeusensP , DequekerJ . Long-term effect of nandrolone decanoate, 1 alpha-hydroxyvitamin D3 or intermittent calcium infusion therapy on bone mineral content, bone remodeling and fracture rate in symptomatic osteoporosis: a double-blind controlled study. Bone and Mineral1986;1(4):347-57. ">Geusens 1986</a>, <a href="./references#CD000227-bbs2-0023" title="HayashiY , FujitaT , InoueT . A multi-center study on efficacy of 1 alpha-hydroxy vitamin D3 in preventing spinal fracture of patients with osteoporosis (abstract). Journal of Bone and Mineral Research1989;4 Suppl 1:Si84. HayashiY , FujitaT , InoueT . Decrease of vertebral fracture in osteoporotics by administration of 1alpha-hydroxy-vitamin D3. Journal of Bone and Mineral Metabolism1992;10(2):50-4. ">Hayashi 1992</a>); the rest recruited women only. The largest trial had 740 participants (<a href="./references#CD000227-bbs2-0023" title="HayashiY , FujitaT , InoueT . A multi-center study on efficacy of 1 alpha-hydroxy vitamin D3 in preventing spinal fracture of patients with osteoporosis (abstract). Journal of Bone and Mineral Research1989;4 Suppl 1:Si84. HayashiY , FujitaT , InoueT . Decrease of vertebral fracture in osteoporotics by administration of 1alpha-hydroxy-vitamin D3. Journal of Bone and Mineral Metabolism1992;10(2):50-4. ">Hayashi 1992</a>). Only four of these trials had more than 200 participants each (<a href="./references#CD000227-bbs2-0011" title="DukasL , BischoffHA , LindpaintnerLS , SchachtE , Birkner-BinderD , DammTN , et al. Alfacalcidol reduces the number of fallers in a community-dwelling elderly population with a minimum calcium intake of more than 500 mg daily. Journal of the American Geriatrics Society2004;52(2):230-6. DukasL , BischoffHA , LindpaintnerLS , SchachtE , Birkner-BinderD , ThalmanB , et al. Alfacalcidol reduces the number of fallers and falls in community-dwelling elderly provided a minimum total daily intake of 500mg calcium [abstract]. Calcified Tissue International2003;72:371. DukasL , SchachtE , MazorZ , StahelinHB . Treatment with alfacalcidol in elderly people significantly decreases the high risk of falls associated with a low creatinine clearance of &lt;65 ml/min. Osteoporosis International2005;16(2):198-203. DukasL , SchachtE , StahelinHB . A significant independent new risk factor for falls in the elderly: a low creatinine clearance of less than 65ml/min. Osteoporosis International2003;14(Suppl 7):S33. DukasL , SchachtE , StahelinHB . High risk of falls related to low D-hormone syndrome and its treatment with alfacalcidol. Osteoporosis International2004;15(Suppl 1):S8-9. DukasL , SchachtE , StahelinHB . Reduction of falls and fallers in high risk patients by D-hormone analogs. Osteoporosis International2004;15(Suppl 1):S144-5. DukasL , SchachtE , StahelinHB . Treatment with alfacalcidol significantly decreases the high incidence of fallers and the high risk of falls associated with low creatinine clearance (&lt;65ml/min) in elderly community-dwelling men and women. Osteoporosis International2003;14(Suppl 7):S33. DukasL , SchachtE . Reduction of falls and fallers using D-hormone analogs. Osteoporosis International2006;17(Suppl 1):S122-3. DukasLC , SchachtE , MazorZ , StahelinHB . The low creatinine clearance associated high risk of falls can significantly be treated with alfacalcidol. Journal of Bone and Mineral Research2004;19(Suppl 1):S95. DukasLC . Personal communication 19 July 2004. ">Dukas 2004</a>; <a href="./references#CD000227-bbs2-0017" title="GallagherJC , FowlerS . Effect of estrogen, calcitriol and a combination of estrogen and calcitriol on bone mineral density and fractures in elderly women. Journal of Bone and Mineral Research1999;14(Suppl 1):S209. GallagherJC , FowlerSE , DetterJR , ShermanSS . Combination treatment with estrogen and calcitriol in the prevention of age-related bone loss. Journal of Clinical Endocrinology and Metabolism2001;86(8):3618-28. GallagherJC , HaynatskiG , FowlerS . Calcitriol therapy reduces falls and fractures in elderly women. Calcified Tissue International2003;72:334. GallagherJC , HaynatzkiG , FowlerS . Effect of estrogen, calcitriol or the combination of both on falls and non vertebral fractures in elderly women. Journal of Bone and Mineral Research2001;17(Suppl 1):S210. GallagherJC , RapuriPB , HaynatzkiG , DetterJR . Effect of discontinuation of estrogen, calcitriol, and the combination of both on bone density and bone markers. Journal of Clinical Endocrinology and Metabolism2002;87(11):4914-23. [12414850]GallagherJC , RapuriPB , HaynatzkiG . A comparison of estrogen, calcitriol or both therapies on the relationship between serum parathyroid hormone and 25 hydroxy vitamin. Journal of Bone and MIneral Research2004;19(Suppl 1):S440. GallagherJC . Personal communication 21 February 2005. GallagherJC . The effects of calcitriol on falls and fractures and physical performance tests. Journal of Steroid Biochemistry and Molecular Biology2004;89-90(1-5):497-501. ">Gallagher 2001</a>; <a href="./references#CD000227-bbs2-0023" title="HayashiY , FujitaT , InoueT . A multi-center study on efficacy of 1 alpha-hydroxy vitamin D3 in preventing spinal fracture of patients with osteoporosis (abstract). Journal of Bone and Mineral Research1989;4 Suppl 1:Si84. HayashiY , FujitaT , InoueT . Decrease of vertebral fracture in osteoporotics by administration of 1alpha-hydroxy-vitamin D3. Journal of Bone and Mineral Metabolism1992;10(2):50-4. ">Hayashi 1992</a>; <a href="./references#CD000227-bbs2-0047" title="MorrisonNA , GeorgePM , VaughanT , TilyardMW , FramptonCM , GilchristNL . Vitamin D receptor genotypes influence the success of calcitriol therapy for recurrent vertebral fracture in osteoporosis. Pharmacogenetics and Genomics2005;15(2):127-35. TilyardM . Low-dose calcitriol versus calcium in established postmenopausal osteoporosis. Metabolism: Clinical &amp; Experimental1990;39(4 Suppl 1):50-2. TilyardMW , SpearsGF , ThomsonJ , DoveyS . Treatment of postmenopausal osteoporosis with calcitriol or calcium. New England Journal of Medicine1992;326(6):357-62. TilyardMW , SpearsGFS , ThomsonJ , DoveyS . Calcitriol or calcium for postmenopausal osteoporosis. New England Journal of Medicine1992;327:284. TilyardMW . 1,25-dihydroxyvitamin D3 (calcitriol) in the treatment of postmenopausal osteoporosis. Aktuelle Rheumatologie1994;19(Suppl 1):23-6. ">Tilyard 1992</a>). </p> <p><a href="#CD000227-tbl-0005">Table 4</a> gives the baseline 25‐hydroxy vitamin D (25(OH)D, vitamin D with one hydroxyl group added equivalent to liver activation) levels in the intervention and control groups of the included studies, where reported. This is a laboratory measure of vitamin D status. These values have to be interpreted with considerable caution, since they depend on the laboratory and method used (<a href="./references#CD000227-bbs2-0177" title="LipsP , ChapuyMC , Dawson-HughesB , PolsHA , HolickMF . An international comparison of serum 25-hydroxyvitamin D measurements. Osteoporosis International1999;9:394-7.">Lips 1999</a>). </p> <div class="table" id="CD000227-tbl-0005"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 4.</span> <span class="table-title">Baseline 25‐hydroxy vitamin D in intervention and control groups</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Study ID</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>25(OH)D nmol/L</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000227-bbs2-0001" title="AloiaJF , VaswaniA , YehJK , EllisK , YasumuraS , CohnSH . Calcitriol in the treatment of postmenopausal osteoporosis. American Journal of Medicine1988;84(3 Pt 1):401-8. AloiaJF . Role of calcitriol in the treatment of postmenopausal osteoporosis. Metabolism1990;39(4 Suppl 1):35-8. GallagherJC . Personal communication 21 February 1995. ">Aloia 1988</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Intervention 54.8 (SD 17.8); Control 66.5 (SD 29.3)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000227-bbs2-0002" title="ArthurRS , PirainoB , CandibD , CoopersteinL , ChenT , WestC , et al. Effect of low-dose calcitriol and calcium therapy on bone histomorphometry and urinary calcium excretion in osteopenic women. Mineral and Electrolyte Metabolism1990;16(6):385-90. [MEDLINE: 1991211662]">Arthur 1990</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Intervention 30 (SD 7.5); Control 52.5 (SD 22.5)* (Considerable difference between intervention and control) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000227-bbs2-0003" title="AvenellA , GrantAM , McGeeM , McPhersonG , CampbellMK , McGee MA for the RECORD Trial Management Group. The effects of an open design on trial participant recruitment, compliance and retention - a randomized controlled trial comparison with a blinded, placebo-controlled design. Clinical Trials Journal2004;1:490-8. AvenellA . Personal communication2005. ">Avenell 2004</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N/A</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000227-bbs2-0004" title="Bischoff-FerrariHA , ConzelmannM , StahelinHB , DickW , CarpenterMG , AdkinAL , et al. Is fall prevention by vitamin D mediated by a change in postural or dynamic balance?Osteoporosis International2006;17(5):656-63. BischoffHA , StahelinHB , DickW , AkosR , KnechtM , SalisC , et al. Effects of vitamin D and calcium supplementation on falls: a randomized controlled trial. Journal of Bone and Mineral Research2003;18(2):343-51. [MEDLINE: 12568412]BischoffHA . Personal communication 13 July 2003. BischoffHA . Vitamin D deficiency in the elderly. Journal of Bone and Mineral Research2003;18(7):1343. [MEDLINE: 12854846]HeaneyR . Vitamin D depletion and effective calcium absorption. Journal of Bone and Mineral Research2003;18(7):1342. ">Bischoff 2003</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Intervention 30.8 (interquartile range 23‐55); Control 29 (interquartile range 23‐55)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000227-bbs2-0005" title="Bolton-SmithC , McMurdoME , PatersonCR , MolePA , HarveyJM , FentonST , et al. Two-year randomized controlled trial of vitamin K1 (phylloquinone) and vitamin D3 plus calcium on bone health of older women. Journal of Bone and Mineral Research2007;22(4):509-19. McMurdoME . Personal communication 1 October 2007. ">Bolton‐Smith 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Intervention 62.5 (SD 15.5); Control 57 (15.3)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000227-bbs2-0006" title="BurleighE , McCollJ , PotterJ . Does vitamin D stop inpatients falling? A randomised controlled trial. Age and Ageing2007;36(5):507-13. ">Burleigh 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Intervention 21.7 (SD 7.1); Control 24.7 (SD 10.0)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000227-bbs2-0007" title="CaniggiaA , DellingG , NutiR , LoreF , VattimoA . Clinical, biochemical and histological results of a double-blind trial with 1,25-dihydroxyvitamin D3, estradiol and placebo in post-menopausal osteoporosis. Acta Vitaminologica et Enzymologica1984;6(2):117-28. ">Caniggia 1984</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N/A</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000227-bbs2-0008" title="ChapuyMC , ArlotM , et al. Prevention of non vertebral fractures and cortical bone loss in elderly women: a prospective controlled trial using calcium and vitamin D3 supplements [abstract]. Osteoporosis International1993;3 Suppl 1:258. ChapuyMC , ArlotME , DelmasPD , MeunierPJ . Effect of calcium and cholecalciferol treatment for three years on hip fractures in elderly women. BMJ1994;308:1081-2. ChapuyMC , ArlotME , DuboeufF , BrunJ , CrouzetB , ArnaudS , et al. Vitamin D3 and calcium to prevent hip fractures in elderly women. New England Journal of Medicine1992;327:1637-42. MeunierPJ , PamphileR , ChapuyMC , SchultenJ , ArlotM , LilluH . A calcium-vitamin D3 combined supplementation is cost-saving for preventing hip fractures in institutionalised elderly women: an economic evaluation from the perspective of seven European countries (Belgium, France, Germany, The Netherlands, Spain, Sweden, United Kingdom). Osteoporosis International2002;13(Suppl 1):S14. ">Chapuy 1992</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Intervention 40.0 (SD 27.5); Control 32.5 (SD 22.5) subgroups</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000227-bbs2-0009" title="BosworthC , deBoerIH , TargherG , KendrickJ , SmitsG , ChoncholM . The effect of combined calcium and cholecalciferol supplementation on bone mineral density in elderly women with moderate chronic kidney disease. Clinical Nephrology2012;77(5):358-65. ChapuyMC , PamphileR , ParisE , KempfC , SchlichtingM , ArnaudS , et al. Combined calcium and vitamin D3 supplementation in elderly women: confirmation of reversal of secondary hyperparathyroidism and hip fracture risk: the Decalyos II study. Osteoporosis International2002;13(3):257-64. [MEDLINE: 11991447]ChapuyMC , PamphileR , ParisE , KempfC , SchlichtingM , ArnaudS , et al. Combined calcium and vitamin D3 supplementation to prevent hip fracture in elderly women. A confirmatory study: Decalyos II. Osteoporosis International2002;13(Suppl 1):S25. MeunierPJ . Personal communication 28 February 2005. ">Chapuy 2002</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Intervention 21.3 (SD 13.3), 22.5 (SD 16.5); Control 22.8 (SD 17.3)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000227-bbs2-0010" title="Bischoff-FerrariHA , OravEJ , Dawson-HughesB . Additive effect of higher testosterone levels and vitamin D plus calcium supplementation in regard to fall risk reduction among older men and women. Osteoporosis International2008;19:1307-14. Bischoff-FerrariHA , OravEJ , Dawson-HughesB . Effect of cholecalciferol plus calcium on falling in ambulatory older men and women: a 3-year randomized controlled trial. Archives of Internal Medicine2006;166(4):424-30. Bischoff-FerrariHA , OravEJ , Dawson-HughesB . Effect of vitamin D3 plus calcium on fall risk in older men and women: a 3-year randomized controlled trial. Journal of Bone and Mineral Research2004;19(Suppl 1):S57. Dawson-HughesB , HarrisSS , KrallEA , DallalGE . Effect of calcium and vitamin D supplementation on bone density in men and women 65 years of age or older. New England Journal of Medicine1997;337(10):670-6. Dawson-HughesB , HarrisSS , KrallEA , DallalGE . Effect of withdrawal of calcium and vitamin D supplements on bone mass in elderly men and women. American Journal of Clinical Nutrition2000;72(3):745-50. Dawson-HughesB , HarrisSS . Calcium intake influences the association of protein intake with rates of bone loss in elderly men and women. American Journal of Clinical Nutrition2002;75(4):773-9. KrallEA , RandallC , HarrisSS , GarciaRI , Dawson-HughesB . Calcium and vitamin D supplements reduce tooth loss in the elderly. Journal of Bone and Mineral Research2000;15(Suppl 1):S191. KrallEA , WehlerC , GarciaRI , HarrisSS , Dawson-HughesB . Calcium and vitamin D supplements reduce tooth loss in the elderly. American Journal of Medicine2001;111(6):452-6. NiramitmahapanyaS , HarrisSS , Dawson-HughesB . Type of dietary fat is associated with the 25-hydroxyvitamin D3 increment in response to vitamin D supplementation. Journal of Clinical Endocrinology and Metabolism2011;96(10):3170-4. ">Dawson‐Hughes 1997</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Intervention 82.5 (SD 40.8) men, 71.8 (SD 33.3) women; Control 84.0 (SD 31.8) men, 61.3 (SD 25.8) women </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000227-bbs2-0011" title="DukasL , BischoffHA , LindpaintnerLS , SchachtE , Birkner-BinderD , DammTN , et al. Alfacalcidol reduces the number of fallers in a community-dwelling elderly population with a minimum calcium intake of more than 500 mg daily. Journal of the American Geriatrics Society2004;52(2):230-6. DukasL , BischoffHA , LindpaintnerLS , SchachtE , Birkner-BinderD , ThalmanB , et al. Alfacalcidol reduces the number of fallers and falls in community-dwelling elderly provided a minimum total daily intake of 500mg calcium [abstract]. Calcified Tissue International2003;72:371. DukasL , SchachtE , MazorZ , StahelinHB . Treatment with alfacalcidol in elderly people significantly decreases the high risk of falls associated with a low creatinine clearance of &lt;65 ml/min. Osteoporosis International2005;16(2):198-203. DukasL , SchachtE , StahelinHB . A significant independent new risk factor for falls in the elderly: a low creatinine clearance of less than 65ml/min. Osteoporosis International2003;14(Suppl 7):S33. DukasL , SchachtE , StahelinHB . High risk of falls related to low D-hormone syndrome and its treatment with alfacalcidol. Osteoporosis International2004;15(Suppl 1):S8-9. DukasL , SchachtE , StahelinHB . Reduction of falls and fallers in high risk patients by D-hormone analogs. Osteoporosis International2004;15(Suppl 1):S144-5. DukasL , SchachtE , StahelinHB . Treatment with alfacalcidol significantly decreases the high incidence of fallers and the high risk of falls associated with low creatinine clearance (&lt;65ml/min) in elderly community-dwelling men and women. Osteoporosis International2003;14(Suppl 7):S33. DukasL , SchachtE . Reduction of falls and fallers using D-hormone analogs. Osteoporosis International2006;17(Suppl 1):S122-3. DukasLC , SchachtE , MazorZ , StahelinHB . The low creatinine clearance associated high risk of falls can significantly be treated with alfacalcidol. Journal of Bone and Mineral Research2004;19(Suppl 1):S95. DukasLC . Personal communication 19 July 2004. ">Dukas 2004</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Intervention 98.8 (SD 30.0); Control 97.8 (SD 27.3)*</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000227-bbs2-0012" title="EbelingPR , WarkJD , YeungS , PoonC , SalehiN , NicholsonGC , et al. Effects of calcitriol or calcium on bone mineral density, bone turnover, and fractures in men with primary osteoporosis: a two-year randomized, double-blind, double placebo study. Journal of Clinical Endocrinology and Metabolism2001;86(9):4098-103. EbelingPR . Personal communication 15 February 2005. ">Ebeling 2001</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Intervention 91 (SD 42); Control 86 (27)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000227-bbs2-0013" title="FalchJA , OdegaardOR , FinnangerAM , MathesonI . Postmenopausal osteoporosis: no effect of three years treatment with 1,25-dihydroxycholecalciferol. Acta Medica Scandinavica1987;221(2):199-204. [MEDLINE: 1987237893]FalchJA , OdegaardOR , FinnangerAM . 3 years treatment with 1.25(OH)2 Vitamin D3 does not reduce bone loss or fracture rate in postmenopausal women with fracture of the distal forearm. In: NormanAW , SchaeferK , Grigoleit H-G, v HerrathD , editors(s). Vitamin D : chemical, biochemical, and clinical update: proceedings of the Sixth Workshop on Vitamin D, Merano, Italy, March 1985. Berlin: de Gruyter, 1985:1004-5. FalchJA . Personal communication1999. ">Falch 1987</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N/A</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000227-bbs2-0014" title="FlickerL , MacInnisR , SteinM , SchererS , MeadK , NowsonC , et al. Should all older people in residential care receive vitamin D to prevent falls? Results of a randomised trial [abstract]. Journal of Bone and Mineral Research2004;19(Suppl 1):S99. FlickerL , MacInnisRJ , SteinMS , SchererSC , MeadKE , et al. Response letter to Dr. Gau et al. Journal of the American Geriatrics Society2006;54:1021-2. FlickerL , MacInnisRJ , SteinMS , SchererSC , MeadKE , NowsonCA , et al. Erratum. Journal of the American Geriatrics Society2012;60:1599. FlickerL , MacInnisRJ , SteinMS , SchererSC , MeadKE , NowsonCA , et al. Should older people in residential care receive vitamin D to prevent falls? Results of a randomized trial. Journal of the American Geriatrics Society2005;53(11):1881-8. FlickerL , MacInnisRJ , SteinMS , SchererSC , MeadKE , NowsonCA . Should all older people in residential care receive vitamin D to prevent falls? Results of a randomised trial. Journal of Bone and Mineral Research2004;19(Suppl 1):S99. FlickerL . Personal communication 7 January 2008. ">Flicker 2005</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Intervention 61% in 25‐40 range; Control 54% in 25‐40 range</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000227-bbs2-0015" title="GallagherJC , RiggsBL , ReckerRR , GoldgarD . The effect of calcitriol on patients with postmenopausal osteoporosis with special reference to fracture frequency. Proceedings of the Society for Experimental Biology and Medicine1989;191(3):287-92. [MEDLINE: 1989296988]">Gallagher 1989</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N/A</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000227-bbs2-0016" title="GallagherJC , GoldgarD . Treatment of postmenopausal osteoporosis with high doses of synthetic calcitriol. A randomized controlled study. Annals of Internal Medicine1990;113(9):649-55. [MEDLINE: 1991023790]GallagherJC . Metabolic effects of synthetic calcitriol (Rocaltrol) in the treatment of postmenopausal osteoporosis. Metabolism: Clinical &amp; Experimental1990;39(4 Suppl 1):27-9. [MEDLINE: 2112606]GallagherJC . Personal communication 21 February 1995. ">Gallagher 1990</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N/A</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000227-bbs2-0017" title="GallagherJC , FowlerS . Effect of estrogen, calcitriol and a combination of estrogen and calcitriol on bone mineral density and fractures in elderly women. Journal of Bone and Mineral Research1999;14(Suppl 1):S209. GallagherJC , FowlerSE , DetterJR , ShermanSS . Combination treatment with estrogen and calcitriol in the prevention of age-related bone loss. Journal of Clinical Endocrinology and Metabolism2001;86(8):3618-28. GallagherJC , HaynatskiG , FowlerS . Calcitriol therapy reduces falls and fractures in elderly women. Calcified Tissue International2003;72:334. GallagherJC , HaynatzkiG , FowlerS . Effect of estrogen, calcitriol or the combination of both on falls and non vertebral fractures in elderly women. Journal of Bone and Mineral Research2001;17(Suppl 1):S210. GallagherJC , RapuriPB , HaynatzkiG , DetterJR . Effect of discontinuation of estrogen, calcitriol, and the combination of both on bone density and bone markers. Journal of Clinical Endocrinology and Metabolism2002;87(11):4914-23. [12414850]GallagherJC , RapuriPB , HaynatzkiG . A comparison of estrogen, calcitriol or both therapies on the relationship between serum parathyroid hormone and 25 hydroxy vitamin. Journal of Bone and MIneral Research2004;19(Suppl 1):S440. GallagherJC . Personal communication 21 February 2005. GallagherJC . The effects of calcitriol on falls and fractures and physical performance tests. Journal of Steroid Biochemistry and Molecular Biology2004;89-90(1-5):497-501. ">Gallagher 2001</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Intervention 78.0 (SD 21.6); Control 80.5 (SD 27.4)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000227-bbs2-0018" title="Garay LilloJ , ParrenoJ , GonzálezY , GonzálezJA . Geminis: a prospective, multicentric, randomised study to evaluate the effect of tricalcium phosphate versus tricalcium phosphate plus 25(OH) Vitamin D on the risk of fractures in older women [Géminis: Estudio prospectivo, multicéntrico y aleatori para valorar el efecto del Fosfato Tricálcico versus Fosfato Tricálcico + 25(OH) Vitamina D sobre el riesgo de fracturas en mujerioes ancianas.]. Geriátrika1997;13(6):24-8. ">Garay Lillo 1997</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Intervention 58.3 (SD 46.3); Control 64.8 (SD 51.3) subgroups</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000227-bbs2-0019" title="GeusensP , DequekerJ . Long-term effect of nandrolone decanoate, 1 alpha-hydroxyvitamin D3 or intermittent calcium infusion therapy on bone mineral content, bone remodeling and fracture rate in symptomatic osteoporosis: a double-blind controlled study. Bone and Mineral1986;1(4):347-57. ">Geusens 1986</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N/A</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000227-bbs2-0020" title="GlendenningP , ZhuK , InderjeethC , HowatP , LewisJR , PrinceRL . Effects of three-monthly oral 150,000 IU cholecalciferol supplementation on falls, mobility, and muscle strength in older postmenopausal women: a randomized controlled trial. Journal of Bone and Mineral Research2012;27(1):170-6. ">Glendenning 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>65.8 (SD 22.7) combined intervention and control subgroup</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000227-bbs2-0021" title="GoraiI , ChakiO , TaguchiY , NakayamaM , OsadaH , SuzukiN , et al. Early postmenopausal bone loss is prevented by estrogen and partially by 1alpha-OH-vitamin D3: therapeutic effects of estrogen and/or 1alpha-OH-vitamin D3. Calcified Tissue International1999;65:16-22. ">Gorai 1999</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N/A</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000227-bbs2-0022" title="HarwoodRH , SahotaO , GaynorK , MasudT , HoskingD . A randomised, controlled comparison of different calcium and vitamin D supplementation regimens in elderly women after hip fracture: The Nottingham Neck of Femur (NoNOF) Study. Age and Ageing2004;33:45-51. [14695863]HarwoodRW . Personal communication 24 January 2003. SahotaO , HarwoodRH , GaynorK , MasudT , HoskingDJ . A randomised, controlled comparison of different calcium and vitamin D regimes: the NoNOF (Nottingham Neck of Femur) study. Osteoporosis International2003;14(Suppl 4):S10-11. ">Harwood 2004</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Intervention 28 (range 10‐67), 30 (range 12‐85), 29 (range 6‐75); Control 30 (range 12‐64) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000227-bbs2-0023" title="HayashiY , FujitaT , InoueT . A multi-center study on efficacy of 1 alpha-hydroxy vitamin D3 in preventing spinal fracture of patients with osteoporosis (abstract). Journal of Bone and Mineral Research1989;4 Suppl 1:Si84. HayashiY , FujitaT , InoueT . Decrease of vertebral fracture in osteoporotics by administration of 1alpha-hydroxy-vitamin D3. Journal of Bone and Mineral Metabolism1992;10(2):50-4. ">Hayashi 1992</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N/A</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000227-bbs2-0024" title="InkovaaraJ , GothoniG , HalttulaR , HeikinheimoR , TokolaO . Calcium, vitamin D and anabolic steroids in treatment of aged bones: double-blind placebo-controlled long-term clinical trial. Age and Ageing1983;12:124-30. ">Inkovaara 1983</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N/A</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000227-bbs2-0025" title="AlpertJS . Concerns about the integrity of Ishida Y, Kawai S. Am J Med. 2004;117:549-555: the reply. American Journal of Medicine2020;133:e315. AvenellA , GreyA , GambleGD , BollandMJ . Concerns about the integrity of the Yamaguchi Osteoporosis Prevention Study (YOPS) report, Am J Med. 2004;117:549-555. American Journal of Medicine2020;133:e311-4. IshidaY , KawaiS . A two-year randomized controlled trial of hormone replacement therapy, etidronate, calcitonin, vitamin D, or vitamin K, in women with postmenopausal osteoporosis. Journal of Bone and Mineral Research2002;17(Suppl 1):S478. IshidaY , KawaiS . Comparative efficacy of hormone replacement therapy, bisphosphonates, calcitonin, vitamin D and vitamin K in postmenopausal women with osteoporosis. Journal of Bone and Mineral Research2003;18(Suppl 2):S158. IshidaY , KawaiS . Comparative efficacy of hormone replacement therapy, etidronate, calcitonin, alfacalcidol, and vitamin K in postmenopausal women with osteoporosis: the Yamaguchi osteoporosis prevention study. American Journal of Medicine2004;117:549-55. IshidaY , KawaiS . Comparative efficacy of hormone replacement therapy, etidronate, calcitonin, vitamin D and vitamin K in postmenopausal osteoporosis. Bone2003;33(5 Suppl1):S220. IshidaY , SohH , OgawaS , KawaharaS , MurataH . A one-year randomized controlled trial of hormone replacement therapy, bisphosphonate, calcitonin, vitamin D, and vitamin K, in women with postmenopausal osteoporosis. Journal of Bone and Mineral Research2000;15(Suppl 1):S310. IshidaY , SohH , TsuchidaS , KawaharaS , MurataH , KawaiS . Effectiveness of hormone replacement therapy, etidronate, calcitonin, vitamin D, and vitamin K in postmenopausal women with osteoporosis [abstract]. Bone2002;30(3 Suppl 1):50S. IshidaY . Personal communication 21 February 2005. ">Ishida 2004 (retracted)</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N/A</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000227-bbs2-0026" title="JanssenHC , SamsonMM , VerhaarHJ . Muscle strength and mobility in vitamin D-insufficient female geriatric patients: a randomized controlled trial on vitamin D and calcium supplementation. Aging Clinical and Experimental Research2010;22(1):78-84. ">Janssen 2010</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Vitamin D and calcium 32.6 (SD 11.6); Placebo and calcium 34.3 (SD 11.5)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000227-bbs2-0027" title="KomulainenM , KrogerH , TuppurainenMT , HeikkinenAM , AlhavaE , HonkanenR , et al. Prevention of femoral and lumbar bone loss with hormone replacement therapy and Vitamin D3 in early postmenopausal women: a population based 5-year randomized trial. Journal of Clinical Endocrinology and Metabolism1999;84(2):546-52. KomulainenM , KrogerH , TuppurainenMT , Keikkinen A-M, HonkanenR , SaarikoskiS , et al. Identification of early postmenopausal women with no bone response to HRT: results of a five-year clinical trial. Osteoporosis International2000;11:211-8. KomulainenMH , KrogerH , TuppurainenMT , Heikkinen A-M, AlhavaE , HonkanenR , et al. HRT and Vit D in prevention of non-vertebral fractures in postmenopausal women; a 5 year randomized trial. Maturitas1998;31(1):45-54. KomulainenMH . Personal communication 11 November 2004. ">Komulainen 1998</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N/A</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000227-bbs2-0028" title="LawM , MorrisJ , WithersH . Cholecalciferol, not ergocalciferol, should be used for vitamin D supplementation [author reply]. Age and Ageing2006;35(6):645. [MEDLINE: 16982666]LawM , MorrisJ , WithersH . Vitamin D supplementation and the prevention of fractures and falls. Reply. Age and Ageing2007;36(2):233. LawM , MorrisJ , WithersH . Vitamin D supplementation and the prevention of fractures and falls [author reply]. Age and Ageing2007;36(2):233. [MEDLINE: 17255084]LawM , WithersH , MorrisJ , AndersonF . Vitamin D supplementation and the prevention of fractures and falls: results of a randomised trial in elderly people in residential accommodation [comment in: Age and Ageing 2006;35(6):645 and Age and Ageing 2007;36(2):232-3]. Age and Ageing2006;35(5):482-6. ">Law 2006</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Intervention 47 median (35‐102, 90th centile range) subgroup; no data for control group </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000227-bbs2-0029" title="GraafmansWC , OomsME , HofsteeHMA , BezemerPD , BouterLM , LipsP . Falls in the elderly: a prospective study of risk factors and risk profiles. American Journal of Epidemiology1996;143(11):1129-36. LipsP , GraafmansWC , OomsME , BezemerPD , BouterLM . The effect of vitamin D supplementation on the incidence of hip fractures in elderly people. Journal of Bone and Mineral Research1994;9 Suppl 1:S148. LipsP , GraafmansWC , OomsME , BezemerPD , BouterLM . Vitamin D supplementation and fracture incidence in elderly persons. Annals of Internal Medicine1996;124:400-6. [MEDLINE: 1996151943]">Lips 1996</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Intervention 27 (25th‐75th centile 19‐36); Control 26 (25th‐75th centile 19‐37) subgroups</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000227-bbs2-0030" title="JohansenA , LyonsRA , StoneM , BrophyS , NewcombeRG , PhillipsCJ , et al. Preventing fractures among older people living in institutional care: a randomised double blind placebo controlled trial of vitamin D supplementation [abstract]. Age and Ageing2006;35(Suppl 3):i41. LyonsRA , JohansenA , BrophyS , NewcombeRG , PhillipsCJ , LervyB , et al. Preventing fractures among older people living in institutional care: a pragmatic randomised double blind placebo controlled trial of vitamin D supplementation. Osteoporosis International2007;18(6):811-8. LyonsRA , JohansenA , StoneMD , BrophyS , NewcombeRG , PhilipsCJ , et al. Preventing fractures among older people living in institutional care: a randomised double blind placebo controlled trial of vitamin D supplementation [abstract]. Osteoporosis International2006;17(Suppl 3):372. ">Lyons 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N/A</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000227-bbs2-0031" title="MenczelJ , FoldesJ , SteinbergR , LeichterI , ShalitaB , Bjolah-AbramT , et al. Alfacalcidol (Alpha D3) and calcium in osteoporosis. Clinical Orthopaedics and Related Research1994;(300):241-7. ">Menczel 1994</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N/A</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000227-bbs2-0032" title="MeyerHE , FalchJA , KvaavikE , SmedshaugGB , TverdalA , PedersenJI . Can vitamin D supplementation reduce the risk of fracture in the elderly? A randomised controlled trial. Osteoporosis International2000;11(Suppl 2):S114-5. MeyerHE , SmedshaugGB , KvaavikE , FalchJA , TverdalA , PedersenJI . Can vitamin D supplementation reduce the risk of fracture in the elderly? A randomized controlled trial. Journal of Bone and Mineral Research2002;17(4):709-15. SmedshaugGB , PedersenJI , MeyerHE . Can vitamin D supplementation improve grip strength in elderly nursing home residents? A double-blinded controlled trial. Scandinavian Journal of Food and Nutrition2007;51(2):74-8. ">Meyer 2002</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Intervention 47 (SD 26); Control 51 (SD 33) subgroups</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000227-bbs2-0033" title="MitriJ , Dawson-HughesB , HuFB , PittasAG . Effects of vitamin D and calcium supplementation on pancreatic β cell function, insulin sensitivity, and glycemia in adults at high risk of diabetes: the Calcium and Vitamin D for Diabetes Mellitus (CaDDM) randomized controlled trial. American Journal of Clinical Nutrition2011;94:486-94. ">Mitri 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Vitamin D and calcium 56 (SE 4), Vitamin D and placebo 66 (SE 4), Calcium and placebo 63 (SE 5), Placebos 61 (SE 3) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000227-bbs2-0034" title="NakatsukaK , InabaM , ArataniH , IbaK , SatoT , KoikeT , et al. Effects of long-term administration of alfacalcidol on bone mass and bone metabolism in patients with primary osteoporosis - comparison with calcium preparations [Japanese]. Nippon Ronen Igakkai Zasshi - Japanese Journal of Geriatrics1997;34(7):569-76. ">Nakatsuka 1997</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Intervention 58.4 (SD 24.5); Control 69.8 (SD 28.5)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000227-bbs2-0035" title="OnesK , SchachtE , DukasL , CaglarN . Effects of combined treatment with alendronate and alfacalcidol on bone mineral density and bone turnover in postmenopausal osteoporosis: a two-years, randomized, multiarm, controlled trial. Internet Journal of Epidemiology2007;4(1):DOI: 10.5580/1523. ">Ones 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N/A</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000227-bbs2-0036" title="OrimoH , ShirakiM , HayashiY , HoshinoT , OnayaT , MiyazakiS , et al. Effects of 1-alpha-hydroxyvitamin D3 on lumbar bone mineral density and vertebral fractures in patients with postmenopausal osteoporosis. Calcified Tissue International1994;54:370-6. ">Orimo 1994</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Intervention 58.0 (SD 22.5); Control 50.3 (SD 16.3)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000227-bbs2-0037" title="KarkkainenM , TuppurainenM , RikkonenT , SalovaaraK , SirolaJ , HonkanenR , et al. Vitamin-D 800IU/day + calcium 1000mg supplementation decreases the risk of recurrent falling among postmenopausal ambulatory women - a population-based, randomized, 3-year study (OSTPRE-FPS). Osteoporosis International2008;19(Suppl 1):S17-18. KarkkainenM , TuppurainenM , RikkonenT , SalovaaraK , SirolaJ , HonkanenR , et al. Vitamin-D 800IU/day + calcium supplementation decreases the risk of falling among postmenopausal ambulatory women - a population-based, randomized 3-year study (OSTPRE-FPS) [abstract]. Journal of Bone and Mineral Research2007;22(Suppl 1):S131. KarkkainenM , TuppurainenM , SalovaaraK , SandiniL , RikkonenT , SirolaJ , et al. Effect of calcium and vitamin D supplementation on bone mineral density in women aged 65-71 years: a 3-year randomized population-based trial (OSTPRE-FPS). Osteoporosis International2010;21:2047-55. KarkkainenMK , TuppurainenM , SalovaaraM , SandiniL , RikkonenT , SirolaJ , et al. Does daily vitamin D 800 IU and calcium 1000 mg supplementation decrease the risk of falling in ambulatory women aged 65-71 years? A 3-year randomized population-based trial (OSTPRE-FPS). Maturitas2010;65:359-65. KrogerHP , TuppurainenM . OSTPRE-FPS Prevention of Fractures and Falls in Postmenopausal Women With Calcium and Vitamin-D Supplementation - a Randomised Study. http://www.controlled-trials.com/mrct/trial/405493/OSTPRE. SalovaaraK , TuppurainenM , KarkkainenM , RikkonenT , SandiniL , SirolaJ , et al. Effect of vitamin D3 and calcium on fracture risk in 65- to 71-year-old women: a population-based 3-year randomized, controlled trial - the OSTPRE-FPS. Journal of Bone and Mineral Research2010;25(7):1487-95. SalovaaraKT , TuppurainenM , RikkonenT , KarkkainenM , SirolaJ , HonkanenR , et al. Effect of vitamin-D3 and calcium on fracture risk in 65-71 year old women in a 3-year randomized clinical trial - preliminary results from the OSTPRE-Fracture Prevention Study. Calcified Tissue International2008;82:545-6. SalovaaraKT , TuppurainenM , RikkonenT , KarkkainenM , SirolaJ , HonkanenR , et al. Effect of vitamin-D3 and calcium on fracture risk in 65-71 year old women in a 3-year randomized clinical trial - preliminary results of the OSTPRE-Fracture Prevention Study. Journal of Bone and Mineral Research2007;22(Suppl 1):S76. ">OSTPRE‐FPS 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Intervention 50.0 (SD 18.7); Control 49.1 (SD 17.7) subgroups</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000227-bbs2-0038" title="OttSM , ChesnutCH . Calcitriol treatment is not effective in postmenopausal osteoporosis: see comments. Annals of Internal Medicine1989;110:267-74. ">Ott 1989</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Intervention 66.8 (SD 31.5); Control 65.8 (SD 39.3)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000227-bbs2-0039" title="PeacockM , LiuG , CareyM , McClintockR , AmbrosiusW , HuiS , et al. Effect of calcium or 25OH vitamin D3 dietary supplementation on bone loss at the hip in men and women over the age of 60. Journal of Clinical Endocrinology and Metabolism2000;85:3011-9. ">Peacock 2000</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Intervention 65.0 (SD 25) men, 57.5 (SD 33) women; Control 65.0 (SD 30) men, 60.0 (SD 30) women </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000227-bbs2-0040" title="MinneHW , PfeiferM , BegerowB , NachtigallD , HansenC . Vitamin D and calcium supplementation reduces falls in elderly women via improvement of body sway and normalisation of blood pressure; a prospective, randomized, and double-blind study. Osteoporosis International2000;11(Suppl 2):S115. PfeiferM , BegerowB , MinneHW , AbramsC , NachtigallD , HansenC . Effects of a short-term vitamin D and calcium supplementation on body sway and secondary hyperparathyroidism in elderly women. Journal of Bone and Mineral Research2000;15(6):1113-8. PfeiferM , BegerowB , NachtigallD , HansenC . Prevention of falls-related fractures: vitamin D reduces body sway in the elderly - a prospective, randomized, double blind study [abstract]. Bone1998;23(5 Suppl 1):1110. ">Pfeifer 2000</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Interventiion 25.7 (SD 13.6); Control 24.6 (SD 12.1)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000227-bbs2-0041" title="BollandMJ , GreyA . Different outcomes of meta-analyses and data inconsistency:response to comments by Pfeifer. Archives of Osteoporosis2015;10:43. BollandMJ , GreyA . Inconsistent data in text and tables. Osteoporosis International2015;26:2713. MinneHW , DobnigH , PfeiferM , SuppanK . Effects of vitamin D and calcium supplementation on falls and parameters of muscle function: a prospective, randomized, double-blind multicenter study [abstract]. Osteoporosis International2006;17(Suppl 2):S212. MinneHW , DobnigH , PfeiferM , SuppanK . Effects of vitamin D and calcium supplementation on falls and parameters of muscle-function - a prospective, randomized, double-blind multi-center study [abstract]. Osteoporosis International2006;17(Suppl 1):S21. PfeiferM , BegerowB , MinneHW , SuppanK , Fahrleitner-PammerA , DobnigH . Effects of a long-term vitamin D and calcium supplementation on falls and parameters of muscle function in community-dwelling older individuals. Osteoporosis International2009;20:315-22. PfeiferM , DobnigH , BegerowB , SuppanK . Effects of vitamin D and calcium supplementation on falls and parameters of muscle function: a prospective randomized, double-blind multi-centre study [abstract]. Journal of Bone and Mineral Research2004;19(Suppl 1):S58. PfeiferM , DobnigH , MinneHW , SuppanK . Effects of vitamin D and calcium supplementation on falls and parameters of muscle function - a prospective, randomized, double-blind multi-center study [abstract]. Osteoporosis International2005;16(Suppl 3):S45. PfeiferM . Different outcomes of meta-analyses and data inconsistency. Osteoporosis International2015;26:2715–2716. PfeiferM . Randomized controlled clinical trials and meta-analyses. Archives of Osteoporosis2015;10:42. ">Pfeifer 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Vitamin D and calcium 55 (SD 18); Calcium 54 (SD 18)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000227-bbs2-0042" title="DumvilleJC , MilesJN , PorthouseJ , CockayneES , SaxonL , KingC , et al. Can vitamin D supplementation prevent seasonal affective disorder? A randomised trial among older women. Osteoporosis International2004;15:S42-3. PorthouseJ , CockayneS , KingC , SaxonL , SteeleE , AsprayT , et al. Randomised controlled trial of calcium and supplementation with cholecalciferol (vitamin D3) for prevention of fractures in primary care. BMJ2005;330(7498):1003-6. PorthouseJ , CockayneS , KingC , SaxonL , SteeleE , AsprayT , et al. Randomised controlled trial of calcium and vitamin D supplementation for fracture prevention in primary care. Osteoporosis International2004;15(Suppl 2):S13. PorthouseJ , CockayneS , KingC , SaxonL , SteeleE , AsprayT , et al. Randomised controlled trial of calcium and vitamin D supplementation for fracture prevention in primary care. Osteoporosis International2005;16:S27. PufferS . Calcium and vitamin D in primary care: adherence results from a randomised controlled trial [abstract 6.9.3]. In: RCN International Nursing Conference; 2004 Mar 21-31; Cambridge (UK). London: Royal College of Nursing, 2004. S Puffer, on behalf of the Calcium and Vitamin D Trial. Calcium and vitamin D in primary care. Compliance results from a randomised controlled trial. Osteoporosis International2003;14(Suppl 4):S8. TorgersonD , on behalf of the trial group. Calcium and vitamin D in preventing fractures [author reply]. BMJ2005;331(7508):109. TorgersonDJ . Personal communication 9-16 February 2005. ">Porthouse 2005</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N/A</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000227-bbs2-0043" title="PrinceRL , AustinN , DevineA , DickIM , BruceD , ZhuK . Effects of ergocalciferol added to calcium on the risk of falls in elderly high-risk women. Archives of Internal Medicine2008;168(1):103-8. ZhuK , BruceD , AustinN , DevineA , EbelingPR , PrinceRL . Randomized controlled trial of the effects of calcium with or without vitamin D on bone structure and bone-related chemistry in elderly women with vitamin D insufficiency. Journal of Bone and Mineral Research2008;23(8):1343-8. ZhuK , DevineA , DickIM , WilsonSG , PrinceRL . Effects of calcium and vitamin D supplementation on hip bone mineral density and calcium-related analytes in elderly ambulatory Australian women: a five-year randomized controlled trial. Journal of Clinical Endocrinology and Metabolism2008;93(3):743-9. ">Prince 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Intervention 45.2 (SD 12.5); Control 44.3 (SD 12.7)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000227-bbs2-0044" title="AndersonFH , GrantAM , AvenellA , CampbellMK , CooperC , DonaldsonC , et al. The RECORD Trial: an evaluation of calcium and/or vitamin D in the secondary prevention of osteoporotic fractures. Bone2005;36(Suppl 2):S122-3. FrancisRM , Grant AM and the RECORD trial group. The RECORD trial: a randomised double-blind study of calcium and/or vitamin D in the secondary prevention of low trauma fractures. Age Ageing2005;34(Suppl 2):ii15. GrantA , on behalf of the RECORD Trial Group. Prevention of low-trauma fractures in older people [author reply]. Lancet2005;366(9485):543-4. GrantAM , AndersonFH , for the RECORD Trial Group. The Medical Research Council RECORD Trial: an evaluation of calcium and/or vitamin D in the secondary prevention of osteoporotic fractures. Osteoporosis International2004;15(Suppl 2):S13. GrantAM , AndersonFH . The RECORD trial: an evaluation of calcium and/or vitamin D in the secondary prevention of osteoporotic fractures. Osteoporosis International2005;16(Suppl 3):S4-5. GrantAM , AvenellA , CampbellMK , McDonaldAM , MacLennanGS , McPhersonGC , et al. Oral vitamin D3 and calcium for secondary prevention of low-trauma fractures in elderly people (Randomised Evaluation of Calcium Or vitamin D, RECORD): a randomised placebo-controlled trial [comment in: Lancet 2005;366(9485):543]. Lancet2005;365(9471):1621-8. GrantAM . Personal communication 11 March 2004. ">RECORD 2005</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Intervention 38.0 (SD 16.3); Control 39.5 (SD 14.8) subgroups*</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000227-bbs2-0045" title="ShirakiM , KushidaK , YamazakiK , NagaiT , InoueT , OrimoH . Effects of 2 years' treatment of osteoporosis with 1alpha-hydroxy vitamin D3 on bone mineral density and incidence of fracture: a placebo-controlled, double-blind prospective study. Endocrine Journal1996;43(2):211-20. ">Shiraki 1996</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N/A</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000227-bbs2-0046" title="AndersonFH , SmithHE , RaphaelHM , CooperC . Intramuscular vitamin D increased serum 1,25-dihydroxycholecalciferol but did not affect 25-hydroxy-cholecalciferol levels in health older adults [abstract]. Journal of Bone and Mineral Research2000;15(Suppl 1):S315. AndersonFH , SmithHE , RaphaelHM , CrozierSR , CooperC . Effect of annual intramuscular vitamin D3 supplementation on fracture risk in 9440 community-living older people: the Wessex fracture prevention trial [abstract]. Journal of Bone and Mineral Research2004;19(Suppl 1):S57. ArdenNK , CrozierS , SmithH , AndersonF , EdwardsC , RaphaelH , et al. Knee pain, knee osteoarthritis, and the risk of fracture. Arthritis and Rheumatism2006;55(4):610-5. CooperC , CrozierS . Personal communication 23 February 2005. RaphaelH , SmithH , AndersonF , CooperC . Tackling the problems of trial management in primary care - experience from the Wessex research network fracture prevention study of annual vitamin D injection in older people [abstract]. Osteoporosis International2000;11(Suppl 1):S63-4. SmithH , AndersonF , RaphaelH , CooperC . The Wessex research network fracture prevention study - a large pragmatic trial of annual vitamin D injection in older people [abstract]. Osteoporosis International2000;11(Suppl 1):S64. SmithH , AndersonF , RaphaelH , CrozierS , CooperC . Effect of annual intramuscular vitamin D supplementation on fracture risk: population-based, randomised, double-blind, placebo-controlled trial [abstract]. Osteoporosis International2004;15(Suppl 1):S8. SmithH , AndersonF , RaphaelH , MaslinP , CrozierS , CooperC . Effect of annual intramuscular vitamin D on fracture risk in elderly men and women--a population-based, randomized, double-blind, placebo-controlled trial. Rheumatology2007;46(12):1852-7. ">Smith 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Intervention 56.5; Control 62.2 subgroups</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000227-bbs2-0047" title="MorrisonNA , GeorgePM , VaughanT , TilyardMW , FramptonCM , GilchristNL . Vitamin D receptor genotypes influence the success of calcitriol therapy for recurrent vertebral fracture in osteoporosis. Pharmacogenetics and Genomics2005;15(2):127-35. TilyardM . Low-dose calcitriol versus calcium in established postmenopausal osteoporosis. Metabolism: Clinical &amp; Experimental1990;39(4 Suppl 1):50-2. TilyardMW , SpearsGF , ThomsonJ , DoveyS . Treatment of postmenopausal osteoporosis with calcitriol or calcium. New England Journal of Medicine1992;326(6):357-62. TilyardMW , SpearsGFS , ThomsonJ , DoveyS . Calcitriol or calcium for postmenopausal osteoporosis. New England Journal of Medicine1992;327:284. TilyardMW . 1,25-dihydroxyvitamin D3 (calcitriol) in the treatment of postmenopausal osteoporosis. Aktuelle Rheumatologie1994;19(Suppl 1):23-6. ">Tilyard 1992</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N/A</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000227-bbs2-0048" title="TrivediDP , DollR , KhawKT . Effect of four monthly oral vitamin D3 (cholecalciferol) supplementation on fractures and mortality in men and women living in the community: randomised double blind controlled trial. BMJ2003;326:469. ">Trivedi 2003</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N/A</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000227-bbs2-0049" title="UshiroyamaT , IkedaA , SakaiM , HigashiyamaT , UekiM . Effects of the combined use of calcitonin and 1alpha-hydroxycholecalciferol on vertebral bone loss and bone turnover in women with postmenopausal osteopenia and osteoporosis: a prospective study of long-term and continuous administration with low dose calcitonin. Maturitas2001;40:229-38. ">Ushiroyama 2001</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N/A</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000227-bbs2-0050" title="SandersK , DuqueG , EbelingP , McCorquodaleT , HerrmannM , Shore-LorentiC , et al. The efficacy of high-does oral vitamin D3 administered once a year: increased fracture risk is associated with 1,25 vitamin D level at 3-months post dose. In: ASBMR Annual Meeting; 2012 Oct 12-15; Minneapolis, Minnesota. http://www.asbmr.org/Meetings/AnnualMeeting/AbstractDetail.aspx?aid=6beb2500-4b8e-472b-8b38-d881cadb80e3. 2012. SandersK , StuartA , WilliamsonE , SimpsonJ , KotowiczM , NicholsonG . The efficacy of high-dose oral vitamin D3 administered once a year: a randomised, double-blind, placebo-controlled trial (Vital D study) for falls and fractures in older women. Osteoporosis International2011;22(Suppl 1):S104-5. SandersKM , DuqueG , McCorquodaleT , StuartAL , WilliamsonEJ , KotowiczMA , et al. Annual high-dose oral vitamin D3: is the increased risk of falls attributable to changes in muscle strength?Osteoporosis International2011;22(Suppl 4):S552. SandersKM , EbelingPR , StuartAL , WilliamsonEJ , KotowiczMA , NicholsonGC . Annual high-dose oral vitamin D3: is increased risk of fractures attributable to changes in bone turnover markers?Osteoporosis International2011;22(Suppl 4):S589. SandersKM , HaylesAL , KotowiczMA , NicholsonGC . Does vitamin D explain the lower fracture rate in rural communities?Bone2007;40(6 Suppl 2):S195. SandersKM , HaylesAL , KotowiczMA , NicholsonGC . The possible role of vitamin D and falls in relation to lower fracture rates in rural communities. Osteoporosis International2007;18(Suppl 1):S120-1. SandersKM , StuartAL , KotowiczMA , NicholsonGC . Annual feedback is an effective tool for a sustained increase in calcium intake among older women. Nutrients2010;2:1018-25. SandersKM , StuartAL , MerrimanEN , ReadML , KotowiczMA , YoungD , et al. Trials and tribulations of recruiting 2,000 older women onto a clinical trial investigating falls and fractures: Vital D study. BMC Medical Research Methodology2009;9:78. SandersKM , StuartAL , NicholsonGC . High-dose oral vitamin D supplementation and risk of falls in older women. JAMA2010;304(8):856-7. SandersKM , StuartAL , WilliamsonEJ , JackaFN , DoddS , NicholsonG , et al. Annual high-dose vitamin D3 and mental well-being: randomised controlled trial. British Journal of Psychiatry2011;198:357-64. SandersKM , StuartAL , WilliamsonEJ , SimpsonJA , KotowiczMA , NicholsonGC . Annual high-dose oral vitamin D for falls and fractures in elderly women: a randomised, double-blind, placebo-controlled trial (Vital D study). Osteoporosis International2010;21(Suppl 1):S30. SandersKM , StuartAL , WilliamsonEJ , SimpsonJA , KotowiczMA , YoungD , et al. Annual high-dose oral vitamin D and falls and fractures in older women. A randomized controlled trial. JAMA2010;303(18):1815-22. Sanders KM et al. Incorrect data. JAMA2010;303(23):2357. ">Vital D</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Intervention 53 (interquartile range 40‐65); Control 45 (interquartile range 40‐57) subgroups </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000227-bbs2-0051" title="CauleyJ , Wactawski-WendeJ , RobbinsJ , RodaboughR , ChenZ , JohnsonK , et al. The Women's Health Initiative (WHI) calcium and vitamin D supplementation trial: health outcomes 5 years after trial completion. ASBMR Annual Meeting; 2012 Oct 12-15; Minneapolis, Minnesota. http://www.asbmr.org/Meetings/AnnualMeeting/AbstractDetail.aspx?aid=6450bf3e-c670-4dc0-814c-8842e23cd80e (accessed 27 December 2012). CauleyJA , LaCroixA , WuL , LeeJ , HorowitzM , BauerD , et al. Serum 25 hydroxy vitamin D 25(OH) and the risk of hip fracture: the Women's Health Initiative (WHI). Journal of Bone and Mineral Research2007;22(Suppl 1):S57. ChenZ , BeckTJ , WrightNC , LaCroixAZ , CauleyJA , LewisCE , et al. The effect of calcium plus vitamin D supplement on hip geometric structures: results from the Women's Health Initiative CaD trial. Journal of Bone and Mineral Research2007;22(Suppl 1):S59. JacksonRD , LaCroixAZ , CauleyJA , McGowanJ . The Women's Health Initiative Calcium-Vitamin D Trial: overview and baseline characteristics of participants. Annals of Epidemiology2003;13:S98-106. JacksonRD , LaCroixAZ , GassM , WallaceRB , RobbinsJ , LewisCE , et al. Calcium plus vitamin D supplementation and the risk of fractures [erratum appears in New England Journal of Medicine 9 March 2006;354(10):1102]. New England Journal of Medicine2006;354(7):669-83. JacksonRD , WrightNC , BeckTJ , SherrillD , CauleyJA , LewisCE , et al. Calcium plus vitamin D supplementation has limited effects on femoral geometric strength in older postmenopausal women: the Women's Health Initiative. Calcified Tissue International2011;88:198-208. McGowanJA , JacksonRD , CauleyJA , LaCroixAZ . Calcium and vitamin D in the prevention of hip and other fractures: an update on the Women's Health Initiative CaD Trial. Journal of Bone and Mineral Research2002;17(Suppl 1):S477. The Women's Health Initiative Study Group. Design of the Women's Health Initiative clinical trial and observational study. Controlled Clinical Trials1998;19(1):61-109. ">WHI 2006</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>46.0 (SD 22.6) subsequent hip fracture, 48.4 (SD 23.5) Controls, subgroups</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000227-bbs2-0052" title="WithamMD , CrightonLJ , GillespieND , StruthersAD , McMurdoME . The effects of vitamin D supplementation on physical function and quality of life in older patients with heart failure. A randomized controlled trial. Circulation: Heart Failure2010;3:195-201. ">Witham 2010</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Intervention 20.5 (SD 8.9); Control 23.7 (SD 10.0)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000227-bbs2-0053" title="WithamM . Can high-dose vitamin D supplementation reduce blood pressure and markers of cardiovascular risk in older people with isolated systolic hypertension? A randomised, double-blind, parallel group placebo controlled trial. http://www.controlled-trials.com/ISRCTN92186858/ (accessed 3 December 2013). WithamMD , PriceRJ , StruthersAD , DonnanPT , MessowM , FordI , et al. Vitamin D supplementation to reduce blood pressure in older patients with isolated systolic hypertension (VitDISH) - a randomised controlled trial. Personal communication ahead of publication 15 January 2013. ">Witham 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Intervention 44(SD 16); Control 45(SD 15)</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>* reported as D3<br/>N/A: not available </p> </div> </div> </section> </section> <section id="CD000227-sec-0045"> <h4 class="title">Excluded studies</h4> <p>Sixty‐three studies were excluded (see <a href="./references#CD000227-sec-0125" title="">Characteristics of excluded studies</a> table for details). Most were excluded because the trials did not present fracture data. </p> <p>Attention is drawn to one particular excluded study, which has been quoted as evidence for effectiveness of single‐dose vitamin D injection in fracture prevention (<a href="./references#CD000227-bbs2-0082" title="HarjuEJ , HeikinheimoRJ , HaavistoMU , InkovaaraJA , KaarelaRH , KatajaM , et al. Prevention of bone fractures by annual intramuscular injection of ergocalciferol in the aged. British Journal of Surgery1991;78:1145. HeikinheimoRJ , InkovaaraJA , HarjuEJ , HaavistoMV , KaarelaRH , KatajaJM , et al. Annual injection of vitamin D and fractures of aged bones. Calcified Tissue International1992;51:105-10. ">Heikinheimo 1992</a>). This study was quasi‐randomised (allocation based on month of birth) and there was no attempt at blinding. Only individuals recruited in the autumn and winter were included, and there was no placebo group. Follow‐up varied between two and five years but the cumulative analysis of fracture incidence did not include confidence intervals despite the decreasing numbers with longer follow‐up. Participants who rejected injection were added to the control group. Although considered ineligible for inclusion in this systematic review, this study was important mainly for raising the hypothesis that this relatively inexpensive, practical proposal for fracture prevention should be tested more rigorously. </p> <p>We also draw attention to an excluded trial that we included in a previous version of this review (<a href="./references#CD000227-bbs2-0195" title="AvenellA , GillespieWJ , GillespieLD , O'ConnellDL . Vitamin D and vitamin D analogues for preventing fractures associated with involutional and post-menopausal osteoporosis. Cochrane Database of Systematic Reviews2005, Issue 3. Art. No: CD000227. [DOI: 10.1002/14651858.CD000227.pub2]">Avenell 2005</a>), with a note that its result should be treated with caution. <a href="./references#CD000227-bbs2-0095" title="LarsenER , MosekildeL , FoldspangA . Determinants of acceptance of a community-based program for the prevention of falls and fractures among the elderly. Preventive Medicine2001;33(2 Pt 1):115-9. LarsenER , MosekildeL , FoldspangA . Vitamin D and calcium supplementation prevents osteoporotic fractures in elderly community dwelling residents: a pragmatic population-based 3-year intervention study. Journal of Bone and Mineral Research2004;19(3):370-8. LarsenER , MosekildeL , FoldspangA . Vitamin D and calcium supplementation prevents severe falls in elderly community-dwelling women: a pragmatic population-based 3-year intervention study. Aging Clinical and Experimental Research2005;17(2):125-32. LarsenER , MosekildeL , FoldspangA . Vitamin D and calcium treatment and environmental adjustment in the prevention of falls and osteoporotic fractures among elderly Danish community residents. Journal of Bone and Mineral Research2002;17(Suppl 1):S157. ">Larsen 2004</a>, a cluster‐randomised study (N = 4 clusters) was not included in our pooled analysis at that time, as the investigators' analysis appeared to be for individually randomised participants. We have now excluded this widely quoted study because it does not meet the inclusion criteria for this review. Participants in each of the three treatment clusters received one or more co‐interventions designed to reduce falls (medication review, environmental hazard and health assessment, and osteoporosis/fall prevention leaflets) but the control group received no intervention. No treatment group received vitamin D and calcium alone. Thus, although the investigators state that this was a factorial study, the reports of the design do not appear to fit that description, and the effect of vitamin D and calcium cannot be separated from the effects of co‐interventions. </p> <p>Trials of included interventions that do not report fracture data, but do report adverse effects are listed in <a href="#CD000227-tbl-0006">Table 5</a> and their details given in the '<a href="./references#CD000227-sec-0125" title="">Characteristics of excluded studies</a>' table. </p> <div class="table" id="CD000227-tbl-0006"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 5.</span> <span class="table-title">Selected adverse effects reported in excluded trials</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Excluded study ID</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Adverse effects</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000227-bbs2-0056" title="AloiaJF , TalwarSA , PollackS , YehJ . A randomized controlled trial of vitamin D3 supplementation in African American women. Archives of Internal Medicine2005;165(14):1618-23. TalwarSA , AloiaJF , PollackS , YehJ . Oral vitamin D3 supplementation in postmenopausal African American women. Calcified Tissue International2004;74(Suppl 1):S102. TalwarSA , AloiaJF , PollackS , YehJ . Oral vitamin D3 supplementation in postmenopausal African American women. Journal of Bone and Mineral Research2004;19(Suppl 1):S324. ">Aloia 2005</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Death, renal stone, hypercalcaemia</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000227-bbs2-0059" title="BinkleyN , ReckerR , HolstA , WalliserJ , LipsP , PfeiferM . Treatment effects of vitamin D3 8400IU once weekly on elderly subjects with vitamin D insufficiency. Osteoporosis International2007;18(Suppl 1):S118. ">Binkley 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Renal insufficiency, hypercalcaemia</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000227-bbs2-0060" title="BrazierM , GradosF , KamelS , MathieuM , MorelA , MaamerM , et al. Clinical and laboratory safety of one year's use of a combination calcium + vitamin D tablet in ambulatory elderly women with vitamin D insufficiency: results of a multicenter, randomized, double-blind, placebo-controlled study. Clinical Therapeutics2005;27(12):1885-93. ">Brazier 2005</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Death, gastrointestinal event, hypercalcaemia</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000227-bbs2-0061" title="BroeKE , ChenTC , WeinbergJ , Bischoff-FerrariHA , HolickMF , KielDP . A higher dose of vitamin D reduces the risk of falls in nursing home residents: a randomized, multiple-dose study. Journal of the American Geriatrics Society2007;55(2):234-9. KielDP , BroeKE , ChenTC , CupplesLA , Bischoff-FerrariH , HolickMF . A higher dose of vitamin D reduces the risk of falls in nursing home residents: a randomized, placebo-controlled, multiple dose study. Journal of Bone and Mineral Research2004;19(Suppl 1):S462-3. ">Broe 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Death</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000227-bbs2-0063" title="ChenJT , ShirakiM , HasumiK , TanakaN , KataseK , KatoT , et al. 1-alpha-hydroxyvitamin D3 treatment decreases bone turnover and modulates calcium-regulating hormones in early postmenopausal women. Bone1997;20:557-62. ">Chen 1997</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Gastrointestinal event, hypercalcaemia</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000227-bbs2-0066" title="CorlessD , DawsonE , FraserF , EllisM , EvansSJW , PerryJD , et al. Do vitamin D supplements improve the physical capabilities of elderly hospital patients?Age and Ageing1985;14:76-84. ">Corless 1985</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Death, hypercalcaemia</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000227-bbs2-0067" title="DalyRM , BassS , NowsonC . Long-term effects of calcium-vitamin-D3-fortified milk on bone geometry and strength in older men. Bone2006;39(4):946-53. DalyRM , BrownM , BassS , KukuljanS , NowsonC . Calcium and vitamin D3 fortified milk reduces bone loss at clinically relevant skeletal sites in older men: a 2-year randomised controlled trial. Journal of Bone and Mineral Research2005;20(Suppl 1):S97. DalyRM , BrownM , BassS , KukuljanS , NowsonC . Calcium- and vitamin D3-fortified milk reduces bone loss at clinically relevant skeletal sites in older men: a 2-year randomized controlled trial. Journal of Bone and Mineral Research2006;21(3):397-405. KukuljanS , DalyRM , BassSL , SandersK , NicholsonGC , TurnerCH , et al. Does calcium-vitamin D3 fortified milk enhance the effects of exercise on BMD in older men: an 18 month randomised controlled trial. Journal of Bone and Mineral Research2006;21(Suppl 1):S184. ">Daly 2006</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Gastrointestinal event</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000227-bbs2-0068" title="Dawson-HughesB , DallalGE , KrallEA , HarrisS , SokollLJ , FalconerG . Effect of vitamin D supplementation on wintertime and overall bone loss in healthy postmenopausal women. Annals of Internal Medicine1991;115:505-12. ">Dawson‐Hughes 1991</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Renal insufficiency and renal stone, hypercalcaemia</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000227-bbs2-0073" title="DoetschAM , FaberJ , LynnerupN , WatjenI , BliddalH , Danneskiold-SamsoeB . The effect of calcium and vitamin D3 supplementation on the healing of the proximal humerus fracture: a randomized placebo-controlled study. Calcified Tissue International2004;75:183-8. ">Doetsch 2004</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Death</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000227-bbs2-0079" title="GradyD , HalloranB , CummingsS , LeveilleS , WellsL , BlackD , et al. 1,25 dihydroxy vitamin D3 and muscle strength in the elderly: a randomized clinical trial. Journal of Clinical Endocrinology and Metabolism1991;73:1111-7. ">Grady 1991</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Death, renal insufficiency</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000227-bbs2-0088" title="JensenC , HollowayL , BlockG , SpillerG , GildengorinG , GundersonE , et al. Long-term effects of nutrient intervention on markers of bone remodeling and calciotropic hormones in late-postmenopausal women. American Journal of Clinical Nutrition2002;75:1114-20. [MEDLINE: 12036821]JensenGF , ChristiansenC , TransbolI . Treatment of post menopausal osteoporosis. A controlled therapeutic trial comparing oestrogen/gestagen, 1,25-dihydroxy-vitamin D3 and calcium. Clinical Endocrinology1982;16:515-24. ">Jensen 1982</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Hypercalcaemia</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000227-bbs2-0091" title="JohnsonKR , JobberJ , StonawskiBJ . Prophylactic vitamin D in the elderly. Age and Ageing1980;9:121-7. ">Johnson 1980</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Hypercalcaemia</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000227-bbs2-0092" title="KeaneEM , HealyM , O'MooreR , CoakleyD , WalshJB . Vitamin D-fortified liquid milk: benefits for the elderly community-based population. Calcified Tissue International1998;62:300-2. ">Keane 1998</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Death</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000227-bbs2-0095" title="LarsenER , MosekildeL , FoldspangA . Determinants of acceptance of a community-based program for the prevention of falls and fractures among the elderly. Preventive Medicine2001;33(2 Pt 1):115-9. LarsenER , MosekildeL , FoldspangA . Vitamin D and calcium supplementation prevents osteoporotic fractures in elderly community dwelling residents: a pragmatic population-based 3-year intervention study. Journal of Bone and Mineral Research2004;19(3):370-8. LarsenER , MosekildeL , FoldspangA . Vitamin D and calcium supplementation prevents severe falls in elderly community-dwelling women: a pragmatic population-based 3-year intervention study. Aging Clinical and Experimental Research2005;17(2):125-32. LarsenER , MosekildeL , FoldspangA . Vitamin D and calcium treatment and environmental adjustment in the prevention of falls and osteoporotic fractures among elderly Danish community residents. Journal of Bone and Mineral Research2002;17(Suppl 1):S157. ">Larsen 2004</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Death</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000227-bbs2-0096" title="LathamNK , AndersonCS , LeeA , BennettDA , MoseleyA , CameronID . A randomized, controlled trial of quadriceps resistance exercise and vitamin D in frail older people: the Frailty Interventions Trial in Elderly Subjects. Journal of the American Geriatrics Society2003;51:291-9. ">Latham 2003</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Death</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000227-bbs2-0097" title="MeierC , WoitgeHW , WitteK , LemmerB , SeibelMJ . Supplementation with oral vitamin D3 and calcium during winter season prevents seasonal bone loss: a randomized controlled open-label prospective trial. Journal of Bone and Mineral Research2004;19:1221-30. ">Meier 2004</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Death</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000227-bbs2-0098" title="MoschonisG , ManiosY . Skeletal site-dependent response of bone mineral density and quantitative ultrasound parameters following a 12-month dietary intervention using dairy products fortified with calcium and vitamin D: the Postmenopausal Health Study. British Journal of Nutrition2006;96(6):1140-8. ">Moschonis 2006</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Gastrointestinal event</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000227-bbs2-0100" title="OngphiphadhanakulB , PiaseuN , Sae TungS , ChailurkitL , RajatanavinR . Prevention of postmenopausal bone loss by low and conventional doses of calcitriol or conjugated equine estrogen. Maturitas2000;34:179-84. ">Ongphiphadhanakul 2000</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Hypercalcaemia</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000227-bbs2-0102" title="OrimoH , NakamuraT , FukunagaM , OhtaH , HosoiT , UemuraY , et al. Effects of alendronate plus alfacalcidol in osteoporosis patients with a high risk of fracture: the Japanese Osteoporosis Intervention Trial (JOINT) - 02. Current Medical Research and Opinion2011;27(6):1273-84. ">Orimo 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Gastrointestinal event, hypercalcaemia</p> </td> </tr> </tbody> </table> </div> <section id="CD000227-sec-0046"> <h5 class="title">Ongoing studies</h5> <p>We identified two ongoing studies, details of which are given in the '<a href="./references#CD000227-sec-0127" title="">Characteristics of ongoing studies</a>' table. </p> </section> <section id="CD000227-sec-0047"> <h5 class="title">Studies awaiting classification</h5> <p>A further 13 trials have met, or may meet, the inclusion criteria, but require further information or revision to the review protocol before their data can be included (<i>see</i> '<a href="./references#CD000227-sec-0126" title="">Characteristics of studies awaiting classification</a>' table). </p> </section> </section> </section> <section id="CD000227-sec-0048"> <h3 class="title">Risk of bias in included studies</h3> <p>The results of the assessment of the methodological quality of each included trial are in <a href="#CD000227-fig-0002">Figure 2</a>, <a href="#CD000227-fig-0003">Figure 3</a> and <a href="#CD000227-tbl-0007">Table 6</a>. </p> <div class="figure" id="CD000227-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies" data-id="CD000227-fig-0002" src="/cdsr/doi/10.1002/14651858.CD000227.pub4/media/CDSR/CD000227/image_n/nCD000227-FIG-02.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies </p> </div> </div> </div> <div class="figure" id="CD000227-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study" data-id="CD000227-fig-0003" src="/cdsr/doi/10.1002/14651858.CD000227.pub4/media/CDSR/CD000227/image_n/nCD000227-FIG-03.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study </p> </div> </div> </div> <div class="table" id="CD000227-tbl-0007"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 6.</span> <span class="table-title">Quality assessment scores</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Study</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Item B</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Item C</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Item D</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Item E</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Item F</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Item G</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Item H</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Item J</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000227-bbs2-0001" title="AloiaJF , VaswaniA , YehJK , EllisK , YasumuraS , CohnSH . Calcitriol in the treatment of postmenopausal osteoporosis. American Journal of Medicine1988;84(3 Pt 1):401-8. AloiaJF . Role of calcitriol in the treatment of postmenopausal osteoporosis. Metabolism1990;39(4 Suppl 1):35-8. GallagherJC . Personal communication 21 February 1995. ">Aloia 1988</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000227-bbs2-0002" title="ArthurRS , PirainoB , CandibD , CoopersteinL , ChenT , WestC , et al. Effect of low-dose calcitriol and calcium therapy on bone histomorphometry and urinary calcium excretion in osteopenic women. Mineral and Electrolyte Metabolism1990;16(6):385-90. [MEDLINE: 1991211662]">Arthur 1990</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000227-bbs2-0003" title="AvenellA , GrantAM , McGeeM , McPhersonG , CampbellMK , McGee MA for the RECORD Trial Management Group. The effects of an open design on trial participant recruitment, compliance and retention - a randomized controlled trial comparison with a blinded, placebo-controlled design. Clinical Trials Journal2004;1:490-8. AvenellA . Personal communication2005. ">Avenell 2004</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000227-bbs2-0004" title="Bischoff-FerrariHA , ConzelmannM , StahelinHB , DickW , CarpenterMG , AdkinAL , et al. Is fall prevention by vitamin D mediated by a change in postural or dynamic balance?Osteoporosis International2006;17(5):656-63. BischoffHA , StahelinHB , DickW , AkosR , KnechtM , SalisC , et al. Effects of vitamin D and calcium supplementation on falls: a randomized controlled trial. Journal of Bone and Mineral Research2003;18(2):343-51. [MEDLINE: 12568412]BischoffHA . Personal communication 13 July 2003. BischoffHA . Vitamin D deficiency in the elderly. Journal of Bone and Mineral Research2003;18(7):1343. [MEDLINE: 12854846]HeaneyR . Vitamin D depletion and effective calcium absorption. Journal of Bone and Mineral Research2003;18(7):1342. ">Bischoff 2003</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000227-bbs2-0005" title="Bolton-SmithC , McMurdoME , PatersonCR , MolePA , HarveyJM , FentonST , et al. Two-year randomized controlled trial of vitamin K1 (phylloquinone) and vitamin D3 plus calcium on bone health of older women. Journal of Bone and Mineral Research2007;22(4):509-19. McMurdoME . Personal communication 1 October 2007. ">Bolton‐Smith 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000227-bbs2-0006" title="BurleighE , McCollJ , PotterJ . Does vitamin D stop inpatients falling? A randomised controlled trial. Age and Ageing2007;36(5):507-13. ">Burleigh 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000227-bbs2-0007" title="CaniggiaA , DellingG , NutiR , LoreF , VattimoA . Clinical, biochemical and histological results of a double-blind trial with 1,25-dihydroxyvitamin D3, estradiol and placebo in post-menopausal osteoporosis. Acta Vitaminologica et Enzymologica1984;6(2):117-28. ">Caniggia 1984</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000227-bbs2-0008" title="ChapuyMC , ArlotM , et al. Prevention of non vertebral fractures and cortical bone loss in elderly women: a prospective controlled trial using calcium and vitamin D3 supplements [abstract]. Osteoporosis International1993;3 Suppl 1:258. ChapuyMC , ArlotME , DelmasPD , MeunierPJ . Effect of calcium and cholecalciferol treatment for three years on hip fractures in elderly women. BMJ1994;308:1081-2. ChapuyMC , ArlotME , DuboeufF , BrunJ , CrouzetB , ArnaudS , et al. Vitamin D3 and calcium to prevent hip fractures in elderly women. New England Journal of Medicine1992;327:1637-42. MeunierPJ , PamphileR , ChapuyMC , SchultenJ , ArlotM , LilluH . A calcium-vitamin D3 combined supplementation is cost-saving for preventing hip fractures in institutionalised elderly women: an economic evaluation from the perspective of seven European countries (Belgium, France, Germany, The Netherlands, Spain, Sweden, United Kingdom). Osteoporosis International2002;13(Suppl 1):S14. ">Chapuy 1992</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000227-bbs2-0009" title="BosworthC , deBoerIH , TargherG , KendrickJ , SmitsG , ChoncholM . The effect of combined calcium and cholecalciferol supplementation on bone mineral density in elderly women with moderate chronic kidney disease. Clinical Nephrology2012;77(5):358-65. ChapuyMC , PamphileR , ParisE , KempfC , SchlichtingM , ArnaudS , et al. Combined calcium and vitamin D3 supplementation in elderly women: confirmation of reversal of secondary hyperparathyroidism and hip fracture risk: the Decalyos II study. Osteoporosis International2002;13(3):257-64. [MEDLINE: 11991447]ChapuyMC , PamphileR , ParisE , KempfC , SchlichtingM , ArnaudS , et al. Combined calcium and vitamin D3 supplementation to prevent hip fracture in elderly women. A confirmatory study: Decalyos II. Osteoporosis International2002;13(Suppl 1):S25. MeunierPJ . Personal communication 28 February 2005. ">Chapuy 2002</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000227-bbs2-0010" title="Bischoff-FerrariHA , OravEJ , Dawson-HughesB . Additive effect of higher testosterone levels and vitamin D plus calcium supplementation in regard to fall risk reduction among older men and women. Osteoporosis International2008;19:1307-14. Bischoff-FerrariHA , OravEJ , Dawson-HughesB . Effect of cholecalciferol plus calcium on falling in ambulatory older men and women: a 3-year randomized controlled trial. Archives of Internal Medicine2006;166(4):424-30. Bischoff-FerrariHA , OravEJ , Dawson-HughesB . Effect of vitamin D3 plus calcium on fall risk in older men and women: a 3-year randomized controlled trial. Journal of Bone and Mineral Research2004;19(Suppl 1):S57. Dawson-HughesB , HarrisSS , KrallEA , DallalGE . Effect of calcium and vitamin D supplementation on bone density in men and women 65 years of age or older. New England Journal of Medicine1997;337(10):670-6. Dawson-HughesB , HarrisSS , KrallEA , DallalGE . Effect of withdrawal of calcium and vitamin D supplements on bone mass in elderly men and women. American Journal of Clinical Nutrition2000;72(3):745-50. Dawson-HughesB , HarrisSS . Calcium intake influences the association of protein intake with rates of bone loss in elderly men and women. American Journal of Clinical Nutrition2002;75(4):773-9. KrallEA , RandallC , HarrisSS , GarciaRI , Dawson-HughesB . Calcium and vitamin D supplements reduce tooth loss in the elderly. Journal of Bone and Mineral Research2000;15(Suppl 1):S191. KrallEA , WehlerC , GarciaRI , HarrisSS , Dawson-HughesB . Calcium and vitamin D supplements reduce tooth loss in the elderly. American Journal of Medicine2001;111(6):452-6. NiramitmahapanyaS , HarrisSS , Dawson-HughesB . Type of dietary fat is associated with the 25-hydroxyvitamin D3 increment in response to vitamin D supplementation. Journal of Clinical Endocrinology and Metabolism2011;96(10):3170-4. ">Dawson‐Hughes 1997</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000227-bbs2-0011" title="DukasL , BischoffHA , LindpaintnerLS , SchachtE , Birkner-BinderD , DammTN , et al. Alfacalcidol reduces the number of fallers in a community-dwelling elderly population with a minimum calcium intake of more than 500 mg daily. Journal of the American Geriatrics Society2004;52(2):230-6. DukasL , BischoffHA , LindpaintnerLS , SchachtE , Birkner-BinderD , ThalmanB , et al. Alfacalcidol reduces the number of fallers and falls in community-dwelling elderly provided a minimum total daily intake of 500mg calcium [abstract]. Calcified Tissue International2003;72:371. DukasL , SchachtE , MazorZ , StahelinHB . Treatment with alfacalcidol in elderly people significantly decreases the high risk of falls associated with a low creatinine clearance of &lt;65 ml/min. Osteoporosis International2005;16(2):198-203. DukasL , SchachtE , StahelinHB . A significant independent new risk factor for falls in the elderly: a low creatinine clearance of less than 65ml/min. Osteoporosis International2003;14(Suppl 7):S33. DukasL , SchachtE , StahelinHB . High risk of falls related to low D-hormone syndrome and its treatment with alfacalcidol. Osteoporosis International2004;15(Suppl 1):S8-9. DukasL , SchachtE , StahelinHB . Reduction of falls and fallers in high risk patients by D-hormone analogs. Osteoporosis International2004;15(Suppl 1):S144-5. DukasL , SchachtE , StahelinHB . Treatment with alfacalcidol significantly decreases the high incidence of fallers and the high risk of falls associated with low creatinine clearance (&lt;65ml/min) in elderly community-dwelling men and women. Osteoporosis International2003;14(Suppl 7):S33. DukasL , SchachtE . Reduction of falls and fallers using D-hormone analogs. Osteoporosis International2006;17(Suppl 1):S122-3. DukasLC , SchachtE , MazorZ , StahelinHB . The low creatinine clearance associated high risk of falls can significantly be treated with alfacalcidol. Journal of Bone and Mineral Research2004;19(Suppl 1):S95. DukasLC . Personal communication 19 July 2004. ">Dukas 2004</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000227-bbs2-0012" title="EbelingPR , WarkJD , YeungS , PoonC , SalehiN , NicholsonGC , et al. Effects of calcitriol or calcium on bone mineral density, bone turnover, and fractures in men with primary osteoporosis: a two-year randomized, double-blind, double placebo study. Journal of Clinical Endocrinology and Metabolism2001;86(9):4098-103. EbelingPR . Personal communication 15 February 2005. ">Ebeling 2001</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000227-bbs2-0013" title="FalchJA , OdegaardOR , FinnangerAM , MathesonI . Postmenopausal osteoporosis: no effect of three years treatment with 1,25-dihydroxycholecalciferol. Acta Medica Scandinavica1987;221(2):199-204. [MEDLINE: 1987237893]FalchJA , OdegaardOR , FinnangerAM . 3 years treatment with 1.25(OH)2 Vitamin D3 does not reduce bone loss or fracture rate in postmenopausal women with fracture of the distal forearm. In: NormanAW , SchaeferK , Grigoleit H-G, v HerrathD , editors(s). Vitamin D : chemical, biochemical, and clinical update: proceedings of the Sixth Workshop on Vitamin D, Merano, Italy, March 1985. Berlin: de Gruyter, 1985:1004-5. FalchJA . Personal communication1999. ">Falch 1987</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000227-bbs2-0014" title="FlickerL , MacInnisR , SteinM , SchererS , MeadK , NowsonC , et al. Should all older people in residential care receive vitamin D to prevent falls? Results of a randomised trial [abstract]. Journal of Bone and Mineral Research2004;19(Suppl 1):S99. FlickerL , MacInnisRJ , SteinMS , SchererSC , MeadKE , et al. Response letter to Dr. Gau et al. Journal of the American Geriatrics Society2006;54:1021-2. FlickerL , MacInnisRJ , SteinMS , SchererSC , MeadKE , NowsonCA , et al. Erratum. Journal of the American Geriatrics Society2012;60:1599. FlickerL , MacInnisRJ , SteinMS , SchererSC , MeadKE , NowsonCA , et al. Should older people in residential care receive vitamin D to prevent falls? Results of a randomized trial. Journal of the American Geriatrics Society2005;53(11):1881-8. FlickerL , MacInnisRJ , SteinMS , SchererSC , MeadKE , NowsonCA . Should all older people in residential care receive vitamin D to prevent falls? Results of a randomised trial. Journal of Bone and Mineral Research2004;19(Suppl 1):S99. FlickerL . Personal communication 7 January 2008. ">Flicker 2005</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000227-bbs2-0015" title="GallagherJC , RiggsBL , ReckerRR , GoldgarD . The effect of calcitriol on patients with postmenopausal osteoporosis with special reference to fracture frequency. Proceedings of the Society for Experimental Biology and Medicine1989;191(3):287-92. [MEDLINE: 1989296988]">Gallagher 1989</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000227-bbs2-0016" title="GallagherJC , GoldgarD . Treatment of postmenopausal osteoporosis with high doses of synthetic calcitriol. A randomized controlled study. Annals of Internal Medicine1990;113(9):649-55. [MEDLINE: 1991023790]GallagherJC . Metabolic effects of synthetic calcitriol (Rocaltrol) in the treatment of postmenopausal osteoporosis. Metabolism: Clinical &amp; Experimental1990;39(4 Suppl 1):27-9. [MEDLINE: 2112606]GallagherJC . Personal communication 21 February 1995. ">Gallagher 1990</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000227-bbs2-0017" title="GallagherJC , FowlerS . Effect of estrogen, calcitriol and a combination of estrogen and calcitriol on bone mineral density and fractures in elderly women. Journal of Bone and Mineral Research1999;14(Suppl 1):S209. GallagherJC , FowlerSE , DetterJR , ShermanSS . Combination treatment with estrogen and calcitriol in the prevention of age-related bone loss. Journal of Clinical Endocrinology and Metabolism2001;86(8):3618-28. GallagherJC , HaynatskiG , FowlerS . Calcitriol therapy reduces falls and fractures in elderly women. Calcified Tissue International2003;72:334. GallagherJC , HaynatzkiG , FowlerS . Effect of estrogen, calcitriol or the combination of both on falls and non vertebral fractures in elderly women. Journal of Bone and Mineral Research2001;17(Suppl 1):S210. GallagherJC , RapuriPB , HaynatzkiG , DetterJR . Effect of discontinuation of estrogen, calcitriol, and the combination of both on bone density and bone markers. Journal of Clinical Endocrinology and Metabolism2002;87(11):4914-23. [12414850]GallagherJC , RapuriPB , HaynatzkiG . A comparison of estrogen, calcitriol or both therapies on the relationship between serum parathyroid hormone and 25 hydroxy vitamin. Journal of Bone and MIneral Research2004;19(Suppl 1):S440. GallagherJC . Personal communication 21 February 2005. GallagherJC . The effects of calcitriol on falls and fractures and physical performance tests. Journal of Steroid Biochemistry and Molecular Biology2004;89-90(1-5):497-501. ">Gallagher 2001</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000227-bbs2-0018" title="Garay LilloJ , ParrenoJ , GonzálezY , GonzálezJA . Geminis: a prospective, multicentric, randomised study to evaluate the effect of tricalcium phosphate versus tricalcium phosphate plus 25(OH) Vitamin D on the risk of fractures in older women [Géminis: Estudio prospectivo, multicéntrico y aleatori para valorar el efecto del Fosfato Tricálcico versus Fosfato Tricálcico + 25(OH) Vitamina D sobre el riesgo de fracturas en mujerioes ancianas.]. Geriátrika1997;13(6):24-8. ">Garay Lillo 1997</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000227-bbs2-0019" title="GeusensP , DequekerJ . Long-term effect of nandrolone decanoate, 1 alpha-hydroxyvitamin D3 or intermittent calcium infusion therapy on bone mineral content, bone remodeling and fracture rate in symptomatic osteoporosis: a double-blind controlled study. Bone and Mineral1986;1(4):347-57. ">Geusens 1986</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000227-bbs2-0020" title="GlendenningP , ZhuK , InderjeethC , HowatP , LewisJR , PrinceRL . Effects of three-monthly oral 150,000 IU cholecalciferol supplementation on falls, mobility, and muscle strength in older postmenopausal women: a randomized controlled trial. Journal of Bone and Mineral Research2012;27(1):170-6. ">Glendenning 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000227-bbs2-0021" title="GoraiI , ChakiO , TaguchiY , NakayamaM , OsadaH , SuzukiN , et al. Early postmenopausal bone loss is prevented by estrogen and partially by 1alpha-OH-vitamin D3: therapeutic effects of estrogen and/or 1alpha-OH-vitamin D3. Calcified Tissue International1999;65:16-22. ">Gorai 1999</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000227-bbs2-0022" title="HarwoodRH , SahotaO , GaynorK , MasudT , HoskingD . A randomised, controlled comparison of different calcium and vitamin D supplementation regimens in elderly women after hip fracture: The Nottingham Neck of Femur (NoNOF) Study. Age and Ageing2004;33:45-51. [14695863]HarwoodRW . Personal communication 24 January 2003. SahotaO , HarwoodRH , GaynorK , MasudT , HoskingDJ . A randomised, controlled comparison of different calcium and vitamin D regimes: the NoNOF (Nottingham Neck of Femur) study. Osteoporosis International2003;14(Suppl 4):S10-11. ">Harwood 2004</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000227-bbs2-0023" title="HayashiY , FujitaT , InoueT . A multi-center study on efficacy of 1 alpha-hydroxy vitamin D3 in preventing spinal fracture of patients with osteoporosis (abstract). Journal of Bone and Mineral Research1989;4 Suppl 1:Si84. HayashiY , FujitaT , InoueT . Decrease of vertebral fracture in osteoporotics by administration of 1alpha-hydroxy-vitamin D3. Journal of Bone and Mineral Metabolism1992;10(2):50-4. ">Hayashi 1992</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000227-bbs2-0024" title="InkovaaraJ , GothoniG , HalttulaR , HeikinheimoR , TokolaO . Calcium, vitamin D and anabolic steroids in treatment of aged bones: double-blind placebo-controlled long-term clinical trial. Age and Ageing1983;12:124-30. ">Inkovaara 1983</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000227-bbs2-0025" title="AlpertJS . Concerns about the integrity of Ishida Y, Kawai S. Am J Med. 2004;117:549-555: the reply. American Journal of Medicine2020;133:e315. AvenellA , GreyA , GambleGD , BollandMJ . Concerns about the integrity of the Yamaguchi Osteoporosis Prevention Study (YOPS) report, Am J Med. 2004;117:549-555. American Journal of Medicine2020;133:e311-4. IshidaY , KawaiS . A two-year randomized controlled trial of hormone replacement therapy, etidronate, calcitonin, vitamin D, or vitamin K, in women with postmenopausal osteoporosis. Journal of Bone and Mineral Research2002;17(Suppl 1):S478. IshidaY , KawaiS . Comparative efficacy of hormone replacement therapy, bisphosphonates, calcitonin, vitamin D and vitamin K in postmenopausal women with osteoporosis. Journal of Bone and Mineral Research2003;18(Suppl 2):S158. IshidaY , KawaiS . Comparative efficacy of hormone replacement therapy, etidronate, calcitonin, alfacalcidol, and vitamin K in postmenopausal women with osteoporosis: the Yamaguchi osteoporosis prevention study. American Journal of Medicine2004;117:549-55. IshidaY , KawaiS . Comparative efficacy of hormone replacement therapy, etidronate, calcitonin, vitamin D and vitamin K in postmenopausal osteoporosis. Bone2003;33(5 Suppl1):S220. IshidaY , SohH , OgawaS , KawaharaS , MurataH . A one-year randomized controlled trial of hormone replacement therapy, bisphosphonate, calcitonin, vitamin D, and vitamin K, in women with postmenopausal osteoporosis. Journal of Bone and Mineral Research2000;15(Suppl 1):S310. IshidaY , SohH , TsuchidaS , KawaharaS , MurataH , KawaiS . Effectiveness of hormone replacement therapy, etidronate, calcitonin, vitamin D, and vitamin K in postmenopausal women with osteoporosis [abstract]. Bone2002;30(3 Suppl 1):50S. IshidaY . Personal communication 21 February 2005. ">Ishida 2004 (retracted)</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000227-bbs2-0026" title="JanssenHC , SamsonMM , VerhaarHJ . Muscle strength and mobility in vitamin D-insufficient female geriatric patients: a randomized controlled trial on vitamin D and calcium supplementation. Aging Clinical and Experimental Research2010;22(1):78-84. ">Janssen 2010</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000227-bbs2-0027" title="KomulainenM , KrogerH , TuppurainenMT , HeikkinenAM , AlhavaE , HonkanenR , et al. Prevention of femoral and lumbar bone loss with hormone replacement therapy and Vitamin D3 in early postmenopausal women: a population based 5-year randomized trial. Journal of Clinical Endocrinology and Metabolism1999;84(2):546-52. KomulainenM , KrogerH , TuppurainenMT , Keikkinen A-M, HonkanenR , SaarikoskiS , et al. Identification of early postmenopausal women with no bone response to HRT: results of a five-year clinical trial. Osteoporosis International2000;11:211-8. KomulainenMH , KrogerH , TuppurainenMT , Heikkinen A-M, AlhavaE , HonkanenR , et al. HRT and Vit D in prevention of non-vertebral fractures in postmenopausal women; a 5 year randomized trial. Maturitas1998;31(1):45-54. KomulainenMH . Personal communication 11 November 2004. ">Komulainen 1998</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000227-bbs2-0028" title="LawM , MorrisJ , WithersH . Cholecalciferol, not ergocalciferol, should be used for vitamin D supplementation [author reply]. Age and Ageing2006;35(6):645. [MEDLINE: 16982666]LawM , MorrisJ , WithersH . Vitamin D supplementation and the prevention of fractures and falls. Reply. Age and Ageing2007;36(2):233. LawM , MorrisJ , WithersH . Vitamin D supplementation and the prevention of fractures and falls [author reply]. Age and Ageing2007;36(2):233. [MEDLINE: 17255084]LawM , WithersH , MorrisJ , AndersonF . Vitamin D supplementation and the prevention of fractures and falls: results of a randomised trial in elderly people in residential accommodation [comment in: Age and Ageing 2006;35(6):645 and Age and Ageing 2007;36(2):232-3]. Age and Ageing2006;35(5):482-6. ">Law 2006</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000227-bbs2-0029" title="GraafmansWC , OomsME , HofsteeHMA , BezemerPD , BouterLM , LipsP . Falls in the elderly: a prospective study of risk factors and risk profiles. American Journal of Epidemiology1996;143(11):1129-36. LipsP , GraafmansWC , OomsME , BezemerPD , BouterLM . The effect of vitamin D supplementation on the incidence of hip fractures in elderly people. Journal of Bone and Mineral Research1994;9 Suppl 1:S148. LipsP , GraafmansWC , OomsME , BezemerPD , BouterLM . Vitamin D supplementation and fracture incidence in elderly persons. Annals of Internal Medicine1996;124:400-6. [MEDLINE: 1996151943]">Lips 1996</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000227-bbs2-0030" title="JohansenA , LyonsRA , StoneM , BrophyS , NewcombeRG , PhillipsCJ , et al. Preventing fractures among older people living in institutional care: a randomised double blind placebo controlled trial of vitamin D supplementation [abstract]. Age and Ageing2006;35(Suppl 3):i41. LyonsRA , JohansenA , BrophyS , NewcombeRG , PhillipsCJ , LervyB , et al. Preventing fractures among older people living in institutional care: a pragmatic randomised double blind placebo controlled trial of vitamin D supplementation. Osteoporosis International2007;18(6):811-8. LyonsRA , JohansenA , StoneMD , BrophyS , NewcombeRG , PhilipsCJ , et al. Preventing fractures among older people living in institutional care: a randomised double blind placebo controlled trial of vitamin D supplementation [abstract]. Osteoporosis International2006;17(Suppl 3):372. ">Lyons 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000227-bbs2-0031" title="MenczelJ , FoldesJ , SteinbergR , LeichterI , ShalitaB , Bjolah-AbramT , et al. Alfacalcidol (Alpha D3) and calcium in osteoporosis. Clinical Orthopaedics and Related Research1994;(300):241-7. ">Menczel 1994</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000227-bbs2-0032" title="MeyerHE , FalchJA , KvaavikE , SmedshaugGB , TverdalA , PedersenJI . Can vitamin D supplementation reduce the risk of fracture in the elderly? A randomised controlled trial. Osteoporosis International2000;11(Suppl 2):S114-5. MeyerHE , SmedshaugGB , KvaavikE , FalchJA , TverdalA , PedersenJI . Can vitamin D supplementation reduce the risk of fracture in the elderly? A randomized controlled trial. Journal of Bone and Mineral Research2002;17(4):709-15. SmedshaugGB , PedersenJI , MeyerHE . Can vitamin D supplementation improve grip strength in elderly nursing home residents? A double-blinded controlled trial. Scandinavian Journal of Food and Nutrition2007;51(2):74-8. ">Meyer 2002</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000227-bbs2-0033" title="MitriJ , Dawson-HughesB , HuFB , PittasAG . Effects of vitamin D and calcium supplementation on pancreatic β cell function, insulin sensitivity, and glycemia in adults at high risk of diabetes: the Calcium and Vitamin D for Diabetes Mellitus (CaDDM) randomized controlled trial. American Journal of Clinical Nutrition2011;94:486-94. ">Mitri 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000227-bbs2-0034" title="NakatsukaK , InabaM , ArataniH , IbaK , SatoT , KoikeT , et al. Effects of long-term administration of alfacalcidol on bone mass and bone metabolism in patients with primary osteoporosis - comparison with calcium preparations [Japanese]. Nippon Ronen Igakkai Zasshi - Japanese Journal of Geriatrics1997;34(7):569-76. ">Nakatsuka 1997</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000227-bbs2-0035" title="OnesK , SchachtE , DukasL , CaglarN . Effects of combined treatment with alendronate and alfacalcidol on bone mineral density and bone turnover in postmenopausal osteoporosis: a two-years, randomized, multiarm, controlled trial. Internet Journal of Epidemiology2007;4(1):DOI: 10.5580/1523. ">Ones 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000227-bbs2-0036" title="OrimoH , ShirakiM , HayashiY , HoshinoT , OnayaT , MiyazakiS , et al. Effects of 1-alpha-hydroxyvitamin D3 on lumbar bone mineral density and vertebral fractures in patients with postmenopausal osteoporosis. Calcified Tissue International1994;54:370-6. ">Orimo 1994</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000227-bbs2-0037" title="KarkkainenM , TuppurainenM , RikkonenT , SalovaaraK , SirolaJ , HonkanenR , et al. Vitamin-D 800IU/day + calcium 1000mg supplementation decreases the risk of recurrent falling among postmenopausal ambulatory women - a population-based, randomized, 3-year study (OSTPRE-FPS). Osteoporosis International2008;19(Suppl 1):S17-18. KarkkainenM , TuppurainenM , RikkonenT , SalovaaraK , SirolaJ , HonkanenR , et al. Vitamin-D 800IU/day + calcium supplementation decreases the risk of falling among postmenopausal ambulatory women - a population-based, randomized 3-year study (OSTPRE-FPS) [abstract]. Journal of Bone and Mineral Research2007;22(Suppl 1):S131. KarkkainenM , TuppurainenM , SalovaaraK , SandiniL , RikkonenT , SirolaJ , et al. Effect of calcium and vitamin D supplementation on bone mineral density in women aged 65-71 years: a 3-year randomized population-based trial (OSTPRE-FPS). Osteoporosis International2010;21:2047-55. KarkkainenMK , TuppurainenM , SalovaaraM , SandiniL , RikkonenT , SirolaJ , et al. Does daily vitamin D 800 IU and calcium 1000 mg supplementation decrease the risk of falling in ambulatory women aged 65-71 years? A 3-year randomized population-based trial (OSTPRE-FPS). Maturitas2010;65:359-65. KrogerHP , TuppurainenM . OSTPRE-FPS Prevention of Fractures and Falls in Postmenopausal Women With Calcium and Vitamin-D Supplementation - a Randomised Study. http://www.controlled-trials.com/mrct/trial/405493/OSTPRE. SalovaaraK , TuppurainenM , KarkkainenM , RikkonenT , SandiniL , SirolaJ , et al. Effect of vitamin D3 and calcium on fracture risk in 65- to 71-year-old women: a population-based 3-year randomized, controlled trial - the OSTPRE-FPS. Journal of Bone and Mineral Research2010;25(7):1487-95. SalovaaraKT , TuppurainenM , RikkonenT , KarkkainenM , SirolaJ , HonkanenR , et al. Effect of vitamin-D3 and calcium on fracture risk in 65-71 year old women in a 3-year randomized clinical trial - preliminary results from the OSTPRE-Fracture Prevention Study. Calcified Tissue International2008;82:545-6. SalovaaraKT , TuppurainenM , RikkonenT , KarkkainenM , SirolaJ , HonkanenR , et al. Effect of vitamin-D3 and calcium on fracture risk in 65-71 year old women in a 3-year randomized clinical trial - preliminary results of the OSTPRE-Fracture Prevention Study. Journal of Bone and Mineral Research2007;22(Suppl 1):S76. ">OSTPRE‐FPS 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000227-bbs2-0038" title="OttSM , ChesnutCH . Calcitriol treatment is not effective in postmenopausal osteoporosis: see comments. Annals of Internal Medicine1989;110:267-74. ">Ott 1989</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000227-bbs2-0039" title="PeacockM , LiuG , CareyM , McClintockR , AmbrosiusW , HuiS , et al. Effect of calcium or 25OH vitamin D3 dietary supplementation on bone loss at the hip in men and women over the age of 60. Journal of Clinical Endocrinology and Metabolism2000;85:3011-9. ">Peacock 2000</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000227-bbs2-0040" title="MinneHW , PfeiferM , BegerowB , NachtigallD , HansenC . Vitamin D and calcium supplementation reduces falls in elderly women via improvement of body sway and normalisation of blood pressure; a prospective, randomized, and double-blind study. Osteoporosis International2000;11(Suppl 2):S115. PfeiferM , BegerowB , MinneHW , AbramsC , NachtigallD , HansenC . Effects of a short-term vitamin D and calcium supplementation on body sway and secondary hyperparathyroidism in elderly women. Journal of Bone and Mineral Research2000;15(6):1113-8. PfeiferM , BegerowB , NachtigallD , HansenC . Prevention of falls-related fractures: vitamin D reduces body sway in the elderly - a prospective, randomized, double blind study [abstract]. Bone1998;23(5 Suppl 1):1110. ">Pfeifer 2000</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000227-bbs2-0041" title="BollandMJ , GreyA . Different outcomes of meta-analyses and data inconsistency:response to comments by Pfeifer. Archives of Osteoporosis2015;10:43. BollandMJ , GreyA . Inconsistent data in text and tables. Osteoporosis International2015;26:2713. MinneHW , DobnigH , PfeiferM , SuppanK . Effects of vitamin D and calcium supplementation on falls and parameters of muscle function: a prospective, randomized, double-blind multicenter study [abstract]. Osteoporosis International2006;17(Suppl 2):S212. MinneHW , DobnigH , PfeiferM , SuppanK . Effects of vitamin D and calcium supplementation on falls and parameters of muscle-function - a prospective, randomized, double-blind multi-center study [abstract]. Osteoporosis International2006;17(Suppl 1):S21. PfeiferM , BegerowB , MinneHW , SuppanK , Fahrleitner-PammerA , DobnigH . Effects of a long-term vitamin D and calcium supplementation on falls and parameters of muscle function in community-dwelling older individuals. Osteoporosis International2009;20:315-22. PfeiferM , DobnigH , BegerowB , SuppanK . Effects of vitamin D and calcium supplementation on falls and parameters of muscle function: a prospective randomized, double-blind multi-centre study [abstract]. Journal of Bone and Mineral Research2004;19(Suppl 1):S58. PfeiferM , DobnigH , MinneHW , SuppanK . Effects of vitamin D and calcium supplementation on falls and parameters of muscle function - a prospective, randomized, double-blind multi-center study [abstract]. Osteoporosis International2005;16(Suppl 3):S45. PfeiferM . Different outcomes of meta-analyses and data inconsistency. Osteoporosis International2015;26:2715–2716. PfeiferM . Randomized controlled clinical trials and meta-analyses. Archives of Osteoporosis2015;10:42. ">Pfeifer 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000227-bbs2-0042" title="DumvilleJC , MilesJN , PorthouseJ , CockayneES , SaxonL , KingC , et al. Can vitamin D supplementation prevent seasonal affective disorder? A randomised trial among older women. Osteoporosis International2004;15:S42-3. PorthouseJ , CockayneS , KingC , SaxonL , SteeleE , AsprayT , et al. Randomised controlled trial of calcium and supplementation with cholecalciferol (vitamin D3) for prevention of fractures in primary care. BMJ2005;330(7498):1003-6. PorthouseJ , CockayneS , KingC , SaxonL , SteeleE , AsprayT , et al. Randomised controlled trial of calcium and vitamin D supplementation for fracture prevention in primary care. Osteoporosis International2004;15(Suppl 2):S13. PorthouseJ , CockayneS , KingC , SaxonL , SteeleE , AsprayT , et al. Randomised controlled trial of calcium and vitamin D supplementation for fracture prevention in primary care. Osteoporosis International2005;16:S27. PufferS . Calcium and vitamin D in primary care: adherence results from a randomised controlled trial [abstract 6.9.3]. In: RCN International Nursing Conference; 2004 Mar 21-31; Cambridge (UK). London: Royal College of Nursing, 2004. S Puffer, on behalf of the Calcium and Vitamin D Trial. Calcium and vitamin D in primary care. Compliance results from a randomised controlled trial. Osteoporosis International2003;14(Suppl 4):S8. TorgersonD , on behalf of the trial group. Calcium and vitamin D in preventing fractures [author reply]. BMJ2005;331(7508):109. TorgersonDJ . Personal communication 9-16 February 2005. ">Porthouse 2005</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000227-bbs2-0043" title="PrinceRL , AustinN , DevineA , DickIM , BruceD , ZhuK . Effects of ergocalciferol added to calcium on the risk of falls in elderly high-risk women. Archives of Internal Medicine2008;168(1):103-8. ZhuK , BruceD , AustinN , DevineA , EbelingPR , PrinceRL . Randomized controlled trial of the effects of calcium with or without vitamin D on bone structure and bone-related chemistry in elderly women with vitamin D insufficiency. Journal of Bone and Mineral Research2008;23(8):1343-8. ZhuK , DevineA , DickIM , WilsonSG , PrinceRL . Effects of calcium and vitamin D supplementation on hip bone mineral density and calcium-related analytes in elderly ambulatory Australian women: a five-year randomized controlled trial. Journal of Clinical Endocrinology and Metabolism2008;93(3):743-9. ">Prince 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000227-bbs2-0044" title="AndersonFH , GrantAM , AvenellA , CampbellMK , CooperC , DonaldsonC , et al. The RECORD Trial: an evaluation of calcium and/or vitamin D in the secondary prevention of osteoporotic fractures. Bone2005;36(Suppl 2):S122-3. FrancisRM , Grant AM and the RECORD trial group. The RECORD trial: a randomised double-blind study of calcium and/or vitamin D in the secondary prevention of low trauma fractures. Age Ageing2005;34(Suppl 2):ii15. GrantA , on behalf of the RECORD Trial Group. Prevention of low-trauma fractures in older people [author reply]. Lancet2005;366(9485):543-4. GrantAM , AndersonFH , for the RECORD Trial Group. The Medical Research Council RECORD Trial: an evaluation of calcium and/or vitamin D in the secondary prevention of osteoporotic fractures. Osteoporosis International2004;15(Suppl 2):S13. GrantAM , AndersonFH . The RECORD trial: an evaluation of calcium and/or vitamin D in the secondary prevention of osteoporotic fractures. Osteoporosis International2005;16(Suppl 3):S4-5. GrantAM , AvenellA , CampbellMK , McDonaldAM , MacLennanGS , McPhersonGC , et al. Oral vitamin D3 and calcium for secondary prevention of low-trauma fractures in elderly people (Randomised Evaluation of Calcium Or vitamin D, RECORD): a randomised placebo-controlled trial [comment in: Lancet 2005;366(9485):543]. Lancet2005;365(9471):1621-8. GrantAM . Personal communication 11 March 2004. ">RECORD 2005</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000227-bbs2-0045" title="ShirakiM , KushidaK , YamazakiK , NagaiT , InoueT , OrimoH . Effects of 2 years' treatment of osteoporosis with 1alpha-hydroxy vitamin D3 on bone mineral density and incidence of fracture: a placebo-controlled, double-blind prospective study. Endocrine Journal1996;43(2):211-20. ">Shiraki 1996</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000227-bbs2-0046" title="AndersonFH , SmithHE , RaphaelHM , CooperC . Intramuscular vitamin D increased serum 1,25-dihydroxycholecalciferol but did not affect 25-hydroxy-cholecalciferol levels in health older adults [abstract]. Journal of Bone and Mineral Research2000;15(Suppl 1):S315. AndersonFH , SmithHE , RaphaelHM , CrozierSR , CooperC . Effect of annual intramuscular vitamin D3 supplementation on fracture risk in 9440 community-living older people: the Wessex fracture prevention trial [abstract]. Journal of Bone and Mineral Research2004;19(Suppl 1):S57. ArdenNK , CrozierS , SmithH , AndersonF , EdwardsC , RaphaelH , et al. Knee pain, knee osteoarthritis, and the risk of fracture. Arthritis and Rheumatism2006;55(4):610-5. CooperC , CrozierS . Personal communication 23 February 2005. RaphaelH , SmithH , AndersonF , CooperC . Tackling the problems of trial management in primary care - experience from the Wessex research network fracture prevention study of annual vitamin D injection in older people [abstract]. Osteoporosis International2000;11(Suppl 1):S63-4. SmithH , AndersonF , RaphaelH , CooperC . The Wessex research network fracture prevention study - a large pragmatic trial of annual vitamin D injection in older people [abstract]. Osteoporosis International2000;11(Suppl 1):S64. SmithH , AndersonF , RaphaelH , CrozierS , CooperC . Effect of annual intramuscular vitamin D supplementation on fracture risk: population-based, randomised, double-blind, placebo-controlled trial [abstract]. Osteoporosis International2004;15(Suppl 1):S8. SmithH , AndersonF , RaphaelH , MaslinP , CrozierS , CooperC . Effect of annual intramuscular vitamin D on fracture risk in elderly men and women--a population-based, randomized, double-blind, placebo-controlled trial. Rheumatology2007;46(12):1852-7. ">Smith 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000227-bbs2-0047" title="MorrisonNA , GeorgePM , VaughanT , TilyardMW , FramptonCM , GilchristNL . Vitamin D receptor genotypes influence the success of calcitriol therapy for recurrent vertebral fracture in osteoporosis. Pharmacogenetics and Genomics2005;15(2):127-35. TilyardM . Low-dose calcitriol versus calcium in established postmenopausal osteoporosis. Metabolism: Clinical &amp; Experimental1990;39(4 Suppl 1):50-2. TilyardMW , SpearsGF , ThomsonJ , DoveyS . Treatment of postmenopausal osteoporosis with calcitriol or calcium. New England Journal of Medicine1992;326(6):357-62. TilyardMW , SpearsGFS , ThomsonJ , DoveyS . Calcitriol or calcium for postmenopausal osteoporosis. New England Journal of Medicine1992;327:284. TilyardMW . 1,25-dihydroxyvitamin D3 (calcitriol) in the treatment of postmenopausal osteoporosis. Aktuelle Rheumatologie1994;19(Suppl 1):23-6. ">Tilyard 1992</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000227-bbs2-0048" title="TrivediDP , DollR , KhawKT . Effect of four monthly oral vitamin D3 (cholecalciferol) supplementation on fractures and mortality in men and women living in the community: randomised double blind controlled trial. BMJ2003;326:469. ">Trivedi 2003</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000227-bbs2-0049" title="UshiroyamaT , IkedaA , SakaiM , HigashiyamaT , UekiM . Effects of the combined use of calcitonin and 1alpha-hydroxycholecalciferol on vertebral bone loss and bone turnover in women with postmenopausal osteopenia and osteoporosis: a prospective study of long-term and continuous administration with low dose calcitonin. Maturitas2001;40:229-38. ">Ushiroyama 2001</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000227-bbs2-0050" title="SandersK , DuqueG , EbelingP , McCorquodaleT , HerrmannM , Shore-LorentiC , et al. The efficacy of high-does oral vitamin D3 administered once a year: increased fracture risk is associated with 1,25 vitamin D level at 3-months post dose. In: ASBMR Annual Meeting; 2012 Oct 12-15; Minneapolis, Minnesota. http://www.asbmr.org/Meetings/AnnualMeeting/AbstractDetail.aspx?aid=6beb2500-4b8e-472b-8b38-d881cadb80e3. 2012. SandersK , StuartA , WilliamsonE , SimpsonJ , KotowiczM , NicholsonG . The efficacy of high-dose oral vitamin D3 administered once a year: a randomised, double-blind, placebo-controlled trial (Vital D study) for falls and fractures in older women. Osteoporosis International2011;22(Suppl 1):S104-5. SandersKM , DuqueG , McCorquodaleT , StuartAL , WilliamsonEJ , KotowiczMA , et al. Annual high-dose oral vitamin D3: is the increased risk of falls attributable to changes in muscle strength?Osteoporosis International2011;22(Suppl 4):S552. SandersKM , EbelingPR , StuartAL , WilliamsonEJ , KotowiczMA , NicholsonGC . Annual high-dose oral vitamin D3: is increased risk of fractures attributable to changes in bone turnover markers?Osteoporosis International2011;22(Suppl 4):S589. SandersKM , HaylesAL , KotowiczMA , NicholsonGC . Does vitamin D explain the lower fracture rate in rural communities?Bone2007;40(6 Suppl 2):S195. SandersKM , HaylesAL , KotowiczMA , NicholsonGC . The possible role of vitamin D and falls in relation to lower fracture rates in rural communities. Osteoporosis International2007;18(Suppl 1):S120-1. SandersKM , StuartAL , KotowiczMA , NicholsonGC . Annual feedback is an effective tool for a sustained increase in calcium intake among older women. Nutrients2010;2:1018-25. SandersKM , StuartAL , MerrimanEN , ReadML , KotowiczMA , YoungD , et al. Trials and tribulations of recruiting 2,000 older women onto a clinical trial investigating falls and fractures: Vital D study. BMC Medical Research Methodology2009;9:78. SandersKM , StuartAL , NicholsonGC . High-dose oral vitamin D supplementation and risk of falls in older women. JAMA2010;304(8):856-7. SandersKM , StuartAL , WilliamsonEJ , JackaFN , DoddS , NicholsonG , et al. Annual high-dose vitamin D3 and mental well-being: randomised controlled trial. British Journal of Psychiatry2011;198:357-64. SandersKM , StuartAL , WilliamsonEJ , SimpsonJA , KotowiczMA , NicholsonGC . Annual high-dose oral vitamin D for falls and fractures in elderly women: a randomised, double-blind, placebo-controlled trial (Vital D study). Osteoporosis International2010;21(Suppl 1):S30. SandersKM , StuartAL , WilliamsonEJ , SimpsonJA , KotowiczMA , YoungD , et al. Annual high-dose oral vitamin D and falls and fractures in older women. A randomized controlled trial. JAMA2010;303(18):1815-22. Sanders KM et al. Incorrect data. JAMA2010;303(23):2357. ">Vital D</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000227-bbs2-0051" title="CauleyJ , Wactawski-WendeJ , RobbinsJ , RodaboughR , ChenZ , JohnsonK , et al. The Women's Health Initiative (WHI) calcium and vitamin D supplementation trial: health outcomes 5 years after trial completion. ASBMR Annual Meeting; 2012 Oct 12-15; Minneapolis, Minnesota. http://www.asbmr.org/Meetings/AnnualMeeting/AbstractDetail.aspx?aid=6450bf3e-c670-4dc0-814c-8842e23cd80e (accessed 27 December 2012). CauleyJA , LaCroixA , WuL , LeeJ , HorowitzM , BauerD , et al. Serum 25 hydroxy vitamin D 25(OH) and the risk of hip fracture: the Women's Health Initiative (WHI). Journal of Bone and Mineral Research2007;22(Suppl 1):S57. ChenZ , BeckTJ , WrightNC , LaCroixAZ , CauleyJA , LewisCE , et al. The effect of calcium plus vitamin D supplement on hip geometric structures: results from the Women's Health Initiative CaD trial. Journal of Bone and Mineral Research2007;22(Suppl 1):S59. JacksonRD , LaCroixAZ , CauleyJA , McGowanJ . The Women's Health Initiative Calcium-Vitamin D Trial: overview and baseline characteristics of participants. Annals of Epidemiology2003;13:S98-106. JacksonRD , LaCroixAZ , GassM , WallaceRB , RobbinsJ , LewisCE , et al. Calcium plus vitamin D supplementation and the risk of fractures [erratum appears in New England Journal of Medicine 9 March 2006;354(10):1102]. New England Journal of Medicine2006;354(7):669-83. JacksonRD , WrightNC , BeckTJ , SherrillD , CauleyJA , LewisCE , et al. Calcium plus vitamin D supplementation has limited effects on femoral geometric strength in older postmenopausal women: the Women's Health Initiative. Calcified Tissue International2011;88:198-208. McGowanJA , JacksonRD , CauleyJA , LaCroixAZ . Calcium and vitamin D in the prevention of hip and other fractures: an update on the Women's Health Initiative CaD Trial. Journal of Bone and Mineral Research2002;17(Suppl 1):S477. The Women's Health Initiative Study Group. Design of the Women's Health Initiative clinical trial and observational study. Controlled Clinical Trials1998;19(1):61-109. ">WHI 2006</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000227-bbs2-0052" title="WithamMD , CrightonLJ , GillespieND , StruthersAD , McMurdoME . The effects of vitamin D supplementation on physical function and quality of life in older patients with heart failure. A randomized controlled trial. Circulation: Heart Failure2010;3:195-201. ">Witham 2010</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000227-bbs2-0053" title="WithamM . Can high-dose vitamin D supplementation reduce blood pressure and markers of cardiovascular risk in older people with isolated systolic hypertension? A randomised, double-blind, parallel group placebo controlled trial. http://www.controlled-trials.com/ISRCTN92186858/ (accessed 3 December 2013). WithamMD , PriceRJ , StruthersAD , DonnanPT , MessowM , FordI , et al. Vitamin D supplementation to reduce blood pressure in older patients with isolated systolic hypertension (VitDISH) - a randomised controlled trial. Personal communication ahead of publication 15 January 2013. ">Witham 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> </tr> </tbody> </table> </div> <section id="CD000227-sec-0049"> <h4 class="title">Allocation</h4> <p><a href="#CD000227-fig-0002">Figure 2</a> and <a href="#CD000227-fig-0003">Figure 3</a> show the results for the random sequence generation and allocation concealment for the Cochrane 'Risk of bias' tool. For random sequence generation: 21 (40%) trials were deemed to be at low risk, 28 trials (53%) were at unclear risk and four trials were at high risk (8%). For allocation concealment: 22 trials were at low risk (42%), 29 trials were at unclear risk (55%) and two trials were at high risk (4%). </p> </section> <section id="CD000227-sec-0050"> <h4 class="title">Blinding</h4> <p>Thirteen trials did not report any attempt to blind assessors to treatment assignment (25%) (item C). In 60% (32 trials) and 57% (30 trials) of trials respectively, the participants (item E) or providers (item F), or both, were blinded to treatment allocation. </p> </section> <section id="CD000227-sec-0051"> <h4 class="title">Incomplete outcome data</h4> <p>Five trials did not provide information about the number of participants allocated to groups at randomisation (<a href="./references#CD000227-bbs2-0007" title="CaniggiaA , DellingG , NutiR , LoreF , VattimoA . Clinical, biochemical and histological results of a double-blind trial with 1,25-dihydroxyvitamin D3, estradiol and placebo in post-menopausal osteoporosis. Acta Vitaminologica et Enzymologica1984;6(2):117-28. ">Caniggia 1984</a>; <a href="./references#CD000227-bbs2-0009" title="BosworthC , deBoerIH , TargherG , KendrickJ , SmitsG , ChoncholM . The effect of combined calcium and cholecalciferol supplementation on bone mineral density in elderly women with moderate chronic kidney disease. Clinical Nephrology2012;77(5):358-65. ChapuyMC , PamphileR , ParisE , KempfC , SchlichtingM , ArnaudS , et al. Combined calcium and vitamin D3 supplementation in elderly women: confirmation of reversal of secondary hyperparathyroidism and hip fracture risk: the Decalyos II study. Osteoporosis International2002;13(3):257-64. [MEDLINE: 11991447]ChapuyMC , PamphileR , ParisE , KempfC , SchlichtingM , ArnaudS , et al. Combined calcium and vitamin D3 supplementation to prevent hip fracture in elderly women. A confirmatory study: Decalyos II. Osteoporosis International2002;13(Suppl 1):S25. MeunierPJ . Personal communication 28 February 2005. ">Chapuy 2002</a>; <a href="./references#CD000227-bbs2-0010" title="Bischoff-FerrariHA , OravEJ , Dawson-HughesB . Additive effect of higher testosterone levels and vitamin D plus calcium supplementation in regard to fall risk reduction among older men and women. Osteoporosis International2008;19:1307-14. Bischoff-FerrariHA , OravEJ , Dawson-HughesB . Effect of cholecalciferol plus calcium on falling in ambulatory older men and women: a 3-year randomized controlled trial. Archives of Internal Medicine2006;166(4):424-30. Bischoff-FerrariHA , OravEJ , Dawson-HughesB . Effect of vitamin D3 plus calcium on fall risk in older men and women: a 3-year randomized controlled trial. Journal of Bone and Mineral Research2004;19(Suppl 1):S57. Dawson-HughesB , HarrisSS , KrallEA , DallalGE . Effect of calcium and vitamin D supplementation on bone density in men and women 65 years of age or older. New England Journal of Medicine1997;337(10):670-6. Dawson-HughesB , HarrisSS , KrallEA , DallalGE . Effect of withdrawal of calcium and vitamin D supplements on bone mass in elderly men and women. American Journal of Clinical Nutrition2000;72(3):745-50. Dawson-HughesB , HarrisSS . Calcium intake influences the association of protein intake with rates of bone loss in elderly men and women. American Journal of Clinical Nutrition2002;75(4):773-9. KrallEA , RandallC , HarrisSS , GarciaRI , Dawson-HughesB . Calcium and vitamin D supplements reduce tooth loss in the elderly. Journal of Bone and Mineral Research2000;15(Suppl 1):S191. KrallEA , WehlerC , GarciaRI , HarrisSS , Dawson-HughesB . Calcium and vitamin D supplements reduce tooth loss in the elderly. American Journal of Medicine2001;111(6):452-6. NiramitmahapanyaS , HarrisSS , Dawson-HughesB . Type of dietary fat is associated with the 25-hydroxyvitamin D3 increment in response to vitamin D supplementation. Journal of Clinical Endocrinology and Metabolism2011;96(10):3170-4. ">Dawson‐Hughes 1997</a>; <a href="./references#CD000227-bbs2-0018" title="Garay LilloJ , ParrenoJ , GonzálezY , GonzálezJA . Geminis: a prospective, multicentric, randomised study to evaluate the effect of tricalcium phosphate versus tricalcium phosphate plus 25(OH) Vitamin D on the risk of fractures in older women [Géminis: Estudio prospectivo, multicéntrico y aleatori para valorar el efecto del Fosfato Tricálcico versus Fosfato Tricálcico + 25(OH) Vitamina D sobre el riesgo de fracturas en mujerioes ancianas.]. Geriátrika1997;13(6):24-8. ">Garay Lillo 1997</a>; <a href="./references#CD000227-bbs2-0019" title="GeusensP , DequekerJ . Long-term effect of nandrolone decanoate, 1 alpha-hydroxyvitamin D3 or intermittent calcium infusion therapy on bone mineral content, bone remodeling and fracture rate in symptomatic osteoporosis: a double-blind controlled study. Bone and Mineral1986;1(4):347-57. ">Geusens 1986</a>); one trial provided this information after we contacted the author (<a href="./references#CD000227-bbs2-0014" title="FlickerL , MacInnisR , SteinM , SchererS , MeadK , NowsonC , et al. Should all older people in residential care receive vitamin D to prevent falls? Results of a randomised trial [abstract]. Journal of Bone and Mineral Research2004;19(Suppl 1):S99. FlickerL , MacInnisRJ , SteinMS , SchererSC , MeadKE , et al. Response letter to Dr. Gau et al. Journal of the American Geriatrics Society2006;54:1021-2. FlickerL , MacInnisRJ , SteinMS , SchererSC , MeadKE , NowsonCA , et al. Erratum. Journal of the American Geriatrics Society2012;60:1599. FlickerL , MacInnisRJ , SteinMS , SchererSC , MeadKE , NowsonCA , et al. Should older people in residential care receive vitamin D to prevent falls? Results of a randomized trial. Journal of the American Geriatrics Society2005;53(11):1881-8. FlickerL , MacInnisRJ , SteinMS , SchererSC , MeadKE , NowsonCA . Should all older people in residential care receive vitamin D to prevent falls? Results of a randomised trial. Journal of Bone and Mineral Research2004;19(Suppl 1):S99. FlickerL . Personal communication 7 January 2008. ">Flicker 2005</a>). One large trial provided results but very sparse information about methods (<a href="./references#CD000227-bbs2-0018" title="Garay LilloJ , ParrenoJ , GonzálezY , GonzálezJA . Geminis: a prospective, multicentric, randomised study to evaluate the effect of tricalcium phosphate versus tricalcium phosphate plus 25(OH) Vitamin D on the risk of fractures in older women [Géminis: Estudio prospectivo, multicéntrico y aleatori para valorar el efecto del Fosfato Tricálcico versus Fosfato Tricálcico + 25(OH) Vitamina D sobre el riesgo de fracturas en mujerioes ancianas.]. Geriátrika1997;13(6):24-8. ">Garay Lillo 1997</a>). Six trials did not report details of withdrawals and exclusions after treatment assignment adequately (11%) (item B). </p> </section> <section id="CD000227-sec-0052"> <h4 class="title">Other potential sources of bias</h4> <p>Although item H relates to applicability rather than bias, we note that the inclusion and exclusion criteria were clearly defined in 42 trials (79%). Only 23 trials (43%) collected outcome data on fractures as they occurred and confirmed them by interview and radiograph (item J). The intervention and control groups were demonstrably comparable in 31 trials (58%) (Item D). In the majority of trials (N = 35, 66%) the comparable nature of the care programmes, other than the trial interventions, was not reported (item G). </p> </section> </section> <section id="CD000227-sec-0053"> <h3 class="title" id="CD000227-sec-0053">Effects of interventions</h3> <p>See: <a href="./full#CD000227-tbl-0001"><b>Summary of findings 1</b> Vitamin D [D2, D3 or 25(OH)D] plus calcium compared with control or placebo for preventing fractures in older people</a> </p> <p>See <a href="#CD000227-tbl-0002">Table 1</a> for a list of vitamin D synonyms and abbreviations. Duration of intervention and follow‐up of individual trials are described in the '<a href="./references#CD000227-sec-0124" title="">Characteristics of included studies</a>'. Due to the randomisation by cluster in <a href="./references#CD000227-bbs2-0028" title="LawM , MorrisJ , WithersH . Cholecalciferol, not ergocalciferol, should be used for vitamin D supplementation [author reply]. Age and Ageing2006;35(6):645. [MEDLINE: 16982666]LawM , MorrisJ , WithersH . Vitamin D supplementation and the prevention of fractures and falls. Reply. Age and Ageing2007;36(2):233. LawM , MorrisJ , WithersH . Vitamin D supplementation and the prevention of fractures and falls [author reply]. Age and Ageing2007;36(2):233. [MEDLINE: 17255084]LawM , WithersH , MorrisJ , AndersonF . Vitamin D supplementation and the prevention of fractures and falls: results of a randomised trial in elderly people in residential accommodation [comment in: Age and Ageing 2006;35(6):645 and Age and Ageing 2007;36(2):232-3]. Age and Ageing2006;35(5):482-6. ">Law 2006</a>, the effective numbers of events and participants have been adjusted by the design effect for inclusion in the relevant meta‐analyses (<i>see</i><a href="./references#CD000227-fig-0006" title="">Analysis 1.1</a>; <a href="./references#CD000227-fig-0009" title="">Analysis 1.4</a>; <a href="./references#CD000227-fig-0041" title="">Analysis 13.2</a>; <a href="./references#CD000227-fig-0040" title="">Analysis 13.1</a>). Therefore the numbers used in these meta‐analyses are lower than those reported in the trial. Throughout the text of the review, the number of participants analysed in each meta‐analysis is reported. </p> <p><a href="./references#CD000227-bbs2-0024" title="InkovaaraJ , GothoniG , HalttulaR , HeikinheimoR , TokolaO . Calcium, vitamin D and anabolic steroids in treatment of aged bones: double-blind placebo-controlled long-term clinical trial. Age and Ageing1983;12:124-30. ">Inkovaara 1983</a>, a quasi‐randomised trial with four intervention groups, compared vitamin D, calcium and vitamin D, and calcium versus placebo. Data for fractures in this trial were reported, but as it was unclear whether the data represent fractures or participants with fractures, these data have not been included in the appropriate meta‐analyses. The authors commented that fractures were more common in the placebo group, but the difference was not statistically significant. </p> <p>Results are presented for fractures for the different comparisons, followed by complications. Results are presented for hip fracture, non‐vertebral fracture, vertebral fracture and any new fracture. </p> <p>In <a href="./references#CD000227-bbs2-0042" title="DumvilleJC , MilesJN , PorthouseJ , CockayneES , SaxonL , KingC , et al. Can vitamin D supplementation prevent seasonal affective disorder? A randomised trial among older women. Osteoporosis International2004;15:S42-3. PorthouseJ , CockayneS , KingC , SaxonL , SteeleE , AsprayT , et al. Randomised controlled trial of calcium and supplementation with cholecalciferol (vitamin D3) for prevention of fractures in primary care. BMJ2005;330(7498):1003-6. PorthouseJ , CockayneS , KingC , SaxonL , SteeleE , AsprayT , et al. Randomised controlled trial of calcium and vitamin D supplementation for fracture prevention in primary care. Osteoporosis International2004;15(Suppl 2):S13. PorthouseJ , CockayneS , KingC , SaxonL , SteeleE , AsprayT , et al. Randomised controlled trial of calcium and vitamin D supplementation for fracture prevention in primary care. Osteoporosis International2005;16:S27. PufferS . Calcium and vitamin D in primary care: adherence results from a randomised controlled trial [abstract 6.9.3]. In: RCN International Nursing Conference; 2004 Mar 21-31; Cambridge (UK). London: Royal College of Nursing, 2004. S Puffer, on behalf of the Calcium and Vitamin D Trial. Calcium and vitamin D in primary care. Compliance results from a randomised controlled trial. Osteoporosis International2003;14(Suppl 4):S8. TorgersonD , on behalf of the trial group. Calcium and vitamin D in preventing fractures [author reply]. BMJ2005;331(7508):109. TorgersonDJ . Personal communication 9-16 February 2005. ">Porthouse 2005</a>, more than half the participants had had a previous fracture, and so this trial is included in the subgroup analysis of trials where participants were selected on this basis. In <a href="./references#CD000227-bbs2-0050" title="SandersK , DuqueG , EbelingP , McCorquodaleT , HerrmannM , Shore-LorentiC , et al. The efficacy of high-does oral vitamin D3 administered once a year: increased fracture risk is associated with 1,25 vitamin D level at 3-months post dose. In: ASBMR Annual Meeting; 2012 Oct 12-15; Minneapolis, Minnesota. http://www.asbmr.org/Meetings/AnnualMeeting/AbstractDetail.aspx?aid=6beb2500-4b8e-472b-8b38-d881cadb80e3. 2012. SandersK , StuartA , WilliamsonE , SimpsonJ , KotowiczM , NicholsonG . The efficacy of high-dose oral vitamin D3 administered once a year: a randomised, double-blind, placebo-controlled trial (Vital D study) for falls and fractures in older women. Osteoporosis International2011;22(Suppl 1):S104-5. SandersKM , DuqueG , McCorquodaleT , StuartAL , WilliamsonEJ , KotowiczMA , et al. Annual high-dose oral vitamin D3: is the increased risk of falls attributable to changes in muscle strength?Osteoporosis International2011;22(Suppl 4):S552. SandersKM , EbelingPR , StuartAL , WilliamsonEJ , KotowiczMA , NicholsonGC . Annual high-dose oral vitamin D3: is increased risk of fractures attributable to changes in bone turnover markers?Osteoporosis International2011;22(Suppl 4):S589. SandersKM , HaylesAL , KotowiczMA , NicholsonGC . Does vitamin D explain the lower fracture rate in rural communities?Bone2007;40(6 Suppl 2):S195. SandersKM , HaylesAL , KotowiczMA , NicholsonGC . The possible role of vitamin D and falls in relation to lower fracture rates in rural communities. Osteoporosis International2007;18(Suppl 1):S120-1. SandersKM , StuartAL , KotowiczMA , NicholsonGC . Annual feedback is an effective tool for a sustained increase in calcium intake among older women. Nutrients2010;2:1018-25. SandersKM , StuartAL , MerrimanEN , ReadML , KotowiczMA , YoungD , et al. Trials and tribulations of recruiting 2,000 older women onto a clinical trial investigating falls and fractures: Vital D study. BMC Medical Research Methodology2009;9:78. SandersKM , StuartAL , NicholsonGC . High-dose oral vitamin D supplementation and risk of falls in older women. JAMA2010;304(8):856-7. SandersKM , StuartAL , WilliamsonEJ , JackaFN , DoddS , NicholsonG , et al. Annual high-dose vitamin D3 and mental well-being: randomised controlled trial. British Journal of Psychiatry2011;198:357-64. SandersKM , StuartAL , WilliamsonEJ , SimpsonJA , KotowiczMA , NicholsonGC . Annual high-dose oral vitamin D for falls and fractures in elderly women: a randomised, double-blind, placebo-controlled trial (Vital D study). Osteoporosis International2010;21(Suppl 1):S30. SandersKM , StuartAL , WilliamsonEJ , SimpsonJA , KotowiczMA , YoungD , et al. Annual high-dose oral vitamin D and falls and fractures in older women. A randomized controlled trial. JAMA2010;303(18):1815-22. Sanders KM et al. Incorrect data. JAMA2010;303(23):2357. ">Vital D</a>, only a third of participants were selected because there was a previous history of fracture, so this trial is not included in this subgroup. </p> <section id="CD000227-sec-0054"> <h4 class="title">Vitamin D alone versus placebo or no treatment</h4> <p>Fifteen trials compared vitamin D alone versus placebo or no treatment (<a href="./references#CD000227-bbs2-0003" title="AvenellA , GrantAM , McGeeM , McPhersonG , CampbellMK , McGee MA for the RECORD Trial Management Group. The effects of an open design on trial participant recruitment, compliance and retention - a randomized controlled trial comparison with a blinded, placebo-controlled design. Clinical Trials Journal2004;1:490-8. AvenellA . Personal communication2005. ">Avenell 2004</a>; <a href="./references#CD000227-bbs2-0020" title="GlendenningP , ZhuK , InderjeethC , HowatP , LewisJR , PrinceRL . Effects of three-monthly oral 150,000 IU cholecalciferol supplementation on falls, mobility, and muscle strength in older postmenopausal women: a randomized controlled trial. Journal of Bone and Mineral Research2012;27(1):170-6. ">Glendenning 2012</a>; <a href="./references#CD000227-bbs2-0022" title="HarwoodRH , SahotaO , GaynorK , MasudT , HoskingD . A randomised, controlled comparison of different calcium and vitamin D supplementation regimens in elderly women after hip fracture: The Nottingham Neck of Femur (NoNOF) Study. Age and Ageing2004;33:45-51. [14695863]HarwoodRW . Personal communication 24 January 2003. SahotaO , HarwoodRH , GaynorK , MasudT , HoskingDJ . A randomised, controlled comparison of different calcium and vitamin D regimes: the NoNOF (Nottingham Neck of Femur) study. Osteoporosis International2003;14(Suppl 4):S10-11. ">Harwood 2004</a>; <a href="./references#CD000227-bbs2-0028" title="LawM , MorrisJ , WithersH . Cholecalciferol, not ergocalciferol, should be used for vitamin D supplementation [author reply]. Age and Ageing2006;35(6):645. [MEDLINE: 16982666]LawM , MorrisJ , WithersH . Vitamin D supplementation and the prevention of fractures and falls. Reply. Age and Ageing2007;36(2):233. LawM , MorrisJ , WithersH . Vitamin D supplementation and the prevention of fractures and falls [author reply]. Age and Ageing2007;36(2):233. [MEDLINE: 17255084]LawM , WithersH , MorrisJ , AndersonF . Vitamin D supplementation and the prevention of fractures and falls: results of a randomised trial in elderly people in residential accommodation [comment in: Age and Ageing 2006;35(6):645 and Age and Ageing 2007;36(2):232-3]. Age and Ageing2006;35(5):482-6. ">Law 2006</a>; <a href="./references#CD000227-bbs2-0029" title="GraafmansWC , OomsME , HofsteeHMA , BezemerPD , BouterLM , LipsP . Falls in the elderly: a prospective study of risk factors and risk profiles. American Journal of Epidemiology1996;143(11):1129-36. LipsP , GraafmansWC , OomsME , BezemerPD , BouterLM . The effect of vitamin D supplementation on the incidence of hip fractures in elderly people. Journal of Bone and Mineral Research1994;9 Suppl 1:S148. LipsP , GraafmansWC , OomsME , BezemerPD , BouterLM . Vitamin D supplementation and fracture incidence in elderly persons. Annals of Internal Medicine1996;124:400-6. [MEDLINE: 1996151943]">Lips 1996</a>; <a href="./references#CD000227-bbs2-0030" title="JohansenA , LyonsRA , StoneM , BrophyS , NewcombeRG , PhillipsCJ , et al. Preventing fractures among older people living in institutional care: a randomised double blind placebo controlled trial of vitamin D supplementation [abstract]. Age and Ageing2006;35(Suppl 3):i41. LyonsRA , JohansenA , BrophyS , NewcombeRG , PhillipsCJ , LervyB , et al. Preventing fractures among older people living in institutional care: a pragmatic randomised double blind placebo controlled trial of vitamin D supplementation. Osteoporosis International2007;18(6):811-8. LyonsRA , JohansenA , StoneMD , BrophyS , NewcombeRG , PhilipsCJ , et al. Preventing fractures among older people living in institutional care: a randomised double blind placebo controlled trial of vitamin D supplementation [abstract]. Osteoporosis International2006;17(Suppl 3):372. ">Lyons 2007</a>; <a href="./references#CD000227-bbs2-0032" title="MeyerHE , FalchJA , KvaavikE , SmedshaugGB , TverdalA , PedersenJI . Can vitamin D supplementation reduce the risk of fracture in the elderly? A randomised controlled trial. Osteoporosis International2000;11(Suppl 2):S114-5. MeyerHE , SmedshaugGB , KvaavikE , FalchJA , TverdalA , PedersenJI . Can vitamin D supplementation reduce the risk of fracture in the elderly? A randomized controlled trial. Journal of Bone and Mineral Research2002;17(4):709-15. SmedshaugGB , PedersenJI , MeyerHE . Can vitamin D supplementation improve grip strength in elderly nursing home residents? A double-blinded controlled trial. Scandinavian Journal of Food and Nutrition2007;51(2):74-8. ">Meyer 2002</a>; <a href="./references#CD000227-bbs2-0033" title="MitriJ , Dawson-HughesB , HuFB , PittasAG . Effects of vitamin D and calcium supplementation on pancreatic β cell function, insulin sensitivity, and glycemia in adults at high risk of diabetes: the Calcium and Vitamin D for Diabetes Mellitus (CaDDM) randomized controlled trial. American Journal of Clinical Nutrition2011;94:486-94. ">Mitri 2011</a>; <a href="./references#CD000227-bbs2-0039" title="PeacockM , LiuG , CareyM , McClintockR , AmbrosiusW , HuiS , et al. Effect of calcium or 25OH vitamin D3 dietary supplementation on bone loss at the hip in men and women over the age of 60. Journal of Clinical Endocrinology and Metabolism2000;85:3011-9. ">Peacock 2000</a>: <a href="./references#CD000227-bbs2-0044" title="AndersonFH , GrantAM , AvenellA , CampbellMK , CooperC , DonaldsonC , et al. The RECORD Trial: an evaluation of calcium and/or vitamin D in the secondary prevention of osteoporotic fractures. Bone2005;36(Suppl 2):S122-3. FrancisRM , Grant AM and the RECORD trial group. The RECORD trial: a randomised double-blind study of calcium and/or vitamin D in the secondary prevention of low trauma fractures. Age Ageing2005;34(Suppl 2):ii15. GrantA , on behalf of the RECORD Trial Group. Prevention of low-trauma fractures in older people [author reply]. Lancet2005;366(9485):543-4. GrantAM , AndersonFH , for the RECORD Trial Group. The Medical Research Council RECORD Trial: an evaluation of calcium and/or vitamin D in the secondary prevention of osteoporotic fractures. Osteoporosis International2004;15(Suppl 2):S13. GrantAM , AndersonFH . The RECORD trial: an evaluation of calcium and/or vitamin D in the secondary prevention of osteoporotic fractures. Osteoporosis International2005;16(Suppl 3):S4-5. GrantAM , AvenellA , CampbellMK , McDonaldAM , MacLennanGS , McPhersonGC , et al. Oral vitamin D3 and calcium for secondary prevention of low-trauma fractures in elderly people (Randomised Evaluation of Calcium Or vitamin D, RECORD): a randomised placebo-controlled trial [comment in: Lancet 2005;366(9485):543]. Lancet2005;365(9471):1621-8. GrantAM . Personal communication 11 March 2004. ">RECORD 2005</a>; <a href="./references#CD000227-bbs2-0046" title="AndersonFH , SmithHE , RaphaelHM , CooperC . Intramuscular vitamin D increased serum 1,25-dihydroxycholecalciferol but did not affect 25-hydroxy-cholecalciferol levels in health older adults [abstract]. Journal of Bone and Mineral Research2000;15(Suppl 1):S315. AndersonFH , SmithHE , RaphaelHM , CrozierSR , CooperC . Effect of annual intramuscular vitamin D3 supplementation on fracture risk in 9440 community-living older people: the Wessex fracture prevention trial [abstract]. Journal of Bone and Mineral Research2004;19(Suppl 1):S57. ArdenNK , CrozierS , SmithH , AndersonF , EdwardsC , RaphaelH , et al. Knee pain, knee osteoarthritis, and the risk of fracture. Arthritis and Rheumatism2006;55(4):610-5. CooperC , CrozierS . Personal communication 23 February 2005. RaphaelH , SmithH , AndersonF , CooperC . Tackling the problems of trial management in primary care - experience from the Wessex research network fracture prevention study of annual vitamin D injection in older people [abstract]. Osteoporosis International2000;11(Suppl 1):S63-4. SmithH , AndersonF , RaphaelH , CooperC . The Wessex research network fracture prevention study - a large pragmatic trial of annual vitamin D injection in older people [abstract]. Osteoporosis International2000;11(Suppl 1):S64. SmithH , AndersonF , RaphaelH , CrozierS , CooperC . Effect of annual intramuscular vitamin D supplementation on fracture risk: population-based, randomised, double-blind, placebo-controlled trial [abstract]. Osteoporosis International2004;15(Suppl 1):S8. SmithH , AndersonF , RaphaelH , MaslinP , CrozierS , CooperC . Effect of annual intramuscular vitamin D on fracture risk in elderly men and women--a population-based, randomized, double-blind, placebo-controlled trial. Rheumatology2007;46(12):1852-7. ">Smith 2007</a>; <a href="./references#CD000227-bbs2-0048" title="TrivediDP , DollR , KhawKT . Effect of four monthly oral vitamin D3 (cholecalciferol) supplementation on fractures and mortality in men and women living in the community: randomised double blind controlled trial. BMJ2003;326:469. ">Trivedi 2003</a>; <a href="./references#CD000227-bbs2-0050" title="SandersK , DuqueG , EbelingP , McCorquodaleT , HerrmannM , Shore-LorentiC , et al. The efficacy of high-does oral vitamin D3 administered once a year: increased fracture risk is associated with 1,25 vitamin D level at 3-months post dose. In: ASBMR Annual Meeting; 2012 Oct 12-15; Minneapolis, Minnesota. http://www.asbmr.org/Meetings/AnnualMeeting/AbstractDetail.aspx?aid=6beb2500-4b8e-472b-8b38-d881cadb80e3. 2012. SandersK , StuartA , WilliamsonE , SimpsonJ , KotowiczM , NicholsonG . The efficacy of high-dose oral vitamin D3 administered once a year: a randomised, double-blind, placebo-controlled trial (Vital D study) for falls and fractures in older women. Osteoporosis International2011;22(Suppl 1):S104-5. SandersKM , DuqueG , McCorquodaleT , StuartAL , WilliamsonEJ , KotowiczMA , et al. Annual high-dose oral vitamin D3: is the increased risk of falls attributable to changes in muscle strength?Osteoporosis International2011;22(Suppl 4):S552. SandersKM , EbelingPR , StuartAL , WilliamsonEJ , KotowiczMA , NicholsonGC . Annual high-dose oral vitamin D3: is increased risk of fractures attributable to changes in bone turnover markers?Osteoporosis International2011;22(Suppl 4):S589. SandersKM , HaylesAL , KotowiczMA , NicholsonGC . Does vitamin D explain the lower fracture rate in rural communities?Bone2007;40(6 Suppl 2):S195. SandersKM , HaylesAL , KotowiczMA , NicholsonGC . The possible role of vitamin D and falls in relation to lower fracture rates in rural communities. Osteoporosis International2007;18(Suppl 1):S120-1. SandersKM , StuartAL , KotowiczMA , NicholsonGC . Annual feedback is an effective tool for a sustained increase in calcium intake among older women. Nutrients2010;2:1018-25. SandersKM , StuartAL , MerrimanEN , ReadML , KotowiczMA , YoungD , et al. Trials and tribulations of recruiting 2,000 older women onto a clinical trial investigating falls and fractures: Vital D study. BMC Medical Research Methodology2009;9:78. SandersKM , StuartAL , NicholsonGC . High-dose oral vitamin D supplementation and risk of falls in older women. JAMA2010;304(8):856-7. SandersKM , StuartAL , WilliamsonEJ , JackaFN , DoddS , NicholsonG , et al. Annual high-dose vitamin D3 and mental well-being: randomised controlled trial. British Journal of Psychiatry2011;198:357-64. SandersKM , StuartAL , WilliamsonEJ , SimpsonJA , KotowiczMA , NicholsonGC . Annual high-dose oral vitamin D for falls and fractures in elderly women: a randomised, double-blind, placebo-controlled trial (Vital D study). Osteoporosis International2010;21(Suppl 1):S30. SandersKM , StuartAL , WilliamsonEJ , SimpsonJA , KotowiczMA , YoungD , et al. Annual high-dose oral vitamin D and falls and fractures in older women. A randomized controlled trial. JAMA2010;303(18):1815-22. Sanders KM et al. Incorrect data. JAMA2010;303(23):2357. ">Vital D</a>; <a href="./references#CD000227-bbs2-0052" title="WithamMD , CrightonLJ , GillespieND , StruthersAD , McMurdoME . The effects of vitamin D supplementation on physical function and quality of life in older patients with heart failure. A randomized controlled trial. Circulation: Heart Failure2010;3:195-201. ">Witham 2010</a>; <a href="./references#CD000227-bbs2-0053" title="WithamM . Can high-dose vitamin D supplementation reduce blood pressure and markers of cardiovascular risk in older people with isolated systolic hypertension? A randomised, double-blind, parallel group placebo controlled trial. http://www.controlled-trials.com/ISRCTN92186858/ (accessed 3 December 2013). WithamMD , PriceRJ , StruthersAD , DonnanPT , MessowM , FordI , et al. Vitamin D supplementation to reduce blood pressure in older patients with isolated systolic hypertension (VitDISH) - a randomised controlled trial. Personal communication ahead of publication 15 January 2013. ">Witham 2013</a>).<br/><br/>Pooled data comparing vitamin D alone with placebo or no treatment showed no statistically significant effect on hip fracture (11 trials, 27,693 participants, RR 1.12, 95% CI 0.98 to 1.29, <i>see</i><a href="./references#CD000227-fig-0006" title="">Analysis 1.1</a>), non‐vertebral fractures (12 trials, 22,930 participants, RR 1.05, 95% CI 0.96 to 1.14, <i>see</i><a href="./references#CD000227-fig-0007" title="">Analysis 1.2</a>), vertebral fractures or deformities (six trials, 11,396 participants, RR 1.03, 95% CI 0.76 to 1.39, <i>see</i><a href="./references#CD000227-fig-0008" title="">Analysis 1.3</a>). For any new fracture vitamin D alone produced no statistically significant reduction (15 trials, 28,271 participants, RR 1.03, 95% CI 0.96 to 1.11, <i>see</i><a href="./references#CD000227-fig-0009" title="">Analysis 1.4</a>). There was evidence of very little heterogeneity (I<sup>2</sup> less than 30%) for all these outcomes. Funnel plots for hip fracture trials (<a href="#CD000227-fig-0004">Figure 4</a>) and any new fracture (<a href="#CD000227-fig-0005">Figure 5</a>) do not suggest evidence of publication bias. </p> <div class="figure" id="CD000227-fig-0004"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 4</div> </div> <hr class="top"/><img alt="Funnel plot of comparison: 1 Vitamin D [D2, D3 or 25(OH)D] versus control or placebo, outcome: 1.1 Persons sustaining new hip fracture" data-id="CD000227-fig-0004" src="/cdsr/doi/10.1002/14651858.CD000227.pub4/media/CDSR/CD000227/image_n/nCD000227-FIG-04.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Funnel plot of comparison: 1 Vitamin D [D2, D3 or 25(OH)D] versus control or placebo, outcome: 1.1 Persons sustaining new hip fracture </p> </div> </div> </div> <div class="figure" id="CD000227-fig-0005"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 5</div> </div> <hr class="top"/><img alt="Funnel plot of comparison: 1 Vitamin D [D2, D3 or 25(OH)D] versus control or placebo, outcome: 1.4 Persons sustaining any new fracture" data-id="CD000227-fig-0005" src="/cdsr/doi/10.1002/14651858.CD000227.pub4/media/CDSR/CD000227/image_n/nCD000227-FIG-05.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Funnel plot of comparison: 1 Vitamin D [D2, D3 or 25(OH)D] versus control or placebo, outcome: 1.4 Persons sustaining any new fracture </p> </div> </div> </div> </section> <section id="CD000227-sec-0055"> <h4 class="title">Vitamin D plus calcium versus calcium alone</h4> <p>Eleven trials compared vitamin D plus calcium with calcium alone (<a href="./references#CD000227-bbs2-0003" title="AvenellA , GrantAM , McGeeM , McPhersonG , CampbellMK , McGee MA for the RECORD Trial Management Group. The effects of an open design on trial participant recruitment, compliance and retention - a randomized controlled trial comparison with a blinded, placebo-controlled design. Clinical Trials Journal2004;1:490-8. AvenellA . Personal communication2005. ">Avenell 2004</a>; <a href="./references#CD000227-bbs2-0004" title="Bischoff-FerrariHA , ConzelmannM , StahelinHB , DickW , CarpenterMG , AdkinAL , et al. Is fall prevention by vitamin D mediated by a change in postural or dynamic balance?Osteoporosis International2006;17(5):656-63. BischoffHA , StahelinHB , DickW , AkosR , KnechtM , SalisC , et al. Effects of vitamin D and calcium supplementation on falls: a randomized controlled trial. Journal of Bone and Mineral Research2003;18(2):343-51. [MEDLINE: 12568412]BischoffHA . Personal communication 13 July 2003. BischoffHA . Vitamin D deficiency in the elderly. Journal of Bone and Mineral Research2003;18(7):1343. [MEDLINE: 12854846]HeaneyR . Vitamin D depletion and effective calcium absorption. Journal of Bone and Mineral Research2003;18(7):1342. ">Bischoff 2003</a>; <a href="./references#CD000227-bbs2-0006" title="BurleighE , McCollJ , PotterJ . Does vitamin D stop inpatients falling? A randomised controlled trial. Age and Ageing2007;36(5):507-13. ">Burleigh 2007</a>; <a href="./references#CD000227-bbs2-0014" title="FlickerL , MacInnisR , SteinM , SchererS , MeadK , NowsonC , et al. Should all older people in residential care receive vitamin D to prevent falls? Results of a randomised trial [abstract]. Journal of Bone and Mineral Research2004;19(Suppl 1):S99. FlickerL , MacInnisRJ , SteinMS , SchererSC , MeadKE , et al. Response letter to Dr. Gau et al. Journal of the American Geriatrics Society2006;54:1021-2. FlickerL , MacInnisRJ , SteinMS , SchererSC , MeadKE , NowsonCA , et al. Erratum. Journal of the American Geriatrics Society2012;60:1599. FlickerL , MacInnisRJ , SteinMS , SchererSC , MeadKE , NowsonCA , et al. Should older people in residential care receive vitamin D to prevent falls? Results of a randomized trial. Journal of the American Geriatrics Society2005;53(11):1881-8. FlickerL , MacInnisRJ , SteinMS , SchererSC , MeadKE , NowsonCA . Should all older people in residential care receive vitamin D to prevent falls? Results of a randomised trial. Journal of Bone and Mineral Research2004;19(Suppl 1):S99. FlickerL . Personal communication 7 January 2008. ">Flicker 2005</a>; <a href="./references#CD000227-bbs2-0018" title="Garay LilloJ , ParrenoJ , GonzálezY , GonzálezJA . Geminis: a prospective, multicentric, randomised study to evaluate the effect of tricalcium phosphate versus tricalcium phosphate plus 25(OH) Vitamin D on the risk of fractures in older women [Géminis: Estudio prospectivo, multicéntrico y aleatori para valorar el efecto del Fosfato Tricálcico versus Fosfato Tricálcico + 25(OH) Vitamina D sobre el riesgo de fracturas en mujerioes ancianas.]. Geriátrika1997;13(6):24-8. ">Garay Lillo 1997</a>; <a href="./references#CD000227-bbs2-0026" title="JanssenHC , SamsonMM , VerhaarHJ . Muscle strength and mobility in vitamin D-insufficient female geriatric patients: a randomized controlled trial on vitamin D and calcium supplementation. Aging Clinical and Experimental Research2010;22(1):78-84. ">Janssen 2010</a>; <a href="./references#CD000227-bbs2-0027" title="KomulainenM , KrogerH , TuppurainenMT , HeikkinenAM , AlhavaE , HonkanenR , et al. Prevention of femoral and lumbar bone loss with hormone replacement therapy and Vitamin D3 in early postmenopausal women: a population based 5-year randomized trial. Journal of Clinical Endocrinology and Metabolism1999;84(2):546-52. KomulainenM , KrogerH , TuppurainenMT , Keikkinen A-M, HonkanenR , SaarikoskiS , et al. Identification of early postmenopausal women with no bone response to HRT: results of a five-year clinical trial. Osteoporosis International2000;11:211-8. KomulainenMH , KrogerH , TuppurainenMT , Heikkinen A-M, AlhavaE , HonkanenR , et al. HRT and Vit D in prevention of non-vertebral fractures in postmenopausal women; a 5 year randomized trial. Maturitas1998;31(1):45-54. KomulainenMH . Personal communication 11 November 2004. ">Komulainen 1998</a>; <a href="./references#CD000227-bbs2-0040" title="MinneHW , PfeiferM , BegerowB , NachtigallD , HansenC . Vitamin D and calcium supplementation reduces falls in elderly women via improvement of body sway and normalisation of blood pressure; a prospective, randomized, and double-blind study. Osteoporosis International2000;11(Suppl 2):S115. PfeiferM , BegerowB , MinneHW , AbramsC , NachtigallD , HansenC . Effects of a short-term vitamin D and calcium supplementation on body sway and secondary hyperparathyroidism in elderly women. Journal of Bone and Mineral Research2000;15(6):1113-8. PfeiferM , BegerowB , NachtigallD , HansenC . Prevention of falls-related fractures: vitamin D reduces body sway in the elderly - a prospective, randomized, double blind study [abstract]. Bone1998;23(5 Suppl 1):1110. ">Pfeifer 2000</a>; <a href="./references#CD000227-bbs2-0041" title="BollandMJ , GreyA . Different outcomes of meta-analyses and data inconsistency:response to comments by Pfeifer. Archives of Osteoporosis2015;10:43. BollandMJ , GreyA . Inconsistent data in text and tables. Osteoporosis International2015;26:2713. MinneHW , DobnigH , PfeiferM , SuppanK . Effects of vitamin D and calcium supplementation on falls and parameters of muscle function: a prospective, randomized, double-blind multicenter study [abstract]. Osteoporosis International2006;17(Suppl 2):S212. MinneHW , DobnigH , PfeiferM , SuppanK . Effects of vitamin D and calcium supplementation on falls and parameters of muscle-function - a prospective, randomized, double-blind multi-center study [abstract]. Osteoporosis International2006;17(Suppl 1):S21. PfeiferM , BegerowB , MinneHW , SuppanK , Fahrleitner-PammerA , DobnigH . Effects of a long-term vitamin D and calcium supplementation on falls and parameters of muscle function in community-dwelling older individuals. Osteoporosis International2009;20:315-22. PfeiferM , DobnigH , BegerowB , SuppanK . Effects of vitamin D and calcium supplementation on falls and parameters of muscle function: a prospective randomized, double-blind multi-centre study [abstract]. Journal of Bone and Mineral Research2004;19(Suppl 1):S58. PfeiferM , DobnigH , MinneHW , SuppanK . Effects of vitamin D and calcium supplementation on falls and parameters of muscle function - a prospective, randomized, double-blind multi-center study [abstract]. Osteoporosis International2005;16(Suppl 3):S45. PfeiferM . Different outcomes of meta-analyses and data inconsistency. Osteoporosis International2015;26:2715–2716. PfeiferM . Randomized controlled clinical trials and meta-analyses. Archives of Osteoporosis2015;10:42. ">Pfeifer 2009</a>; <a href="./references#CD000227-bbs2-0043" title="PrinceRL , AustinN , DevineA , DickIM , BruceD , ZhuK . Effects of ergocalciferol added to calcium on the risk of falls in elderly high-risk women. Archives of Internal Medicine2008;168(1):103-8. ZhuK , BruceD , AustinN , DevineA , EbelingPR , PrinceRL . Randomized controlled trial of the effects of calcium with or without vitamin D on bone structure and bone-related chemistry in elderly women with vitamin D insufficiency. Journal of Bone and Mineral Research2008;23(8):1343-8. ZhuK , DevineA , DickIM , WilsonSG , PrinceRL . Effects of calcium and vitamin D supplementation on hip bone mineral density and calcium-related analytes in elderly ambulatory Australian women: a five-year randomized controlled trial. Journal of Clinical Endocrinology and Metabolism2008;93(3):743-9. ">Prince 2008</a>; <a href="./references#CD000227-bbs2-0044" title="AndersonFH , GrantAM , AvenellA , CampbellMK , CooperC , DonaldsonC , et al. The RECORD Trial: an evaluation of calcium and/or vitamin D in the secondary prevention of osteoporotic fractures. Bone2005;36(Suppl 2):S122-3. FrancisRM , Grant AM and the RECORD trial group. The RECORD trial: a randomised double-blind study of calcium and/or vitamin D in the secondary prevention of low trauma fractures. Age Ageing2005;34(Suppl 2):ii15. GrantA , on behalf of the RECORD Trial Group. Prevention of low-trauma fractures in older people [author reply]. Lancet2005;366(9485):543-4. GrantAM , AndersonFH , for the RECORD Trial Group. The Medical Research Council RECORD Trial: an evaluation of calcium and/or vitamin D in the secondary prevention of osteoporotic fractures. Osteoporosis International2004;15(Suppl 2):S13. GrantAM , AndersonFH . The RECORD trial: an evaluation of calcium and/or vitamin D in the secondary prevention of osteoporotic fractures. Osteoporosis International2005;16(Suppl 3):S4-5. GrantAM , AvenellA , CampbellMK , McDonaldAM , MacLennanGS , McPhersonGC , et al. Oral vitamin D3 and calcium for secondary prevention of low-trauma fractures in elderly people (Randomised Evaluation of Calcium Or vitamin D, RECORD): a randomised placebo-controlled trial [comment in: Lancet 2005;366(9485):543]. Lancet2005;365(9471):1621-8. GrantAM . Personal communication 11 March 2004. ">RECORD 2005</a>). </p> <p>In the populations studied, vitamin D (including 25‐hydroxy vitamin D) plus calcium was no more effective than calcium alone for hip fracture (seven trials, 7411 participants, RR 0.84, 95% CI 0.63 to 1.13, <i>see</i><a href="./references#CD000227-fig-0010" title="">Analysis 2.1</a>), any non‐vertebral fracture (six trials, 3336 participants, RR 0.96, 95% CI 0.79 to 1.16, <i>see</i><a href="./references#CD000227-fig-0011" title="">Analysis 2.2</a>), and vertebral fracture (two trials, 2681 participants, RR 0.14, 95% CI 0.01 to 2.77, <i>see</i><a href="./references#CD000227-fig-0012" title="">Analysis 2.3</a>). The three vertebral fractures from <a href="./references#CD000227-bbs2-0044" title="AndersonFH , GrantAM , AvenellA , CampbellMK , CooperC , DonaldsonC , et al. The RECORD Trial: an evaluation of calcium and/or vitamin D in the secondary prevention of osteoporotic fractures. Bone2005;36(Suppl 2):S122-3. FrancisRM , Grant AM and the RECORD trial group. The RECORD trial: a randomised double-blind study of calcium and/or vitamin D in the secondary prevention of low trauma fractures. Age Ageing2005;34(Suppl 2):ii15. GrantA , on behalf of the RECORD Trial Group. Prevention of low-trauma fractures in older people [author reply]. Lancet2005;366(9485):543-4. GrantAM , AndersonFH , for the RECORD Trial Group. The Medical Research Council RECORD Trial: an evaluation of calcium and/or vitamin D in the secondary prevention of osteoporotic fractures. Osteoporosis International2004;15(Suppl 2):S13. GrantAM , AndersonFH . The RECORD trial: an evaluation of calcium and/or vitamin D in the secondary prevention of osteoporotic fractures. Osteoporosis International2005;16(Suppl 3):S4-5. GrantAM , AvenellA , CampbellMK , McDonaldAM , MacLennanGS , McPhersonGC , et al. Oral vitamin D3 and calcium for secondary prevention of low-trauma fractures in elderly people (Randomised Evaluation of Calcium Or vitamin D, RECORD): a randomised placebo-controlled trial [comment in: Lancet 2005;366(9485):543]. Lancet2005;365(9471):1621-8. GrantAM . Personal communication 11 March 2004. ">RECORD 2005</a> relate only to vertebral fractures presenting to clinical attention, rather than deformities detected by imaging. For any fracture there was no overall statistically significant effect (11 trials, 8812 participants, RR 0.87, 95% CI 0.74 to 1.02, <i>see</i><a href="./references#CD000227-fig-0013" title="">Analysis 2.4</a>). There was some evidence that, for those participants not selected on the basis of a previous fracture, risk for any new fracture was reduced (nine trials, 6131 participants, RR 0.70, 95% CI 0.53 to 0.92) compared with evidence that those participants selected with a previous fracture were less likely to have a reduction in fractures (two trials, 2681 participants, RR 0.98, 95% CI 0.80 to 1.20); test for subgroup differences P value 0.05. </p> </section> <section id="CD000227-sec-0056"> <h4 class="title">Vitamin D versus calcium</h4> <p>Four trials compared vitamin D versus calcium (<a href="./references#CD000227-bbs2-0003" title="AvenellA , GrantAM , McGeeM , McPhersonG , CampbellMK , McGee MA for the RECORD Trial Management Group. The effects of an open design on trial participant recruitment, compliance and retention - a randomized controlled trial comparison with a blinded, placebo-controlled design. Clinical Trials Journal2004;1:490-8. AvenellA . Personal communication2005. ">Avenell 2004</a>; <a href="./references#CD000227-bbs2-0033" title="MitriJ , Dawson-HughesB , HuFB , PittasAG . Effects of vitamin D and calcium supplementation on pancreatic β cell function, insulin sensitivity, and glycemia in adults at high risk of diabetes: the Calcium and Vitamin D for Diabetes Mellitus (CaDDM) randomized controlled trial. American Journal of Clinical Nutrition2011;94:486-94. ">Mitri 2011</a>; <a href="./references#CD000227-bbs2-0039" title="PeacockM , LiuG , CareyM , McClintockR , AmbrosiusW , HuiS , et al. Effect of calcium or 25OH vitamin D3 dietary supplementation on bone loss at the hip in men and women over the age of 60. Journal of Clinical Endocrinology and Metabolism2000;85:3011-9. ">Peacock 2000</a>; <a href="./references#CD000227-bbs2-0044" title="AndersonFH , GrantAM , AvenellA , CampbellMK , CooperC , DonaldsonC , et al. The RECORD Trial: an evaluation of calcium and/or vitamin D in the secondary prevention of osteoporotic fractures. Bone2005;36(Suppl 2):S122-3. FrancisRM , Grant AM and the RECORD trial group. The RECORD trial: a randomised double-blind study of calcium and/or vitamin D in the secondary prevention of low trauma fractures. Age Ageing2005;34(Suppl 2):ii15. GrantA , on behalf of the RECORD Trial Group. Prevention of low-trauma fractures in older people [author reply]. Lancet2005;366(9485):543-4. GrantAM , AndersonFH , for the RECORD Trial Group. The Medical Research Council RECORD Trial: an evaluation of calcium and/or vitamin D in the secondary prevention of osteoporotic fractures. Osteoporosis International2004;15(Suppl 2):S13. GrantAM , AndersonFH . The RECORD trial: an evaluation of calcium and/or vitamin D in the secondary prevention of osteoporotic fractures. Osteoporosis International2005;16(Suppl 3):S4-5. GrantAM , AvenellA , CampbellMK , McDonaldAM , MacLennanGS , McPhersonGC , et al. Oral vitamin D3 and calcium for secondary prevention of low-trauma fractures in elderly people (Randomised Evaluation of Calcium Or vitamin D, RECORD): a randomised placebo-controlled trial [comment in: Lancet 2005;366(9485):543]. Lancet2005;365(9471):1621-8. GrantAM . Personal communication 11 March 2004. ">RECORD 2005</a>). </p> <p>There was no evidence of a statistically significant difference between vitamin D alone and calcium in the prevention of hip fracture (two trials, 2718 participants, RR 0.90, 95% CI 0.61 to 1.32, <i>see</i><a href="./references#CD000227-fig-0014" title="">Analysis 3.1</a>), non‐vertebral fractures (four trials, 3021 participants, RR 1.10, 95% CI 0.91 to 1.33, <i>see</i><a href="./references#CD000227-fig-0015" title="">Analysis 3.2</a>) or any fracture (four trials, 3021 participants, RR 1.11, 95% CI 0.92 to 1.33, <i>see</i><a href="./references#CD000227-fig-0017" title="">Analysis 3.4</a>). There was evidence that vitamin D alone was less effective than calcium for the prevention of vertebral fracture or deformity (three trials, 2976 participants, RR 2.21, 95% CI 1.08 to 4.53, <i>see</i><a href="./references#CD000227-fig-0016" title="">Analysis 3.3</a>). </p> </section> <section id="CD000227-sec-0057"> <h4 class="title">Vitamin D plus calcium versus placebo or no treatment</h4> <section id="CD000227-sec-0058"> <h5 class="title">Hip fracture</h5> <p>Nine trials compared vitamin D plus calcium versus placebo or no treatment for hip fracture (<a href="./references#CD000227-bbs2-0003" title="AvenellA , GrantAM , McGeeM , McPhersonG , CampbellMK , McGee MA for the RECORD Trial Management Group. The effects of an open design on trial participant recruitment, compliance and retention - a randomized controlled trial comparison with a blinded, placebo-controlled design. Clinical Trials Journal2004;1:490-8. AvenellA . Personal communication2005. ">Avenell 2004</a>; <a href="./references#CD000227-bbs2-0008" title="ChapuyMC , ArlotM , et al. Prevention of non vertebral fractures and cortical bone loss in elderly women: a prospective controlled trial using calcium and vitamin D3 supplements [abstract]. Osteoporosis International1993;3 Suppl 1:258. ChapuyMC , ArlotME , DelmasPD , MeunierPJ . Effect of calcium and cholecalciferol treatment for three years on hip fractures in elderly women. BMJ1994;308:1081-2. ChapuyMC , ArlotME , DuboeufF , BrunJ , CrouzetB , ArnaudS , et al. Vitamin D3 and calcium to prevent hip fractures in elderly women. New England Journal of Medicine1992;327:1637-42. MeunierPJ , PamphileR , ChapuyMC , SchultenJ , ArlotM , LilluH . A calcium-vitamin D3 combined supplementation is cost-saving for preventing hip fractures in institutionalised elderly women: an economic evaluation from the perspective of seven European countries (Belgium, France, Germany, The Netherlands, Spain, Sweden, United Kingdom). Osteoporosis International2002;13(Suppl 1):S14. ">Chapuy 1992</a>; <a href="./references#CD000227-bbs2-0009" title="BosworthC , deBoerIH , TargherG , KendrickJ , SmitsG , ChoncholM . The effect of combined calcium and cholecalciferol supplementation on bone mineral density in elderly women with moderate chronic kidney disease. Clinical Nephrology2012;77(5):358-65. ChapuyMC , PamphileR , ParisE , KempfC , SchlichtingM , ArnaudS , et al. Combined calcium and vitamin D3 supplementation in elderly women: confirmation of reversal of secondary hyperparathyroidism and hip fracture risk: the Decalyos II study. Osteoporosis International2002;13(3):257-64. [MEDLINE: 11991447]ChapuyMC , PamphileR , ParisE , KempfC , SchlichtingM , ArnaudS , et al. Combined calcium and vitamin D3 supplementation to prevent hip fracture in elderly women. A confirmatory study: Decalyos II. Osteoporosis International2002;13(Suppl 1):S25. MeunierPJ . Personal communication 28 February 2005. ">Chapuy 2002</a>; <a href="./references#CD000227-bbs2-0010" title="Bischoff-FerrariHA , OravEJ , Dawson-HughesB . Additive effect of higher testosterone levels and vitamin D plus calcium supplementation in regard to fall risk reduction among older men and women. Osteoporosis International2008;19:1307-14. Bischoff-FerrariHA , OravEJ , Dawson-HughesB . Effect of cholecalciferol plus calcium on falling in ambulatory older men and women: a 3-year randomized controlled trial. Archives of Internal Medicine2006;166(4):424-30. Bischoff-FerrariHA , OravEJ , Dawson-HughesB . Effect of vitamin D3 plus calcium on fall risk in older men and women: a 3-year randomized controlled trial. Journal of Bone and Mineral Research2004;19(Suppl 1):S57. Dawson-HughesB , HarrisSS , KrallEA , DallalGE . Effect of calcium and vitamin D supplementation on bone density in men and women 65 years of age or older. New England Journal of Medicine1997;337(10):670-6. Dawson-HughesB , HarrisSS , KrallEA , DallalGE . Effect of withdrawal of calcium and vitamin D supplements on bone mass in elderly men and women. American Journal of Clinical Nutrition2000;72(3):745-50. Dawson-HughesB , HarrisSS . Calcium intake influences the association of protein intake with rates of bone loss in elderly men and women. American Journal of Clinical Nutrition2002;75(4):773-9. KrallEA , RandallC , HarrisSS , GarciaRI , Dawson-HughesB . Calcium and vitamin D supplements reduce tooth loss in the elderly. Journal of Bone and Mineral Research2000;15(Suppl 1):S191. KrallEA , WehlerC , GarciaRI , HarrisSS , Dawson-HughesB . Calcium and vitamin D supplements reduce tooth loss in the elderly. American Journal of Medicine2001;111(6):452-6. NiramitmahapanyaS , HarrisSS , Dawson-HughesB . Type of dietary fat is associated with the 25-hydroxyvitamin D3 increment in response to vitamin D supplementation. Journal of Clinical Endocrinology and Metabolism2011;96(10):3170-4. ">Dawson‐Hughes 1997</a>; <a href="./references#CD000227-bbs2-0022" title="HarwoodRH , SahotaO , GaynorK , MasudT , HoskingD . A randomised, controlled comparison of different calcium and vitamin D supplementation regimens in elderly women after hip fracture: The Nottingham Neck of Femur (NoNOF) Study. Age and Ageing2004;33:45-51. [14695863]HarwoodRW . Personal communication 24 January 2003. SahotaO , HarwoodRH , GaynorK , MasudT , HoskingDJ . A randomised, controlled comparison of different calcium and vitamin D regimes: the NoNOF (Nottingham Neck of Femur) study. Osteoporosis International2003;14(Suppl 4):S10-11. ">Harwood 2004</a>; <a href="./references#CD000227-bbs2-0037" title="KarkkainenM , TuppurainenM , RikkonenT , SalovaaraK , SirolaJ , HonkanenR , et al. Vitamin-D 800IU/day + calcium 1000mg supplementation decreases the risk of recurrent falling among postmenopausal ambulatory women - a population-based, randomized, 3-year study (OSTPRE-FPS). Osteoporosis International2008;19(Suppl 1):S17-18. KarkkainenM , TuppurainenM , RikkonenT , SalovaaraK , SirolaJ , HonkanenR , et al. Vitamin-D 800IU/day + calcium supplementation decreases the risk of falling among postmenopausal ambulatory women - a population-based, randomized 3-year study (OSTPRE-FPS) [abstract]. Journal of Bone and Mineral Research2007;22(Suppl 1):S131. KarkkainenM , TuppurainenM , SalovaaraK , SandiniL , RikkonenT , SirolaJ , et al. Effect of calcium and vitamin D supplementation on bone mineral density in women aged 65-71 years: a 3-year randomized population-based trial (OSTPRE-FPS). Osteoporosis International2010;21:2047-55. KarkkainenMK , TuppurainenM , SalovaaraM , SandiniL , RikkonenT , SirolaJ , et al. Does daily vitamin D 800 IU and calcium 1000 mg supplementation decrease the risk of falling in ambulatory women aged 65-71 years? A 3-year randomized population-based trial (OSTPRE-FPS). Maturitas2010;65:359-65. KrogerHP , TuppurainenM . OSTPRE-FPS Prevention of Fractures and Falls in Postmenopausal Women With Calcium and Vitamin-D Supplementation - a Randomised Study. http://www.controlled-trials.com/mrct/trial/405493/OSTPRE. SalovaaraK , TuppurainenM , KarkkainenM , RikkonenT , SandiniL , SirolaJ , et al. Effect of vitamin D3 and calcium on fracture risk in 65- to 71-year-old women: a population-based 3-year randomized, controlled trial - the OSTPRE-FPS. Journal of Bone and Mineral Research2010;25(7):1487-95. SalovaaraKT , TuppurainenM , RikkonenT , KarkkainenM , SirolaJ , HonkanenR , et al. Effect of vitamin-D3 and calcium on fracture risk in 65-71 year old women in a 3-year randomized clinical trial - preliminary results from the OSTPRE-Fracture Prevention Study. Calcified Tissue International2008;82:545-6. SalovaaraKT , TuppurainenM , RikkonenT , KarkkainenM , SirolaJ , HonkanenR , et al. Effect of vitamin-D3 and calcium on fracture risk in 65-71 year old women in a 3-year randomized clinical trial - preliminary results of the OSTPRE-Fracture Prevention Study. Journal of Bone and Mineral Research2007;22(Suppl 1):S76. ">OSTPRE‐FPS 2007</a>; <a href="./references#CD000227-bbs2-0042" title="DumvilleJC , MilesJN , PorthouseJ , CockayneES , SaxonL , KingC , et al. Can vitamin D supplementation prevent seasonal affective disorder? A randomised trial among older women. Osteoporosis International2004;15:S42-3. PorthouseJ , CockayneS , KingC , SaxonL , SteeleE , AsprayT , et al. Randomised controlled trial of calcium and supplementation with cholecalciferol (vitamin D3) for prevention of fractures in primary care. BMJ2005;330(7498):1003-6. PorthouseJ , CockayneS , KingC , SaxonL , SteeleE , AsprayT , et al. Randomised controlled trial of calcium and vitamin D supplementation for fracture prevention in primary care. Osteoporosis International2004;15(Suppl 2):S13. PorthouseJ , CockayneS , KingC , SaxonL , SteeleE , AsprayT , et al. Randomised controlled trial of calcium and vitamin D supplementation for fracture prevention in primary care. Osteoporosis International2005;16:S27. PufferS . Calcium and vitamin D in primary care: adherence results from a randomised controlled trial [abstract 6.9.3]. In: RCN International Nursing Conference; 2004 Mar 21-31; Cambridge (UK). London: Royal College of Nursing, 2004. S Puffer, on behalf of the Calcium and Vitamin D Trial. Calcium and vitamin D in primary care. Compliance results from a randomised controlled trial. Osteoporosis International2003;14(Suppl 4):S8. TorgersonD , on behalf of the trial group. Calcium and vitamin D in preventing fractures [author reply]. BMJ2005;331(7508):109. TorgersonDJ . Personal communication 9-16 February 2005. ">Porthouse 2005</a>; <a href="./references#CD000227-bbs2-0044" title="AndersonFH , GrantAM , AvenellA , CampbellMK , CooperC , DonaldsonC , et al. The RECORD Trial: an evaluation of calcium and/or vitamin D in the secondary prevention of osteoporotic fractures. Bone2005;36(Suppl 2):S122-3. FrancisRM , Grant AM and the RECORD trial group. The RECORD trial: a randomised double-blind study of calcium and/or vitamin D in the secondary prevention of low trauma fractures. Age Ageing2005;34(Suppl 2):ii15. GrantA , on behalf of the RECORD Trial Group. Prevention of low-trauma fractures in older people [author reply]. Lancet2005;366(9485):543-4. GrantAM , AndersonFH , for the RECORD Trial Group. The Medical Research Council RECORD Trial: an evaluation of calcium and/or vitamin D in the secondary prevention of osteoporotic fractures. Osteoporosis International2004;15(Suppl 2):S13. GrantAM , AndersonFH . The RECORD trial: an evaluation of calcium and/or vitamin D in the secondary prevention of osteoporotic fractures. Osteoporosis International2005;16(Suppl 3):S4-5. GrantAM , AvenellA , CampbellMK , McDonaldAM , MacLennanGS , McPhersonGC , et al. Oral vitamin D3 and calcium for secondary prevention of low-trauma fractures in elderly people (Randomised Evaluation of Calcium Or vitamin D, RECORD): a randomised placebo-controlled trial [comment in: Lancet 2005;366(9485):543]. Lancet2005;365(9471):1621-8. GrantAM . Personal communication 11 March 2004. ">RECORD 2005</a>; <a href="./references#CD000227-bbs2-0051" title="CauleyJ , Wactawski-WendeJ , RobbinsJ , RodaboughR , ChenZ , JohnsonK , et al. The Women's Health Initiative (WHI) calcium and vitamin D supplementation trial: health outcomes 5 years after trial completion. ASBMR Annual Meeting; 2012 Oct 12-15; Minneapolis, Minnesota. http://www.asbmr.org/Meetings/AnnualMeeting/AbstractDetail.aspx?aid=6450bf3e-c670-4dc0-814c-8842e23cd80e (accessed 27 December 2012). CauleyJA , LaCroixA , WuL , LeeJ , HorowitzM , BauerD , et al. Serum 25 hydroxy vitamin D 25(OH) and the risk of hip fracture: the Women's Health Initiative (WHI). Journal of Bone and Mineral Research2007;22(Suppl 1):S57. ChenZ , BeckTJ , WrightNC , LaCroixAZ , CauleyJA , LewisCE , et al. The effect of calcium plus vitamin D supplement on hip geometric structures: results from the Women's Health Initiative CaD trial. Journal of Bone and Mineral Research2007;22(Suppl 1):S59. JacksonRD , LaCroixAZ , CauleyJA , McGowanJ . The Women's Health Initiative Calcium-Vitamin D Trial: overview and baseline characteristics of participants. Annals of Epidemiology2003;13:S98-106. JacksonRD , LaCroixAZ , GassM , WallaceRB , RobbinsJ , LewisCE , et al. Calcium plus vitamin D supplementation and the risk of fractures [erratum appears in New England Journal of Medicine 9 March 2006;354(10):1102]. New England Journal of Medicine2006;354(7):669-83. JacksonRD , WrightNC , BeckTJ , SherrillD , CauleyJA , LewisCE , et al. Calcium plus vitamin D supplementation has limited effects on femoral geometric strength in older postmenopausal women: the Women's Health Initiative. Calcified Tissue International2011;88:198-208. McGowanJA , JacksonRD , CauleyJA , LaCroixAZ . Calcium and vitamin D in the prevention of hip and other fractures: an update on the Women's Health Initiative CaD Trial. Journal of Bone and Mineral Research2002;17(Suppl 1):S477. The Women's Health Initiative Study Group. Design of the Women's Health Initiative clinical trial and observational study. Controlled Clinical Trials1998;19(1):61-109. ">WHI 2006</a>). </p> <p>Pooled data found a statistically significant reduction in the incidence of hip fracture in the population receiving vitamin D plus calcium (nine trials, 49,853 participants, RR 0.84, 95% CI 0.74 to 0.96, <i>see</i><a href="./references#CD000227-fig-0018" title="">Analysis 4.1</a>). Heterogeneity was not evident (I<sup>2</sup> = 0%). In studies where a previous osteoporotic fracture was not a selection criterion, the RR was 0.82, 95% CI 0.71 to 0.94 (five trials, 43,719 participants); and in participants with a history of prior fracture, the RR was 1.02, 95% CI 0.71 to 1.47 (four trials, 6134 participants). The test for subgroup differences was not significant (P value 0.26). </p> <p>In the subgroup analysis by residential status (institution versus community: <i>see</i><a href="./references#CD000227-fig-0019" title="">Analysis 4.2</a>) there was evidence that hip fracture incidence was reduced in institutional residents with a RR of 0.75, 95% CI 0.62 to 0.92 (two trials, 3853 participants); it was also reduced in the community dwelling group but this was a non‐significant finding (RR of 0.91, 95% CI 0.77 to 1.09, seven trials, 46,000 participants; <i>see</i><a href="./references#CD000227-fig-0019" title="">Analysis 4.2</a>). The test for subgroup differences was not significant (P value 0.15). </p> </section> <section id="CD000227-sec-0059"> <h5 class="title">Non‐vertebral fracture</h5> <p>Eight trials compared vitamin D plus calcium versus placebo or no treatment for non‐vertebral fracture (<a href="./references#CD000227-bbs2-0003" title="AvenellA , GrantAM , McGeeM , McPhersonG , CampbellMK , McGee MA for the RECORD Trial Management Group. The effects of an open design on trial participant recruitment, compliance and retention - a randomized controlled trial comparison with a blinded, placebo-controlled design. Clinical Trials Journal2004;1:490-8. AvenellA . Personal communication2005. ">Avenell 2004</a>; <a href="./references#CD000227-bbs2-0005" title="Bolton-SmithC , McMurdoME , PatersonCR , MolePA , HarveyJM , FentonST , et al. Two-year randomized controlled trial of vitamin K1 (phylloquinone) and vitamin D3 plus calcium on bone health of older women. Journal of Bone and Mineral Research2007;22(4):509-19. McMurdoME . Personal communication 1 October 2007. ">Bolton‐Smith 2007</a>; <a href="./references#CD000227-bbs2-0008" title="ChapuyMC , ArlotM , et al. Prevention of non vertebral fractures and cortical bone loss in elderly women: a prospective controlled trial using calcium and vitamin D3 supplements [abstract]. Osteoporosis International1993;3 Suppl 1:258. ChapuyMC , ArlotME , DelmasPD , MeunierPJ . Effect of calcium and cholecalciferol treatment for three years on hip fractures in elderly women. BMJ1994;308:1081-2. ChapuyMC , ArlotME , DuboeufF , BrunJ , CrouzetB , ArnaudS , et al. Vitamin D3 and calcium to prevent hip fractures in elderly women. New England Journal of Medicine1992;327:1637-42. MeunierPJ , PamphileR , ChapuyMC , SchultenJ , ArlotM , LilluH . A calcium-vitamin D3 combined supplementation is cost-saving for preventing hip fractures in institutionalised elderly women: an economic evaluation from the perspective of seven European countries (Belgium, France, Germany, The Netherlands, Spain, Sweden, United Kingdom). Osteoporosis International2002;13(Suppl 1):S14. ">Chapuy 1992</a>; <a href="./references#CD000227-bbs2-0009" title="BosworthC , deBoerIH , TargherG , KendrickJ , SmitsG , ChoncholM . The effect of combined calcium and cholecalciferol supplementation on bone mineral density in elderly women with moderate chronic kidney disease. Clinical Nephrology2012;77(5):358-65. ChapuyMC , PamphileR , ParisE , KempfC , SchlichtingM , ArnaudS , et al. Combined calcium and vitamin D3 supplementation in elderly women: confirmation of reversal of secondary hyperparathyroidism and hip fracture risk: the Decalyos II study. Osteoporosis International2002;13(3):257-64. [MEDLINE: 11991447]ChapuyMC , PamphileR , ParisE , KempfC , SchlichtingM , ArnaudS , et al. Combined calcium and vitamin D3 supplementation to prevent hip fracture in elderly women. A confirmatory study: Decalyos II. Osteoporosis International2002;13(Suppl 1):S25. MeunierPJ . Personal communication 28 February 2005. ">Chapuy 2002</a>; <a href="./references#CD000227-bbs2-0010" title="Bischoff-FerrariHA , OravEJ , Dawson-HughesB . Additive effect of higher testosterone levels and vitamin D plus calcium supplementation in regard to fall risk reduction among older men and women. Osteoporosis International2008;19:1307-14. Bischoff-FerrariHA , OravEJ , Dawson-HughesB . Effect of cholecalciferol plus calcium on falling in ambulatory older men and women: a 3-year randomized controlled trial. Archives of Internal Medicine2006;166(4):424-30. Bischoff-FerrariHA , OravEJ , Dawson-HughesB . Effect of vitamin D3 plus calcium on fall risk in older men and women: a 3-year randomized controlled trial. Journal of Bone and Mineral Research2004;19(Suppl 1):S57. Dawson-HughesB , HarrisSS , KrallEA , DallalGE . Effect of calcium and vitamin D supplementation on bone density in men and women 65 years of age or older. New England Journal of Medicine1997;337(10):670-6. Dawson-HughesB , HarrisSS , KrallEA , DallalGE . Effect of withdrawal of calcium and vitamin D supplements on bone mass in elderly men and women. American Journal of Clinical Nutrition2000;72(3):745-50. Dawson-HughesB , HarrisSS . Calcium intake influences the association of protein intake with rates of bone loss in elderly men and women. American Journal of Clinical Nutrition2002;75(4):773-9. KrallEA , RandallC , HarrisSS , GarciaRI , Dawson-HughesB . Calcium and vitamin D supplements reduce tooth loss in the elderly. Journal of Bone and Mineral Research2000;15(Suppl 1):S191. KrallEA , WehlerC , GarciaRI , HarrisSS , Dawson-HughesB . Calcium and vitamin D supplements reduce tooth loss in the elderly. American Journal of Medicine2001;111(6):452-6. NiramitmahapanyaS , HarrisSS , Dawson-HughesB . Type of dietary fat is associated with the 25-hydroxyvitamin D3 increment in response to vitamin D supplementation. Journal of Clinical Endocrinology and Metabolism2011;96(10):3170-4. ">Dawson‐Hughes 1997</a>; <a href="./references#CD000227-bbs2-0022" title="HarwoodRH , SahotaO , GaynorK , MasudT , HoskingD . A randomised, controlled comparison of different calcium and vitamin D supplementation regimens in elderly women after hip fracture: The Nottingham Neck of Femur (NoNOF) Study. Age and Ageing2004;33:45-51. [14695863]HarwoodRW . Personal communication 24 January 2003. SahotaO , HarwoodRH , GaynorK , MasudT , HoskingDJ . A randomised, controlled comparison of different calcium and vitamin D regimes: the NoNOF (Nottingham Neck of Femur) study. Osteoporosis International2003;14(Suppl 4):S10-11. ">Harwood 2004</a>; <a href="./references#CD000227-bbs2-0037" title="KarkkainenM , TuppurainenM , RikkonenT , SalovaaraK , SirolaJ , HonkanenR , et al. Vitamin-D 800IU/day + calcium 1000mg supplementation decreases the risk of recurrent falling among postmenopausal ambulatory women - a population-based, randomized, 3-year study (OSTPRE-FPS). Osteoporosis International2008;19(Suppl 1):S17-18. KarkkainenM , TuppurainenM , RikkonenT , SalovaaraK , SirolaJ , HonkanenR , et al. Vitamin-D 800IU/day + calcium supplementation decreases the risk of falling among postmenopausal ambulatory women - a population-based, randomized 3-year study (OSTPRE-FPS) [abstract]. Journal of Bone and Mineral Research2007;22(Suppl 1):S131. KarkkainenM , TuppurainenM , SalovaaraK , SandiniL , RikkonenT , SirolaJ , et al. Effect of calcium and vitamin D supplementation on bone mineral density in women aged 65-71 years: a 3-year randomized population-based trial (OSTPRE-FPS). Osteoporosis International2010;21:2047-55. KarkkainenMK , TuppurainenM , SalovaaraM , SandiniL , RikkonenT , SirolaJ , et al. Does daily vitamin D 800 IU and calcium 1000 mg supplementation decrease the risk of falling in ambulatory women aged 65-71 years? A 3-year randomized population-based trial (OSTPRE-FPS). Maturitas2010;65:359-65. KrogerHP , TuppurainenM . OSTPRE-FPS Prevention of Fractures and Falls in Postmenopausal Women With Calcium and Vitamin-D Supplementation - a Randomised Study. http://www.controlled-trials.com/mrct/trial/405493/OSTPRE. SalovaaraK , TuppurainenM , KarkkainenM , RikkonenT , SandiniL , SirolaJ , et al. Effect of vitamin D3 and calcium on fracture risk in 65- to 71-year-old women: a population-based 3-year randomized, controlled trial - the OSTPRE-FPS. Journal of Bone and Mineral Research2010;25(7):1487-95. SalovaaraKT , TuppurainenM , RikkonenT , KarkkainenM , SirolaJ , HonkanenR , et al. Effect of vitamin-D3 and calcium on fracture risk in 65-71 year old women in a 3-year randomized clinical trial - preliminary results from the OSTPRE-Fracture Prevention Study. Calcified Tissue International2008;82:545-6. SalovaaraKT , TuppurainenM , RikkonenT , KarkkainenM , SirolaJ , HonkanenR , et al. Effect of vitamin-D3 and calcium on fracture risk in 65-71 year old women in a 3-year randomized clinical trial - preliminary results of the OSTPRE-Fracture Prevention Study. Journal of Bone and Mineral Research2007;22(Suppl 1):S76. ">OSTPRE‐FPS 2007</a>; <a href="./references#CD000227-bbs2-0044" title="AndersonFH , GrantAM , AvenellA , CampbellMK , CooperC , DonaldsonC , et al. The RECORD Trial: an evaluation of calcium and/or vitamin D in the secondary prevention of osteoporotic fractures. Bone2005;36(Suppl 2):S122-3. FrancisRM , Grant AM and the RECORD trial group. The RECORD trial: a randomised double-blind study of calcium and/or vitamin D in the secondary prevention of low trauma fractures. Age Ageing2005;34(Suppl 2):ii15. GrantA , on behalf of the RECORD Trial Group. Prevention of low-trauma fractures in older people [author reply]. Lancet2005;366(9485):543-4. GrantAM , AndersonFH , for the RECORD Trial Group. The Medical Research Council RECORD Trial: an evaluation of calcium and/or vitamin D in the secondary prevention of osteoporotic fractures. Osteoporosis International2004;15(Suppl 2):S13. GrantAM , AndersonFH . The RECORD trial: an evaluation of calcium and/or vitamin D in the secondary prevention of osteoporotic fractures. Osteoporosis International2005;16(Suppl 3):S4-5. GrantAM , AvenellA , CampbellMK , McDonaldAM , MacLennanGS , McPhersonGC , et al. Oral vitamin D3 and calcium for secondary prevention of low-trauma fractures in elderly people (Randomised Evaluation of Calcium Or vitamin D, RECORD): a randomised placebo-controlled trial [comment in: Lancet 2005;366(9485):543]. Lancet2005;365(9471):1621-8. GrantAM . Personal communication 11 March 2004. ">RECORD 2005</a>).<br/><br/>Overall, administration of vitamin D and calcium was associated with a statistically significant reduction in incidence of new non‐vertebral fracture (eight trials, 10,380 participants, RR 0.86, 95% CI 0.78 to 0.96, <i>see</i><a href="./references#CD000227-fig-0020" title="">Analysis 4.3</a>). </p> </section> <section id="CD000227-sec-0060"> <h5 class="title">Vertebral fracture</h5> <p>Four trials compared vitamin D plus calcium versus placebo or no treatment for vertebral fracture (<a href="./references#CD000227-bbs2-0003" title="AvenellA , GrantAM , McGeeM , McPhersonG , CampbellMK , McGee MA for the RECORD Trial Management Group. The effects of an open design on trial participant recruitment, compliance and retention - a randomized controlled trial comparison with a blinded, placebo-controlled design. Clinical Trials Journal2004;1:490-8. AvenellA . Personal communication2005. ">Avenell 2004</a>; <a href="./references#CD000227-bbs2-0037" title="KarkkainenM , TuppurainenM , RikkonenT , SalovaaraK , SirolaJ , HonkanenR , et al. Vitamin-D 800IU/day + calcium 1000mg supplementation decreases the risk of recurrent falling among postmenopausal ambulatory women - a population-based, randomized, 3-year study (OSTPRE-FPS). Osteoporosis International2008;19(Suppl 1):S17-18. KarkkainenM , TuppurainenM , RikkonenT , SalovaaraK , SirolaJ , HonkanenR , et al. Vitamin-D 800IU/day + calcium supplementation decreases the risk of falling among postmenopausal ambulatory women - a population-based, randomized 3-year study (OSTPRE-FPS) [abstract]. Journal of Bone and Mineral Research2007;22(Suppl 1):S131. KarkkainenM , TuppurainenM , SalovaaraK , SandiniL , RikkonenT , SirolaJ , et al. Effect of calcium and vitamin D supplementation on bone mineral density in women aged 65-71 years: a 3-year randomized population-based trial (OSTPRE-FPS). Osteoporosis International2010;21:2047-55. KarkkainenMK , TuppurainenM , SalovaaraM , SandiniL , RikkonenT , SirolaJ , et al. Does daily vitamin D 800 IU and calcium 1000 mg supplementation decrease the risk of falling in ambulatory women aged 65-71 years? A 3-year randomized population-based trial (OSTPRE-FPS). Maturitas2010;65:359-65. KrogerHP , TuppurainenM . OSTPRE-FPS Prevention of Fractures and Falls in Postmenopausal Women With Calcium and Vitamin-D Supplementation - a Randomised Study. http://www.controlled-trials.com/mrct/trial/405493/OSTPRE. SalovaaraK , TuppurainenM , KarkkainenM , RikkonenT , SandiniL , SirolaJ , et al. Effect of vitamin D3 and calcium on fracture risk in 65- to 71-year-old women: a population-based 3-year randomized, controlled trial - the OSTPRE-FPS. Journal of Bone and Mineral Research2010;25(7):1487-95. SalovaaraKT , TuppurainenM , RikkonenT , KarkkainenM , SirolaJ , HonkanenR , et al. Effect of vitamin-D3 and calcium on fracture risk in 65-71 year old women in a 3-year randomized clinical trial - preliminary results from the OSTPRE-Fracture Prevention Study. Calcified Tissue International2008;82:545-6. SalovaaraKT , TuppurainenM , RikkonenT , KarkkainenM , SirolaJ , HonkanenR , et al. Effect of vitamin-D3 and calcium on fracture risk in 65-71 year old women in a 3-year randomized clinical trial - preliminary results of the OSTPRE-Fracture Prevention Study. Journal of Bone and Mineral Research2007;22(Suppl 1):S76. ">OSTPRE‐FPS 2007</a>; <a href="./references#CD000227-bbs2-0044" title="AndersonFH , GrantAM , AvenellA , CampbellMK , CooperC , DonaldsonC , et al. The RECORD Trial: an evaluation of calcium and/or vitamin D in the secondary prevention of osteoporotic fractures. Bone2005;36(Suppl 2):S122-3. FrancisRM , Grant AM and the RECORD trial group. The RECORD trial: a randomised double-blind study of calcium and/or vitamin D in the secondary prevention of low trauma fractures. Age Ageing2005;34(Suppl 2):ii15. GrantA , on behalf of the RECORD Trial Group. Prevention of low-trauma fractures in older people [author reply]. Lancet2005;366(9485):543-4. GrantAM , AndersonFH , for the RECORD Trial Group. The Medical Research Council RECORD Trial: an evaluation of calcium and/or vitamin D in the secondary prevention of osteoporotic fractures. Osteoporosis International2004;15(Suppl 2):S13. GrantAM , AndersonFH . The RECORD trial: an evaluation of calcium and/or vitamin D in the secondary prevention of osteoporotic fractures. Osteoporosis International2005;16(Suppl 3):S4-5. GrantAM , AvenellA , CampbellMK , McDonaldAM , MacLennanGS , McPhersonGC , et al. Oral vitamin D3 and calcium for secondary prevention of low-trauma fractures in elderly people (Randomised Evaluation of Calcium Or vitamin D, RECORD): a randomised placebo-controlled trial [comment in: Lancet 2005;366(9485):543]. Lancet2005;365(9471):1621-8. GrantAM . Personal communication 11 March 2004. ">RECORD 2005</a>; <a href="./references#CD000227-bbs2-0051" title="CauleyJ , Wactawski-WendeJ , RobbinsJ , RodaboughR , ChenZ , JohnsonK , et al. The Women's Health Initiative (WHI) calcium and vitamin D supplementation trial: health outcomes 5 years after trial completion. ASBMR Annual Meeting; 2012 Oct 12-15; Minneapolis, Minnesota. http://www.asbmr.org/Meetings/AnnualMeeting/AbstractDetail.aspx?aid=6450bf3e-c670-4dc0-814c-8842e23cd80e (accessed 27 December 2012). CauleyJA , LaCroixA , WuL , LeeJ , HorowitzM , BauerD , et al. Serum 25 hydroxy vitamin D 25(OH) and the risk of hip fracture: the Women's Health Initiative (WHI). Journal of Bone and Mineral Research2007;22(Suppl 1):S57. ChenZ , BeckTJ , WrightNC , LaCroixAZ , CauleyJA , LewisCE , et al. The effect of calcium plus vitamin D supplement on hip geometric structures: results from the Women's Health Initiative CaD trial. Journal of Bone and Mineral Research2007;22(Suppl 1):S59. JacksonRD , LaCroixAZ , CauleyJA , McGowanJ . The Women's Health Initiative Calcium-Vitamin D Trial: overview and baseline characteristics of participants. Annals of Epidemiology2003;13:S98-106. JacksonRD , LaCroixAZ , GassM , WallaceRB , RobbinsJ , LewisCE , et al. Calcium plus vitamin D supplementation and the risk of fractures [erratum appears in New England Journal of Medicine 9 March 2006;354(10):1102]. New England Journal of Medicine2006;354(7):669-83. JacksonRD , WrightNC , BeckTJ , SherrillD , CauleyJA , LewisCE , et al. Calcium plus vitamin D supplementation has limited effects on femoral geometric strength in older postmenopausal women: the Women's Health Initiative. Calcified Tissue International2011;88:198-208. McGowanJA , JacksonRD , CauleyJA , LaCroixAZ . Calcium and vitamin D in the prevention of hip and other fractures: an update on the Women's Health Initiative CaD Trial. Journal of Bone and Mineral Research2002;17(Suppl 1):S477. The Women's Health Initiative Study Group. Design of the Women's Health Initiative clinical trial and observational study. Controlled Clinical Trials1998;19(1):61-109. ">WHI 2006</a>).<br/><br/>There was no evidence of a statistically significant preventive effect on clinical vertebral fractures from the administration of vitamin D and calcium (four trials, 42,185 participants, RR 0.89, 95% CI 0.74 to 1.09, <i>see</i><a href="./references#CD000227-fig-0021" title="">Analysis 4.4</a>). </p> <p>The Women's Health Initiative has recently reported (<a href="./references#CD000227-bbs2-0051" title="CauleyJ , Wactawski-WendeJ , RobbinsJ , RodaboughR , ChenZ , JohnsonK , et al. The Women's Health Initiative (WHI) calcium and vitamin D supplementation trial: health outcomes 5 years after trial completion. ASBMR Annual Meeting; 2012 Oct 12-15; Minneapolis, Minnesota. http://www.asbmr.org/Meetings/AnnualMeeting/AbstractDetail.aspx?aid=6450bf3e-c670-4dc0-814c-8842e23cd80e (accessed 27 December 2012). CauleyJA , LaCroixA , WuL , LeeJ , HorowitzM , BauerD , et al. Serum 25 hydroxy vitamin D 25(OH) and the risk of hip fracture: the Women's Health Initiative (WHI). Journal of Bone and Mineral Research2007;22(Suppl 1):S57. ChenZ , BeckTJ , WrightNC , LaCroixAZ , CauleyJA , LewisCE , et al. The effect of calcium plus vitamin D supplement on hip geometric structures: results from the Women's Health Initiative CaD trial. Journal of Bone and Mineral Research2007;22(Suppl 1):S59. JacksonRD , LaCroixAZ , CauleyJA , McGowanJ . The Women's Health Initiative Calcium-Vitamin D Trial: overview and baseline characteristics of participants. Annals of Epidemiology2003;13:S98-106. JacksonRD , LaCroixAZ , GassM , WallaceRB , RobbinsJ , LewisCE , et al. Calcium plus vitamin D supplementation and the risk of fractures [erratum appears in New England Journal of Medicine 9 March 2006;354(10):1102]. New England Journal of Medicine2006;354(7):669-83. JacksonRD , WrightNC , BeckTJ , SherrillD , CauleyJA , LewisCE , et al. Calcium plus vitamin D supplementation has limited effects on femoral geometric strength in older postmenopausal women: the Women's Health Initiative. Calcified Tissue International2011;88:198-208. McGowanJA , JacksonRD , CauleyJA , LaCroixAZ . Calcium and vitamin D in the prevention of hip and other fractures: an update on the Women's Health Initiative CaD Trial. Journal of Bone and Mineral Research2002;17(Suppl 1):S477. The Women's Health Initiative Study Group. Design of the Women's Health Initiative clinical trial and observational study. Controlled Clinical Trials1998;19(1):61-109. ">WHI 2006</a>) ‐ in abstract form ‐ fracture outcomes after seven years of the trial and a further five years of follow‐up (<a href="./references#CD000227-bbs2-0149" title="CauleyJ , Wactawski-WendeJ , RobbinsJ , RodaboughR , ChenZ , JohnsonK , et al. The Women's Health Initiative (WHI) calcium and vitamin D supplementation trial: health outcomes 5 years after trial completion. In: ASBMR Annual Meeting; 2012 Oct 12-15; Minneapolis, Minnesota. http://www.asbmr.org/Meetings/AnnualMeeting/AbstractDetail.aspx?aid=6450bf3e-c670-4dc0-814c-8842e23cd80e. (accessed 27 December 2012).">Cauley 2012</a>). For the overall period of follow‐up, no significant differences between treatment and placebo groups were found for hip fractures or total fractures, but clinical vertebral fractures were 13% lower in women randomised to calcium and vitamin D (reported hazard ratio 0.87, 95% CI 0.76 to 0.98). </p> </section> <section id="CD000227-sec-0061"> <h5 class="title">Any fracture</h5> <p>Ten trials compared vitamin D plus calcium versus placebo or no treatment for any fracture (<a href="./references#CD000227-bbs2-0003" title="AvenellA , GrantAM , McGeeM , McPhersonG , CampbellMK , McGee MA for the RECORD Trial Management Group. The effects of an open design on trial participant recruitment, compliance and retention - a randomized controlled trial comparison with a blinded, placebo-controlled design. Clinical Trials Journal2004;1:490-8. AvenellA . Personal communication2005. ">Avenell 2004</a>; <a href="./references#CD000227-bbs2-0005" title="Bolton-SmithC , McMurdoME , PatersonCR , MolePA , HarveyJM , FentonST , et al. Two-year randomized controlled trial of vitamin K1 (phylloquinone) and vitamin D3 plus calcium on bone health of older women. Journal of Bone and Mineral Research2007;22(4):509-19. McMurdoME . Personal communication 1 October 2007. ">Bolton‐Smith 2007</a>; <a href="./references#CD000227-bbs2-0008" title="ChapuyMC , ArlotM , et al. Prevention of non vertebral fractures and cortical bone loss in elderly women: a prospective controlled trial using calcium and vitamin D3 supplements [abstract]. Osteoporosis International1993;3 Suppl 1:258. ChapuyMC , ArlotME , DelmasPD , MeunierPJ . Effect of calcium and cholecalciferol treatment for three years on hip fractures in elderly women. BMJ1994;308:1081-2. ChapuyMC , ArlotME , DuboeufF , BrunJ , CrouzetB , ArnaudS , et al. Vitamin D3 and calcium to prevent hip fractures in elderly women. New England Journal of Medicine1992;327:1637-42. MeunierPJ , PamphileR , ChapuyMC , SchultenJ , ArlotM , LilluH . A calcium-vitamin D3 combined supplementation is cost-saving for preventing hip fractures in institutionalised elderly women: an economic evaluation from the perspective of seven European countries (Belgium, France, Germany, The Netherlands, Spain, Sweden, United Kingdom). Osteoporosis International2002;13(Suppl 1):S14. ">Chapuy 1992</a>; <a href="./references#CD000227-bbs2-0009" title="BosworthC , deBoerIH , TargherG , KendrickJ , SmitsG , ChoncholM . The effect of combined calcium and cholecalciferol supplementation on bone mineral density in elderly women with moderate chronic kidney disease. Clinical Nephrology2012;77(5):358-65. ChapuyMC , PamphileR , ParisE , KempfC , SchlichtingM , ArnaudS , et al. Combined calcium and vitamin D3 supplementation in elderly women: confirmation of reversal of secondary hyperparathyroidism and hip fracture risk: the Decalyos II study. Osteoporosis International2002;13(3):257-64. [MEDLINE: 11991447]ChapuyMC , PamphileR , ParisE , KempfC , SchlichtingM , ArnaudS , et al. Combined calcium and vitamin D3 supplementation to prevent hip fracture in elderly women. A confirmatory study: Decalyos II. Osteoporosis International2002;13(Suppl 1):S25. MeunierPJ . Personal communication 28 February 2005. ">Chapuy 2002</a>; <a href="./references#CD000227-bbs2-0010" title="Bischoff-FerrariHA , OravEJ , Dawson-HughesB . Additive effect of higher testosterone levels and vitamin D plus calcium supplementation in regard to fall risk reduction among older men and women. Osteoporosis International2008;19:1307-14. Bischoff-FerrariHA , OravEJ , Dawson-HughesB . Effect of cholecalciferol plus calcium on falling in ambulatory older men and women: a 3-year randomized controlled trial. Archives of Internal Medicine2006;166(4):424-30. Bischoff-FerrariHA , OravEJ , Dawson-HughesB . Effect of vitamin D3 plus calcium on fall risk in older men and women: a 3-year randomized controlled trial. Journal of Bone and Mineral Research2004;19(Suppl 1):S57. Dawson-HughesB , HarrisSS , KrallEA , DallalGE . Effect of calcium and vitamin D supplementation on bone density in men and women 65 years of age or older. New England Journal of Medicine1997;337(10):670-6. Dawson-HughesB , HarrisSS , KrallEA , DallalGE . Effect of withdrawal of calcium and vitamin D supplements on bone mass in elderly men and women. American Journal of Clinical Nutrition2000;72(3):745-50. Dawson-HughesB , HarrisSS . Calcium intake influences the association of protein intake with rates of bone loss in elderly men and women. American Journal of Clinical Nutrition2002;75(4):773-9. KrallEA , RandallC , HarrisSS , GarciaRI , Dawson-HughesB . Calcium and vitamin D supplements reduce tooth loss in the elderly. Journal of Bone and Mineral Research2000;15(Suppl 1):S191. KrallEA , WehlerC , GarciaRI , HarrisSS , Dawson-HughesB . Calcium and vitamin D supplements reduce tooth loss in the elderly. American Journal of Medicine2001;111(6):452-6. NiramitmahapanyaS , HarrisSS , Dawson-HughesB . Type of dietary fat is associated with the 25-hydroxyvitamin D3 increment in response to vitamin D supplementation. Journal of Clinical Endocrinology and Metabolism2011;96(10):3170-4. ">Dawson‐Hughes 1997</a>; <a href="./references#CD000227-bbs2-0022" title="HarwoodRH , SahotaO , GaynorK , MasudT , HoskingD . A randomised, controlled comparison of different calcium and vitamin D supplementation regimens in elderly women after hip fracture: The Nottingham Neck of Femur (NoNOF) Study. Age and Ageing2004;33:45-51. [14695863]HarwoodRW . Personal communication 24 January 2003. SahotaO , HarwoodRH , GaynorK , MasudT , HoskingDJ . A randomised, controlled comparison of different calcium and vitamin D regimes: the NoNOF (Nottingham Neck of Femur) study. Osteoporosis International2003;14(Suppl 4):S10-11. ">Harwood 2004</a>; <a href="./references#CD000227-bbs2-0037" title="KarkkainenM , TuppurainenM , RikkonenT , SalovaaraK , SirolaJ , HonkanenR , et al. Vitamin-D 800IU/day + calcium 1000mg supplementation decreases the risk of recurrent falling among postmenopausal ambulatory women - a population-based, randomized, 3-year study (OSTPRE-FPS). Osteoporosis International2008;19(Suppl 1):S17-18. KarkkainenM , TuppurainenM , RikkonenT , SalovaaraK , SirolaJ , HonkanenR , et al. Vitamin-D 800IU/day + calcium supplementation decreases the risk of falling among postmenopausal ambulatory women - a population-based, randomized 3-year study (OSTPRE-FPS) [abstract]. Journal of Bone and Mineral Research2007;22(Suppl 1):S131. KarkkainenM , TuppurainenM , SalovaaraK , SandiniL , RikkonenT , SirolaJ , et al. Effect of calcium and vitamin D supplementation on bone mineral density in women aged 65-71 years: a 3-year randomized population-based trial (OSTPRE-FPS). Osteoporosis International2010;21:2047-55. KarkkainenMK , TuppurainenM , SalovaaraM , SandiniL , RikkonenT , SirolaJ , et al. Does daily vitamin D 800 IU and calcium 1000 mg supplementation decrease the risk of falling in ambulatory women aged 65-71 years? A 3-year randomized population-based trial (OSTPRE-FPS). Maturitas2010;65:359-65. KrogerHP , TuppurainenM . OSTPRE-FPS Prevention of Fractures and Falls in Postmenopausal Women With Calcium and Vitamin-D Supplementation - a Randomised Study. http://www.controlled-trials.com/mrct/trial/405493/OSTPRE. SalovaaraK , TuppurainenM , KarkkainenM , RikkonenT , SandiniL , SirolaJ , et al. Effect of vitamin D3 and calcium on fracture risk in 65- to 71-year-old women: a population-based 3-year randomized, controlled trial - the OSTPRE-FPS. Journal of Bone and Mineral Research2010;25(7):1487-95. SalovaaraKT , TuppurainenM , RikkonenT , KarkkainenM , SirolaJ , HonkanenR , et al. Effect of vitamin-D3 and calcium on fracture risk in 65-71 year old women in a 3-year randomized clinical trial - preliminary results from the OSTPRE-Fracture Prevention Study. Calcified Tissue International2008;82:545-6. SalovaaraKT , TuppurainenM , RikkonenT , KarkkainenM , SirolaJ , HonkanenR , et al. Effect of vitamin-D3 and calcium on fracture risk in 65-71 year old women in a 3-year randomized clinical trial - preliminary results of the OSTPRE-Fracture Prevention Study. Journal of Bone and Mineral Research2007;22(Suppl 1):S76. ">OSTPRE‐FPS 2007</a>; <a href="./references#CD000227-bbs2-0042" title="DumvilleJC , MilesJN , PorthouseJ , CockayneES , SaxonL , KingC , et al. Can vitamin D supplementation prevent seasonal affective disorder? A randomised trial among older women. Osteoporosis International2004;15:S42-3. PorthouseJ , CockayneS , KingC , SaxonL , SteeleE , AsprayT , et al. Randomised controlled trial of calcium and supplementation with cholecalciferol (vitamin D3) for prevention of fractures in primary care. BMJ2005;330(7498):1003-6. PorthouseJ , CockayneS , KingC , SaxonL , SteeleE , AsprayT , et al. Randomised controlled trial of calcium and vitamin D supplementation for fracture prevention in primary care. Osteoporosis International2004;15(Suppl 2):S13. PorthouseJ , CockayneS , KingC , SaxonL , SteeleE , AsprayT , et al. Randomised controlled trial of calcium and vitamin D supplementation for fracture prevention in primary care. Osteoporosis International2005;16:S27. PufferS . Calcium and vitamin D in primary care: adherence results from a randomised controlled trial [abstract 6.9.3]. In: RCN International Nursing Conference; 2004 Mar 21-31; Cambridge (UK). London: Royal College of Nursing, 2004. S Puffer, on behalf of the Calcium and Vitamin D Trial. Calcium and vitamin D in primary care. Compliance results from a randomised controlled trial. Osteoporosis International2003;14(Suppl 4):S8. TorgersonD , on behalf of the trial group. Calcium and vitamin D in preventing fractures [author reply]. BMJ2005;331(7508):109. TorgersonDJ . Personal communication 9-16 February 2005. ">Porthouse 2005</a>; <a href="./references#CD000227-bbs2-0044" title="AndersonFH , GrantAM , AvenellA , CampbellMK , CooperC , DonaldsonC , et al. The RECORD Trial: an evaluation of calcium and/or vitamin D in the secondary prevention of osteoporotic fractures. Bone2005;36(Suppl 2):S122-3. FrancisRM , Grant AM and the RECORD trial group. The RECORD trial: a randomised double-blind study of calcium and/or vitamin D in the secondary prevention of low trauma fractures. Age Ageing2005;34(Suppl 2):ii15. GrantA , on behalf of the RECORD Trial Group. Prevention of low-trauma fractures in older people [author reply]. Lancet2005;366(9485):543-4. GrantAM , AndersonFH , for the RECORD Trial Group. The Medical Research Council RECORD Trial: an evaluation of calcium and/or vitamin D in the secondary prevention of osteoporotic fractures. Osteoporosis International2004;15(Suppl 2):S13. GrantAM , AndersonFH . The RECORD trial: an evaluation of calcium and/or vitamin D in the secondary prevention of osteoporotic fractures. Osteoporosis International2005;16(Suppl 3):S4-5. GrantAM , AvenellA , CampbellMK , McDonaldAM , MacLennanGS , McPhersonGC , et al. Oral vitamin D3 and calcium for secondary prevention of low-trauma fractures in elderly people (Randomised Evaluation of Calcium Or vitamin D, RECORD): a randomised placebo-controlled trial [comment in: Lancet 2005;366(9485):543]. Lancet2005;365(9471):1621-8. GrantAM . Personal communication 11 March 2004. ">RECORD 2005</a>; <a href="./references#CD000227-bbs2-0051" title="CauleyJ , Wactawski-WendeJ , RobbinsJ , RodaboughR , ChenZ , JohnsonK , et al. The Women's Health Initiative (WHI) calcium and vitamin D supplementation trial: health outcomes 5 years after trial completion. ASBMR Annual Meeting; 2012 Oct 12-15; Minneapolis, Minnesota. http://www.asbmr.org/Meetings/AnnualMeeting/AbstractDetail.aspx?aid=6450bf3e-c670-4dc0-814c-8842e23cd80e (accessed 27 December 2012). CauleyJA , LaCroixA , WuL , LeeJ , HorowitzM , BauerD , et al. Serum 25 hydroxy vitamin D 25(OH) and the risk of hip fracture: the Women's Health Initiative (WHI). Journal of Bone and Mineral Research2007;22(Suppl 1):S57. ChenZ , BeckTJ , WrightNC , LaCroixAZ , CauleyJA , LewisCE , et al. The effect of calcium plus vitamin D supplement on hip geometric structures: results from the Women's Health Initiative CaD trial. Journal of Bone and Mineral Research2007;22(Suppl 1):S59. JacksonRD , LaCroixAZ , CauleyJA , McGowanJ . The Women's Health Initiative Calcium-Vitamin D Trial: overview and baseline characteristics of participants. Annals of Epidemiology2003;13:S98-106. JacksonRD , LaCroixAZ , GassM , WallaceRB , RobbinsJ , LewisCE , et al. Calcium plus vitamin D supplementation and the risk of fractures [erratum appears in New England Journal of Medicine 9 March 2006;354(10):1102]. New England Journal of Medicine2006;354(7):669-83. JacksonRD , WrightNC , BeckTJ , SherrillD , CauleyJA , LewisCE , et al. Calcium plus vitamin D supplementation has limited effects on femoral geometric strength in older postmenopausal women: the Women's Health Initiative. Calcified Tissue International2011;88:198-208. McGowanJA , JacksonRD , CauleyJA , LaCroixAZ . Calcium and vitamin D in the prevention of hip and other fractures: an update on the Women's Health Initiative CaD Trial. Journal of Bone and Mineral Research2002;17(Suppl 1):S477. The Women's Health Initiative Study Group. Design of the Women's Health Initiative clinical trial and observational study. Controlled Clinical Trials1998;19(1):61-109. ">WHI 2006</a>). </p> <p>There was evidence of a statistically significant reduction in the incidence of any fracture (10 trials, 49,976 participants, RR 0.95, 95% CI 0.90 to 0.99, <i>see</i><a href="./references#CD000227-fig-0022" title="">Analysis 4.5</a>). In participants selected on the basis of no previous fracture, the RR was 0.95, 95% CI 0.90 to 1.00 (six trials, 43,842 participants); and in those with a previous history of fracture, the RR was 0.93, 95% CI 0.79 to 1.10 (four trials, 6134 participants). The test for subgroup differences was not significant (P value 0.84). </p> <p>There was evidence for a reduction in any fracture for residents in institutions (RR 0.85, 95% CI 0.74 to 0.98, two trials, 3853 participants; <i>see</i><a href="./references#CD000227-fig-0023" title="">Analysis 4.6</a>), and a non‐significant effect for people living in the community (RR 0.96, 95% CI 0.91 to 1.01, eight trials, 46,123 participants, <i>see</i><a href="./references#CD000227-fig-0023" title="">Analysis 4.6</a>). However, the test for subgroup differences was not significant (P value 0.13). </p> </section> </section> <section id="CD000227-sec-0062"> <h4 class="title">Alfacalcidol (1‐alphahydroxyvitamin D3) versus placebo or no treatment</h4> <section id="CD000227-sec-0063"> <h5 class="title">Non‐vertebral fracture</h5> <p>Three trials compared alfacalcidol (1‐alphahydroxyvitamin D3) versus placebo or no treatment for non‐vertebral fracture (<a href="./references#CD000227-bbs2-0011" title="DukasL , BischoffHA , LindpaintnerLS , SchachtE , Birkner-BinderD , DammTN , et al. Alfacalcidol reduces the number of fallers in a community-dwelling elderly population with a minimum calcium intake of more than 500 mg daily. Journal of the American Geriatrics Society2004;52(2):230-6. DukasL , BischoffHA , LindpaintnerLS , SchachtE , Birkner-BinderD , ThalmanB , et al. Alfacalcidol reduces the number of fallers and falls in community-dwelling elderly provided a minimum total daily intake of 500mg calcium [abstract]. Calcified Tissue International2003;72:371. DukasL , SchachtE , MazorZ , StahelinHB . Treatment with alfacalcidol in elderly people significantly decreases the high risk of falls associated with a low creatinine clearance of &lt;65 ml/min. Osteoporosis International2005;16(2):198-203. DukasL , SchachtE , StahelinHB . A significant independent new risk factor for falls in the elderly: a low creatinine clearance of less than 65ml/min. Osteoporosis International2003;14(Suppl 7):S33. DukasL , SchachtE , StahelinHB . High risk of falls related to low D-hormone syndrome and its treatment with alfacalcidol. Osteoporosis International2004;15(Suppl 1):S8-9. DukasL , SchachtE , StahelinHB . Reduction of falls and fallers in high risk patients by D-hormone analogs. Osteoporosis International2004;15(Suppl 1):S144-5. DukasL , SchachtE , StahelinHB . Treatment with alfacalcidol significantly decreases the high incidence of fallers and the high risk of falls associated with low creatinine clearance (&lt;65ml/min) in elderly community-dwelling men and women. Osteoporosis International2003;14(Suppl 7):S33. DukasL , SchachtE . Reduction of falls and fallers using D-hormone analogs. Osteoporosis International2006;17(Suppl 1):S122-3. DukasLC , SchachtE , MazorZ , StahelinHB . The low creatinine clearance associated high risk of falls can significantly be treated with alfacalcidol. Journal of Bone and Mineral Research2004;19(Suppl 1):S95. DukasLC . Personal communication 19 July 2004. ">Dukas 2004</a>; <a href="./references#CD000227-bbs2-0021" title="GoraiI , ChakiO , TaguchiY , NakayamaM , OsadaH , SuzukiN , et al. Early postmenopausal bone loss is prevented by estrogen and partially by 1alpha-OH-vitamin D3: therapeutic effects of estrogen and/or 1alpha-OH-vitamin D3. Calcified Tissue International1999;65:16-22. ">Gorai 1999</a>; <a href="./references#CD000227-bbs2-0049" title="UshiroyamaT , IkedaA , SakaiM , HigashiyamaT , UekiM . Effects of the combined use of calcitonin and 1alpha-hydroxycholecalciferol on vertebral bone loss and bone turnover in women with postmenopausal osteopenia and osteoporosis: a prospective study of long-term and continuous administration with low dose calcitonin. Maturitas2001;40:229-38. ">Ushiroyama 2001</a>).<br/><br/>There was no statistically significant reduction in non‐vertebral fractures in people with and without pre‐existing osteoporotic fracture (three trials, 526 participants, RR 0.97, 95% CI 0.25 to 3.82, <i>see</i><a href="./references#CD000227-fig-0024" title="">Analysis 5.1</a>). </p> </section> <section id="CD000227-sec-0064"> <h5 class="title">Vertebral fracture</h5> <p>One trial compared alfacalcidol (1‐alphahydroxyvitamin D3) versus placebo or no treatment for vertebral fracture (<a href="./references#CD000227-bbs2-0023" title="HayashiY , FujitaT , InoueT . A multi-center study on efficacy of 1 alpha-hydroxy vitamin D3 in preventing spinal fracture of patients with osteoporosis (abstract). Journal of Bone and Mineral Research1989;4 Suppl 1:Si84. HayashiY , FujitaT , InoueT . Decrease of vertebral fracture in osteoporotics by administration of 1alpha-hydroxy-vitamin D3. Journal of Bone and Mineral Metabolism1992;10(2):50-4. ">Hayashi 1992</a>).<br/><br/>There was a statistically significant reduction in vertebral fractures (one trial, 740 participants, RR 0.56, 95% CI 0.48 to 0.65, <i>see</i><a href="./references#CD000227-fig-0025" title="">Analysis 5.2</a>). </p> </section> </section> <section id="CD000227-sec-0065"> <h4 class="title">Alfacalcidol (1‐alphahydroxyvitamin D3) plus calcium versus calcium</h4> <p>Five trials compared alfacalcidol (1‐alphahydroxyvitamin D3) plus calcium versus calcium (<a href="./references#CD000227-bbs2-0031" title="MenczelJ , FoldesJ , SteinbergR , LeichterI , ShalitaB , Bjolah-AbramT , et al. Alfacalcidol (Alpha D3) and calcium in osteoporosis. Clinical Orthopaedics and Related Research1994;(300):241-7. ">Menczel 1994</a>; <a href="./references#CD000227-bbs2-0034" title="NakatsukaK , InabaM , ArataniH , IbaK , SatoT , KoikeT , et al. Effects of long-term administration of alfacalcidol on bone mass and bone metabolism in patients with primary osteoporosis - comparison with calcium preparations [Japanese]. Nippon Ronen Igakkai Zasshi - Japanese Journal of Geriatrics1997;34(7):569-76. ">Nakatsuka 1997</a>; <a href="./references#CD000227-bbs2-0035" title="OnesK , SchachtE , DukasL , CaglarN . Effects of combined treatment with alendronate and alfacalcidol on bone mineral density and bone turnover in postmenopausal osteoporosis: a two-years, randomized, multiarm, controlled trial. Internet Journal of Epidemiology2007;4(1):DOI: 10.5580/1523. ">Ones 2007</a>; <a href="./references#CD000227-bbs2-0036" title="OrimoH , ShirakiM , HayashiY , HoshinoT , OnayaT , MiyazakiS , et al. Effects of 1-alpha-hydroxyvitamin D3 on lumbar bone mineral density and vertebral fractures in patients with postmenopausal osteoporosis. Calcified Tissue International1994;54:370-6. ">Orimo 1994</a>; <a href="./references#CD000227-bbs2-0045" title="ShirakiM , KushidaK , YamazakiK , NagaiT , InoueT , OrimoH . Effects of 2 years' treatment of osteoporosis with 1alpha-hydroxy vitamin D3 on bone mineral density and incidence of fracture: a placebo-controlled, double-blind prospective study. Endocrine Journal1996;43(2):211-20. ">Shiraki 1996</a>). </p> <p>There was no statistically significant reduction in hip fractures (one trial, 113 participants, RR 0.20, 95% CI 0.01 to 4.00, <i>see</i><a href="./references#CD000227-fig-0026" title="">Analysis 6.1</a>), but there was a statistically significant effect on the development of new vertebral deformity (five trials, 390 participants, RR 0.44, 95% CI 0.21 to 0.96, <i>see</i><a href="./references#CD000227-fig-0027" title="">Analysis 6.2</a>). </p> </section> <section id="CD000227-sec-0066"> <h4 class="title">Alfacalcidol (1‐alphahydroxyvitamin D3) versus calcium</h4> <p>One trial in participants with osteoporosis found no statistically significant effect of alfacalcidol (1‐alphahydroxyvitamin D3) compared with calcium on people with new vertebral deformities (one trial, 23 participants, RR 0.95, 95% CI 0.52 to 1.74, <i>see</i><a href="./references#CD000227-fig-0028" title="">Analysis 7.1</a>) (<a href="./references#CD000227-bbs2-0019" title="GeusensP , DequekerJ . Long-term effect of nandrolone decanoate, 1 alpha-hydroxyvitamin D3 or intermittent calcium infusion therapy on bone mineral content, bone remodeling and fracture rate in symptomatic osteoporosis: a double-blind controlled study. Bone and Mineral1986;1(4):347-57. ">Geusens 1986</a>). </p> </section> <section id="CD000227-sec-0067"> <h4 class="title">Calcitriol (1,25‐dihydroxyvitamin D3) versus placebo or no treatment</h4> <p>Three trials compared calcitriol (1,25‐dihydroxyvitamin D3) versus placebo or no treatment (<a href="./references#CD000227-bbs2-0007" title="CaniggiaA , DellingG , NutiR , LoreF , VattimoA . Clinical, biochemical and histological results of a double-blind trial with 1,25-dihydroxyvitamin D3, estradiol and placebo in post-menopausal osteoporosis. Acta Vitaminologica et Enzymologica1984;6(2):117-28. ">Caniggia 1984</a>; <a href="./references#CD000227-bbs2-0015" title="GallagherJC , RiggsBL , ReckerRR , GoldgarD . The effect of calcitriol on patients with postmenopausal osteoporosis with special reference to fracture frequency. Proceedings of the Society for Experimental Biology and Medicine1989;191(3):287-92. [MEDLINE: 1989296988]">Gallagher 1989</a>; <a href="./references#CD000227-bbs2-0017" title="GallagherJC , FowlerS . Effect of estrogen, calcitriol and a combination of estrogen and calcitriol on bone mineral density and fractures in elderly women. Journal of Bone and Mineral Research1999;14(Suppl 1):S209. GallagherJC , FowlerSE , DetterJR , ShermanSS . Combination treatment with estrogen and calcitriol in the prevention of age-related bone loss. Journal of Clinical Endocrinology and Metabolism2001;86(8):3618-28. GallagherJC , HaynatskiG , FowlerS . Calcitriol therapy reduces falls and fractures in elderly women. Calcified Tissue International2003;72:334. GallagherJC , HaynatzkiG , FowlerS . Effect of estrogen, calcitriol or the combination of both on falls and non vertebral fractures in elderly women. Journal of Bone and Mineral Research2001;17(Suppl 1):S210. GallagherJC , RapuriPB , HaynatzkiG , DetterJR . Effect of discontinuation of estrogen, calcitriol, and the combination of both on bone density and bone markers. Journal of Clinical Endocrinology and Metabolism2002;87(11):4914-23. [12414850]GallagherJC , RapuriPB , HaynatzkiG . A comparison of estrogen, calcitriol or both therapies on the relationship between serum parathyroid hormone and 25 hydroxy vitamin. Journal of Bone and MIneral Research2004;19(Suppl 1):S440. GallagherJC . Personal communication 21 February 2005. GallagherJC . The effects of calcitriol on falls and fractures and physical performance tests. Journal of Steroid Biochemistry and Molecular Biology2004;89-90(1-5):497-501. ">Gallagher 2001</a>). </p> <p>Calcitriol had no statistically significant effect on hip fracture (one trial, 246 participants RR 0.33, 95% CI 0.01 to 8.10, <i>see</i><a href="./references#CD000227-fig-0029" title="">Analysis 8.1</a>), non‐vertebral fracture (one trial, 246 participants, RR 0.42, 95% CI 0.15 to 1.15, <i>see</i><a href="./references#CD000227-fig-0030" title="">Analysis 8.2</a>), or new vertebral deformity (three trials, 327 participants RR 0.75, 95% CI 0.40 to 1.41, <i>see</i><a href="./references#CD000227-fig-0031" title="">Analysis 8.3</a>). </p> </section> <section id="CD000227-sec-0068"> <h4 class="title">Calcitriol (1,25‐dihydroxyvitamin D3) plus calcium versus calcium</h4> <p>One trial compared calcitriol (1,25‐dihydroxyvitamin D3) plus calcium versus calcium (<a href="./references#CD000227-bbs2-0038" title="OttSM , ChesnutCH . Calcitriol treatment is not effective in postmenopausal osteoporosis: see comments. Annals of Internal Medicine1989;110:267-74. ">Ott 1989</a>). Additional supplementation with calcitriol in people with osteoporosis already taking calcium showed no statistically significant effect on the incidence of new non‐vertebral fracture (one trial, 86 participants, RR 2.50, 95% CI 0.51 to 12.19, <i>see</i><a href="./references#CD000227-fig-0032" title="">Analysis 9.1</a>), or new vertebral deformity (one trial, 86 participants, RR 1.50, 95% CI 0.58 to 3.85, <i>see</i><a href="./references#CD000227-fig-0033" title="">Analysis 9.2</a>). </p> </section> <section id="CD000227-sec-0069"> <h4 class="title">Calcitriol (1,25‐dihydroxyvitamin D3) plus vitamin D plus calcium versus vitamin D plus calcium </h4> <p>Two studies that compared calcitriol (1,25‐dihydroxyvitamin D3) plus vitamin D and calcium versus vitamin D plus calcium found no statistically significant effect on the number of people developing new vertebral deformities (two trials, 84 participants, RR 0.79, 95% CI 0.41 to 1.52, <i>see</i><a href="./references#CD000227-fig-0034" title="">Analysis 10.1</a>) (<a href="./references#CD000227-bbs2-0001" title="AloiaJF , VaswaniA , YehJK , EllisK , YasumuraS , CohnSH . Calcitriol in the treatment of postmenopausal osteoporosis. American Journal of Medicine1988;84(3 Pt 1):401-8. AloiaJF . Role of calcitriol in the treatment of postmenopausal osteoporosis. Metabolism1990;39(4 Suppl 1):35-8. GallagherJC . Personal communication 21 February 1995. ">Aloia 1988</a>; <a href="./references#CD000227-bbs2-0016" title="GallagherJC , GoldgarD . Treatment of postmenopausal osteoporosis with high doses of synthetic calcitriol. A randomized controlled study. Annals of Internal Medicine1990;113(9):649-55. [MEDLINE: 1991023790]GallagherJC . Metabolic effects of synthetic calcitriol (Rocaltrol) in the treatment of postmenopausal osteoporosis. Metabolism: Clinical &amp; Experimental1990;39(4 Suppl 1):27-9. [MEDLINE: 2112606]GallagherJC . Personal communication 21 February 1995. ">Gallagher 1990</a>). </p> </section> <section id="CD000227-sec-0070"> <h4 class="title">Calcitriol (1,25‐dihydroxyvitamin D3) versus calcium</h4> <p>Two trials compared calcitriol (1,25‐dihydroxyvitamin D3) versus calcium (<a href="./references#CD000227-bbs2-0012" title="EbelingPR , WarkJD , YeungS , PoonC , SalehiN , NicholsonGC , et al. Effects of calcitriol or calcium on bone mineral density, bone turnover, and fractures in men with primary osteoporosis: a two-year randomized, double-blind, double placebo study. Journal of Clinical Endocrinology and Metabolism2001;86(9):4098-103. EbelingPR . Personal communication 15 February 2005. ">Ebeling 2001</a>; <a href="./references#CD000227-bbs2-0047" title="MorrisonNA , GeorgePM , VaughanT , TilyardMW , FramptonCM , GilchristNL . Vitamin D receptor genotypes influence the success of calcitriol therapy for recurrent vertebral fracture in osteoporosis. Pharmacogenetics and Genomics2005;15(2):127-35. TilyardM . Low-dose calcitriol versus calcium in established postmenopausal osteoporosis. Metabolism: Clinical &amp; Experimental1990;39(4 Suppl 1):50-2. TilyardMW , SpearsGF , ThomsonJ , DoveyS . Treatment of postmenopausal osteoporosis with calcitriol or calcium. New England Journal of Medicine1992;326(6):357-62. TilyardMW , SpearsGFS , ThomsonJ , DoveyS . Calcitriol or calcium for postmenopausal osteoporosis. New England Journal of Medicine1992;327:284. TilyardMW . 1,25-dihydroxyvitamin D3 (calcitriol) in the treatment of postmenopausal osteoporosis. Aktuelle Rheumatologie1994;19(Suppl 1):23-6. ">Tilyard 1992</a>). </p> <p>Overall, there was no statistically significant effect on the incidence of non‐vertebral fractures (two trials, 663 participants, random‐effects RR 1.23, 95% CI 0.10 to 14.78, <i>see</i><a href="./references#CD000227-fig-0035" title="">Analysis 11.1</a>), or vertebral deformities (two trials, 556 participants, random‐effects RR 1.69, 95% CI 0.25 to 11.28, <i>see</i><a href="./references#CD000227-fig-0036" title="">Analysis 11.2</a>). There was, however, considerable heterogeneity for both analyses (I<sup>2</sup> values of 67% and 70%, respectively). </p> <p>In <a href="./references#CD000227-bbs2-0047" title="MorrisonNA , GeorgePM , VaughanT , TilyardMW , FramptonCM , GilchristNL . Vitamin D receptor genotypes influence the success of calcitriol therapy for recurrent vertebral fracture in osteoporosis. Pharmacogenetics and Genomics2005;15(2):127-35. TilyardM . Low-dose calcitriol versus calcium in established postmenopausal osteoporosis. Metabolism: Clinical &amp; Experimental1990;39(4 Suppl 1):50-2. TilyardMW , SpearsGF , ThomsonJ , DoveyS . Treatment of postmenopausal osteoporosis with calcitriol or calcium. New England Journal of Medicine1992;326(6):357-62. TilyardMW , SpearsGFS , ThomsonJ , DoveyS . Calcitriol or calcium for postmenopausal osteoporosis. New England Journal of Medicine1992;327:284. TilyardMW . 1,25-dihydroxyvitamin D3 (calcitriol) in the treatment of postmenopausal osteoporosis. Aktuelle Rheumatologie1994;19(Suppl 1):23-6. ">Tilyard 1992</a>, the duration of treatment was critical (<i>see</i><a href="./references#CD000227-fig-0037" title="">Analysis 11.3</a>). At the end of one year, no effect could be shown. Fewer vertebral deformities occurred in the calcitriol group during the second year (RR 0.47, 95% CI 0.26 to 0.87), and during the third year (RR 0.28, 95% CI 0.15 to 0.52). </p> </section> <section id="CD000227-sec-0071"> <h4 class="title">Calcitriol (1,25‐dihydroxyvitamin D3) versus vitamin D</h4> <p>Two trials compared calcitriol (1,25‐dihydroxyvitamin D3) versus vitamin D (<a href="./references#CD000227-bbs2-0002" title="ArthurRS , PirainoB , CandibD , CoopersteinL , ChenT , WestC , et al. Effect of low-dose calcitriol and calcium therapy on bone histomorphometry and urinary calcium excretion in osteopenic women. Mineral and Electrolyte Metabolism1990;16(6):385-90. [MEDLINE: 1991211662]">Arthur 1990</a>; <a href="./references#CD000227-bbs2-0013" title="FalchJA , OdegaardOR , FinnangerAM , MathesonI . Postmenopausal osteoporosis: no effect of three years treatment with 1,25-dihydroxycholecalciferol. Acta Medica Scandinavica1987;221(2):199-204. [MEDLINE: 1987237893]FalchJA , OdegaardOR , FinnangerAM . 3 years treatment with 1.25(OH)2 Vitamin D3 does not reduce bone loss or fracture rate in postmenopausal women with fracture of the distal forearm. In: NormanAW , SchaeferK , Grigoleit H-G, v HerrathD , editors(s). Vitamin D : chemical, biochemical, and clinical update: proceedings of the Sixth Workshop on Vitamin D, Merano, Italy, March 1985. Berlin: de Gruyter, 1985:1004-5. FalchJA . Personal communication1999. ">Falch 1987</a>). </p> <p>When calcitriol was compared with vitamin D in people with pre‐existing osteoporosis no statistically significant effect was seen for non‐vertebral fractures (one trial, 86 participants, RR 1.16, 95% CI 0.40 to 3.37, <i>see</i><a href="./references#CD000227-fig-0038" title="">Analysis 12.1</a>), or vertebral deformities (two trials, 96 participants RR 1.38, 95% CI, 0.55 to 3.47, <i>see</i><a href="./references#CD000227-fig-0039" title="">Analysis 12.2</a>). </p> </section> <section id="CD000227-sec-0072"> <h4 class="title">Reported adverse effects: vitamin D (D2, D3 or 25(OH)D) or any analogue with/without calcium </h4> <section id="CD000227-sec-0073"> <h5 class="title">Death</h5> <p>The risk of death during the studies appeared marginally lower in participants given vitamin D or its analogues with or without calcium than in those given placebo or calcium (29 trials, 71,032 participants, RR 0.97, 95% CI 0.93 to 1.01, <a href="./references#CD000227-fig-0040" title="">Analysis 13.1</a>). </p> </section> <section id="CD000227-sec-0074"> <h5 class="title">Hypercalcaemia</h5> <p>Only twenty‐one trials reported on the presence or absence of hypercalcaemia, which was usually mild (2.6 to 2.8 mmol/L) (<a href="./references#CD000227-bbs2-0001" title="AloiaJF , VaswaniA , YehJK , EllisK , YasumuraS , CohnSH . Calcitriol in the treatment of postmenopausal osteoporosis. American Journal of Medicine1988;84(3 Pt 1):401-8. AloiaJF . Role of calcitriol in the treatment of postmenopausal osteoporosis. Metabolism1990;39(4 Suppl 1):35-8. GallagherJC . Personal communication 21 February 1995. ">Aloia 1988</a>; <a href="./references#CD000227-bbs2-0003" title="AvenellA , GrantAM , McGeeM , McPhersonG , CampbellMK , McGee MA for the RECORD Trial Management Group. The effects of an open design on trial participant recruitment, compliance and retention - a randomized controlled trial comparison with a blinded, placebo-controlled design. Clinical Trials Journal2004;1:490-8. AvenellA . Personal communication2005. ">Avenell 2004</a>; <a href="./references#CD000227-bbs2-0004" title="Bischoff-FerrariHA , ConzelmannM , StahelinHB , DickW , CarpenterMG , AdkinAL , et al. Is fall prevention by vitamin D mediated by a change in postural or dynamic balance?Osteoporosis International2006;17(5):656-63. BischoffHA , StahelinHB , DickW , AkosR , KnechtM , SalisC , et al. Effects of vitamin D and calcium supplementation on falls: a randomized controlled trial. Journal of Bone and Mineral Research2003;18(2):343-51. [MEDLINE: 12568412]BischoffHA . Personal communication 13 July 2003. BischoffHA . Vitamin D deficiency in the elderly. Journal of Bone and Mineral Research2003;18(7):1343. [MEDLINE: 12854846]HeaneyR . Vitamin D depletion and effective calcium absorption. Journal of Bone and Mineral Research2003;18(7):1342. ">Bischoff 2003</a>; <a href="./references#CD000227-bbs2-0006" title="BurleighE , McCollJ , PotterJ . Does vitamin D stop inpatients falling? A randomised controlled trial. Age and Ageing2007;36(5):507-13. ">Burleigh 2007</a>; <a href="./references#CD000227-bbs2-0009" title="BosworthC , deBoerIH , TargherG , KendrickJ , SmitsG , ChoncholM . The effect of combined calcium and cholecalciferol supplementation on bone mineral density in elderly women with moderate chronic kidney disease. Clinical Nephrology2012;77(5):358-65. ChapuyMC , PamphileR , ParisE , KempfC , SchlichtingM , ArnaudS , et al. Combined calcium and vitamin D3 supplementation in elderly women: confirmation of reversal of secondary hyperparathyroidism and hip fracture risk: the Decalyos II study. Osteoporosis International2002;13(3):257-64. [MEDLINE: 11991447]ChapuyMC , PamphileR , ParisE , KempfC , SchlichtingM , ArnaudS , et al. Combined calcium and vitamin D3 supplementation to prevent hip fracture in elderly women. A confirmatory study: Decalyos II. Osteoporosis International2002;13(Suppl 1):S25. MeunierPJ . Personal communication 28 February 2005. ">Chapuy 2002</a>; <a href="./references#CD000227-bbs2-0011" title="DukasL , BischoffHA , LindpaintnerLS , SchachtE , Birkner-BinderD , DammTN , et al. Alfacalcidol reduces the number of fallers in a community-dwelling elderly population with a minimum calcium intake of more than 500 mg daily. Journal of the American Geriatrics Society2004;52(2):230-6. DukasL , BischoffHA , LindpaintnerLS , SchachtE , Birkner-BinderD , ThalmanB , et al. Alfacalcidol reduces the number of fallers and falls in community-dwelling elderly provided a minimum total daily intake of 500mg calcium [abstract]. Calcified Tissue International2003;72:371. DukasL , SchachtE , MazorZ , StahelinHB . Treatment with alfacalcidol in elderly people significantly decreases the high risk of falls associated with a low creatinine clearance of &lt;65 ml/min. Osteoporosis International2005;16(2):198-203. DukasL , SchachtE , StahelinHB . A significant independent new risk factor for falls in the elderly: a low creatinine clearance of less than 65ml/min. Osteoporosis International2003;14(Suppl 7):S33. DukasL , SchachtE , StahelinHB . High risk of falls related to low D-hormone syndrome and its treatment with alfacalcidol. Osteoporosis International2004;15(Suppl 1):S8-9. DukasL , SchachtE , StahelinHB . Reduction of falls and fallers in high risk patients by D-hormone analogs. Osteoporosis International2004;15(Suppl 1):S144-5. DukasL , SchachtE , StahelinHB . Treatment with alfacalcidol significantly decreases the high incidence of fallers and the high risk of falls associated with low creatinine clearance (&lt;65ml/min) in elderly community-dwelling men and women. Osteoporosis International2003;14(Suppl 7):S33. DukasL , SchachtE . Reduction of falls and fallers using D-hormone analogs. Osteoporosis International2006;17(Suppl 1):S122-3. DukasLC , SchachtE , MazorZ , StahelinHB . The low creatinine clearance associated high risk of falls can significantly be treated with alfacalcidol. Journal of Bone and Mineral Research2004;19(Suppl 1):S95. DukasLC . Personal communication 19 July 2004. ">Dukas 2004</a>; <a href="./references#CD000227-bbs2-0017" title="GallagherJC , FowlerS . Effect of estrogen, calcitriol and a combination of estrogen and calcitriol on bone mineral density and fractures in elderly women. Journal of Bone and Mineral Research1999;14(Suppl 1):S209. GallagherJC , FowlerSE , DetterJR , ShermanSS . Combination treatment with estrogen and calcitriol in the prevention of age-related bone loss. Journal of Clinical Endocrinology and Metabolism2001;86(8):3618-28. GallagherJC , HaynatskiG , FowlerS . Calcitriol therapy reduces falls and fractures in elderly women. Calcified Tissue International2003;72:334. GallagherJC , HaynatzkiG , FowlerS . Effect of estrogen, calcitriol or the combination of both on falls and non vertebral fractures in elderly women. Journal of Bone and Mineral Research2001;17(Suppl 1):S210. GallagherJC , RapuriPB , HaynatzkiG , DetterJR . Effect of discontinuation of estrogen, calcitriol, and the combination of both on bone density and bone markers. Journal of Clinical Endocrinology and Metabolism2002;87(11):4914-23. [12414850]GallagherJC , RapuriPB , HaynatzkiG . A comparison of estrogen, calcitriol or both therapies on the relationship between serum parathyroid hormone and 25 hydroxy vitamin. Journal of Bone and MIneral Research2004;19(Suppl 1):S440. GallagherJC . Personal communication 21 February 2005. GallagherJC . The effects of calcitriol on falls and fractures and physical performance tests. Journal of Steroid Biochemistry and Molecular Biology2004;89-90(1-5):497-501. ">Gallagher 2001</a>; <a href="./references#CD000227-bbs2-0021" title="GoraiI , ChakiO , TaguchiY , NakayamaM , OsadaH , SuzukiN , et al. Early postmenopausal bone loss is prevented by estrogen and partially by 1alpha-OH-vitamin D3: therapeutic effects of estrogen and/or 1alpha-OH-vitamin D3. Calcified Tissue International1999;65:16-22. ">Gorai 1999</a>; <a href="./references#CD000227-bbs2-0022" title="HarwoodRH , SahotaO , GaynorK , MasudT , HoskingD . A randomised, controlled comparison of different calcium and vitamin D supplementation regimens in elderly women after hip fracture: The Nottingham Neck of Femur (NoNOF) Study. Age and Ageing2004;33:45-51. [14695863]HarwoodRW . Personal communication 24 January 2003. SahotaO , HarwoodRH , GaynorK , MasudT , HoskingDJ . A randomised, controlled comparison of different calcium and vitamin D regimes: the NoNOF (Nottingham Neck of Femur) study. Osteoporosis International2003;14(Suppl 4):S10-11. ">Harwood 2004</a>; <a href="./references#CD000227-bbs2-0028" title="LawM , MorrisJ , WithersH . Cholecalciferol, not ergocalciferol, should be used for vitamin D supplementation [author reply]. Age and Ageing2006;35(6):645. [MEDLINE: 16982666]LawM , MorrisJ , WithersH . Vitamin D supplementation and the prevention of fractures and falls. Reply. Age and Ageing2007;36(2):233. LawM , MorrisJ , WithersH . Vitamin D supplementation and the prevention of fractures and falls [author reply]. Age and Ageing2007;36(2):233. [MEDLINE: 17255084]LawM , WithersH , MorrisJ , AndersonF . Vitamin D supplementation and the prevention of fractures and falls: results of a randomised trial in elderly people in residential accommodation [comment in: Age and Ageing 2006;35(6):645 and Age and Ageing 2007;36(2):232-3]. Age and Ageing2006;35(5):482-6. ">Law 2006</a>; <a href="./references#CD000227-bbs2-0031" title="MenczelJ , FoldesJ , SteinbergR , LeichterI , ShalitaB , Bjolah-AbramT , et al. Alfacalcidol (Alpha D3) and calcium in osteoporosis. Clinical Orthopaedics and Related Research1994;(300):241-7. ">Menczel 1994</a>; <a href="./references#CD000227-bbs2-0036" title="OrimoH , ShirakiM , HayashiY , HoshinoT , OnayaT , MiyazakiS , et al. Effects of 1-alpha-hydroxyvitamin D3 on lumbar bone mineral density and vertebral fractures in patients with postmenopausal osteoporosis. Calcified Tissue International1994;54:370-6. ">Orimo 1994</a>; <a href="./references#CD000227-bbs2-0038" title="OttSM , ChesnutCH . Calcitriol treatment is not effective in postmenopausal osteoporosis: see comments. Annals of Internal Medicine1989;110:267-74. ">Ott 1989</a>; <a href="./references#CD000227-bbs2-0039" title="PeacockM , LiuG , CareyM , McClintockR , AmbrosiusW , HuiS , et al. Effect of calcium or 25OH vitamin D3 dietary supplementation on bone loss at the hip in men and women over the age of 60. Journal of Clinical Endocrinology and Metabolism2000;85:3011-9. ">Peacock 2000</a>; <a href="./references#CD000227-bbs2-0043" title="PrinceRL , AustinN , DevineA , DickIM , BruceD , ZhuK . Effects of ergocalciferol added to calcium on the risk of falls in elderly high-risk women. Archives of Internal Medicine2008;168(1):103-8. ZhuK , BruceD , AustinN , DevineA , EbelingPR , PrinceRL . Randomized controlled trial of the effects of calcium with or without vitamin D on bone structure and bone-related chemistry in elderly women with vitamin D insufficiency. Journal of Bone and Mineral Research2008;23(8):1343-8. ZhuK , DevineA , DickIM , WilsonSG , PrinceRL . Effects of calcium and vitamin D supplementation on hip bone mineral density and calcium-related analytes in elderly ambulatory Australian women: a five-year randomized controlled trial. Journal of Clinical Endocrinology and Metabolism2008;93(3):743-9. ">Prince 2008</a>; <a href="./references#CD000227-bbs2-0044" title="AndersonFH , GrantAM , AvenellA , CampbellMK , CooperC , DonaldsonC , et al. The RECORD Trial: an evaluation of calcium and/or vitamin D in the secondary prevention of osteoporotic fractures. Bone2005;36(Suppl 2):S122-3. FrancisRM , Grant AM and the RECORD trial group. The RECORD trial: a randomised double-blind study of calcium and/or vitamin D in the secondary prevention of low trauma fractures. Age Ageing2005;34(Suppl 2):ii15. GrantA , on behalf of the RECORD Trial Group. Prevention of low-trauma fractures in older people [author reply]. Lancet2005;366(9485):543-4. GrantAM , AndersonFH , for the RECORD Trial Group. The Medical Research Council RECORD Trial: an evaluation of calcium and/or vitamin D in the secondary prevention of osteoporotic fractures. Osteoporosis International2004;15(Suppl 2):S13. GrantAM , AndersonFH . The RECORD trial: an evaluation of calcium and/or vitamin D in the secondary prevention of osteoporotic fractures. Osteoporosis International2005;16(Suppl 3):S4-5. GrantAM , AvenellA , CampbellMK , McDonaldAM , MacLennanGS , McPhersonGC , et al. Oral vitamin D3 and calcium for secondary prevention of low-trauma fractures in elderly people (Randomised Evaluation of Calcium Or vitamin D, RECORD): a randomised placebo-controlled trial [comment in: Lancet 2005;366(9485):543]. Lancet2005;365(9471):1621-8. GrantAM . Personal communication 11 March 2004. ">RECORD 2005</a>; <a href="./references#CD000227-bbs2-0047" title="MorrisonNA , GeorgePM , VaughanT , TilyardMW , FramptonCM , GilchristNL . Vitamin D receptor genotypes influence the success of calcitriol therapy for recurrent vertebral fracture in osteoporosis. Pharmacogenetics and Genomics2005;15(2):127-35. TilyardM . Low-dose calcitriol versus calcium in established postmenopausal osteoporosis. Metabolism: Clinical &amp; Experimental1990;39(4 Suppl 1):50-2. TilyardMW , SpearsGF , ThomsonJ , DoveyS . Treatment of postmenopausal osteoporosis with calcitriol or calcium. New England Journal of Medicine1992;326(6):357-62. TilyardMW , SpearsGFS , ThomsonJ , DoveyS . Calcitriol or calcium for postmenopausal osteoporosis. New England Journal of Medicine1992;327:284. TilyardMW . 1,25-dihydroxyvitamin D3 (calcitriol) in the treatment of postmenopausal osteoporosis. Aktuelle Rheumatologie1994;19(Suppl 1):23-6. ">Tilyard 1992</a>; <a href="./references#CD000227-bbs2-0049" title="UshiroyamaT , IkedaA , SakaiM , HigashiyamaT , UekiM . Effects of the combined use of calcitonin and 1alpha-hydroxycholecalciferol on vertebral bone loss and bone turnover in women with postmenopausal osteopenia and osteoporosis: a prospective study of long-term and continuous administration with low dose calcitonin. Maturitas2001;40:229-38. ">Ushiroyama 2001</a>; <a href="./references#CD000227-bbs2-0050" title="SandersK , DuqueG , EbelingP , McCorquodaleT , HerrmannM , Shore-LorentiC , et al. The efficacy of high-does oral vitamin D3 administered once a year: increased fracture risk is associated with 1,25 vitamin D level at 3-months post dose. In: ASBMR Annual Meeting; 2012 Oct 12-15; Minneapolis, Minnesota. http://www.asbmr.org/Meetings/AnnualMeeting/AbstractDetail.aspx?aid=6beb2500-4b8e-472b-8b38-d881cadb80e3. 2012. SandersK , StuartA , WilliamsonE , SimpsonJ , KotowiczM , NicholsonG . The efficacy of high-dose oral vitamin D3 administered once a year: a randomised, double-blind, placebo-controlled trial (Vital D study) for falls and fractures in older women. Osteoporosis International2011;22(Suppl 1):S104-5. SandersKM , DuqueG , McCorquodaleT , StuartAL , WilliamsonEJ , KotowiczMA , et al. Annual high-dose oral vitamin D3: is the increased risk of falls attributable to changes in muscle strength?Osteoporosis International2011;22(Suppl 4):S552. SandersKM , EbelingPR , StuartAL , WilliamsonEJ , KotowiczMA , NicholsonGC . Annual high-dose oral vitamin D3: is increased risk of fractures attributable to changes in bone turnover markers?Osteoporosis International2011;22(Suppl 4):S589. SandersKM , HaylesAL , KotowiczMA , NicholsonGC . Does vitamin D explain the lower fracture rate in rural communities?Bone2007;40(6 Suppl 2):S195. SandersKM , HaylesAL , KotowiczMA , NicholsonGC . The possible role of vitamin D and falls in relation to lower fracture rates in rural communities. Osteoporosis International2007;18(Suppl 1):S120-1. SandersKM , StuartAL , KotowiczMA , NicholsonGC . Annual feedback is an effective tool for a sustained increase in calcium intake among older women. Nutrients2010;2:1018-25. SandersKM , StuartAL , MerrimanEN , ReadML , KotowiczMA , YoungD , et al. Trials and tribulations of recruiting 2,000 older women onto a clinical trial investigating falls and fractures: Vital D study. BMC Medical Research Methodology2009;9:78. SandersKM , StuartAL , NicholsonGC . High-dose oral vitamin D supplementation and risk of falls in older women. JAMA2010;304(8):856-7. SandersKM , StuartAL , WilliamsonEJ , JackaFN , DoddS , NicholsonG , et al. Annual high-dose vitamin D3 and mental well-being: randomised controlled trial. British Journal of Psychiatry2011;198:357-64. SandersKM , StuartAL , WilliamsonEJ , SimpsonJA , KotowiczMA , NicholsonGC . Annual high-dose oral vitamin D for falls and fractures in elderly women: a randomised, double-blind, placebo-controlled trial (Vital D study). Osteoporosis International2010;21(Suppl 1):S30. SandersKM , StuartAL , WilliamsonEJ , SimpsonJA , KotowiczMA , YoungD , et al. Annual high-dose oral vitamin D and falls and fractures in older women. A randomized controlled trial. JAMA2010;303(18):1815-22. Sanders KM et al. Incorrect data. JAMA2010;303(23):2357. ">Vital D</a>; <a href="./references#CD000227-bbs2-0052" title="WithamMD , CrightonLJ , GillespieND , StruthersAD , McMurdoME . The effects of vitamin D supplementation on physical function and quality of life in older patients with heart failure. A randomized controlled trial. Circulation: Heart Failure2010;3:195-201. ">Witham 2010</a>; <a href="./references#CD000227-bbs2-0053" title="WithamM . Can high-dose vitamin D supplementation reduce blood pressure and markers of cardiovascular risk in older people with isolated systolic hypertension? A randomised, double-blind, parallel group placebo controlled trial. http://www.controlled-trials.com/ISRCTN92186858/ (accessed 3 December 2013). WithamMD , PriceRJ , StruthersAD , DonnanPT , MessowM , FordI , et al. Vitamin D supplementation to reduce blood pressure in older patients with isolated systolic hypertension (VitDISH) - a randomised controlled trial. Personal communication ahead of publication 15 January 2013. ">Witham 2013</a>). Hypercalcaemia was reported more commonly when vitamin D or its analogues were given compared with placebo or calcium (21 trials, 17,124 participants, RR 2.28, 95% CI 1.57 to 3.31, <a href="./references#CD000227-fig-0041" title="">Analysis 13.2</a>). The risk of hypercalcaemia was particularly high for the use of calcitriol (four trials, 988 participants, RR 4.41, 95% CI 2.14 to 9.09, <a href="./references#CD000227-fig-0041" title="">Analysis 13.2</a>). </p> </section> <section id="CD000227-sec-0075"> <h5 class="title">Gastrointestinal symptoms</h5> <p>Fifteen trials reported on gastrointestinal symptoms (<a href="./references#CD000227-bbs2-0003" title="AvenellA , GrantAM , McGeeM , McPhersonG , CampbellMK , McGee MA for the RECORD Trial Management Group. The effects of an open design on trial participant recruitment, compliance and retention - a randomized controlled trial comparison with a blinded, placebo-controlled design. Clinical Trials Journal2004;1:490-8. AvenellA . Personal communication2005. ">Avenell 2004</a>; <a href="./references#CD000227-bbs2-0004" title="Bischoff-FerrariHA , ConzelmannM , StahelinHB , DickW , CarpenterMG , AdkinAL , et al. Is fall prevention by vitamin D mediated by a change in postural or dynamic balance?Osteoporosis International2006;17(5):656-63. BischoffHA , StahelinHB , DickW , AkosR , KnechtM , SalisC , et al. Effects of vitamin D and calcium supplementation on falls: a randomized controlled trial. Journal of Bone and Mineral Research2003;18(2):343-51. [MEDLINE: 12568412]BischoffHA . Personal communication 13 July 2003. BischoffHA . Vitamin D deficiency in the elderly. Journal of Bone and Mineral Research2003;18(7):1343. [MEDLINE: 12854846]HeaneyR . Vitamin D depletion and effective calcium absorption. Journal of Bone and Mineral Research2003;18(7):1342. ">Bischoff 2003</a>; <a href="./references#CD000227-bbs2-0006" title="BurleighE , McCollJ , PotterJ . Does vitamin D stop inpatients falling? A randomised controlled trial. Age and Ageing2007;36(5):507-13. ">Burleigh 2007</a>; <a href="./references#CD000227-bbs2-0008" title="ChapuyMC , ArlotM , et al. Prevention of non vertebral fractures and cortical bone loss in elderly women: a prospective controlled trial using calcium and vitamin D3 supplements [abstract]. Osteoporosis International1993;3 Suppl 1:258. ChapuyMC , ArlotME , DelmasPD , MeunierPJ . Effect of calcium and cholecalciferol treatment for three years on hip fractures in elderly women. BMJ1994;308:1081-2. ChapuyMC , ArlotME , DuboeufF , BrunJ , CrouzetB , ArnaudS , et al. Vitamin D3 and calcium to prevent hip fractures in elderly women. New England Journal of Medicine1992;327:1637-42. MeunierPJ , PamphileR , ChapuyMC , SchultenJ , ArlotM , LilluH . A calcium-vitamin D3 combined supplementation is cost-saving for preventing hip fractures in institutionalised elderly women: an economic evaluation from the perspective of seven European countries (Belgium, France, Germany, The Netherlands, Spain, Sweden, United Kingdom). Osteoporosis International2002;13(Suppl 1):S14. ">Chapuy 1992</a>; <a href="./references#CD000227-bbs2-0009" title="BosworthC , deBoerIH , TargherG , KendrickJ , SmitsG , ChoncholM . The effect of combined calcium and cholecalciferol supplementation on bone mineral density in elderly women with moderate chronic kidney disease. Clinical Nephrology2012;77(5):358-65. ChapuyMC , PamphileR , ParisE , KempfC , SchlichtingM , ArnaudS , et al. Combined calcium and vitamin D3 supplementation in elderly women: confirmation of reversal of secondary hyperparathyroidism and hip fracture risk: the Decalyos II study. Osteoporosis International2002;13(3):257-64. [MEDLINE: 11991447]ChapuyMC , PamphileR , ParisE , KempfC , SchlichtingM , ArnaudS , et al. Combined calcium and vitamin D3 supplementation to prevent hip fracture in elderly women. A confirmatory study: Decalyos II. Osteoporosis International2002;13(Suppl 1):S25. MeunierPJ . Personal communication 28 February 2005. ">Chapuy 2002</a>; <a href="./references#CD000227-bbs2-0010" title="Bischoff-FerrariHA , OravEJ , Dawson-HughesB . Additive effect of higher testosterone levels and vitamin D plus calcium supplementation in regard to fall risk reduction among older men and women. Osteoporosis International2008;19:1307-14. Bischoff-FerrariHA , OravEJ , Dawson-HughesB . Effect of cholecalciferol plus calcium on falling in ambulatory older men and women: a 3-year randomized controlled trial. Archives of Internal Medicine2006;166(4):424-30. Bischoff-FerrariHA , OravEJ , Dawson-HughesB . Effect of vitamin D3 plus calcium on fall risk in older men and women: a 3-year randomized controlled trial. Journal of Bone and Mineral Research2004;19(Suppl 1):S57. Dawson-HughesB , HarrisSS , KrallEA , DallalGE . Effect of calcium and vitamin D supplementation on bone density in men and women 65 years of age or older. New England Journal of Medicine1997;337(10):670-6. Dawson-HughesB , HarrisSS , KrallEA , DallalGE . Effect of withdrawal of calcium and vitamin D supplements on bone mass in elderly men and women. American Journal of Clinical Nutrition2000;72(3):745-50. Dawson-HughesB , HarrisSS . Calcium intake influences the association of protein intake with rates of bone loss in elderly men and women. American Journal of Clinical Nutrition2002;75(4):773-9. KrallEA , RandallC , HarrisSS , GarciaRI , Dawson-HughesB . Calcium and vitamin D supplements reduce tooth loss in the elderly. Journal of Bone and Mineral Research2000;15(Suppl 1):S191. KrallEA , WehlerC , GarciaRI , HarrisSS , Dawson-HughesB . Calcium and vitamin D supplements reduce tooth loss in the elderly. American Journal of Medicine2001;111(6):452-6. NiramitmahapanyaS , HarrisSS , Dawson-HughesB . Type of dietary fat is associated with the 25-hydroxyvitamin D3 increment in response to vitamin D supplementation. Journal of Clinical Endocrinology and Metabolism2011;96(10):3170-4. ">Dawson‐Hughes 1997</a>; <a href="./references#CD000227-bbs2-0012" title="EbelingPR , WarkJD , YeungS , PoonC , SalehiN , NicholsonGC , et al. Effects of calcitriol or calcium on bone mineral density, bone turnover, and fractures in men with primary osteoporosis: a two-year randomized, double-blind, double placebo study. Journal of Clinical Endocrinology and Metabolism2001;86(9):4098-103. EbelingPR . Personal communication 15 February 2005. ">Ebeling 2001</a>; <a href="./references#CD000227-bbs2-0017" title="GallagherJC , FowlerS . Effect of estrogen, calcitriol and a combination of estrogen and calcitriol on bone mineral density and fractures in elderly women. Journal of Bone and Mineral Research1999;14(Suppl 1):S209. GallagherJC , FowlerSE , DetterJR , ShermanSS . Combination treatment with estrogen and calcitriol in the prevention of age-related bone loss. Journal of Clinical Endocrinology and Metabolism2001;86(8):3618-28. GallagherJC , HaynatskiG , FowlerS . Calcitriol therapy reduces falls and fractures in elderly women. Calcified Tissue International2003;72:334. GallagherJC , HaynatzkiG , FowlerS . Effect of estrogen, calcitriol or the combination of both on falls and non vertebral fractures in elderly women. Journal of Bone and Mineral Research2001;17(Suppl 1):S210. GallagherJC , RapuriPB , HaynatzkiG , DetterJR . Effect of discontinuation of estrogen, calcitriol, and the combination of both on bone density and bone markers. Journal of Clinical Endocrinology and Metabolism2002;87(11):4914-23. [12414850]GallagherJC , RapuriPB , HaynatzkiG . A comparison of estrogen, calcitriol or both therapies on the relationship between serum parathyroid hormone and 25 hydroxy vitamin. Journal of Bone and MIneral Research2004;19(Suppl 1):S440. GallagherJC . Personal communication 21 February 2005. GallagherJC . The effects of calcitriol on falls and fractures and physical performance tests. Journal of Steroid Biochemistry and Molecular Biology2004;89-90(1-5):497-501. ">Gallagher 2001</a>; <a href="./references#CD000227-bbs2-0026" title="JanssenHC , SamsonMM , VerhaarHJ . Muscle strength and mobility in vitamin D-insufficient female geriatric patients: a randomized controlled trial on vitamin D and calcium supplementation. Aging Clinical and Experimental Research2010;22(1):78-84. ">Janssen 2010</a>; <a href="./references#CD000227-bbs2-0035" title="OnesK , SchachtE , DukasL , CaglarN . Effects of combined treatment with alendronate and alfacalcidol on bone mineral density and bone turnover in postmenopausal osteoporosis: a two-years, randomized, multiarm, controlled trial. Internet Journal of Epidemiology2007;4(1):DOI: 10.5580/1523. ">Ones 2007</a>; <a href="./references#CD000227-bbs2-0043" title="PrinceRL , AustinN , DevineA , DickIM , BruceD , ZhuK . Effects of ergocalciferol added to calcium on the risk of falls in elderly high-risk women. Archives of Internal Medicine2008;168(1):103-8. ZhuK , BruceD , AustinN , DevineA , EbelingPR , PrinceRL . Randomized controlled trial of the effects of calcium with or without vitamin D on bone structure and bone-related chemistry in elderly women with vitamin D insufficiency. Journal of Bone and Mineral Research2008;23(8):1343-8. ZhuK , DevineA , DickIM , WilsonSG , PrinceRL . Effects of calcium and vitamin D supplementation on hip bone mineral density and calcium-related analytes in elderly ambulatory Australian women: a five-year randomized controlled trial. Journal of Clinical Endocrinology and Metabolism2008;93(3):743-9. ">Prince 2008</a>; <a href="./references#CD000227-bbs2-0044" title="AndersonFH , GrantAM , AvenellA , CampbellMK , CooperC , DonaldsonC , et al. The RECORD Trial: an evaluation of calcium and/or vitamin D in the secondary prevention of osteoporotic fractures. Bone2005;36(Suppl 2):S122-3. FrancisRM , Grant AM and the RECORD trial group. The RECORD trial: a randomised double-blind study of calcium and/or vitamin D in the secondary prevention of low trauma fractures. Age Ageing2005;34(Suppl 2):ii15. GrantA , on behalf of the RECORD Trial Group. Prevention of low-trauma fractures in older people [author reply]. Lancet2005;366(9485):543-4. GrantAM , AndersonFH , for the RECORD Trial Group. The Medical Research Council RECORD Trial: an evaluation of calcium and/or vitamin D in the secondary prevention of osteoporotic fractures. Osteoporosis International2004;15(Suppl 2):S13. GrantAM , AndersonFH . The RECORD trial: an evaluation of calcium and/or vitamin D in the secondary prevention of osteoporotic fractures. Osteoporosis International2005;16(Suppl 3):S4-5. GrantAM , AvenellA , CampbellMK , McDonaldAM , MacLennanGS , McPhersonGC , et al. Oral vitamin D3 and calcium for secondary prevention of low-trauma fractures in elderly people (Randomised Evaluation of Calcium Or vitamin D, RECORD): a randomised placebo-controlled trial [comment in: Lancet 2005;366(9485):543]. Lancet2005;365(9471):1621-8. GrantAM . Personal communication 11 March 2004. ">RECORD 2005</a>; <a href="./references#CD000227-bbs2-0047" title="MorrisonNA , GeorgePM , VaughanT , TilyardMW , FramptonCM , GilchristNL . Vitamin D receptor genotypes influence the success of calcitriol therapy for recurrent vertebral fracture in osteoporosis. Pharmacogenetics and Genomics2005;15(2):127-35. TilyardM . Low-dose calcitriol versus calcium in established postmenopausal osteoporosis. Metabolism: Clinical &amp; Experimental1990;39(4 Suppl 1):50-2. TilyardMW , SpearsGF , ThomsonJ , DoveyS . Treatment of postmenopausal osteoporosis with calcitriol or calcium. New England Journal of Medicine1992;326(6):357-62. TilyardMW , SpearsGFS , ThomsonJ , DoveyS . Calcitriol or calcium for postmenopausal osteoporosis. New England Journal of Medicine1992;327:284. TilyardMW . 1,25-dihydroxyvitamin D3 (calcitriol) in the treatment of postmenopausal osteoporosis. Aktuelle Rheumatologie1994;19(Suppl 1):23-6. ">Tilyard 1992</a>, <a href="./references#CD000227-bbs2-0051" title="CauleyJ , Wactawski-WendeJ , RobbinsJ , RodaboughR , ChenZ , JohnsonK , et al. The Women's Health Initiative (WHI) calcium and vitamin D supplementation trial: health outcomes 5 years after trial completion. ASBMR Annual Meeting; 2012 Oct 12-15; Minneapolis, Minnesota. http://www.asbmr.org/Meetings/AnnualMeeting/AbstractDetail.aspx?aid=6450bf3e-c670-4dc0-814c-8842e23cd80e (accessed 27 December 2012). CauleyJA , LaCroixA , WuL , LeeJ , HorowitzM , BauerD , et al. Serum 25 hydroxy vitamin D 25(OH) and the risk of hip fracture: the Women's Health Initiative (WHI). Journal of Bone and Mineral Research2007;22(Suppl 1):S57. ChenZ , BeckTJ , WrightNC , LaCroixAZ , CauleyJA , LewisCE , et al. The effect of calcium plus vitamin D supplement on hip geometric structures: results from the Women's Health Initiative CaD trial. Journal of Bone and Mineral Research2007;22(Suppl 1):S59. JacksonRD , LaCroixAZ , CauleyJA , McGowanJ . The Women's Health Initiative Calcium-Vitamin D Trial: overview and baseline characteristics of participants. Annals of Epidemiology2003;13:S98-106. JacksonRD , LaCroixAZ , GassM , WallaceRB , RobbinsJ , LewisCE , et al. Calcium plus vitamin D supplementation and the risk of fractures [erratum appears in New England Journal of Medicine 9 March 2006;354(10):1102]. New England Journal of Medicine2006;354(7):669-83. JacksonRD , WrightNC , BeckTJ , SherrillD , CauleyJA , LewisCE , et al. Calcium plus vitamin D supplementation has limited effects on femoral geometric strength in older postmenopausal women: the Women's Health Initiative. Calcified Tissue International2011;88:198-208. McGowanJA , JacksonRD , CauleyJA , LaCroixAZ . Calcium and vitamin D in the prevention of hip and other fractures: an update on the Women's Health Initiative CaD Trial. Journal of Bone and Mineral Research2002;17(Suppl 1):S477. The Women's Health Initiative Study Group. Design of the Women's Health Initiative clinical trial and observational study. Controlled Clinical Trials1998;19(1):61-109. ">WHI 2006</a>; <a href="./references#CD000227-bbs2-0052" title="WithamMD , CrightonLJ , GillespieND , StruthersAD , McMurdoME . The effects of vitamin D supplementation on physical function and quality of life in older patients with heart failure. A randomized controlled trial. Circulation: Heart Failure2010;3:195-201. ">Witham 2010</a>). There was evidence of a small increase in gastrointestinal symptoms with interventions containing vitamin D (15 trials, 47,761 participants, RR 1.04, 95% CI 1.00 to 1.08, <i>see</i><a href="./references#CD000227-fig-0042" title="">Analysis 13.3</a>). The risk of gastrointestinal effects was higher for the use of vitamin D and calcium (four trials, 40,524 participants, RR 1.05, 95% CI 1.01 to 1.09). </p> </section> <section id="CD000227-sec-0076"> <h5 class="title">Occurrence of renal calculi or renal insufficiency</h5> <p>Eleven trials reported on the occurrence of renal calculi or renal insufficiency (<a href="./references#CD000227-bbs2-0001" title="AloiaJF , VaswaniA , YehJK , EllisK , YasumuraS , CohnSH . Calcitriol in the treatment of postmenopausal osteoporosis. American Journal of Medicine1988;84(3 Pt 1):401-8. AloiaJF . Role of calcitriol in the treatment of postmenopausal osteoporosis. Metabolism1990;39(4 Suppl 1):35-8. GallagherJC . Personal communication 21 February 1995. ">Aloia 1988</a>; <a href="./references#CD000227-bbs2-0003" title="AvenellA , GrantAM , McGeeM , McPhersonG , CampbellMK , McGee MA for the RECORD Trial Management Group. The effects of an open design on trial participant recruitment, compliance and retention - a randomized controlled trial comparison with a blinded, placebo-controlled design. Clinical Trials Journal2004;1:490-8. AvenellA . Personal communication2005. ">Avenell 2004</a>; <a href="./references#CD000227-bbs2-0009" title="BosworthC , deBoerIH , TargherG , KendrickJ , SmitsG , ChoncholM . The effect of combined calcium and cholecalciferol supplementation on bone mineral density in elderly women with moderate chronic kidney disease. Clinical Nephrology2012;77(5):358-65. ChapuyMC , PamphileR , ParisE , KempfC , SchlichtingM , ArnaudS , et al. Combined calcium and vitamin D3 supplementation in elderly women: confirmation of reversal of secondary hyperparathyroidism and hip fracture risk: the Decalyos II study. Osteoporosis International2002;13(3):257-64. [MEDLINE: 11991447]ChapuyMC , PamphileR , ParisE , KempfC , SchlichtingM , ArnaudS , et al. Combined calcium and vitamin D3 supplementation to prevent hip fracture in elderly women. A confirmatory study: Decalyos II. Osteoporosis International2002;13(Suppl 1):S25. MeunierPJ . Personal communication 28 February 2005. ">Chapuy 2002</a>; <a href="./references#CD000227-bbs2-0016" title="GallagherJC , GoldgarD . Treatment of postmenopausal osteoporosis with high doses of synthetic calcitriol. A randomized controlled study. Annals of Internal Medicine1990;113(9):649-55. [MEDLINE: 1991023790]GallagherJC . Metabolic effects of synthetic calcitriol (Rocaltrol) in the treatment of postmenopausal osteoporosis. Metabolism: Clinical &amp; Experimental1990;39(4 Suppl 1):27-9. [MEDLINE: 2112606]GallagherJC . Personal communication 21 February 1995. ">Gallagher 1990</a>; <a href="./references#CD000227-bbs2-0017" title="GallagherJC , FowlerS . Effect of estrogen, calcitriol and a combination of estrogen and calcitriol on bone mineral density and fractures in elderly women. Journal of Bone and Mineral Research1999;14(Suppl 1):S209. GallagherJC , FowlerSE , DetterJR , ShermanSS . Combination treatment with estrogen and calcitriol in the prevention of age-related bone loss. Journal of Clinical Endocrinology and Metabolism2001;86(8):3618-28. GallagherJC , HaynatskiG , FowlerS . Calcitriol therapy reduces falls and fractures in elderly women. Calcified Tissue International2003;72:334. GallagherJC , HaynatzkiG , FowlerS . Effect of estrogen, calcitriol or the combination of both on falls and non vertebral fractures in elderly women. Journal of Bone and Mineral Research2001;17(Suppl 1):S210. GallagherJC , RapuriPB , HaynatzkiG , DetterJR . Effect of discontinuation of estrogen, calcitriol, and the combination of both on bone density and bone markers. Journal of Clinical Endocrinology and Metabolism2002;87(11):4914-23. [12414850]GallagherJC , RapuriPB , HaynatzkiG . A comparison of estrogen, calcitriol or both therapies on the relationship between serum parathyroid hormone and 25 hydroxy vitamin. Journal of Bone and MIneral Research2004;19(Suppl 1):S440. GallagherJC . Personal communication 21 February 2005. GallagherJC . The effects of calcitriol on falls and fractures and physical performance tests. Journal of Steroid Biochemistry and Molecular Biology2004;89-90(1-5):497-501. ">Gallagher 2001</a>; <a href="./references#CD000227-bbs2-0031" title="MenczelJ , FoldesJ , SteinbergR , LeichterI , ShalitaB , Bjolah-AbramT , et al. Alfacalcidol (Alpha D3) and calcium in osteoporosis. Clinical Orthopaedics and Related Research1994;(300):241-7. ">Menczel 1994</a>; <a href="./references#CD000227-bbs2-0039" title="PeacockM , LiuG , CareyM , McClintockR , AmbrosiusW , HuiS , et al. Effect of calcium or 25OH vitamin D3 dietary supplementation on bone loss at the hip in men and women over the age of 60. Journal of Clinical Endocrinology and Metabolism2000;85:3011-9. ">Peacock 2000</a>; <a href="./references#CD000227-bbs2-0044" title="AndersonFH , GrantAM , AvenellA , CampbellMK , CooperC , DonaldsonC , et al. The RECORD Trial: an evaluation of calcium and/or vitamin D in the secondary prevention of osteoporotic fractures. Bone2005;36(Suppl 2):S122-3. FrancisRM , Grant AM and the RECORD trial group. The RECORD trial: a randomised double-blind study of calcium and/or vitamin D in the secondary prevention of low trauma fractures. Age Ageing2005;34(Suppl 2):ii15. GrantA , on behalf of the RECORD Trial Group. Prevention of low-trauma fractures in older people [author reply]. Lancet2005;366(9485):543-4. GrantAM , AndersonFH , for the RECORD Trial Group. The Medical Research Council RECORD Trial: an evaluation of calcium and/or vitamin D in the secondary prevention of osteoporotic fractures. Osteoporosis International2004;15(Suppl 2):S13. GrantAM , AndersonFH . The RECORD trial: an evaluation of calcium and/or vitamin D in the secondary prevention of osteoporotic fractures. Osteoporosis International2005;16(Suppl 3):S4-5. GrantAM , AvenellA , CampbellMK , McDonaldAM , MacLennanGS , McPhersonGC , et al. Oral vitamin D3 and calcium for secondary prevention of low-trauma fractures in elderly people (Randomised Evaluation of Calcium Or vitamin D, RECORD): a randomised placebo-controlled trial [comment in: Lancet 2005;366(9485):543]. Lancet2005;365(9471):1621-8. GrantAM . Personal communication 11 March 2004. ">RECORD 2005</a>; <a href="./references#CD000227-bbs2-0047" title="MorrisonNA , GeorgePM , VaughanT , TilyardMW , FramptonCM , GilchristNL . Vitamin D receptor genotypes influence the success of calcitriol therapy for recurrent vertebral fracture in osteoporosis. Pharmacogenetics and Genomics2005;15(2):127-35. TilyardM . Low-dose calcitriol versus calcium in established postmenopausal osteoporosis. Metabolism: Clinical &amp; Experimental1990;39(4 Suppl 1):50-2. TilyardMW , SpearsGF , ThomsonJ , DoveyS . Treatment of postmenopausal osteoporosis with calcitriol or calcium. New England Journal of Medicine1992;326(6):357-62. TilyardMW , SpearsGFS , ThomsonJ , DoveyS . Calcitriol or calcium for postmenopausal osteoporosis. New England Journal of Medicine1992;327:284. TilyardMW . 1,25-dihydroxyvitamin D3 (calcitriol) in the treatment of postmenopausal osteoporosis. Aktuelle Rheumatologie1994;19(Suppl 1):23-6. ">Tilyard 1992</a>; <a href="./references#CD000227-bbs2-0051" title="CauleyJ , Wactawski-WendeJ , RobbinsJ , RodaboughR , ChenZ , JohnsonK , et al. The Women's Health Initiative (WHI) calcium and vitamin D supplementation trial: health outcomes 5 years after trial completion. ASBMR Annual Meeting; 2012 Oct 12-15; Minneapolis, Minnesota. http://www.asbmr.org/Meetings/AnnualMeeting/AbstractDetail.aspx?aid=6450bf3e-c670-4dc0-814c-8842e23cd80e (accessed 27 December 2012). CauleyJA , LaCroixA , WuL , LeeJ , HorowitzM , BauerD , et al. Serum 25 hydroxy vitamin D 25(OH) and the risk of hip fracture: the Women's Health Initiative (WHI). Journal of Bone and Mineral Research2007;22(Suppl 1):S57. ChenZ , BeckTJ , WrightNC , LaCroixAZ , CauleyJA , LewisCE , et al. The effect of calcium plus vitamin D supplement on hip geometric structures: results from the Women's Health Initiative CaD trial. Journal of Bone and Mineral Research2007;22(Suppl 1):S59. JacksonRD , LaCroixAZ , CauleyJA , McGowanJ . The Women's Health Initiative Calcium-Vitamin D Trial: overview and baseline characteristics of participants. Annals of Epidemiology2003;13:S98-106. JacksonRD , LaCroixAZ , GassM , WallaceRB , RobbinsJ , LewisCE , et al. Calcium plus vitamin D supplementation and the risk of fractures [erratum appears in New England Journal of Medicine 9 March 2006;354(10):1102]. New England Journal of Medicine2006;354(7):669-83. JacksonRD , WrightNC , BeckTJ , SherrillD , CauleyJA , LewisCE , et al. Calcium plus vitamin D supplementation has limited effects on femoral geometric strength in older postmenopausal women: the Women's Health Initiative. Calcified Tissue International2011;88:198-208. McGowanJA , JacksonRD , CauleyJA , LaCroixAZ . Calcium and vitamin D in the prevention of hip and other fractures: an update on the Women's Health Initiative CaD Trial. Journal of Bone and Mineral Research2002;17(Suppl 1):S477. The Women's Health Initiative Study Group. Design of the Women's Health Initiative clinical trial and observational study. Controlled Clinical Trials1998;19(1):61-109. ">WHI 2006</a>; <a href="./references#CD000227-bbs2-0053" title="WithamM . Can high-dose vitamin D supplementation reduce blood pressure and markers of cardiovascular risk in older people with isolated systolic hypertension? A randomised, double-blind, parallel group placebo controlled trial. http://www.controlled-trials.com/ISRCTN92186858/ (accessed 3 December 2013). WithamMD , PriceRJ , StruthersAD , DonnanPT , MessowM , FordI , et al. Vitamin D supplementation to reduce blood pressure in older patients with isolated systolic hypertension (VitDISH) - a randomised controlled trial. Personal communication ahead of publication 15 January 2013. ">Witham 2013</a>). </p> <p>There was evidence of a statistically significant increase in the incidence of renal calculi or renal insufficiency (11 trials, 46,548 participants, RR 1.16, 95% CI 1.02 to 1.33, <i>see</i><a href="./references#CD000227-fig-0043" title="">Analysis 13.4</a>). This was mainly due to the influence of <a href="./references#CD000227-bbs2-0051" title="CauleyJ , Wactawski-WendeJ , RobbinsJ , RodaboughR , ChenZ , JohnsonK , et al. The Women's Health Initiative (WHI) calcium and vitamin D supplementation trial: health outcomes 5 years after trial completion. ASBMR Annual Meeting; 2012 Oct 12-15; Minneapolis, Minnesota. http://www.asbmr.org/Meetings/AnnualMeeting/AbstractDetail.aspx?aid=6450bf3e-c670-4dc0-814c-8842e23cd80e (accessed 27 December 2012). CauleyJA , LaCroixA , WuL , LeeJ , HorowitzM , BauerD , et al. Serum 25 hydroxy vitamin D 25(OH) and the risk of hip fracture: the Women's Health Initiative (WHI). Journal of Bone and Mineral Research2007;22(Suppl 1):S57. ChenZ , BeckTJ , WrightNC , LaCroixAZ , CauleyJA , LewisCE , et al. The effect of calcium plus vitamin D supplement on hip geometric structures: results from the Women's Health Initiative CaD trial. Journal of Bone and Mineral Research2007;22(Suppl 1):S59. JacksonRD , LaCroixAZ , CauleyJA , McGowanJ . The Women's Health Initiative Calcium-Vitamin D Trial: overview and baseline characteristics of participants. Annals of Epidemiology2003;13:S98-106. JacksonRD , LaCroixAZ , GassM , WallaceRB , RobbinsJ , LewisCE , et al. Calcium plus vitamin D supplementation and the risk of fractures [erratum appears in New England Journal of Medicine 9 March 2006;354(10):1102]. New England Journal of Medicine2006;354(7):669-83. JacksonRD , WrightNC , BeckTJ , SherrillD , CauleyJA , LewisCE , et al. Calcium plus vitamin D supplementation has limited effects on femoral geometric strength in older postmenopausal women: the Women's Health Initiative. Calcified Tissue International2011;88:198-208. McGowanJA , JacksonRD , CauleyJA , LaCroixAZ . Calcium and vitamin D in the prevention of hip and other fractures: an update on the Women's Health Initiative CaD Trial. Journal of Bone and Mineral Research2002;17(Suppl 1):S477. The Women's Health Initiative Study Group. Design of the Women's Health Initiative clinical trial and observational study. Controlled Clinical Trials1998;19(1):61-109. ">WHI 2006</a>through possibly more intensive follow‐up (<a href="./references#CD000227-bbs2-0051" title="CauleyJ , Wactawski-WendeJ , RobbinsJ , RodaboughR , ChenZ , JohnsonK , et al. The Women's Health Initiative (WHI) calcium and vitamin D supplementation trial: health outcomes 5 years after trial completion. ASBMR Annual Meeting; 2012 Oct 12-15; Minneapolis, Minnesota. http://www.asbmr.org/Meetings/AnnualMeeting/AbstractDetail.aspx?aid=6450bf3e-c670-4dc0-814c-8842e23cd80e (accessed 27 December 2012). CauleyJA , LaCroixA , WuL , LeeJ , HorowitzM , BauerD , et al. Serum 25 hydroxy vitamin D 25(OH) and the risk of hip fracture: the Women's Health Initiative (WHI). Journal of Bone and Mineral Research2007;22(Suppl 1):S57. ChenZ , BeckTJ , WrightNC , LaCroixAZ , CauleyJA , LewisCE , et al. The effect of calcium plus vitamin D supplement on hip geometric structures: results from the Women's Health Initiative CaD trial. Journal of Bone and Mineral Research2007;22(Suppl 1):S59. JacksonRD , LaCroixAZ , CauleyJA , McGowanJ . The Women's Health Initiative Calcium-Vitamin D Trial: overview and baseline characteristics of participants. Annals of Epidemiology2003;13:S98-106. JacksonRD , LaCroixAZ , GassM , WallaceRB , RobbinsJ , LewisCE , et al. Calcium plus vitamin D supplementation and the risk of fractures [erratum appears in New England Journal of Medicine 9 March 2006;354(10):1102]. New England Journal of Medicine2006;354(7):669-83. JacksonRD , WrightNC , BeckTJ , SherrillD , CauleyJA , LewisCE , et al. Calcium plus vitamin D supplementation has limited effects on femoral geometric strength in older postmenopausal women: the Women's Health Initiative. Calcified Tissue International2011;88:198-208. McGowanJA , JacksonRD , CauleyJA , LaCroixAZ . Calcium and vitamin D in the prevention of hip and other fractures: an update on the Women's Health Initiative CaD Trial. Journal of Bone and Mineral Research2002;17(Suppl 1):S477. The Women's Health Initiative Study Group. Design of the Women's Health Initiative clinical trial and observational study. Controlled Clinical Trials1998;19(1):61-109. ">WHI 2006</a> reported 10 times more renal adverse events than the large <a href="./references#CD000227-bbs2-0044" title="AndersonFH , GrantAM , AvenellA , CampbellMK , CooperC , DonaldsonC , et al. The RECORD Trial: an evaluation of calcium and/or vitamin D in the secondary prevention of osteoporotic fractures. Bone2005;36(Suppl 2):S122-3. FrancisRM , Grant AM and the RECORD trial group. The RECORD trial: a randomised double-blind study of calcium and/or vitamin D in the secondary prevention of low trauma fractures. Age Ageing2005;34(Suppl 2):ii15. GrantA , on behalf of the RECORD Trial Group. Prevention of low-trauma fractures in older people [author reply]. Lancet2005;366(9485):543-4. GrantAM , AndersonFH , for the RECORD Trial Group. The Medical Research Council RECORD Trial: an evaluation of calcium and/or vitamin D in the secondary prevention of osteoporotic fractures. Osteoporosis International2004;15(Suppl 2):S13. GrantAM , AndersonFH . The RECORD trial: an evaluation of calcium and/or vitamin D in the secondary prevention of osteoporotic fractures. Osteoporosis International2005;16(Suppl 3):S4-5. GrantAM , AvenellA , CampbellMK , McDonaldAM , MacLennanGS , McPhersonGC , et al. Oral vitamin D3 and calcium for secondary prevention of low-trauma fractures in elderly people (Randomised Evaluation of Calcium Or vitamin D, RECORD): a randomised placebo-controlled trial [comment in: Lancet 2005;366(9485):543]. Lancet2005;365(9471):1621-8. GrantAM . Personal communication 11 March 2004. ">RECORD 2005</a> trial). If <a href="./references#CD000227-bbs2-0051" title="CauleyJ , Wactawski-WendeJ , RobbinsJ , RodaboughR , ChenZ , JohnsonK , et al. The Women's Health Initiative (WHI) calcium and vitamin D supplementation trial: health outcomes 5 years after trial completion. ASBMR Annual Meeting; 2012 Oct 12-15; Minneapolis, Minnesota. http://www.asbmr.org/Meetings/AnnualMeeting/AbstractDetail.aspx?aid=6450bf3e-c670-4dc0-814c-8842e23cd80e (accessed 27 December 2012). CauleyJA , LaCroixA , WuL , LeeJ , HorowitzM , BauerD , et al. Serum 25 hydroxy vitamin D 25(OH) and the risk of hip fracture: the Women's Health Initiative (WHI). Journal of Bone and Mineral Research2007;22(Suppl 1):S57. ChenZ , BeckTJ , WrightNC , LaCroixAZ , CauleyJA , LewisCE , et al. The effect of calcium plus vitamin D supplement on hip geometric structures: results from the Women's Health Initiative CaD trial. Journal of Bone and Mineral Research2007;22(Suppl 1):S59. JacksonRD , LaCroixAZ , CauleyJA , McGowanJ . The Women's Health Initiative Calcium-Vitamin D Trial: overview and baseline characteristics of participants. Annals of Epidemiology2003;13:S98-106. JacksonRD , LaCroixAZ , GassM , WallaceRB , RobbinsJ , LewisCE , et al. Calcium plus vitamin D supplementation and the risk of fractures [erratum appears in New England Journal of Medicine 9 March 2006;354(10):1102]. New England Journal of Medicine2006;354(7):669-83. JacksonRD , WrightNC , BeckTJ , SherrillD , CauleyJA , LewisCE , et al. Calcium plus vitamin D supplementation has limited effects on femoral geometric strength in older postmenopausal women: the Women's Health Initiative. Calcified Tissue International2011;88:198-208. McGowanJA , JacksonRD , CauleyJA , LaCroixAZ . Calcium and vitamin D in the prevention of hip and other fractures: an update on the Women's Health Initiative CaD Trial. Journal of Bone and Mineral Research2002;17(Suppl 1):S477. The Women's Health Initiative Study Group. Design of the Women's Health Initiative clinical trial and observational study. Controlled Clinical Trials1998;19(1):61-109. ">WHI 2006</a> is removed from the analysis the difference for this outcome is no longer statistically significant (10 trials, 10,266 participants, RR 0.91, 95% CI 0.44 to 1.86). </p> <p>A separate Cochrane review has reported adverse effects from trials of vitamin D supplementation (<a href="./references#CD000227-bbs2-0142" title="BjelakovicG , GluudLL , NikolovaD , WhitfieldK , WetterslevJ , SimonettiRG , et al. Vitamin D supplementation for prevention of mortality in adults. Cochrane Database of Systematic Reviews2014, Issue 1. Art. No: CD007470. [DOI: 10.1002/14651858.CD007470.pub3]">Bjelakovic 2014</a>), where trials were not limited to those for fracture prevention. Adverse effects reported include all cause mortality, cardiovascular disorders and mortality, hypercalcaemia, renal calculi, renal insufficiency and gastrointestinal disorders. </p> <p><a href="#CD000227-tbl-0006">Table 5</a> lists adverse effects reported in trials of interventions that met the inclusion criteria but were excluded because they did not report fracture data. </p> </section> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD000227-sec-0077" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD000227-sec-0077"></div> <section id="CD000227-sec-0078"> <h3 class="title" id="CD000227-sec-0078">Summary of main results</h3> <section id="CD000227-sec-0079"> <h4 class="title">Vitamin D alone versus placebo or no treatment</h4> <p>Vitamin D alone, in the formats and doses tested, appears unlikely to be effective in preventing hip fracture (11 trials, 27,693 participants, RR 1.12, 95% CI 0.98 to 1.29). Vitamin D alone, in the formats and doses tested, also appears unlikely to reduce any new fracture (15 trials, 28,271 participants, RR 1.03, 95% CI 0.96 to 1.11). The high quality of this evidence is reinforced by the visual impression of an absence of publication bias shown for both outcomes. </p> <p>Vitamin D was administered in a variety of formats and doses (oral daily, oral intermittent, intra‐muscular). However, none of the trials in this review tested daily vitamin D<sub>3</sub> in doses greater than 800 IU. It has been suggested that higher doses of vitamin D are required, such as 1800 IU/day to 4000 IU/day (<a href="./references#CD000227-bbs2-0140" title="Bischoff-FerrariHA , ShaoA , Dawson-HughesB , HathcockJ , GiovannucciE , WillettWC . Benefit-risk assessment of vitamin D supplementation. Osteoporosis International2010;21:1121-32.">Bischoff‐Ferrari 2010</a>), in order to raise 25(OH)D to at least 75 to 110 nmol/L; although the US Institute of Medicine's report on calcium and vitamin D concluded that a 25(OH)D of 50 nmol/L (equivalent to 20 ng/ml) should be adequate for 97.5% of the population (<a href="./references#CD000227-bbs2-0166" title="Committee to review dietary reference intakes for vitamin D and calcium. Dietary reference intakes for calcium and Vitamin D. http://www.nap.edu/catalog.php?record_id=13050 (accessed 4th April 2014)2010.">Institute of Medicine 2010</a>). Gallagher and colleagues evaluated doses of 400 IU to 4800 IU cholecalciferol taken daily for one year (<a href="./references#CD000227-bbs2-0159" title="GallagherJC , SaiA , TemplinT , SmithL . Dose response to vitamin D supplementation in postmenopausal women. A randomized trial. Annals of Internal Medicine2012;156:425-37.">Gallagher 2012</a>), and concluded that 800 IU daily increased 25(OH)D to over 50 nmol/L in 97.5% of women (and 1600 IU/d to over 75 nmol/L in 97.5% of women), where baseline 25(OH)D was 37 nmol/L. </p> <p>Intermittent annual high oral dosing (<a href="./references#CD000227-bbs2-0050" title="SandersK , DuqueG , EbelingP , McCorquodaleT , HerrmannM , Shore-LorentiC , et al. The efficacy of high-does oral vitamin D3 administered once a year: increased fracture risk is associated with 1,25 vitamin D level at 3-months post dose. In: ASBMR Annual Meeting; 2012 Oct 12-15; Minneapolis, Minnesota. http://www.asbmr.org/Meetings/AnnualMeeting/AbstractDetail.aspx?aid=6beb2500-4b8e-472b-8b38-d881cadb80e3. 2012. SandersK , StuartA , WilliamsonE , SimpsonJ , KotowiczM , NicholsonG . The efficacy of high-dose oral vitamin D3 administered once a year: a randomised, double-blind, placebo-controlled trial (Vital D study) for falls and fractures in older women. Osteoporosis International2011;22(Suppl 1):S104-5. SandersKM , DuqueG , McCorquodaleT , StuartAL , WilliamsonEJ , KotowiczMA , et al. Annual high-dose oral vitamin D3: is the increased risk of falls attributable to changes in muscle strength?Osteoporosis International2011;22(Suppl 4):S552. SandersKM , EbelingPR , StuartAL , WilliamsonEJ , KotowiczMA , NicholsonGC . Annual high-dose oral vitamin D3: is increased risk of fractures attributable to changes in bone turnover markers?Osteoporosis International2011;22(Suppl 4):S589. SandersKM , HaylesAL , KotowiczMA , NicholsonGC . Does vitamin D explain the lower fracture rate in rural communities?Bone2007;40(6 Suppl 2):S195. SandersKM , HaylesAL , KotowiczMA , NicholsonGC . The possible role of vitamin D and falls in relation to lower fracture rates in rural communities. Osteoporosis International2007;18(Suppl 1):S120-1. SandersKM , StuartAL , KotowiczMA , NicholsonGC . Annual feedback is an effective tool for a sustained increase in calcium intake among older women. Nutrients2010;2:1018-25. SandersKM , StuartAL , MerrimanEN , ReadML , KotowiczMA , YoungD , et al. Trials and tribulations of recruiting 2,000 older women onto a clinical trial investigating falls and fractures: Vital D study. BMC Medical Research Methodology2009;9:78. SandersKM , StuartAL , NicholsonGC . High-dose oral vitamin D supplementation and risk of falls in older women. JAMA2010;304(8):856-7. SandersKM , StuartAL , WilliamsonEJ , JackaFN , DoddS , NicholsonG , et al. Annual high-dose vitamin D3 and mental well-being: randomised controlled trial. British Journal of Psychiatry2011;198:357-64. SandersKM , StuartAL , WilliamsonEJ , SimpsonJA , KotowiczMA , NicholsonGC . Annual high-dose oral vitamin D for falls and fractures in elderly women: a randomised, double-blind, placebo-controlled trial (Vital D study). Osteoporosis International2010;21(Suppl 1):S30. SandersKM , StuartAL , WilliamsonEJ , SimpsonJA , KotowiczMA , YoungD , et al. Annual high-dose oral vitamin D and falls and fractures in older women. A randomized controlled trial. JAMA2010;303(18):1815-22. Sanders KM et al. Incorrect data. JAMA2010;303(23):2357. ">Vital D</a>) or intra‐muscular injections (<a href="./references#CD000227-bbs2-0046" title="AndersonFH , SmithHE , RaphaelHM , CooperC . Intramuscular vitamin D increased serum 1,25-dihydroxycholecalciferol but did not affect 25-hydroxy-cholecalciferol levels in health older adults [abstract]. Journal of Bone and Mineral Research2000;15(Suppl 1):S315. AndersonFH , SmithHE , RaphaelHM , CrozierSR , CooperC . Effect of annual intramuscular vitamin D3 supplementation on fracture risk in 9440 community-living older people: the Wessex fracture prevention trial [abstract]. Journal of Bone and Mineral Research2004;19(Suppl 1):S57. ArdenNK , CrozierS , SmithH , AndersonF , EdwardsC , RaphaelH , et al. Knee pain, knee osteoarthritis, and the risk of fracture. Arthritis and Rheumatism2006;55(4):610-5. CooperC , CrozierS . Personal communication 23 February 2005. RaphaelH , SmithH , AndersonF , CooperC . Tackling the problems of trial management in primary care - experience from the Wessex research network fracture prevention study of annual vitamin D injection in older people [abstract]. Osteoporosis International2000;11(Suppl 1):S63-4. SmithH , AndersonF , RaphaelH , CooperC . The Wessex research network fracture prevention study - a large pragmatic trial of annual vitamin D injection in older people [abstract]. Osteoporosis International2000;11(Suppl 1):S64. SmithH , AndersonF , RaphaelH , CrozierS , CooperC . Effect of annual intramuscular vitamin D supplementation on fracture risk: population-based, randomised, double-blind, placebo-controlled trial [abstract]. Osteoporosis International2004;15(Suppl 1):S8. SmithH , AndersonF , RaphaelH , MaslinP , CrozierS , CooperC . Effect of annual intramuscular vitamin D on fracture risk in elderly men and women--a population-based, randomized, double-blind, placebo-controlled trial. Rheumatology2007;46(12):1852-7. ">Smith 2007</a>) were not effective. In the case of <a href="./references#CD000227-bbs2-0050" title="SandersK , DuqueG , EbelingP , McCorquodaleT , HerrmannM , Shore-LorentiC , et al. The efficacy of high-does oral vitamin D3 administered once a year: increased fracture risk is associated with 1,25 vitamin D level at 3-months post dose. In: ASBMR Annual Meeting; 2012 Oct 12-15; Minneapolis, Minnesota. http://www.asbmr.org/Meetings/AnnualMeeting/AbstractDetail.aspx?aid=6beb2500-4b8e-472b-8b38-d881cadb80e3. 2012. SandersK , StuartA , WilliamsonE , SimpsonJ , KotowiczM , NicholsonG . The efficacy of high-dose oral vitamin D3 administered once a year: a randomised, double-blind, placebo-controlled trial (Vital D study) for falls and fractures in older women. Osteoporosis International2011;22(Suppl 1):S104-5. SandersKM , DuqueG , McCorquodaleT , StuartAL , WilliamsonEJ , KotowiczMA , et al. Annual high-dose oral vitamin D3: is the increased risk of falls attributable to changes in muscle strength?Osteoporosis International2011;22(Suppl 4):S552. SandersKM , EbelingPR , StuartAL , WilliamsonEJ , KotowiczMA , NicholsonGC . Annual high-dose oral vitamin D3: is increased risk of fractures attributable to changes in bone turnover markers?Osteoporosis International2011;22(Suppl 4):S589. SandersKM , HaylesAL , KotowiczMA , NicholsonGC . Does vitamin D explain the lower fracture rate in rural communities?Bone2007;40(6 Suppl 2):S195. SandersKM , HaylesAL , KotowiczMA , NicholsonGC . The possible role of vitamin D and falls in relation to lower fracture rates in rural communities. Osteoporosis International2007;18(Suppl 1):S120-1. SandersKM , StuartAL , KotowiczMA , NicholsonGC . Annual feedback is an effective tool for a sustained increase in calcium intake among older women. Nutrients2010;2:1018-25. SandersKM , StuartAL , MerrimanEN , ReadML , KotowiczMA , YoungD , et al. Trials and tribulations of recruiting 2,000 older women onto a clinical trial investigating falls and fractures: Vital D study. BMC Medical Research Methodology2009;9:78. SandersKM , StuartAL , NicholsonGC . High-dose oral vitamin D supplementation and risk of falls in older women. JAMA2010;304(8):856-7. SandersKM , StuartAL , WilliamsonEJ , JackaFN , DoddS , NicholsonG , et al. Annual high-dose vitamin D3 and mental well-being: randomised controlled trial. British Journal of Psychiatry2011;198:357-64. SandersKM , StuartAL , WilliamsonEJ , SimpsonJA , KotowiczMA , NicholsonGC . Annual high-dose oral vitamin D for falls and fractures in elderly women: a randomised, double-blind, placebo-controlled trial (Vital D study). Osteoporosis International2010;21(Suppl 1):S30. SandersKM , StuartAL , WilliamsonEJ , SimpsonJA , KotowiczMA , YoungD , et al. Annual high-dose oral vitamin D and falls and fractures in older women. A randomized controlled trial. JAMA2010;303(18):1815-22. Sanders KM et al. Incorrect data. JAMA2010;303(23):2357. ">Vital D</a>, one oral dose of 500,000 IU Vitamin D3 appeared to increase the risk of falls, particularly in the three months after dosing, which might have been related to the very high dose leading to lower 1,25‐dihydroxyvitamin D (the active form of the vitamin) (<a href="./references#CD000227-bbs2-0156" title="Dawson-HughesB , HarrisSS . High-dose vitamin D supplementation. Too much of a good thing?JAMA2010;303:1861-2.">Dawson‐Hughes 2010</a>), possibly accentuated by a lack of regular daily vitamin D replacement (<a href="./references#CD000227-bbs2-0179" title="MakJC . High-dose oral vitamin D supplementation and risk of falls in older women. JAMA2010;304(8):854.">Mak 2010</a>). Neither of these trials appeared to recruit participants with very low baseline 25(OH)D levels (mean or medians of 45 nmol/L to 62 nmol/L) implying that participants may have had transient supratherapeutic levels. However, when these two trials (<a href="./references#CD000227-bbs2-0046" title="AndersonFH , SmithHE , RaphaelHM , CooperC . Intramuscular vitamin D increased serum 1,25-dihydroxycholecalciferol but did not affect 25-hydroxy-cholecalciferol levels in health older adults [abstract]. Journal of Bone and Mineral Research2000;15(Suppl 1):S315. AndersonFH , SmithHE , RaphaelHM , CrozierSR , CooperC . Effect of annual intramuscular vitamin D3 supplementation on fracture risk in 9440 community-living older people: the Wessex fracture prevention trial [abstract]. Journal of Bone and Mineral Research2004;19(Suppl 1):S57. ArdenNK , CrozierS , SmithH , AndersonF , EdwardsC , RaphaelH , et al. Knee pain, knee osteoarthritis, and the risk of fracture. Arthritis and Rheumatism2006;55(4):610-5. CooperC , CrozierS . Personal communication 23 February 2005. RaphaelH , SmithH , AndersonF , CooperC . Tackling the problems of trial management in primary care - experience from the Wessex research network fracture prevention study of annual vitamin D injection in older people [abstract]. Osteoporosis International2000;11(Suppl 1):S63-4. SmithH , AndersonF , RaphaelH , CooperC . The Wessex research network fracture prevention study - a large pragmatic trial of annual vitamin D injection in older people [abstract]. Osteoporosis International2000;11(Suppl 1):S64. SmithH , AndersonF , RaphaelH , CrozierS , CooperC . Effect of annual intramuscular vitamin D supplementation on fracture risk: population-based, randomised, double-blind, placebo-controlled trial [abstract]. Osteoporosis International2004;15(Suppl 1):S8. SmithH , AndersonF , RaphaelH , MaslinP , CrozierS , CooperC . Effect of annual intramuscular vitamin D on fracture risk in elderly men and women--a population-based, randomized, double-blind, placebo-controlled trial. Rheumatology2007;46(12):1852-7. ">Smith 2007</a>; <a href="./references#CD000227-bbs2-0050" title="SandersK , DuqueG , EbelingP , McCorquodaleT , HerrmannM , Shore-LorentiC , et al. The efficacy of high-does oral vitamin D3 administered once a year: increased fracture risk is associated with 1,25 vitamin D level at 3-months post dose. In: ASBMR Annual Meeting; 2012 Oct 12-15; Minneapolis, Minnesota. http://www.asbmr.org/Meetings/AnnualMeeting/AbstractDetail.aspx?aid=6beb2500-4b8e-472b-8b38-d881cadb80e3. 2012. SandersK , StuartA , WilliamsonE , SimpsonJ , KotowiczM , NicholsonG . The efficacy of high-dose oral vitamin D3 administered once a year: a randomised, double-blind, placebo-controlled trial (Vital D study) for falls and fractures in older women. Osteoporosis International2011;22(Suppl 1):S104-5. SandersKM , DuqueG , McCorquodaleT , StuartAL , WilliamsonEJ , KotowiczMA , et al. Annual high-dose oral vitamin D3: is the increased risk of falls attributable to changes in muscle strength?Osteoporosis International2011;22(Suppl 4):S552. SandersKM , EbelingPR , StuartAL , WilliamsonEJ , KotowiczMA , NicholsonGC . Annual high-dose oral vitamin D3: is increased risk of fractures attributable to changes in bone turnover markers?Osteoporosis International2011;22(Suppl 4):S589. SandersKM , HaylesAL , KotowiczMA , NicholsonGC . Does vitamin D explain the lower fracture rate in rural communities?Bone2007;40(6 Suppl 2):S195. SandersKM , HaylesAL , KotowiczMA , NicholsonGC . The possible role of vitamin D and falls in relation to lower fracture rates in rural communities. Osteoporosis International2007;18(Suppl 1):S120-1. SandersKM , StuartAL , KotowiczMA , NicholsonGC . Annual feedback is an effective tool for a sustained increase in calcium intake among older women. Nutrients2010;2:1018-25. SandersKM , StuartAL , MerrimanEN , ReadML , KotowiczMA , YoungD , et al. Trials and tribulations of recruiting 2,000 older women onto a clinical trial investigating falls and fractures: Vital D study. BMC Medical Research Methodology2009;9:78. SandersKM , StuartAL , NicholsonGC . High-dose oral vitamin D supplementation and risk of falls in older women. JAMA2010;304(8):856-7. SandersKM , StuartAL , WilliamsonEJ , JackaFN , DoddS , NicholsonG , et al. Annual high-dose vitamin D3 and mental well-being: randomised controlled trial. British Journal of Psychiatry2011;198:357-64. SandersKM , StuartAL , WilliamsonEJ , SimpsonJA , KotowiczMA , NicholsonGC . Annual high-dose oral vitamin D for falls and fractures in elderly women: a randomised, double-blind, placebo-controlled trial (Vital D study). Osteoporosis International2010;21(Suppl 1):S30. SandersKM , StuartAL , WilliamsonEJ , SimpsonJA , KotowiczMA , YoungD , et al. Annual high-dose oral vitamin D and falls and fractures in older women. A randomized controlled trial. JAMA2010;303(18):1815-22. Sanders KM et al. Incorrect data. JAMA2010;303(23):2357. ">Vital D</a>), and the trial by <a href="./references#CD000227-bbs2-0028" title="LawM , MorrisJ , WithersH . Cholecalciferol, not ergocalciferol, should be used for vitamin D supplementation [author reply]. Age and Ageing2006;35(6):645. [MEDLINE: 16982666]LawM , MorrisJ , WithersH . Vitamin D supplementation and the prevention of fractures and falls. Reply. Age and Ageing2007;36(2):233. LawM , MorrisJ , WithersH . Vitamin D supplementation and the prevention of fractures and falls [author reply]. Age and Ageing2007;36(2):233. [MEDLINE: 17255084]LawM , WithersH , MorrisJ , AndersonF . Vitamin D supplementation and the prevention of fractures and falls: results of a randomised trial in elderly people in residential accommodation [comment in: Age and Ageing 2006;35(6):645 and Age and Ageing 2007;36(2):232-3]. Age and Ageing2006;35(5):482-6. ">Law 2006</a> (for which the effects of clustering might not have been adequately controlled in our meta‐analyses) are removed from the results, the conclusions of the meta‐analyses are not changed. </p> <p>A variety of new vitamin D oral dosing strategies are being tested for their effects on baseline 25(OH)D, namely: loading, daily, weekly, monthly and less frequent dosing strategies, and comparison of ergocalciferol and cholecalciferol (<a href="./references#CD000227-bbs2-0135" title="BaconCJ , GambleGD , HorneAM , ScottMA , ReidIR . High-dose oral vitamin D3 supplementation in the elderly. Osteoporosis International2009;20:1407-15.">Bacon 2009</a>; <a href="./references#CD000227-bbs2-0137" title="BinkleyN , GemarD , EngelkeJ , GangnonR , RamamurthyR , KruegerD , et al. Evaluation of ergocalciferol or cholecalciferol dosing, 1,600 IU daily or 50,000 IU monthly in older adults. Journal of Clinical Endocrinology and Metabolism2011;96:981-8.">Binkley 2011</a>; <a href="./references#CD000227-bbs2-0159" title="GallagherJC , SaiA , TemplinT , SmithL . Dose response to vitamin D supplementation in postmenopausal women. A randomized trial. Annals of Internal Medicine2012;156:425-37.">Gallagher 2012</a>; <a href="./references#CD000227-bbs2-0167" title="Ish-ShalomS , SegalE , SalganikT , RazB , BrombergL , ViethR . Comparison of daily, weekly, and monthly vitamin D3 in ethanol dosing protocols for two months in elderly hip fracture patients. Journal of Clinical Endocrinology and Metabolism2008;93:3430-5.">Ish‐Shalom 2008</a>; <a href="./references#CD000227-bbs2-0185" title="PekkarinenT , ValimakiVV , AarumS , TurpeinenU , HamalainenE , LoyttyniemiE , et al. The same annual dose of 292000 IU of vitamin D3 (cholecalciferol) on either daily or four monthly basis for elderly women: 1-year comparative study of the effects on serum 25(OH)D3 concentrations and renal function. Clinical Endocrinology2010;72:455-61.">Pekkarinen 2010</a>). These newer regimens have not been tested in large trials of fracture prevention, where longer‐term compliance might be improved by intermittent dosing. </p> </section> <section id="CD000227-sec-0080"> <h4 class="title">Vitamin D plus calcium versus calcium alone</h4> <p>Although there was no firm evidence that vitamin D (including 25‐hydroxy vitamin D) with calcium was any more effective than calcium alone for preventing hip fracture, any non‐vertebral fracture or vertebral fracture, there was some evidence that, for those participants not selected on the basis of a previous fracture, risk for any new fracture was reduced (nine trials, 6131 participants; RR 0.70, 95% CI 0.53 to 0.92) compared with those participants selected with a previous fracture (two trials, 2681 participants, RR 0.98, 95% CI 0.80 to 1.20). Trials generally used a dose of cholecalciferol of 400 IU to 1000 IU given daily. The biological rationale for the subgroup differences is unclear, as is the practical application of this finding, since the decision to add vitamin D to existing calcium supplementation rarely arises. This finding also appears to contradict the results for vitamin D alone, and might suggest that vitamin D and calcium interact in the prevention of fractures. </p> </section> <section id="CD000227-sec-0081"> <h4 class="title">Vitamin D versus calcium</h4> <p>Few trials examined the comparison of vitamin D versus calcium, and the results are dominated by those from the <a href="./references#CD000227-bbs2-0044" title="AndersonFH , GrantAM , AvenellA , CampbellMK , CooperC , DonaldsonC , et al. The RECORD Trial: an evaluation of calcium and/or vitamin D in the secondary prevention of osteoporotic fractures. Bone2005;36(Suppl 2):S122-3. FrancisRM , Grant AM and the RECORD trial group. The RECORD trial: a randomised double-blind study of calcium and/or vitamin D in the secondary prevention of low trauma fractures. Age Ageing2005;34(Suppl 2):ii15. GrantA , on behalf of the RECORD Trial Group. Prevention of low-trauma fractures in older people [author reply]. Lancet2005;366(9485):543-4. GrantAM , AndersonFH , for the RECORD Trial Group. The Medical Research Council RECORD Trial: an evaluation of calcium and/or vitamin D in the secondary prevention of osteoporotic fractures. Osteoporosis International2004;15(Suppl 2):S13. GrantAM , AndersonFH . The RECORD trial: an evaluation of calcium and/or vitamin D in the secondary prevention of osteoporotic fractures. Osteoporosis International2005;16(Suppl 3):S4-5. GrantAM , AvenellA , CampbellMK , McDonaldAM , MacLennanGS , McPhersonGC , et al. Oral vitamin D3 and calcium for secondary prevention of low-trauma fractures in elderly people (Randomised Evaluation of Calcium Or vitamin D, RECORD): a randomised placebo-controlled trial [comment in: Lancet 2005;366(9485):543]. Lancet2005;365(9471):1621-8. GrantAM . Personal communication 11 March 2004. ">RECORD 2005</a> trial. Although calcium appeared to be more effective than vitamin D in the prevention of vertebral fractures or deformity, this result should be interpreted with caution as reflected in the wide confidence intervals (RR 2.21, 95% CI 1.08 to 4.53), where results are dominated by <a href="./references#CD000227-bbs2-0039" title="PeacockM , LiuG , CareyM , McClintockR , AmbrosiusW , HuiS , et al. Effect of calcium or 25OH vitamin D3 dietary supplementation on bone loss at the hip in men and women over the age of 60. Journal of Clinical Endocrinology and Metabolism2000;85:3011-9. ">Peacock 2000</a> with only 258 participants. <a href="./references#CD000227-bbs2-0044" title="AndersonFH , GrantAM , AvenellA , CampbellMK , CooperC , DonaldsonC , et al. The RECORD Trial: an evaluation of calcium and/or vitamin D in the secondary prevention of osteoporotic fractures. Bone2005;36(Suppl 2):S122-3. FrancisRM , Grant AM and the RECORD trial group. The RECORD trial: a randomised double-blind study of calcium and/or vitamin D in the secondary prevention of low trauma fractures. Age Ageing2005;34(Suppl 2):ii15. GrantA , on behalf of the RECORD Trial Group. Prevention of low-trauma fractures in older people [author reply]. Lancet2005;366(9485):543-4. GrantAM , AndersonFH , for the RECORD Trial Group. The Medical Research Council RECORD Trial: an evaluation of calcium and/or vitamin D in the secondary prevention of osteoporotic fractures. Osteoporosis International2004;15(Suppl 2):S13. GrantAM , AndersonFH . The RECORD trial: an evaluation of calcium and/or vitamin D in the secondary prevention of osteoporotic fractures. Osteoporosis International2005;16(Suppl 3):S4-5. GrantAM , AvenellA , CampbellMK , McDonaldAM , MacLennanGS , McPhersonGC , et al. Oral vitamin D3 and calcium for secondary prevention of low-trauma fractures in elderly people (Randomised Evaluation of Calcium Or vitamin D, RECORD): a randomised placebo-controlled trial [comment in: Lancet 2005;366(9485):543]. Lancet2005;365(9471):1621-8. GrantAM . Personal communication 11 March 2004. ">RECORD 2005</a> only assessed vertebral fractures that came to clinical attention (seven events in 2654 participants). </p> </section> <section id="CD000227-sec-0082"> <h4 class="title">Vitamin D plus calcium versus placebo or no treatment</h4> <p>There was high quality evidence that vitamin D and calcium resulted in a small reduction in hip fracture risk (nine trials, 49,853 participants; RR 0.(RR 0.84; 95% CI 0.74 to 0.96) (RR 0.84; 95% CI 0.74 to 0.96) 84, 95% CI 0.74 to 0.96) (<i>see</i><a href="./full#CD000227-tbl-0001">summary of findings Table 1</a>). As an illustration, in low‐risk populations (i.e. residents in the community: with an estimated eight hip fractures per 1000 per year), this equates to one fewer hip fracture per 1000 older adults per year (95% CI 0 to 2). In high risk populations (i.e. residents in institutions: with an estimated 54 hip fractures per 1000 per year), this equates to nine fewer hip fractures per 1000 older adults per year (95% CI 2 to 14).  </p> <p>There was high quality evidence that vitamin D and calcium was associated with a statistically significant reduction in incidence of new non‐vertebral fractures. However, there was only moderate quality evidence of an absence of a statistically significant preventive effect on clinical vertebral fractures. </p> <p>There was high quality evidence that vitamin D and calcium resulted in a small reduction in any new fracture risk (10 trials, 49,976 participants; RR 0.95, 95% CI 0.90 to 0.99) (<i>see</i><a href="./full#CD000227-tbl-0001">summary of findings Table 1</a>). As an illustration, in low‐risk populations (i.e. residents in the community: with an estimated 26 fractures per 1000 per year), this equates to one fewer fracture per 1000 older adults per year (95% CI 0 to 3). In high risk populations (i.e. residents in institutions: with an estimated 75 fractures per 1000 per year), this equates to four fewer hip fractures per 1000 older adults per year (95% CI 1 to 7).  </p> <p>Most trials used 400 IU to 800 IU vitamin D3 daily with co‐administration of 1000 mg calcium. Not all trials provided vertebral fracture data, and no statistically significant effect on vertebral fracture was found (four trials, 42,185 participants, RR 0.89, 95% CI 0.74 to 1.09). The very large <a href="./references#CD000227-bbs2-0051" title="CauleyJ , Wactawski-WendeJ , RobbinsJ , RodaboughR , ChenZ , JohnsonK , et al. The Women's Health Initiative (WHI) calcium and vitamin D supplementation trial: health outcomes 5 years after trial completion. ASBMR Annual Meeting; 2012 Oct 12-15; Minneapolis, Minnesota. http://www.asbmr.org/Meetings/AnnualMeeting/AbstractDetail.aspx?aid=6450bf3e-c670-4dc0-814c-8842e23cd80e (accessed 27 December 2012). CauleyJA , LaCroixA , WuL , LeeJ , HorowitzM , BauerD , et al. Serum 25 hydroxy vitamin D 25(OH) and the risk of hip fracture: the Women's Health Initiative (WHI). Journal of Bone and Mineral Research2007;22(Suppl 1):S57. ChenZ , BeckTJ , WrightNC , LaCroixAZ , CauleyJA , LewisCE , et al. The effect of calcium plus vitamin D supplement on hip geometric structures: results from the Women's Health Initiative CaD trial. Journal of Bone and Mineral Research2007;22(Suppl 1):S59. JacksonRD , LaCroixAZ , CauleyJA , McGowanJ . The Women's Health Initiative Calcium-Vitamin D Trial: overview and baseline characteristics of participants. Annals of Epidemiology2003;13:S98-106. JacksonRD , LaCroixAZ , GassM , WallaceRB , RobbinsJ , LewisCE , et al. Calcium plus vitamin D supplementation and the risk of fractures [erratum appears in New England Journal of Medicine 9 March 2006;354(10):1102]. New England Journal of Medicine2006;354(7):669-83. JacksonRD , WrightNC , BeckTJ , SherrillD , CauleyJA , LewisCE , et al. Calcium plus vitamin D supplementation has limited effects on femoral geometric strength in older postmenopausal women: the Women's Health Initiative. Calcified Tissue International2011;88:198-208. McGowanJA , JacksonRD , CauleyJA , LaCroixAZ . Calcium and vitamin D in the prevention of hip and other fractures: an update on the Women's Health Initiative CaD Trial. Journal of Bone and Mineral Research2002;17(Suppl 1):S477. The Women's Health Initiative Study Group. Design of the Women's Health Initiative clinical trial and observational study. Controlled Clinical Trials1998;19(1):61-109. ">WHI 2006</a> trial used a lower dose of 400 IU vitamin D and 1000 mg calcium and showed a trend only for hip fracture reduction. However, 44% of women in <a href="./references#CD000227-bbs2-0051" title="CauleyJ , Wactawski-WendeJ , RobbinsJ , RodaboughR , ChenZ , JohnsonK , et al. The Women's Health Initiative (WHI) calcium and vitamin D supplementation trial: health outcomes 5 years after trial completion. ASBMR Annual Meeting; 2012 Oct 12-15; Minneapolis, Minnesota. http://www.asbmr.org/Meetings/AnnualMeeting/AbstractDetail.aspx?aid=6450bf3e-c670-4dc0-814c-8842e23cd80e (accessed 27 December 2012). CauleyJA , LaCroixA , WuL , LeeJ , HorowitzM , BauerD , et al. Serum 25 hydroxy vitamin D 25(OH) and the risk of hip fracture: the Women's Health Initiative (WHI). Journal of Bone and Mineral Research2007;22(Suppl 1):S57. ChenZ , BeckTJ , WrightNC , LaCroixAZ , CauleyJA , LewisCE , et al. The effect of calcium plus vitamin D supplement on hip geometric structures: results from the Women's Health Initiative CaD trial. Journal of Bone and Mineral Research2007;22(Suppl 1):S59. JacksonRD , LaCroixAZ , CauleyJA , McGowanJ . The Women's Health Initiative Calcium-Vitamin D Trial: overview and baseline characteristics of participants. Annals of Epidemiology2003;13:S98-106. JacksonRD , LaCroixAZ , GassM , WallaceRB , RobbinsJ , LewisCE , et al. Calcium plus vitamin D supplementation and the risk of fractures [erratum appears in New England Journal of Medicine 9 March 2006;354(10):1102]. New England Journal of Medicine2006;354(7):669-83. JacksonRD , WrightNC , BeckTJ , SherrillD , CauleyJA , LewisCE , et al. Calcium plus vitamin D supplementation has limited effects on femoral geometric strength in older postmenopausal women: the Women's Health Initiative. Calcified Tissue International2011;88:198-208. McGowanJA , JacksonRD , CauleyJA , LaCroixAZ . Calcium and vitamin D in the prevention of hip and other fractures: an update on the Women's Health Initiative CaD Trial. Journal of Bone and Mineral Research2002;17(Suppl 1):S477. The Women's Health Initiative Study Group. Design of the Women's Health Initiative clinical trial and observational study. Controlled Clinical Trials1998;19(1):61-109. ">WHI 2006</a> were taking calcium and vitamin D at baseline and 3% were taking vitamin D. Analysis of women with and without the use of personal supplements of calcium and vitamin D at baseline did not suggest that this influenced the outcome for hip, or any fracture (<a href="./references#CD000227-bbs2-0146" title="BollandMJ , GreyA , GambleGG , ReidIR . Calcium and vitamin D supplements and health outcomes: a reanalysis of the Women’s Health Initiative (WHI) limited-access data set. American Journal of Clinical Nutrition2011;94:1144-9.">Bolland 2011b</a>). Using data from women who were not taking such supplements in our analyses, instead of the entire <a href="./references#CD000227-bbs2-0051" title="CauleyJ , Wactawski-WendeJ , RobbinsJ , RodaboughR , ChenZ , JohnsonK , et al. The Women's Health Initiative (WHI) calcium and vitamin D supplementation trial: health outcomes 5 years after trial completion. ASBMR Annual Meeting; 2012 Oct 12-15; Minneapolis, Minnesota. http://www.asbmr.org/Meetings/AnnualMeeting/AbstractDetail.aspx?aid=6450bf3e-c670-4dc0-814c-8842e23cd80e (accessed 27 December 2012). CauleyJA , LaCroixA , WuL , LeeJ , HorowitzM , BauerD , et al. Serum 25 hydroxy vitamin D 25(OH) and the risk of hip fracture: the Women's Health Initiative (WHI). Journal of Bone and Mineral Research2007;22(Suppl 1):S57. ChenZ , BeckTJ , WrightNC , LaCroixAZ , CauleyJA , LewisCE , et al. The effect of calcium plus vitamin D supplement on hip geometric structures: results from the Women's Health Initiative CaD trial. Journal of Bone and Mineral Research2007;22(Suppl 1):S59. JacksonRD , LaCroixAZ , CauleyJA , McGowanJ . The Women's Health Initiative Calcium-Vitamin D Trial: overview and baseline characteristics of participants. Annals of Epidemiology2003;13:S98-106. JacksonRD , LaCroixAZ , GassM , WallaceRB , RobbinsJ , LewisCE , et al. Calcium plus vitamin D supplementation and the risk of fractures [erratum appears in New England Journal of Medicine 9 March 2006;354(10):1102]. New England Journal of Medicine2006;354(7):669-83. JacksonRD , WrightNC , BeckTJ , SherrillD , CauleyJA , LewisCE , et al. Calcium plus vitamin D supplementation has limited effects on femoral geometric strength in older postmenopausal women: the Women's Health Initiative. Calcified Tissue International2011;88:198-208. McGowanJA , JacksonRD , CauleyJA , LaCroixAZ . Calcium and vitamin D in the prevention of hip and other fractures: an update on the Women's Health Initiative CaD Trial. Journal of Bone and Mineral Research2002;17(Suppl 1):S477. The Women's Health Initiative Study Group. Design of the Women's Health Initiative clinical trial and observational study. Controlled Clinical Trials1998;19(1):61-109. ">WHI 2006</a> trial population, does not affect the conclusions of the meta‐analyses (data not shown). In a post hoc sensitivity analysis, removal of <a href="./references#CD000227-bbs2-0051" title="CauleyJ , Wactawski-WendeJ , RobbinsJ , RodaboughR , ChenZ , JohnsonK , et al. The Women's Health Initiative (WHI) calcium and vitamin D supplementation trial: health outcomes 5 years after trial completion. ASBMR Annual Meeting; 2012 Oct 12-15; Minneapolis, Minnesota. http://www.asbmr.org/Meetings/AnnualMeeting/AbstractDetail.aspx?aid=6450bf3e-c670-4dc0-814c-8842e23cd80e (accessed 27 December 2012). CauleyJA , LaCroixA , WuL , LeeJ , HorowitzM , BauerD , et al. Serum 25 hydroxy vitamin D 25(OH) and the risk of hip fracture: the Women's Health Initiative (WHI). Journal of Bone and Mineral Research2007;22(Suppl 1):S57. ChenZ , BeckTJ , WrightNC , LaCroixAZ , CauleyJA , LewisCE , et al. The effect of calcium plus vitamin D supplement on hip geometric structures: results from the Women's Health Initiative CaD trial. Journal of Bone and Mineral Research2007;22(Suppl 1):S59. JacksonRD , LaCroixAZ , CauleyJA , McGowanJ . The Women's Health Initiative Calcium-Vitamin D Trial: overview and baseline characteristics of participants. Annals of Epidemiology2003;13:S98-106. JacksonRD , LaCroixAZ , GassM , WallaceRB , RobbinsJ , LewisCE , et al. Calcium plus vitamin D supplementation and the risk of fractures [erratum appears in New England Journal of Medicine 9 March 2006;354(10):1102]. New England Journal of Medicine2006;354(7):669-83. JacksonRD , WrightNC , BeckTJ , SherrillD , CauleyJA , LewisCE , et al. Calcium plus vitamin D supplementation has limited effects on femoral geometric strength in older postmenopausal women: the Women's Health Initiative. Calcified Tissue International2011;88:198-208. McGowanJA , JacksonRD , CauleyJA , LaCroixAZ . Calcium and vitamin D in the prevention of hip and other fractures: an update on the Women's Health Initiative CaD Trial. Journal of Bone and Mineral Research2002;17(Suppl 1):S477. The Women's Health Initiative Study Group. Design of the Women's Health Initiative clinical trial and observational study. Controlled Clinical Trials1998;19(1):61-109. ">WHI 2006</a> data for the entire trial population did not affect the conclusions of any of the fracture outcome analyses, including those of the subgroups, discussed below.<br/><br/>We conducted two subgroup analyses. The first separated the data by the residential status of the participants at recruitment. We defined institutional as residence in a nursing home or residential care home. We recognise that differences exist in nomenclature between different countries (for example nursing homes in Australia can mean high‐level residential care homes or residential care homes in general) but found the descriptions provided by trialists sufficient to make a judgement in most cases. Studies with a mixed population were categorised as 'institutional' or 'community' based on the dominant place of residence of participants. For example, we classified <a href="./references#CD000227-bbs2-0044" title="AndersonFH , GrantAM , AvenellA , CampbellMK , CooperC , DonaldsonC , et al. The RECORD Trial: an evaluation of calcium and/or vitamin D in the secondary prevention of osteoporotic fractures. Bone2005;36(Suppl 2):S122-3. FrancisRM , Grant AM and the RECORD trial group. The RECORD trial: a randomised double-blind study of calcium and/or vitamin D in the secondary prevention of low trauma fractures. Age Ageing2005;34(Suppl 2):ii15. GrantA , on behalf of the RECORD Trial Group. Prevention of low-trauma fractures in older people [author reply]. Lancet2005;366(9485):543-4. GrantAM , AndersonFH , for the RECORD Trial Group. The Medical Research Council RECORD Trial: an evaluation of calcium and/or vitamin D in the secondary prevention of osteoporotic fractures. Osteoporosis International2004;15(Suppl 2):S13. GrantAM , AndersonFH . The RECORD trial: an evaluation of calcium and/or vitamin D in the secondary prevention of osteoporotic fractures. Osteoporosis International2005;16(Suppl 3):S4-5. GrantAM , AvenellA , CampbellMK , McDonaldAM , MacLennanGS , McPhersonGC , et al. Oral vitamin D3 and calcium for secondary prevention of low-trauma fractures in elderly people (Randomised Evaluation of Calcium Or vitamin D, RECORD): a randomised placebo-controlled trial [comment in: Lancet 2005;366(9485):543]. Lancet2005;365(9471):1621-8. GrantAM . Personal communication 11 March 2004. ">RECORD 2005</a> as a community study, as 94% of participants were resident in their own homes and only 6% were resident in institutions. This subgroup analysis was not pre‐defined in the original review in 1995, but emerged for an earlier update from the accumulation of evidence, from clinical biochemistry and epidemiology, that many frail, institutionalised older people are vitamin D deficient, and likely to have lower 25(OH)vitamin D status. We hypothesised that they, in particular, might benefit from the administration of vitamin D and calcium. This analysis is particularly influenced by the two trials conducted amongst frail people living in nursing homes or apartments for older people in France (<a href="./references#CD000227-bbs2-0008" title="ChapuyMC , ArlotM , et al. Prevention of non vertebral fractures and cortical bone loss in elderly women: a prospective controlled trial using calcium and vitamin D3 supplements [abstract]. Osteoporosis International1993;3 Suppl 1:258. ChapuyMC , ArlotME , DelmasPD , MeunierPJ . Effect of calcium and cholecalciferol treatment for three years on hip fractures in elderly women. BMJ1994;308:1081-2. ChapuyMC , ArlotME , DuboeufF , BrunJ , CrouzetB , ArnaudS , et al. Vitamin D3 and calcium to prevent hip fractures in elderly women. New England Journal of Medicine1992;327:1637-42. MeunierPJ , PamphileR , ChapuyMC , SchultenJ , ArlotM , LilluH . A calcium-vitamin D3 combined supplementation is cost-saving for preventing hip fractures in institutionalised elderly women: an economic evaluation from the perspective of seven European countries (Belgium, France, Germany, The Netherlands, Spain, Sweden, United Kingdom). Osteoporosis International2002;13(Suppl 1):S14. ">Chapuy 1992</a>; <a href="./references#CD000227-bbs2-0009" title="BosworthC , deBoerIH , TargherG , KendrickJ , SmitsG , ChoncholM . The effect of combined calcium and cholecalciferol supplementation on bone mineral density in elderly women with moderate chronic kidney disease. Clinical Nephrology2012;77(5):358-65. ChapuyMC , PamphileR , ParisE , KempfC , SchlichtingM , ArnaudS , et al. Combined calcium and vitamin D3 supplementation in elderly women: confirmation of reversal of secondary hyperparathyroidism and hip fracture risk: the Decalyos II study. Osteoporosis International2002;13(3):257-64. [MEDLINE: 11991447]ChapuyMC , PamphileR , ParisE , KempfC , SchlichtingM , ArnaudS , et al. Combined calcium and vitamin D3 supplementation to prevent hip fracture in elderly women. A confirmatory study: Decalyos II. Osteoporosis International2002;13(Suppl 1):S25. MeunierPJ . Personal communication 28 February 2005. ">Chapuy 2002</a>). Tests for subgroup differences found no statistically significant differences between community or institutional residence populations for hip or any new fracture. </p> <p>Considerable epidemiologic evidence supports the association between prior osteoporotic fracture and subsequent hip fracture; <a href="./references#CD000227-bbs2-0044" title="AndersonFH , GrantAM , AvenellA , CampbellMK , CooperC , DonaldsonC , et al. The RECORD Trial: an evaluation of calcium and/or vitamin D in the secondary prevention of osteoporotic fractures. Bone2005;36(Suppl 2):S122-3. FrancisRM , Grant AM and the RECORD trial group. The RECORD trial: a randomised double-blind study of calcium and/or vitamin D in the secondary prevention of low trauma fractures. Age Ageing2005;34(Suppl 2):ii15. GrantA , on behalf of the RECORD Trial Group. Prevention of low-trauma fractures in older people [author reply]. Lancet2005;366(9485):543-4. GrantAM , AndersonFH , for the RECORD Trial Group. The Medical Research Council RECORD Trial: an evaluation of calcium and/or vitamin D in the secondary prevention of osteoporotic fractures. Osteoporosis International2004;15(Suppl 2):S13. GrantAM , AndersonFH . The RECORD trial: an evaluation of calcium and/or vitamin D in the secondary prevention of osteoporotic fractures. Osteoporosis International2005;16(Suppl 3):S4-5. GrantAM , AvenellA , CampbellMK , McDonaldAM , MacLennanGS , McPhersonGC , et al. Oral vitamin D3 and calcium for secondary prevention of low-trauma fractures in elderly people (Randomised Evaluation of Calcium Or vitamin D, RECORD): a randomised placebo-controlled trial [comment in: Lancet 2005;366(9485):543]. Lancet2005;365(9471):1621-8. GrantAM . Personal communication 11 March 2004. ">RECORD 2005</a> therefore recruited participants with a prior fracture history. We found no evidence from our subgroup analyses (which was heavily dominated by <a href="./references#CD000227-bbs2-0044" title="AndersonFH , GrantAM , AvenellA , CampbellMK , CooperC , DonaldsonC , et al. The RECORD Trial: an evaluation of calcium and/or vitamin D in the secondary prevention of osteoporotic fractures. Bone2005;36(Suppl 2):S122-3. FrancisRM , Grant AM and the RECORD trial group. The RECORD trial: a randomised double-blind study of calcium and/or vitamin D in the secondary prevention of low trauma fractures. Age Ageing2005;34(Suppl 2):ii15. GrantA , on behalf of the RECORD Trial Group. Prevention of low-trauma fractures in older people [author reply]. Lancet2005;366(9485):543-4. GrantAM , AndersonFH , for the RECORD Trial Group. The Medical Research Council RECORD Trial: an evaluation of calcium and/or vitamin D in the secondary prevention of osteoporotic fractures. Osteoporosis International2004;15(Suppl 2):S13. GrantAM , AndersonFH . The RECORD trial: an evaluation of calcium and/or vitamin D in the secondary prevention of osteoporotic fractures. Osteoporosis International2005;16(Suppl 3):S4-5. GrantAM , AvenellA , CampbellMK , McDonaldAM , MacLennanGS , McPhersonGC , et al. Oral vitamin D3 and calcium for secondary prevention of low-trauma fractures in elderly people (Randomised Evaluation of Calcium Or vitamin D, RECORD): a randomised placebo-controlled trial [comment in: Lancet 2005;366(9485):543]. Lancet2005;365(9471):1621-8. GrantAM . Personal communication 11 March 2004. ">RECORD 2005</a>), that a population with such a history, irrespective of age, benefits in respect of fracture incidence from receiving vitamin D and calcium. Although the dose of vitamin D3 used in <a href="./references#CD000227-bbs2-0044" title="AndersonFH , GrantAM , AvenellA , CampbellMK , CooperC , DonaldsonC , et al. The RECORD Trial: an evaluation of calcium and/or vitamin D in the secondary prevention of osteoporotic fractures. Bone2005;36(Suppl 2):S122-3. FrancisRM , Grant AM and the RECORD trial group. The RECORD trial: a randomised double-blind study of calcium and/or vitamin D in the secondary prevention of low trauma fractures. Age Ageing2005;34(Suppl 2):ii15. GrantA , on behalf of the RECORD Trial Group. Prevention of low-trauma fractures in older people [author reply]. Lancet2005;366(9485):543-4. GrantAM , AndersonFH , for the RECORD Trial Group. The Medical Research Council RECORD Trial: an evaluation of calcium and/or vitamin D in the secondary prevention of osteoporotic fractures. Osteoporosis International2004;15(Suppl 2):S13. GrantAM , AndersonFH . The RECORD trial: an evaluation of calcium and/or vitamin D in the secondary prevention of osteoporotic fractures. Osteoporosis International2005;16(Suppl 3):S4-5. GrantAM , AvenellA , CampbellMK , McDonaldAM , MacLennanGS , McPhersonGC , et al. Oral vitamin D3 and calcium for secondary prevention of low-trauma fractures in elderly people (Randomised Evaluation of Calcium Or vitamin D, RECORD): a randomised placebo-controlled trial [comment in: Lancet 2005;366(9485):543]. Lancet2005;365(9471):1621-8. GrantAM . Personal communication 11 March 2004. ">RECORD 2005</a> was the same as was used in <a href="./references#CD000227-bbs2-0008" title="ChapuyMC , ArlotM , et al. Prevention of non vertebral fractures and cortical bone loss in elderly women: a prospective controlled trial using calcium and vitamin D3 supplements [abstract]. Osteoporosis International1993;3 Suppl 1:258. ChapuyMC , ArlotME , DelmasPD , MeunierPJ . Effect of calcium and cholecalciferol treatment for three years on hip fractures in elderly women. BMJ1994;308:1081-2. ChapuyMC , ArlotME , DuboeufF , BrunJ , CrouzetB , ArnaudS , et al. Vitamin D3 and calcium to prevent hip fractures in elderly women. New England Journal of Medicine1992;327:1637-42. MeunierPJ , PamphileR , ChapuyMC , SchultenJ , ArlotM , LilluH . A calcium-vitamin D3 combined supplementation is cost-saving for preventing hip fractures in institutionalised elderly women: an economic evaluation from the perspective of seven European countries (Belgium, France, Germany, The Netherlands, Spain, Sweden, United Kingdom). Osteoporosis International2002;13(Suppl 1):S14. ">Chapuy 1992</a> and <a href="./references#CD000227-bbs2-0009" title="BosworthC , deBoerIH , TargherG , KendrickJ , SmitsG , ChoncholM . The effect of combined calcium and cholecalciferol supplementation on bone mineral density in elderly women with moderate chronic kidney disease. Clinical Nephrology2012;77(5):358-65. ChapuyMC , PamphileR , ParisE , KempfC , SchlichtingM , ArnaudS , et al. Combined calcium and vitamin D3 supplementation in elderly women: confirmation of reversal of secondary hyperparathyroidism and hip fracture risk: the Decalyos II study. Osteoporosis International2002;13(3):257-64. [MEDLINE: 11991447]ChapuyMC , PamphileR , ParisE , KempfC , SchlichtingM , ArnaudS , et al. Combined calcium and vitamin D3 supplementation to prevent hip fracture in elderly women. A confirmatory study: Decalyos II. Osteoporosis International2002;13(Suppl 1):S25. MeunierPJ . Personal communication 28 February 2005. ">Chapuy 2002</a>, poorer compliance may have reduced the effect in <a href="./references#CD000227-bbs2-0044" title="AndersonFH , GrantAM , AvenellA , CampbellMK , CooperC , DonaldsonC , et al. The RECORD Trial: an evaluation of calcium and/or vitamin D in the secondary prevention of osteoporotic fractures. Bone2005;36(Suppl 2):S122-3. FrancisRM , Grant AM and the RECORD trial group. The RECORD trial: a randomised double-blind study of calcium and/or vitamin D in the secondary prevention of low trauma fractures. Age Ageing2005;34(Suppl 2):ii15. GrantA , on behalf of the RECORD Trial Group. Prevention of low-trauma fractures in older people [author reply]. Lancet2005;366(9485):543-4. GrantAM , AndersonFH , for the RECORD Trial Group. The Medical Research Council RECORD Trial: an evaluation of calcium and/or vitamin D in the secondary prevention of osteoporotic fractures. Osteoporosis International2004;15(Suppl 2):S13. GrantAM , AndersonFH . The RECORD trial: an evaluation of calcium and/or vitamin D in the secondary prevention of osteoporotic fractures. Osteoporosis International2005;16(Suppl 3):S4-5. GrantAM , AvenellA , CampbellMK , McDonaldAM , MacLennanGS , McPhersonGC , et al. Oral vitamin D3 and calcium for secondary prevention of low-trauma fractures in elderly people (Randomised Evaluation of Calcium Or vitamin D, RECORD): a randomised placebo-controlled trial [comment in: Lancet 2005;366(9485):543]. Lancet2005;365(9471):1621-8. GrantAM . Personal communication 11 March 2004. ">RECORD 2005</a>. Compliance appears to have been very good in both <a href="./references#CD000227-bbs2-0009" title="BosworthC , deBoerIH , TargherG , KendrickJ , SmitsG , ChoncholM . The effect of combined calcium and cholecalciferol supplementation on bone mineral density in elderly women with moderate chronic kidney disease. Clinical Nephrology2012;77(5):358-65. ChapuyMC , PamphileR , ParisE , KempfC , SchlichtingM , ArnaudS , et al. Combined calcium and vitamin D3 supplementation in elderly women: confirmation of reversal of secondary hyperparathyroidism and hip fracture risk: the Decalyos II study. Osteoporosis International2002;13(3):257-64. [MEDLINE: 11991447]ChapuyMC , PamphileR , ParisE , KempfC , SchlichtingM , ArnaudS , et al. Combined calcium and vitamin D3 supplementation to prevent hip fracture in elderly women. A confirmatory study: Decalyos II. Osteoporosis International2002;13(Suppl 1):S25. MeunierPJ . Personal communication 28 February 2005. ">Chapuy 2002</a> and <a href="./references#CD000227-bbs2-0008" title="ChapuyMC , ArlotM , et al. Prevention of non vertebral fractures and cortical bone loss in elderly women: a prospective controlled trial using calcium and vitamin D3 supplements [abstract]. Osteoporosis International1993;3 Suppl 1:258. ChapuyMC , ArlotME , DelmasPD , MeunierPJ . Effect of calcium and cholecalciferol treatment for three years on hip fractures in elderly women. BMJ1994;308:1081-2. ChapuyMC , ArlotME , DuboeufF , BrunJ , CrouzetB , ArnaudS , et al. Vitamin D3 and calcium to prevent hip fractures in elderly women. New England Journal of Medicine1992;327:1637-42. MeunierPJ , PamphileR , ChapuyMC , SchultenJ , ArlotM , LilluH . A calcium-vitamin D3 combined supplementation is cost-saving for preventing hip fractures in institutionalised elderly women: an economic evaluation from the perspective of seven European countries (Belgium, France, Germany, The Netherlands, Spain, Sweden, United Kingdom). Osteoporosis International2002;13(Suppl 1):S14. ">Chapuy 1992</a> (see reference in <a href="./references#CD000227-bbs2-0141" title="Bischoff-FerrariHA , WillettWC , OravEJ , LipsP , MeunierPJ , LyonsRA , et al. A pooled analysis of vitamin dose requirements for fracture prevention. New England Journal of Medicine2012;367:40-9.">Bischoff‐Ferrari 2012</a>). Ways to improve compliance with bone‐active medication of all forms in this population needs to be researched (<a href="./references#CD000227-bbs2-0191" title="SeemanE , CompstonJ , AdachiJ , BrandiML , CooperC , Dawson-HughesB , et al. Non-compliance: the Achilles' heel of anti-fracture efficacy. Osteoporosis International2007;18(6):711-9.">Seeman 2007</a>). Pooled data from studies where a previous osteoporotic fracture was not a selection criterion did show a statistically significant reduction in hip fracture or any type of fracture, but tests for subgroup differences between this group and those with a previous fracture did not show statistical significance. </p> </section> <section id="CD000227-sec-0083"> <h4 class="title">Alfacalcidol</h4> <p>One trial of alfacalcidol suggested that vertebral fractures may be prevented by taking alfacalcidol (one trial, 740 participants, RR 0.56, 95% CI 0.48 to 0.65), although the evidence did not suggest prevention of non‐vertebral fractures. The data for vertebral fractures are from <a href="./references#CD000227-bbs2-0023" title="HayashiY , FujitaT , InoueT . A multi-center study on efficacy of 1 alpha-hydroxy vitamin D3 in preventing spinal fracture of patients with osteoporosis (abstract). Journal of Bone and Mineral Research1989;4 Suppl 1:Si84. HayashiY , FujitaT , InoueT . Decrease of vertebral fracture in osteoporotics by administration of 1alpha-hydroxy-vitamin D3. Journal of Bone and Mineral Metabolism1992;10(2):50-4. ">Hayashi 1992</a>, which was quasi‐randomised and thus susceptible to bias. Other small studies, which compared alfacalcidol and calcium with calcium alone, also suggested protection against vertebral fractures. </p> </section> <section id="CD000227-sec-0084"> <h4 class="title">Calcitriol</h4> <p>The effect of calcitriol in fracture prevention is unclear, with the best evidence for effectiveness coming from the trial of <a href="./references#CD000227-bbs2-0047" title="MorrisonNA , GeorgePM , VaughanT , TilyardMW , FramptonCM , GilchristNL . Vitamin D receptor genotypes influence the success of calcitriol therapy for recurrent vertebral fracture in osteoporosis. Pharmacogenetics and Genomics2005;15(2):127-35. TilyardM . Low-dose calcitriol versus calcium in established postmenopausal osteoporosis. Metabolism: Clinical &amp; Experimental1990;39(4 Suppl 1):50-2. TilyardMW , SpearsGF , ThomsonJ , DoveyS . Treatment of postmenopausal osteoporosis with calcitriol or calcium. New England Journal of Medicine1992;326(6):357-62. TilyardMW , SpearsGFS , ThomsonJ , DoveyS . Calcitriol or calcium for postmenopausal osteoporosis. New England Journal of Medicine1992;327:284. TilyardMW . 1,25-dihydroxyvitamin D3 (calcitriol) in the treatment of postmenopausal osteoporosis. Aktuelle Rheumatologie1994;19(Suppl 1):23-6. ">Tilyard 1992</a> that compared calcitriol with calcium and where vertebral deformities were significantly reduced only in the second and third years (<i>see</i><a href="./references#CD000227-fig-0037" title="">Analysis 11.3</a>). However, the use of calcitriol is associated with a statistically significant increase in risk of hypercalcaemia (four trials, 988 participants, RR 4.41, 95% CI 2.14 to 9.09). </p> </section> <section id="CD000227-sec-0085"> <h4 class="title">Adverse effects</h4> <p>Not all trials reported adverse effects. Overall, there was no significant effect of vitamin D on mortality, or from groups of supplement types such as vitamin D and calcium (see also <a href="./full#CD000227-tbl-0001">summary of findings Table 1</a>), in the trials examined here, which only encompassed fracture prevention (29 trials, 71,032 participants, RR 0.97, 95% CI 0.93 to 1.01, <a href="./references#CD000227-fig-0040" title="">Analysis 13.1</a>). In the previous version of the review (<a href="./references#CD000227-bbs2-0134" title="AvenellA , GillespieWJ , GillespieLD , O'ConnellD . Vitamin D and vitamin D analogues for preventing fractures associated with involutional and post-menopausal osteoporosis. Cochrane Database of Systematic Reviews2009, Issue 2. Art. No: CD000227. [DOI: 10.1002/14651858.CD000227.pub3]">Avenell 2009a</a>), vitamin D and calcium were associated with a reduction in mortality (RR 0.94, 95% CI 0.89 to 0.99). This partly relates to reclassification of some of the trials in the subgroups in this analysis due to the use of the factorial design, as well as the inclusion of one new trial (<a href="./references#CD000227-bbs2-0037" title="KarkkainenM , TuppurainenM , RikkonenT , SalovaaraK , SirolaJ , HonkanenR , et al. Vitamin-D 800IU/day + calcium 1000mg supplementation decreases the risk of recurrent falling among postmenopausal ambulatory women - a population-based, randomized, 3-year study (OSTPRE-FPS). Osteoporosis International2008;19(Suppl 1):S17-18. KarkkainenM , TuppurainenM , RikkonenT , SalovaaraK , SirolaJ , HonkanenR , et al. Vitamin-D 800IU/day + calcium supplementation decreases the risk of falling among postmenopausal ambulatory women - a population-based, randomized 3-year study (OSTPRE-FPS) [abstract]. Journal of Bone and Mineral Research2007;22(Suppl 1):S131. KarkkainenM , TuppurainenM , SalovaaraK , SandiniL , RikkonenT , SirolaJ , et al. Effect of calcium and vitamin D supplementation on bone mineral density in women aged 65-71 years: a 3-year randomized population-based trial (OSTPRE-FPS). Osteoporosis International2010;21:2047-55. KarkkainenMK , TuppurainenM , SalovaaraM , SandiniL , RikkonenT , SirolaJ , et al. Does daily vitamin D 800 IU and calcium 1000 mg supplementation decrease the risk of falling in ambulatory women aged 65-71 years? A 3-year randomized population-based trial (OSTPRE-FPS). Maturitas2010;65:359-65. KrogerHP , TuppurainenM . OSTPRE-FPS Prevention of Fractures and Falls in Postmenopausal Women With Calcium and Vitamin-D Supplementation - a Randomised Study. http://www.controlled-trials.com/mrct/trial/405493/OSTPRE. SalovaaraK , TuppurainenM , KarkkainenM , RikkonenT , SandiniL , SirolaJ , et al. Effect of vitamin D3 and calcium on fracture risk in 65- to 71-year-old women: a population-based 3-year randomized, controlled trial - the OSTPRE-FPS. Journal of Bone and Mineral Research2010;25(7):1487-95. SalovaaraKT , TuppurainenM , RikkonenT , KarkkainenM , SirolaJ , HonkanenR , et al. Effect of vitamin-D3 and calcium on fracture risk in 65-71 year old women in a 3-year randomized clinical trial - preliminary results from the OSTPRE-Fracture Prevention Study. Calcified Tissue International2008;82:545-6. SalovaaraKT , TuppurainenM , RikkonenT , KarkkainenM , SirolaJ , HonkanenR , et al. Effect of vitamin-D3 and calcium on fracture risk in 65-71 year old women in a 3-year randomized clinical trial - preliminary results of the OSTPRE-Fracture Prevention Study. Journal of Bone and Mineral Research2007;22(Suppl 1):S76. ">OSTPRE‐FPS 2007</a>). A Cochrane review examined all forms of vitamin D supplementation including with calcium (as in our overall meta‐analysis of mortality) in 56 trials and found a similar RR to our study with narrower and statistically significant confidence intervals: RR 0.97, 95% CI 0.94 to 0.99 (<a href="./references#CD000227-bbs2-0142" title="BjelakovicG , GluudLL , NikolovaD , WhitfieldK , WetterslevJ , SimonettiRG , et al. Vitamin D supplementation for prevention of mortality in adults. Cochrane Database of Systematic Reviews2014, Issue 1. Art. No: CD007470. [DOI: 10.1002/14651858.CD007470.pub3]">Bjelakovic 2014</a>). </p> <p>Calcium supplements could increase the risk of myocardial infarction (<a href="./references#CD000227-bbs2-0144" title="BollandMJ , AvenellA , BaronJA , GreyA , MacLennanGS , GambleGD , et al. Effect of calcium supplementation on the risk of myocardial infarction and cardiovascular events: a meta-analysis. BMJ2010;341:c3691.">Bolland 2010</a>), particularly in people with a higher dietary calcium intake, suggesting over‐therapeutic usage of supplements. Supplements of calcium and vitamin D could also increase the risk of myocardial infarction and stroke (<a href="./references#CD000227-bbs2-0145" title="BollandMJ , GreyA , AvenellA , GambleGD , ReidIR . Calcium supplements with or without vitamin D and risk of cardiovascular events: reanalysis of the Women's Health Initiative limited access dataset and meta-analysis. BMJ2011;342:d2040.">Bolland 2011a</a>), but might also decrease the risk of total and breast cancer (<a href="./references#CD000227-bbs2-0146" title="BollandMJ , GreyA , GambleGG , ReidIR . Calcium and vitamin D supplements and health outcomes: a reanalysis of the Women’s Health Initiative (WHI) limited-access data set. American Journal of Clinical Nutrition2011;94:1144-9.">Bolland 2011b</a>). However, this review found no significant increase in mortality in trials of vitamin D and calcium. </p> <p>Gastrointestinal effects and renal disease were particularly likely to be not reported. In the past, there has been serious concern that cholecalciferol or ergocalciferol may be associated with hypercalcaemia when given in only moderate doses, which may have led to cautious use of low doses in the trials of vitamin D. There is some evidence that potential toxicity in this respect has been seriously overestimated (<a href="./references#CD000227-bbs2-0159" title="GallagherJC , SaiA , TemplinT , SmithL . Dose response to vitamin D supplementation in postmenopausal women. A randomized trial. Annals of Internal Medicine2012;156:425-37.">Gallagher 2012</a>), and that requirements for vitamin D3 might be more than previously recognised (<a href="./references#CD000227-bbs2-0194" title="ViethR , ChanPC , MacFarlaneGD . Efficacy and safety of vitamin D3 intake exceeding the lowest observed adverse effect level. American Journal of Clinical Nutrition2001;73:288-94.">Vieth 2001</a>). However, hypercalcaemia was found more often in participants taking vitamin D, but this mainly related to the use of calcitriol. Gastrointestinal effects and renal disease (especially calculi) were more common amongst participants receiving vitamin D, and in these cases calcium and vitamin D appeared to be most associated with increased risk (see also <a href="./full#CD000227-tbl-0001">summary of findings Table 1</a>). These analyses were dominated by <a href="./references#CD000227-bbs2-0051" title="CauleyJ , Wactawski-WendeJ , RobbinsJ , RodaboughR , ChenZ , JohnsonK , et al. The Women's Health Initiative (WHI) calcium and vitamin D supplementation trial: health outcomes 5 years after trial completion. ASBMR Annual Meeting; 2012 Oct 12-15; Minneapolis, Minnesota. http://www.asbmr.org/Meetings/AnnualMeeting/AbstractDetail.aspx?aid=6450bf3e-c670-4dc0-814c-8842e23cd80e (accessed 27 December 2012). CauleyJA , LaCroixA , WuL , LeeJ , HorowitzM , BauerD , et al. Serum 25 hydroxy vitamin D 25(OH) and the risk of hip fracture: the Women's Health Initiative (WHI). Journal of Bone and Mineral Research2007;22(Suppl 1):S57. ChenZ , BeckTJ , WrightNC , LaCroixAZ , CauleyJA , LewisCE , et al. The effect of calcium plus vitamin D supplement on hip geometric structures: results from the Women's Health Initiative CaD trial. Journal of Bone and Mineral Research2007;22(Suppl 1):S59. JacksonRD , LaCroixAZ , CauleyJA , McGowanJ . The Women's Health Initiative Calcium-Vitamin D Trial: overview and baseline characteristics of participants. Annals of Epidemiology2003;13:S98-106. JacksonRD , LaCroixAZ , GassM , WallaceRB , RobbinsJ , LewisCE , et al. Calcium plus vitamin D supplementation and the risk of fractures [erratum appears in New England Journal of Medicine 9 March 2006;354(10):1102]. New England Journal of Medicine2006;354(7):669-83. JacksonRD , WrightNC , BeckTJ , SherrillD , CauleyJA , LewisCE , et al. Calcium plus vitamin D supplementation has limited effects on femoral geometric strength in older postmenopausal women: the Women's Health Initiative. Calcified Tissue International2011;88:198-208. McGowanJA , JacksonRD , CauleyJA , LaCroixAZ . Calcium and vitamin D in the prevention of hip and other fractures: an update on the Women's Health Initiative CaD Trial. Journal of Bone and Mineral Research2002;17(Suppl 1):S477. The Women's Health Initiative Study Group. Design of the Women's Health Initiative clinical trial and observational study. Controlled Clinical Trials1998;19(1):61-109. ">WHI 2006</a> in which calcium supplements were also given (with the associated use of off‐study calcium and vitamin D), but there was no significant difference between the subgroups with and without calcium supplementation in our meta‐analysis. Our results for hypercalcaemia, gastrointestinal effects and renal disease were similar to those from the Cochrane review by <a href="./references#CD000227-bbs2-0142" title="BjelakovicG , GluudLL , NikolovaD , WhitfieldK , WetterslevJ , SimonettiRG , et al. Vitamin D supplementation for prevention of mortality in adults. Cochrane Database of Systematic Reviews2014, Issue 1. Art. No: CD007470. [DOI: 10.1002/14651858.CD007470.pub3]">Bjelakovic 2014</a>, although the latter review also included trials of vitamin D whose aim was not fracture prevention. </p> </section> </section> <section id="CD000227-sec-0086"> <h3 class="title" id="CD000227-sec-0086">Overall completeness and applicability of evidence</h3> <p>This review included a large evidence base from 31 trials that examined vitamin D (including 25‐hydroxy vitamin D) with or without calcium in the prevention of fractures, mostly set in the community, nursing home or hospital inpatient population, and generally with older participants than in the second group of trials described below. Twelve trials had participants with a mean or median age of 80 years or over. Only three trials recruited participants because they had all had a previous fracture (<a href="./references#CD000227-bbs2-0003" title="AvenellA , GrantAM , McGeeM , McPhersonG , CampbellMK , McGee MA for the RECORD Trial Management Group. The effects of an open design on trial participant recruitment, compliance and retention - a randomized controlled trial comparison with a blinded, placebo-controlled design. Clinical Trials Journal2004;1:490-8. AvenellA . Personal communication2005. ">Avenell 2004</a>; <a href="./references#CD000227-bbs2-0022" title="HarwoodRH , SahotaO , GaynorK , MasudT , HoskingD . A randomised, controlled comparison of different calcium and vitamin D supplementation regimens in elderly women after hip fracture: The Nottingham Neck of Femur (NoNOF) Study. Age and Ageing2004;33:45-51. [14695863]HarwoodRW . Personal communication 24 January 2003. SahotaO , HarwoodRH , GaynorK , MasudT , HoskingDJ . A randomised, controlled comparison of different calcium and vitamin D regimes: the NoNOF (Nottingham Neck of Femur) study. Osteoporosis International2003;14(Suppl 4):S10-11. ">Harwood 2004</a>; <a href="./references#CD000227-bbs2-0044" title="AndersonFH , GrantAM , AvenellA , CampbellMK , CooperC , DonaldsonC , et al. The RECORD Trial: an evaluation of calcium and/or vitamin D in the secondary prevention of osteoporotic fractures. Bone2005;36(Suppl 2):S122-3. FrancisRM , Grant AM and the RECORD trial group. The RECORD trial: a randomised double-blind study of calcium and/or vitamin D in the secondary prevention of low trauma fractures. Age Ageing2005;34(Suppl 2):ii15. GrantA , on behalf of the RECORD Trial Group. Prevention of low-trauma fractures in older people [author reply]. Lancet2005;366(9485):543-4. GrantAM , AndersonFH , for the RECORD Trial Group. The Medical Research Council RECORD Trial: an evaluation of calcium and/or vitamin D in the secondary prevention of osteoporotic fractures. Osteoporosis International2004;15(Suppl 2):S13. GrantAM , AndersonFH . The RECORD trial: an evaluation of calcium and/or vitamin D in the secondary prevention of osteoporotic fractures. Osteoporosis International2005;16(Suppl 3):S4-5. GrantAM , AvenellA , CampbellMK , McDonaldAM , MacLennanGS , McPhersonGC , et al. Oral vitamin D3 and calcium for secondary prevention of low-trauma fractures in elderly people (Randomised Evaluation of Calcium Or vitamin D, RECORD): a randomised placebo-controlled trial [comment in: Lancet 2005;366(9485):543]. Lancet2005;365(9471):1621-8. GrantAM . Personal communication 11 March 2004. ">RECORD 2005</a>). </p> <p>The second group of 21 smaller trials of calcitriol or alfacalcidol ‐ almost all of which recruited from referral populations with established osteoporosis ‐ were carried out in the setting of institutional referral clinics or hospitals. In the majority of cases, osteoporosis had been formally diagnosed, and often the presence of one or more deformed vertebrae on an initial radiograph was required for inclusion in the trial. None of this group of trials had participants with a mean or median age of 80 years or more. </p> <p>It is unclear whether the effectiveness of vitamin D and calcium found in the nursing home trials in France by <a href="./references#CD000227-bbs2-0008" title="ChapuyMC , ArlotM , et al. Prevention of non vertebral fractures and cortical bone loss in elderly women: a prospective controlled trial using calcium and vitamin D3 supplements [abstract]. Osteoporosis International1993;3 Suppl 1:258. ChapuyMC , ArlotME , DelmasPD , MeunierPJ . Effect of calcium and cholecalciferol treatment for three years on hip fractures in elderly women. BMJ1994;308:1081-2. ChapuyMC , ArlotME , DuboeufF , BrunJ , CrouzetB , ArnaudS , et al. Vitamin D3 and calcium to prevent hip fractures in elderly women. New England Journal of Medicine1992;327:1637-42. MeunierPJ , PamphileR , ChapuyMC , SchultenJ , ArlotM , LilluH . A calcium-vitamin D3 combined supplementation is cost-saving for preventing hip fractures in institutionalised elderly women: an economic evaluation from the perspective of seven European countries (Belgium, France, Germany, The Netherlands, Spain, Sweden, United Kingdom). Osteoporosis International2002;13(Suppl 1):S14. ">Chapuy 1992</a> and <a href="./references#CD000227-bbs2-0009" title="BosworthC , deBoerIH , TargherG , KendrickJ , SmitsG , ChoncholM . The effect of combined calcium and cholecalciferol supplementation on bone mineral density in elderly women with moderate chronic kidney disease. Clinical Nephrology2012;77(5):358-65. ChapuyMC , PamphileR , ParisE , KempfC , SchlichtingM , ArnaudS , et al. Combined calcium and vitamin D3 supplementation in elderly women: confirmation of reversal of secondary hyperparathyroidism and hip fracture risk: the Decalyos II study. Osteoporosis International2002;13(3):257-64. [MEDLINE: 11991447]ChapuyMC , PamphileR , ParisE , KempfC , SchlichtingM , ArnaudS , et al. Combined calcium and vitamin D3 supplementation to prevent hip fracture in elderly women. A confirmatory study: Decalyos II. Osteoporosis International2002;13(Suppl 1):S25. MeunierPJ . Personal communication 28 February 2005. ">Chapuy 2002</a> is transferable to other institutional populations in other countries. Further trials in similar settings in other countries would be valuable, although the adoption of use of vitamin D and calcium in these settings, based on these two studies, might raise ethical issues and make further placebo‐controlled trials difficult to carry out. There is also suggestion that the focus be shifted from high‐dose supplementary calcium to dietary calcium in the calcium/vitamin D supplementation regime, given the evidence provided by <a href="./references#CD000227-bbs2-0144" title="BollandMJ , AvenellA , BaronJA , GreyA , MacLennanGS , GambleGD , et al. Effect of calcium supplementation on the risk of myocardial infarction and cardiovascular events: a meta-analysis. BMJ2010;341:c3691.">Bolland 2010</a> and <a href="./references#CD000227-bbs2-0145" title="BollandMJ , GreyA , AvenellA , GambleGD , ReidIR . Calcium supplements with or without vitamin D and risk of cardiovascular events: reanalysis of the Women's Health Initiative limited access dataset and meta-analysis. BMJ2011;342:d2040.">Bolland 2011a</a> of increased cardiovascular disease with oral calcium supplementation, with or without co‐supplementation with vitamin D, especially in those who are calcium‐replete in their diet. </p> <p><a href="#CD000227-tbl-0005">Table 4</a> gives the baseline 25(OH)D levels in the intervention and control groups of the included studies. The values have to be interpreted with caution, since they depend on the laboratory and method used (<a href="./references#CD000227-bbs2-0177" title="LipsP , ChapuyMC , Dawson-HughesB , PolsHA , HolickMF . An international comparison of serum 25-hydroxyvitamin D measurements. Osteoporosis International1999;9:394-7.">Lips 1999</a>). It might be expected that those people with the lowest 25(OH)D levels would benefit most from supplementation, and there is some suggestion of this in <a href="./references#CD000227-bbs2-0008" title="ChapuyMC , ArlotM , et al. Prevention of non vertebral fractures and cortical bone loss in elderly women: a prospective controlled trial using calcium and vitamin D3 supplements [abstract]. Osteoporosis International1993;3 Suppl 1:258. ChapuyMC , ArlotME , DelmasPD , MeunierPJ . Effect of calcium and cholecalciferol treatment for three years on hip fractures in elderly women. BMJ1994;308:1081-2. ChapuyMC , ArlotME , DuboeufF , BrunJ , CrouzetB , ArnaudS , et al. Vitamin D3 and calcium to prevent hip fractures in elderly women. New England Journal of Medicine1992;327:1637-42. MeunierPJ , PamphileR , ChapuyMC , SchultenJ , ArlotM , LilluH . A calcium-vitamin D3 combined supplementation is cost-saving for preventing hip fractures in institutionalised elderly women: an economic evaluation from the perspective of seven European countries (Belgium, France, Germany, The Netherlands, Spain, Sweden, United Kingdom). Osteoporosis International2002;13(Suppl 1):S14. ">Chapuy 1992</a> (25(OH)D of 40 nmol/L) and <a href="./references#CD000227-bbs2-0009" title="BosworthC , deBoerIH , TargherG , KendrickJ , SmitsG , ChoncholM . The effect of combined calcium and cholecalciferol supplementation on bone mineral density in elderly women with moderate chronic kidney disease. Clinical Nephrology2012;77(5):358-65. ChapuyMC , PamphileR , ParisE , KempfC , SchlichtingM , ArnaudS , et al. Combined calcium and vitamin D3 supplementation in elderly women: confirmation of reversal of secondary hyperparathyroidism and hip fracture risk: the Decalyos II study. Osteoporosis International2002;13(3):257-64. [MEDLINE: 11991447]ChapuyMC , PamphileR , ParisE , KempfC , SchlichtingM , ArnaudS , et al. Combined calcium and vitamin D3 supplementation to prevent hip fracture in elderly women. A confirmatory study: Decalyos II. Osteoporosis International2002;13(Suppl 1):S25. MeunierPJ . Personal communication 28 February 2005. ">Chapuy 2002</a> (22 nmol/L). <a href="./references#CD000227-bbs2-0029" title="GraafmansWC , OomsME , HofsteeHMA , BezemerPD , BouterLM , LipsP . Falls in the elderly: a prospective study of risk factors and risk profiles. American Journal of Epidemiology1996;143(11):1129-36. LipsP , GraafmansWC , OomsME , BezemerPD , BouterLM . The effect of vitamin D supplementation on the incidence of hip fractures in elderly people. Journal of Bone and Mineral Research1994;9 Suppl 1:S148. LipsP , GraafmansWC , OomsME , BezemerPD , BouterLM . Vitamin D supplementation and fracture incidence in elderly persons. Annals of Internal Medicine1996;124:400-6. [MEDLINE: 1996151943]">Lips 1996</a> (27 nmol/L) also had low values, but had a lower dose of supplementation of 400 IU vitamin D3 daily. The results of the <a href="./references#CD000227-bbs2-0044" title="AndersonFH , GrantAM , AvenellA , CampbellMK , CooperC , DonaldsonC , et al. The RECORD Trial: an evaluation of calcium and/or vitamin D in the secondary prevention of osteoporotic fractures. Bone2005;36(Suppl 2):S122-3. FrancisRM , Grant AM and the RECORD trial group. The RECORD trial: a randomised double-blind study of calcium and/or vitamin D in the secondary prevention of low trauma fractures. Age Ageing2005;34(Suppl 2):ii15. GrantA , on behalf of the RECORD Trial Group. Prevention of low-trauma fractures in older people [author reply]. Lancet2005;366(9485):543-4. GrantAM , AndersonFH , for the RECORD Trial Group. The Medical Research Council RECORD Trial: an evaluation of calcium and/or vitamin D in the secondary prevention of osteoporotic fractures. Osteoporosis International2004;15(Suppl 2):S13. GrantAM , AndersonFH . The RECORD trial: an evaluation of calcium and/or vitamin D in the secondary prevention of osteoporotic fractures. Osteoporosis International2005;16(Suppl 3):S4-5. GrantAM , AvenellA , CampbellMK , McDonaldAM , MacLennanGS , McPhersonGC , et al. Oral vitamin D3 and calcium for secondary prevention of low-trauma fractures in elderly people (Randomised Evaluation of Calcium Or vitamin D, RECORD): a randomised placebo-controlled trial [comment in: Lancet 2005;366(9485):543]. Lancet2005;365(9471):1621-8. GrantAM . Personal communication 11 March 2004. ">RECORD 2005</a> trial are somewhat contradictory, given the 25(OH)D3 level of 38 nmol/L. <a href="./references#CD000227-bbs2-0037" title="KarkkainenM , TuppurainenM , RikkonenT , SalovaaraK , SirolaJ , HonkanenR , et al. Vitamin-D 800IU/day + calcium 1000mg supplementation decreases the risk of recurrent falling among postmenopausal ambulatory women - a population-based, randomized, 3-year study (OSTPRE-FPS). Osteoporosis International2008;19(Suppl 1):S17-18. KarkkainenM , TuppurainenM , RikkonenT , SalovaaraK , SirolaJ , HonkanenR , et al. Vitamin-D 800IU/day + calcium supplementation decreases the risk of falling among postmenopausal ambulatory women - a population-based, randomized 3-year study (OSTPRE-FPS) [abstract]. Journal of Bone and Mineral Research2007;22(Suppl 1):S131. KarkkainenM , TuppurainenM , SalovaaraK , SandiniL , RikkonenT , SirolaJ , et al. Effect of calcium and vitamin D supplementation on bone mineral density in women aged 65-71 years: a 3-year randomized population-based trial (OSTPRE-FPS). Osteoporosis International2010;21:2047-55. KarkkainenMK , TuppurainenM , SalovaaraM , SandiniL , RikkonenT , SirolaJ , et al. Does daily vitamin D 800 IU and calcium 1000 mg supplementation decrease the risk of falling in ambulatory women aged 65-71 years? A 3-year randomized population-based trial (OSTPRE-FPS). Maturitas2010;65:359-65. KrogerHP , TuppurainenM . OSTPRE-FPS Prevention of Fractures and Falls in Postmenopausal Women With Calcium and Vitamin-D Supplementation - a Randomised Study. http://www.controlled-trials.com/mrct/trial/405493/OSTPRE. SalovaaraK , TuppurainenM , KarkkainenM , RikkonenT , SandiniL , SirolaJ , et al. Effect of vitamin D3 and calcium on fracture risk in 65- to 71-year-old women: a population-based 3-year randomized, controlled trial - the OSTPRE-FPS. Journal of Bone and Mineral Research2010;25(7):1487-95. SalovaaraKT , TuppurainenM , RikkonenT , KarkkainenM , SirolaJ , HonkanenR , et al. Effect of vitamin-D3 and calcium on fracture risk in 65-71 year old women in a 3-year randomized clinical trial - preliminary results from the OSTPRE-Fracture Prevention Study. Calcified Tissue International2008;82:545-6. SalovaaraKT , TuppurainenM , RikkonenT , KarkkainenM , SirolaJ , HonkanenR , et al. Effect of vitamin-D3 and calcium on fracture risk in 65-71 year old women in a 3-year randomized clinical trial - preliminary results of the OSTPRE-Fracture Prevention Study. Journal of Bone and Mineral Research2007;22(Suppl 1):S76. ">OSTPRE‐FPS 2007</a> and <a href="./references#CD000227-bbs2-0050" title="SandersK , DuqueG , EbelingP , McCorquodaleT , HerrmannM , Shore-LorentiC , et al. The efficacy of high-does oral vitamin D3 administered once a year: increased fracture risk is associated with 1,25 vitamin D level at 3-months post dose. In: ASBMR Annual Meeting; 2012 Oct 12-15; Minneapolis, Minnesota. http://www.asbmr.org/Meetings/AnnualMeeting/AbstractDetail.aspx?aid=6beb2500-4b8e-472b-8b38-d881cadb80e3. 2012. SandersK , StuartA , WilliamsonE , SimpsonJ , KotowiczM , NicholsonG . The efficacy of high-dose oral vitamin D3 administered once a year: a randomised, double-blind, placebo-controlled trial (Vital D study) for falls and fractures in older women. Osteoporosis International2011;22(Suppl 1):S104-5. SandersKM , DuqueG , McCorquodaleT , StuartAL , WilliamsonEJ , KotowiczMA , et al. Annual high-dose oral vitamin D3: is the increased risk of falls attributable to changes in muscle strength?Osteoporosis International2011;22(Suppl 4):S552. SandersKM , EbelingPR , StuartAL , WilliamsonEJ , KotowiczMA , NicholsonGC . Annual high-dose oral vitamin D3: is increased risk of fractures attributable to changes in bone turnover markers?Osteoporosis International2011;22(Suppl 4):S589. SandersKM , HaylesAL , KotowiczMA , NicholsonGC . Does vitamin D explain the lower fracture rate in rural communities?Bone2007;40(6 Suppl 2):S195. SandersKM , HaylesAL , KotowiczMA , NicholsonGC . The possible role of vitamin D and falls in relation to lower fracture rates in rural communities. Osteoporosis International2007;18(Suppl 1):S120-1. SandersKM , StuartAL , KotowiczMA , NicholsonGC . Annual feedback is an effective tool for a sustained increase in calcium intake among older women. Nutrients2010;2:1018-25. SandersKM , StuartAL , MerrimanEN , ReadML , KotowiczMA , YoungD , et al. Trials and tribulations of recruiting 2,000 older women onto a clinical trial investigating falls and fractures: Vital D study. BMC Medical Research Methodology2009;9:78. SandersKM , StuartAL , NicholsonGC . High-dose oral vitamin D supplementation and risk of falls in older women. JAMA2010;304(8):856-7. SandersKM , StuartAL , WilliamsonEJ , JackaFN , DoddS , NicholsonG , et al. Annual high-dose vitamin D3 and mental well-being: randomised controlled trial. British Journal of Psychiatry2011;198:357-64. SandersKM , StuartAL , WilliamsonEJ , SimpsonJA , KotowiczMA , NicholsonGC . Annual high-dose oral vitamin D for falls and fractures in elderly women: a randomised, double-blind, placebo-controlled trial (Vital D study). Osteoporosis International2010;21(Suppl 1):S30. SandersKM , StuartAL , WilliamsonEJ , SimpsonJA , KotowiczMA , YoungD , et al. Annual high-dose oral vitamin D and falls and fractures in older women. A randomized controlled trial. JAMA2010;303(18):1815-22. Sanders KM et al. Incorrect data. JAMA2010;303(23):2357. ">Vital D</a> had 25(OH)D levels in intervention groups of 50 nmol/L and 53 nmol/L, respectively. The statistically significant treatment effect for all fractures from the trial of <a href="./references#CD000227-bbs2-0010" title="Bischoff-FerrariHA , OravEJ , Dawson-HughesB . Additive effect of higher testosterone levels and vitamin D plus calcium supplementation in regard to fall risk reduction among older men and women. Osteoporosis International2008;19:1307-14. Bischoff-FerrariHA , OravEJ , Dawson-HughesB . Effect of cholecalciferol plus calcium on falling in ambulatory older men and women: a 3-year randomized controlled trial. Archives of Internal Medicine2006;166(4):424-30. Bischoff-FerrariHA , OravEJ , Dawson-HughesB . Effect of vitamin D3 plus calcium on fall risk in older men and women: a 3-year randomized controlled trial. Journal of Bone and Mineral Research2004;19(Suppl 1):S57. Dawson-HughesB , HarrisSS , KrallEA , DallalGE . Effect of calcium and vitamin D supplementation on bone density in men and women 65 years of age or older. New England Journal of Medicine1997;337(10):670-6. Dawson-HughesB , HarrisSS , KrallEA , DallalGE . Effect of withdrawal of calcium and vitamin D supplements on bone mass in elderly men and women. American Journal of Clinical Nutrition2000;72(3):745-50. Dawson-HughesB , HarrisSS . Calcium intake influences the association of protein intake with rates of bone loss in elderly men and women. American Journal of Clinical Nutrition2002;75(4):773-9. KrallEA , RandallC , HarrisSS , GarciaRI , Dawson-HughesB . Calcium and vitamin D supplements reduce tooth loss in the elderly. Journal of Bone and Mineral Research2000;15(Suppl 1):S191. KrallEA , WehlerC , GarciaRI , HarrisSS , Dawson-HughesB . Calcium and vitamin D supplements reduce tooth loss in the elderly. American Journal of Medicine2001;111(6):452-6. NiramitmahapanyaS , HarrisSS , Dawson-HughesB . Type of dietary fat is associated with the 25-hydroxyvitamin D3 increment in response to vitamin D supplementation. Journal of Clinical Endocrinology and Metabolism2011;96(10):3170-4. ">Dawson‐Hughes 1997</a> is also unusual given the high average baseline value of 77 nmol/L. </p> <p>Despite the ability of injection of vitamin D to reduce the winter decline in serum vitamin D concentrations (<a href="./references#CD000227-bbs2-0173" title="Khaw K-T, ScraggR , MurphyS . Single dose cholecalciferol suppresses the winter increase in parathyroid hormone concentrations in healthy older men and women: a randomized trial. American Journal of Clinical Nutrition1994;59:1040-4.">Khaw 1994</a>), and the apparently positive findings of <a href="./references#CD000227-bbs2-0048" title="TrivediDP , DollR , KhawKT . Effect of four monthly oral vitamin D3 (cholecalciferol) supplementation on fractures and mortality in men and women living in the community: randomised double blind controlled trial. BMJ2003;326:469. ">Trivedi 2003</a>, there is robust evidence that the administration of vitamin D alone, whether by annual injection, periodic bolus oral dosage, or daily oral dosage, is unlikely to be effective for fracture prevention in the doses used here. </p> </section> <section id="CD000227-sec-0087"> <h3 class="title" id="CD000227-sec-0087">Quality of the evidence</h3> <p>This review included a large body of evidence from 53 trials with 91,791 participants. Our assessments of risk of bias and quality assessment are presented in <a href="#CD000227-fig-0002">Figure 2</a>, <a href="#CD000227-fig-0003">Figure 3</a> and <a href="#CD000227-tbl-0007">Table 6</a>. There were only four trials with high risk of bias for random sequence generation and two trials with high risk for allocation concealment, and these had no influence on the findings for vitamin D or vitamin D and calcium trials. The evidence base from trials examining vitamin D alone versus placebo or no treatment, and vitamin D and calcium together versus placebo or no treatment was of high (“Further research is very unlikely to change our confidence in the estimate of effect”) or moderate quality (“Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.”). </p> </section> <section id="CD000227-sec-0088"> <h3 class="title" id="CD000227-sec-0088">Potential biases in the review process</h3> <p>We believe that selection bias is unlikely in this review. We have searched a wide range of databases and handsearched numerous relevant journals. We note, though, that we have identified 12 reports of studies that may, if further information becomes available, be eligible for inclusion. The contact author for the review is in touch with research groups in this field. Action was taken to minimise bias in the selection of studies for inclusion, and during the process of quality assessment and data extraction, as recommended in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD000227-bbs2-0162" title="HigginsJPT , Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.">Higgins 2011</a>). Authors who had participated in included trials (AA and WJG, a previous author) were not involved in the quality assessment or data extraction relating to those studies. </p> <p>However the reporting of adverse effects (Analyses 14.1 to 14.4) includes only RCTs in which vitamin D or vitamin D analogues had fracture data. Our search strategy was not designed to identify studies in which vitamin D was administered in studies with no fracture data. Nor would it have identified other study types that might have provided useful data on adverse effects. So, the data used in these analyses are incomplete, although there is no reason to suspect that they are not representative. </p> <p>Ascertainment bias cannot be completely ruled out. Incomplete information was available to us on the number of drop outs from intervention and control groups in a number of trials. Thus, it is possible that our analyses, based on the principles of intention‐to‐treat, might have under‐estimated the number of outcome events in the intervention or control groups, or both. </p> </section> <section id="CD000227-sec-0089"> <h3 class="title" id="CD000227-sec-0089">Agreements and disagreements with other studies or reviews</h3> <p>There have been a large number of recent trial level and individual patient data meta‐analyses of vitamin D, with or without calcium, for the prevention of fracture. The meta‐analyses (like those here) are limited by the small number of trials and limited combinations of treatments and doses, although this Cochrane review includes more trials than any of the previous systematic reviews. Most reported that calcium was required in addition to vitamin D for effectiveness (<a href="./references#CD000227-bbs2-0136" title="BergmanGJ , FanT , McFetridegeJT , SenSS . Efficacy of vitamin D3 supplementation in preventing fractures in elderly women: a meta-analysis. Current Medical Research and Opinion2010;26:1193-201.">Bergman 2010</a>; <a href="./references#CD000227-bbs2-0150" title="ChungM , LeeJ , TerasawaT , LauJ , TrikalinosTA . Vitamin D with and without calcium supplementation for prevention of cancer and fractures: an updated meta-analysis for the U.S. preventive services task force. Annals of Internal Medicine2011;155:827-38.">Chung 2011</a>; <a href="./references#CD000227-bbs2-0157" title="The DIPART (vitamin D Individual Patient Analysis of Randomized Trials) Group. Patient level pooled analysis of 68500 patients from seven major vitamin D fracture trials in US and Europe. BMJ2010;340:b5463.">DIPART 2010</a>; <a href="./references#CD000227-bbs2-0174" title="LaiJK , LucasRM , ClementsMS , RoddamAW , BanksE . Hip fracture risk in relation to vitamin D supplementation and serum 25-hydroxyvitamin D levels: a systematic review and meta-analysis of randomised controlled trials and observational studies. BMC Public Health2010;10:331.">Lai 2010</a>; <a href="./references#CD000227-bbs2-0181" title="MuradMH , DrakeMT , MullanRJ , MauckKF , StuartLM , LaneMA , et al. Comparative effectiveness of drug treatments to prevent fragility fractures: a systematic review and network meta-analysis. Journal of Clinical Endocrinology and Metabolism2012;97:1871-80.">Murad 2012</a>). However, Bischoff‐Ferrari and colleagues (<a href="./references#CD000227-bbs2-0139" title="Bischoff-FerrariHA , WillettWC , WongJB , StuckAE , StaehelinHB , OravJ , et al. Prevention of nonvertebral fractures with oral vitamin D and dose dependency. Archives of Internal Medicine2009;169:551-61.">Bischoff‐Ferrari 2009b</a>; <a href="./references#CD000227-bbs2-0141" title="Bischoff-FerrariHA , WillettWC , OravEJ , LipsP , MeunierPJ , LyonsRA , et al. A pooled analysis of vitamin dose requirements for fracture prevention. New England Journal of Medicine2012;367:40-9.">Bischoff‐Ferrari 2012</a>), in an attempt to correct for compliance and off‐study use of supplements, reported that calcium did not improve the anti‐fracture efficacy of vitamin D. <a href="./references#CD000227-bbs2-0141" title="Bischoff-FerrariHA , WillettWC , OravEJ , LipsP , MeunierPJ , LyonsRA , et al. A pooled analysis of vitamin dose requirements for fracture prevention. New England Journal of Medicine2012;367:40-9.">Bischoff‐Ferrari 2012</a> has been criticised for the methods used, including compromising the benefits of randomisation in the trials analysed (<a href="./references#CD000227-bbs2-0132" title="AbrahamsenB , AvenellA , BollandM , RejnmarkL , MacLennanGS , MacdonaldHM , et al. Commentary, a pooled analysis of vitamin D dose requirements for fracture prevention. BoneKEy2013;10:256.">Abrahamsen 2013</a>). </p> <p><a href="./references#CD000227-bbs2-0192" title="TangBM , EslickGD , NowsonC , SmithC , BensoussanA . Use of calcium or calcium in combination with vitamin D supplementation to prevent fractures and bone loss in people aged 50 years and older: a meta-analysis. Lancet2007;370:657-66.">Tang 2007</a> and colleagues undertook a systematic review of calcium, with and without vitamin D, in the prevention of fractures. The addition of vitamin D to calcium did not significantly change the effect of calcium alone. However, no meta‐analysis of trials with treatment arms of vitamin D and calcium compared with calcium was undertaken, as in our comparison (<a href="./references#CD000227-fig-0010" title="">Analysis 2.1</a>; <a href="./references#CD000227-fig-0011" title="">Analysis 2.2</a>; <a href="./references#CD000227-fig-0012" title="">Analysis 2.3</a>; <a href="./references#CD000227-fig-0013" title="">Analysis 2.4</a>), and we have included several newer trials. </p> <p>Fractures may result from falls, so we would draw readers' attention to two recent Cochrane reviews on prevention of falls in the community (<a href="./references#CD000227-bbs2-0160" title="GillespieLD , RobertsonMC , GillespieWJ , SherringtonC , GatesS , ClemsonLM , et al. Interventions for preventing falls in older people living in the community. Cochrane Database of Systematic Reviews2012, Issue 9. Art. No: CD007146. [DOI: 10.1002/14651858.CD007146.pub3]">Gillespie 2012</a>), and in institutions (<a href="./references#CD000227-bbs2-0147" title="CameronID , GillespieLD , RobertsonMC , MurrayGR , HillKD , CummingRG , et al. Interventions for preventing falls in older people in care facilities and hospitals. Cochrane Database of Systematic Reviews2012, Issue 12. Art. No: CD005465. [DOI: 10.1002/14651858.CD005465.pub3]">Cameron 2012</a>), which include many of the trials here. In the community, vitamin D with or without calcium may reduce the rate or risk of falls in people if they have lower 25(OH)D status (25 nmol/L to 55 nmol/L in the trials). In residents in institutions, vitamin D alone appeared to reduce the rate of falls, with two of the trials comparing vitamin D and calcium to calcium alone. Other systematic reviews have examined the effect of vitamin D in preventing falls (<a href="./references#CD000227-bbs2-0138" title="Bischoff-FerrariHA , Dawson-HughesB , StaehelinHB , OravJE , StuckAE , TheilerR , et al. Fall prevention with supplemental and active forms of vitamin D: a meta-analysis of randomised controlled trials. BMJ2009;339:b3692.">Bischoff‐Ferrari 2009a</a>; <a href="./references#CD000227-bbs2-0170" title="KalyaniRR , SteinB , ValiyilR , MannoR , MaynardJW , CrewsD . Vitamin D treatment for the prevention of falls in older adults. Journal of the American Geriatrics Society2010;58:1299-310.">Kalyani 2010</a>; <a href="./references#CD000227-bbs2-0180" title="MuradMH , ElaminKB , ElnourNO , ElaminMB , AlkatibAA , FatourechiMM , et al. The effect of vitamin D on falls: a systematic review and meta-analysis. Journal of Clinical Endocrinology and Metabolism2011;96:2997-3006.">Murad 2011</a>; <a href="./references#CD000227-bbs2-0184" title="O'DonnellS , MoherD , ThomasK , HanleyDA , CranneyA . Systematic review of the benefits and harms of calcitriol and alfacalcidol for fractures and falls. Journal of Bone and Mineral Metabolism2008;26:531-42.">O'Donnell 2008</a>), with some finding calcium was required too (<a href="./references#CD000227-bbs2-0170" title="KalyaniRR , SteinB , ValiyilR , MannoR , MaynardJW , CrewsD . Vitamin D treatment for the prevention of falls in older adults. Journal of the American Geriatrics Society2010;58:1299-310.">Kalyani 2010</a>; <a href="./references#CD000227-bbs2-0180" title="MuradMH , ElaminKB , ElnourNO , ElaminMB , AlkatibAA , FatourechiMM , et al. The effect of vitamin D on falls: a systematic review and meta-analysis. Journal of Clinical Endocrinology and Metabolism2011;96:2997-3006.">Murad 2011</a>), but this was not always clear (<a href="./references#CD000227-bbs2-0138" title="Bischoff-FerrariHA , Dawson-HughesB , StaehelinHB , OravJE , StuckAE , TheilerR , et al. Fall prevention with supplemental and active forms of vitamin D: a meta-analysis of randomised controlled trials. BMJ2009;339:b3692.">Bischoff‐Ferrari 2009a</a>). A systematic review by <a href="./references#CD000227-bbs2-0184" title="O'DonnellS , MoherD , ThomasK , HanleyDA , CranneyA . Systematic review of the benefits and harms of calcitriol and alfacalcidol for fractures and falls. Journal of Bone and Mineral Metabolism2008;26:531-42.">O'Donnell 2008</a> and colleagues reported that alfacalcidol or calcitriol could reduce the risk of experiencing one or more falls. </p> <p>In an individual patient data and trial‐level meta‐analysis of vitamin D with or without calcium, while vitamin D plus calcium was associated with a reduction in mortality, vitamin D alone was not (<a href="./references#CD000227-bbs2-0187" title="RejnmarkL , AvenellA , MasudT , AndersonF , MeyerHE , SandersKM , et al. Vitamin D with calcium reduces mortality: patient level pooled analysis of 70,528 patients from eight major vitamin D trials. Journal of Clinical Endocrinology and Metabolism2012;97:2670-81.">Rejnmark 2012</a>). An earlier systematic review of randomised trials found that vitamin D was associated with a reduced risk of mortality, which did not appear to relate to additional calcium provision (<a href="./references#CD000227-bbs2-0133" title="AutierP , GandiniS . Vitamin D supplementation and total mortality. A meta-analysis of randomized controlled trials. Archives of Internal Medicine2007;167(16):1730-7.">Autier 2007</a>). In the Cochrane review of vitamin D supplementation and mortality, cholecalciferol and calcium were associated with a reduction in mortality (RR 0.96, 95% CI 0.92 to 0.99), but cholecalciferol alone was not (RR 0.92, 95% CI 0.85 to 1.00) (<a href="./references#CD000227-bbs2-0142" title="BjelakovicG , GluudLL , NikolovaD , WhitfieldK , WetterslevJ , SimonettiRG , et al. Vitamin D supplementation for prevention of mortality in adults. Cochrane Database of Systematic Reviews2014, Issue 1. Art. No: CD007470. [DOI: 10.1002/14651858.CD007470.pub3]">Bjelakovic 2014</a>). </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD000227-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000227.pub4/media/CDSR/CD000227/urn:x-wiley:14651858:media:CD000227:CD000227-FIG-01" target="_blank"><b></b></a></p> </div><img alt="tudy flow diagram for the updated search (December 2012)" data-id="CD000227-fig-0001" src="/cdsr/doi/10.1002/14651858.CD000227.pub4/media/CDSR/CD000227/image_n/nCD000227-FIG-01.png"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000227.pub4/media/CDSR/CD000227/image_t/tCD000227-FIG-01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>tudy flow diagram for the updated search (December 2012)</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000227.pub4/full#CD000227-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000227.pub4/media/CDSR/CD000227/image_n/nCD000227-FIG-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000227-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000227.pub4/media/CDSR/CD000227/urn:x-wiley:14651858:media:CD000227:CD000227-FIG-02" target="_blank"><b></b></a></p> </div><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies" data-id="CD000227-fig-0002" src="/cdsr/doi/10.1002/14651858.CD000227.pub4/media/CDSR/CD000227/image_n/nCD000227-FIG-02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000227.pub4/media/CDSR/CD000227/image_t/tCD000227-FIG-02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000227.pub4/full#CD000227-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000227.pub4/media/CDSR/CD000227/image_n/nCD000227-FIG-02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000227-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000227.pub4/media/CDSR/CD000227/urn:x-wiley:14651858:media:CD000227:CD000227-FIG-03" target="_blank"><b></b></a></p> </div><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study" data-id="CD000227-fig-0003" src="/cdsr/doi/10.1002/14651858.CD000227.pub4/media/CDSR/CD000227/image_n/nCD000227-FIG-03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000227.pub4/media/CDSR/CD000227/image_t/tCD000227-FIG-03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000227.pub4/full#CD000227-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000227.pub4/media/CDSR/CD000227/image_n/nCD000227-FIG-03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000227-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000227.pub4/media/CDSR/CD000227/urn:x-wiley:14651858:media:CD000227:CD000227-FIG-04" target="_blank"><b></b></a></p> </div><img alt="Funnel plot of comparison: 1 Vitamin D [D2, D3 or 25(OH)D] versus control or placebo, outcome: 1.1 Persons sustaining new hip fracture" data-id="CD000227-fig-0004" src="/cdsr/doi/10.1002/14651858.CD000227.pub4/media/CDSR/CD000227/image_n/nCD000227-FIG-04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000227.pub4/media/CDSR/CD000227/image_t/tCD000227-FIG-04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 4</div> <div class="figure-caption"> <p>Funnel plot of comparison: 1 Vitamin D [D2, D3 or 25(OH)D] versus control or placebo, outcome: 1.1 Persons sustaining new hip fracture </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000227.pub4/full#CD000227-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000227.pub4/media/CDSR/CD000227/image_n/nCD000227-FIG-04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000227-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000227.pub4/media/CDSR/CD000227/urn:x-wiley:14651858:media:CD000227:CD000227-FIG-05" target="_blank"><b></b></a></p> </div><img alt="Funnel plot of comparison: 1 Vitamin D [D2, D3 or 25(OH)D] versus control or placebo, outcome: 1.4 Persons sustaining any new fracture" data-id="CD000227-fig-0005" src="/cdsr/doi/10.1002/14651858.CD000227.pub4/media/CDSR/CD000227/image_n/nCD000227-FIG-05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000227.pub4/media/CDSR/CD000227/image_t/tCD000227-FIG-05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 5</div> <div class="figure-caption"> <p>Funnel plot of comparison: 1 Vitamin D [D2, D3 or 25(OH)D] versus control or placebo, outcome: 1.4 Persons sustaining any new fracture </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000227.pub4/full#CD000227-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000227.pub4/media/CDSR/CD000227/image_n/nCD000227-FIG-05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000227-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000227.pub4/media/CDSR/CD000227/urn:x-wiley:14651858:media:CD000227:CD000227-CMP-001.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Vitamin D [D2, D3 or 25(OH)D] versus control or placebo, Outcome 1: Persons sustaining new hip fracture" data-id="CD000227-fig-0006" src="/cdsr/doi/10.1002/14651858.CD000227.pub4/media/CDSR/CD000227/image_n/nCD000227-CMP-001.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000227.pub4/media/CDSR/CD000227/image_t/tCD000227-CMP-001.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1: Vitamin D [D2, D3 or 25(OH)D] versus control or placebo, Outcome 1: Persons sustaining new hip fracture </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000227.pub4/references#CD000227-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000227.pub4/media/CDSR/CD000227/image_n/nCD000227-CMP-001.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000227-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000227.pub4/media/CDSR/CD000227/urn:x-wiley:14651858:media:CD000227:CD000227-CMP-001.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Vitamin D [D2, D3 or 25(OH)D] versus control or placebo, Outcome 2: Persons sustaining new non‐vertebral fracture" data-id="CD000227-fig-0007" src="/cdsr/doi/10.1002/14651858.CD000227.pub4/media/CDSR/CD000227/image_n/nCD000227-CMP-001.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000227.pub4/media/CDSR/CD000227/image_t/tCD000227-CMP-001.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1: Vitamin D [D2, D3 or 25(OH)D] versus control or placebo, Outcome 2: Persons sustaining new non‐vertebral fracture </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000227.pub4/references#CD000227-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000227.pub4/media/CDSR/CD000227/image_n/nCD000227-CMP-001.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000227-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000227.pub4/media/CDSR/CD000227/urn:x-wiley:14651858:media:CD000227:CD000227-CMP-001.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Vitamin D [D2, D3 or 25(OH)D] versus control or placebo, Outcome 3: Persons sustaining new vertebral fracture or deformity" data-id="CD000227-fig-0008" src="/cdsr/doi/10.1002/14651858.CD000227.pub4/media/CDSR/CD000227/image_n/nCD000227-CMP-001.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000227.pub4/media/CDSR/CD000227/image_t/tCD000227-CMP-001.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1: Vitamin D [D2, D3 or 25(OH)D] versus control or placebo, Outcome 3: Persons sustaining new vertebral fracture or deformity </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000227.pub4/references#CD000227-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000227.pub4/media/CDSR/CD000227/image_n/nCD000227-CMP-001.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000227-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000227.pub4/media/CDSR/CD000227/urn:x-wiley:14651858:media:CD000227:CD000227-CMP-001.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Vitamin D [D2, D3 or 25(OH)D] versus control or placebo, Outcome 4: Persons sustaining any new fracture" data-id="CD000227-fig-0009" src="/cdsr/doi/10.1002/14651858.CD000227.pub4/media/CDSR/CD000227/image_n/nCD000227-CMP-001.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000227.pub4/media/CDSR/CD000227/image_t/tCD000227-CMP-001.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.4</div> <div class="figure-caption"> <p>Comparison 1: Vitamin D [D2, D3 or 25(OH)D] versus control or placebo, Outcome 4: Persons sustaining any new fracture </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000227.pub4/references#CD000227-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000227.pub4/media/CDSR/CD000227/image_n/nCD000227-CMP-001.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000227-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000227.pub4/media/CDSR/CD000227/urn:x-wiley:14651858:media:CD000227:CD000227-CMP-002.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Vitamin D [D2, D3 or 25(OH)D] plus calcium versus calcium, Outcome 1: Persons sustaining new hip fracture" data-id="CD000227-fig-0010" src="/cdsr/doi/10.1002/14651858.CD000227.pub4/media/CDSR/CD000227/image_n/nCD000227-CMP-002.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000227.pub4/media/CDSR/CD000227/image_t/tCD000227-CMP-002.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.1</div> <div class="figure-caption"> <p>Comparison 2: Vitamin D [D2, D3 or 25(OH)D] plus calcium versus calcium, Outcome 1: Persons sustaining new hip fracture </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000227.pub4/references#CD000227-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000227.pub4/media/CDSR/CD000227/image_n/nCD000227-CMP-002.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000227-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000227.pub4/media/CDSR/CD000227/urn:x-wiley:14651858:media:CD000227:CD000227-CMP-002.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Vitamin D [D2, D3 or 25(OH)D] plus calcium versus calcium, Outcome 2: Persons sustaining new non‐vertebral fracture" data-id="CD000227-fig-0011" src="/cdsr/doi/10.1002/14651858.CD000227.pub4/media/CDSR/CD000227/image_n/nCD000227-CMP-002.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000227.pub4/media/CDSR/CD000227/image_t/tCD000227-CMP-002.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.2</div> <div class="figure-caption"> <p>Comparison 2: Vitamin D [D2, D3 or 25(OH)D] plus calcium versus calcium, Outcome 2: Persons sustaining new non‐vertebral fracture </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000227.pub4/references#CD000227-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000227.pub4/media/CDSR/CD000227/image_n/nCD000227-CMP-002.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000227-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000227.pub4/media/CDSR/CD000227/urn:x-wiley:14651858:media:CD000227:CD000227-CMP-002.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Vitamin D [D2, D3 or 25(OH)D] plus calcium versus calcium, Outcome 3: Persons sustaining new vertebral fracture" data-id="CD000227-fig-0012" src="/cdsr/doi/10.1002/14651858.CD000227.pub4/media/CDSR/CD000227/image_n/nCD000227-CMP-002.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000227.pub4/media/CDSR/CD000227/image_t/tCD000227-CMP-002.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.3</div> <div class="figure-caption"> <p>Comparison 2: Vitamin D [D2, D3 or 25(OH)D] plus calcium versus calcium, Outcome 3: Persons sustaining new vertebral fracture </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000227.pub4/references#CD000227-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000227.pub4/media/CDSR/CD000227/image_n/nCD000227-CMP-002.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000227-fig-0013"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000227.pub4/media/CDSR/CD000227/urn:x-wiley:14651858:media:CD000227:CD000227-CMP-002.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Vitamin D [D2, D3 or 25(OH)D] plus calcium versus calcium, Outcome 4: Persons sustaining any new fracture" data-id="CD000227-fig-0013" src="/cdsr/doi/10.1002/14651858.CD000227.pub4/media/CDSR/CD000227/image_n/nCD000227-CMP-002.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000227.pub4/media/CDSR/CD000227/image_t/tCD000227-CMP-002.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.4</div> <div class="figure-caption"> <p>Comparison 2: Vitamin D [D2, D3 or 25(OH)D] plus calcium versus calcium, Outcome 4: Persons sustaining any new fracture </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000227.pub4/references#CD000227-fig-0013">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000227.pub4/media/CDSR/CD000227/image_n/nCD000227-CMP-002.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000227-fig-0014"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000227.pub4/media/CDSR/CD000227/urn:x-wiley:14651858:media:CD000227:CD000227-CMP-003.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Vitamin D [D2, D3 or 25(OH)D] versus calcium, Outcome 1: Persons sustaining new hip fracture" data-id="CD000227-fig-0014" src="/cdsr/doi/10.1002/14651858.CD000227.pub4/media/CDSR/CD000227/image_n/nCD000227-CMP-003.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000227.pub4/media/CDSR/CD000227/image_t/tCD000227-CMP-003.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.1</div> <div class="figure-caption"> <p>Comparison 3: Vitamin D [D2, D3 or 25(OH)D] versus calcium, Outcome 1: Persons sustaining new hip fracture </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000227.pub4/references#CD000227-fig-0014">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000227.pub4/media/CDSR/CD000227/image_n/nCD000227-CMP-003.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000227-fig-0015"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000227.pub4/media/CDSR/CD000227/urn:x-wiley:14651858:media:CD000227:CD000227-CMP-003.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Vitamin D [D2, D3 or 25(OH)D] versus calcium, Outcome 2: Persons sustaining new non‐vertebral fracture" data-id="CD000227-fig-0015" src="/cdsr/doi/10.1002/14651858.CD000227.pub4/media/CDSR/CD000227/image_n/nCD000227-CMP-003.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000227.pub4/media/CDSR/CD000227/image_t/tCD000227-CMP-003.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.2</div> <div class="figure-caption"> <p>Comparison 3: Vitamin D [D2, D3 or 25(OH)D] versus calcium, Outcome 2: Persons sustaining new non‐vertebral fracture </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000227.pub4/references#CD000227-fig-0015">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000227.pub4/media/CDSR/CD000227/image_n/nCD000227-CMP-003.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000227-fig-0016"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000227.pub4/media/CDSR/CD000227/urn:x-wiley:14651858:media:CD000227:CD000227-CMP-003.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Vitamin D [D2, D3 or 25(OH)D] versus calcium, Outcome 3: Persons sustaining new vertebral fracture or deformity" data-id="CD000227-fig-0016" src="/cdsr/doi/10.1002/14651858.CD000227.pub4/media/CDSR/CD000227/image_n/nCD000227-CMP-003.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000227.pub4/media/CDSR/CD000227/image_t/tCD000227-CMP-003.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.3</div> <div class="figure-caption"> <p>Comparison 3: Vitamin D [D2, D3 or 25(OH)D] versus calcium, Outcome 3: Persons sustaining new vertebral fracture or deformity </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000227.pub4/references#CD000227-fig-0016">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000227.pub4/media/CDSR/CD000227/image_n/nCD000227-CMP-003.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000227-fig-0017"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000227.pub4/media/CDSR/CD000227/urn:x-wiley:14651858:media:CD000227:CD000227-CMP-003.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Vitamin D [D2, D3 or 25(OH)D] versus calcium, Outcome 4: Persons sustaining any new fracture" data-id="CD000227-fig-0017" src="/cdsr/doi/10.1002/14651858.CD000227.pub4/media/CDSR/CD000227/image_n/nCD000227-CMP-003.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000227.pub4/media/CDSR/CD000227/image_t/tCD000227-CMP-003.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.4</div> <div class="figure-caption"> <p>Comparison 3: Vitamin D [D2, D3 or 25(OH)D] versus calcium, Outcome 4: Persons sustaining any new fracture </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000227.pub4/references#CD000227-fig-0017">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000227.pub4/media/CDSR/CD000227/image_n/nCD000227-CMP-003.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000227-fig-0018"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000227.pub4/media/CDSR/CD000227/urn:x-wiley:14651858:media:CD000227:CD000227-CMP-004.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Vitamin D [D2, D3 or 25(OH)D] plus calcium versus control or placebo, Outcome 1: Persons sustaining new hip fracture" data-id="CD000227-fig-0018" src="/cdsr/doi/10.1002/14651858.CD000227.pub4/media/CDSR/CD000227/image_n/nCD000227-CMP-004.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000227.pub4/media/CDSR/CD000227/image_t/tCD000227-CMP-004.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.1</div> <div class="figure-caption"> <p>Comparison 4: Vitamin D [D2, D3 or 25(OH)D] plus calcium versus control or placebo, Outcome 1: Persons sustaining new hip fracture </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000227.pub4/references#CD000227-fig-0018">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000227.pub4/media/CDSR/CD000227/image_n/nCD000227-CMP-004.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000227-fig-0019"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000227.pub4/media/CDSR/CD000227/urn:x-wiley:14651858:media:CD000227:CD000227-CMP-004.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Vitamin D [D2, D3 or 25(OH)D] plus calcium versus control or placebo, Outcome 2: Persons sustaining new hip fracture: subgroup analysis by residential status (institution vs community)" data-id="CD000227-fig-0019" src="/cdsr/doi/10.1002/14651858.CD000227.pub4/media/CDSR/CD000227/image_n/nCD000227-CMP-004.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000227.pub4/media/CDSR/CD000227/image_t/tCD000227-CMP-004.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.2</div> <div class="figure-caption"> <p>Comparison 4: Vitamin D [D2, D3 or 25(OH)D] plus calcium versus control or placebo, Outcome 2: Persons sustaining new hip fracture: subgroup analysis by residential status (institution vs community) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000227.pub4/references#CD000227-fig-0019">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000227.pub4/media/CDSR/CD000227/image_n/nCD000227-CMP-004.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000227-fig-0020"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000227.pub4/media/CDSR/CD000227/urn:x-wiley:14651858:media:CD000227:CD000227-CMP-004.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Vitamin D [D2, D3 or 25(OH)D] plus calcium versus control or placebo, Outcome 3: Persons sustaining new non‐vertebral fracture" data-id="CD000227-fig-0020" src="/cdsr/doi/10.1002/14651858.CD000227.pub4/media/CDSR/CD000227/image_n/nCD000227-CMP-004.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000227.pub4/media/CDSR/CD000227/image_t/tCD000227-CMP-004.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.3</div> <div class="figure-caption"> <p>Comparison 4: Vitamin D [D2, D3 or 25(OH)D] plus calcium versus control or placebo, Outcome 3: Persons sustaining new non‐vertebral fracture </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000227.pub4/references#CD000227-fig-0020">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000227.pub4/media/CDSR/CD000227/image_n/nCD000227-CMP-004.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000227-fig-0021"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000227.pub4/media/CDSR/CD000227/urn:x-wiley:14651858:media:CD000227:CD000227-CMP-004.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Vitamin D [D2, D3 or 25(OH)D] plus calcium versus control or placebo, Outcome 4: Persons sustaining new vertebral fracture" data-id="CD000227-fig-0021" src="/cdsr/doi/10.1002/14651858.CD000227.pub4/media/CDSR/CD000227/image_n/nCD000227-CMP-004.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000227.pub4/media/CDSR/CD000227/image_t/tCD000227-CMP-004.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.4</div> <div class="figure-caption"> <p>Comparison 4: Vitamin D [D2, D3 or 25(OH)D] plus calcium versus control or placebo, Outcome 4: Persons sustaining new vertebral fracture </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000227.pub4/references#CD000227-fig-0021">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000227.pub4/media/CDSR/CD000227/image_n/nCD000227-CMP-004.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000227-fig-0022"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000227.pub4/media/CDSR/CD000227/urn:x-wiley:14651858:media:CD000227:CD000227-CMP-004.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Vitamin D [D2, D3 or 25(OH)D] plus calcium versus control or placebo, Outcome 5: Persons sustaining any new fracture" data-id="CD000227-fig-0022" src="/cdsr/doi/10.1002/14651858.CD000227.pub4/media/CDSR/CD000227/image_n/nCD000227-CMP-004.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000227.pub4/media/CDSR/CD000227/image_t/tCD000227-CMP-004.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.5</div> <div class="figure-caption"> <p>Comparison 4: Vitamin D [D2, D3 or 25(OH)D] plus calcium versus control or placebo, Outcome 5: Persons sustaining any new fracture </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000227.pub4/references#CD000227-fig-0022">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000227.pub4/media/CDSR/CD000227/image_n/nCD000227-CMP-004.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000227-fig-0023"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000227.pub4/media/CDSR/CD000227/urn:x-wiley:14651858:media:CD000227:CD000227-CMP-004.06" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Vitamin D [D2, D3 or 25(OH)D] plus calcium versus control or placebo, Outcome 6: Persons sustaining any new fracture: subgroup analysis by residential status (institution vs community)" data-id="CD000227-fig-0023" src="/cdsr/doi/10.1002/14651858.CD000227.pub4/media/CDSR/CD000227/image_n/nCD000227-CMP-004.06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000227.pub4/media/CDSR/CD000227/image_t/tCD000227-CMP-004.06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.6</div> <div class="figure-caption"> <p>Comparison 4: Vitamin D [D2, D3 or 25(OH)D] plus calcium versus control or placebo, Outcome 6: Persons sustaining any new fracture: subgroup analysis by residential status (institution vs community) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000227.pub4/references#CD000227-fig-0023">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000227.pub4/media/CDSR/CD000227/image_n/nCD000227-CMP-004.06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000227-fig-0024"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000227.pub4/media/CDSR/CD000227/urn:x-wiley:14651858:media:CD000227:CD000227-CMP-005.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: Alfacalcidol [1‐alpha(OH)D3] versus control or placebo, Outcome 1: Persons sustaining new non‐vertebral fracture" data-id="CD000227-fig-0024" src="/cdsr/doi/10.1002/14651858.CD000227.pub4/media/CDSR/CD000227/image_n/nCD000227-CMP-005.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000227.pub4/media/CDSR/CD000227/image_t/tCD000227-CMP-005.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.1</div> <div class="figure-caption"> <p>Comparison 5: Alfacalcidol [1‐alpha(OH)D3] versus control or placebo, Outcome 1: Persons sustaining new non‐vertebral fracture </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000227.pub4/references#CD000227-fig-0024">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000227.pub4/media/CDSR/CD000227/image_n/nCD000227-CMP-005.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000227-fig-0025"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000227.pub4/media/CDSR/CD000227/urn:x-wiley:14651858:media:CD000227:CD000227-CMP-005.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: Alfacalcidol [1‐alpha(OH)D3] versus control or placebo, Outcome 2: Persons sustaining new vertebral fracture" data-id="CD000227-fig-0025" src="/cdsr/doi/10.1002/14651858.CD000227.pub4/media/CDSR/CD000227/image_n/nCD000227-CMP-005.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000227.pub4/media/CDSR/CD000227/image_t/tCD000227-CMP-005.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.2</div> <div class="figure-caption"> <p>Comparison 5: Alfacalcidol [1‐alpha(OH)D3] versus control or placebo, Outcome 2: Persons sustaining new vertebral fracture </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000227.pub4/references#CD000227-fig-0025">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000227.pub4/media/CDSR/CD000227/image_n/nCD000227-CMP-005.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000227-fig-0026"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000227.pub4/media/CDSR/CD000227/urn:x-wiley:14651858:media:CD000227:CD000227-CMP-006.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 6: Alfacalcidol [1‐alpha(OH)D3] plus calcium versus calcium, Outcome 1: Persons sustaining new hip fracture" data-id="CD000227-fig-0026" src="/cdsr/doi/10.1002/14651858.CD000227.pub4/media/CDSR/CD000227/image_n/nCD000227-CMP-006.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000227.pub4/media/CDSR/CD000227/image_t/tCD000227-CMP-006.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.1</div> <div class="figure-caption"> <p>Comparison 6: Alfacalcidol [1‐alpha(OH)D3] plus calcium versus calcium, Outcome 1: Persons sustaining new hip fracture </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000227.pub4/references#CD000227-fig-0026">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000227.pub4/media/CDSR/CD000227/image_n/nCD000227-CMP-006.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000227-fig-0027"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000227.pub4/media/CDSR/CD000227/urn:x-wiley:14651858:media:CD000227:CD000227-CMP-006.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 6: Alfacalcidol [1‐alpha(OH)D3] plus calcium versus calcium, Outcome 2: Persons sustaining new vertebral deformity" data-id="CD000227-fig-0027" src="/cdsr/doi/10.1002/14651858.CD000227.pub4/media/CDSR/CD000227/image_n/nCD000227-CMP-006.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000227.pub4/media/CDSR/CD000227/image_t/tCD000227-CMP-006.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.2</div> <div class="figure-caption"> <p>Comparison 6: Alfacalcidol [1‐alpha(OH)D3] plus calcium versus calcium, Outcome 2: Persons sustaining new vertebral deformity </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000227.pub4/references#CD000227-fig-0027">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000227.pub4/media/CDSR/CD000227/image_n/nCD000227-CMP-006.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000227-fig-0028"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000227.pub4/media/CDSR/CD000227/urn:x-wiley:14651858:media:CD000227:CD000227-CMP-007.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 7: Alfacalcidol [1‐alpha(OH)D3] versus calcium, Outcome 1: Persons sustaining new vertebral deformity" data-id="CD000227-fig-0028" src="/cdsr/doi/10.1002/14651858.CD000227.pub4/media/CDSR/CD000227/image_n/nCD000227-CMP-007.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000227.pub4/media/CDSR/CD000227/image_t/tCD000227-CMP-007.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.1</div> <div class="figure-caption"> <p>Comparison 7: Alfacalcidol [1‐alpha(OH)D3] versus calcium, Outcome 1: Persons sustaining new vertebral deformity </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000227.pub4/references#CD000227-fig-0028">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000227.pub4/media/CDSR/CD000227/image_n/nCD000227-CMP-007.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000227-fig-0029"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000227.pub4/media/CDSR/CD000227/urn:x-wiley:14651858:media:CD000227:CD000227-CMP-008.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 8: Calcitriol [1,25(OH)2D3] versus control or placebo, Outcome 1: Persons sustaining new hip fracture" data-id="CD000227-fig-0029" src="/cdsr/doi/10.1002/14651858.CD000227.pub4/media/CDSR/CD000227/image_n/nCD000227-CMP-008.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000227.pub4/media/CDSR/CD000227/image_t/tCD000227-CMP-008.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.1</div> <div class="figure-caption"> <p>Comparison 8: Calcitriol [1,25(OH)<sub>2</sub>D3] versus control or placebo, Outcome 1: Persons sustaining new hip fracture </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000227.pub4/references#CD000227-fig-0029">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000227.pub4/media/CDSR/CD000227/image_n/nCD000227-CMP-008.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000227-fig-0030"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000227.pub4/media/CDSR/CD000227/urn:x-wiley:14651858:media:CD000227:CD000227-CMP-008.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 8: Calcitriol [1,25(OH)2D3] versus control or placebo, Outcome 2: Persons sustaining new non‐vertebral fracture" data-id="CD000227-fig-0030" src="/cdsr/doi/10.1002/14651858.CD000227.pub4/media/CDSR/CD000227/image_n/nCD000227-CMP-008.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000227.pub4/media/CDSR/CD000227/image_t/tCD000227-CMP-008.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.2</div> <div class="figure-caption"> <p>Comparison 8: Calcitriol [1,25(OH)<sub>2</sub>D3] versus control or placebo, Outcome 2: Persons sustaining new non‐vertebral fracture </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000227.pub4/references#CD000227-fig-0030">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000227.pub4/media/CDSR/CD000227/image_n/nCD000227-CMP-008.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000227-fig-0031"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000227.pub4/media/CDSR/CD000227/urn:x-wiley:14651858:media:CD000227:CD000227-CMP-008.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 8: Calcitriol [1,25(OH)2D3] versus control or placebo, Outcome 3: Persons sustaining new vertebral deformity" data-id="CD000227-fig-0031" src="/cdsr/doi/10.1002/14651858.CD000227.pub4/media/CDSR/CD000227/image_n/nCD000227-CMP-008.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000227.pub4/media/CDSR/CD000227/image_t/tCD000227-CMP-008.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.3</div> <div class="figure-caption"> <p>Comparison 8: Calcitriol [1,25(OH)<sub>2</sub>D3] versus control or placebo, Outcome 3: Persons sustaining new vertebral deformity </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000227.pub4/references#CD000227-fig-0031">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000227.pub4/media/CDSR/CD000227/image_n/nCD000227-CMP-008.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000227-fig-0032"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000227.pub4/media/CDSR/CD000227/urn:x-wiley:14651858:media:CD000227:CD000227-CMP-009.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 9: Calcitriol [1,25(OH)2D3] plus calcium versus calcium, Outcome 1: Persons sustaining new non‐vertebral fracture" data-id="CD000227-fig-0032" src="/cdsr/doi/10.1002/14651858.CD000227.pub4/media/CDSR/CD000227/image_n/nCD000227-CMP-009.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000227.pub4/media/CDSR/CD000227/image_t/tCD000227-CMP-009.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 9.1</div> <div class="figure-caption"> <p>Comparison 9: Calcitriol [1,25(OH)2D3] plus calcium versus calcium, Outcome 1: Persons sustaining new non‐vertebral fracture </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000227.pub4/references#CD000227-fig-0032">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000227.pub4/media/CDSR/CD000227/image_n/nCD000227-CMP-009.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000227-fig-0033"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000227.pub4/media/CDSR/CD000227/urn:x-wiley:14651858:media:CD000227:CD000227-CMP-009.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 9: Calcitriol [1,25(OH)2D3] plus calcium versus calcium, Outcome 2: Persons sustaining new vertebral deformity" data-id="CD000227-fig-0033" src="/cdsr/doi/10.1002/14651858.CD000227.pub4/media/CDSR/CD000227/image_n/nCD000227-CMP-009.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000227.pub4/media/CDSR/CD000227/image_t/tCD000227-CMP-009.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 9.2</div> <div class="figure-caption"> <p>Comparison 9: Calcitriol [1,25(OH)2D3] plus calcium versus calcium, Outcome 2: Persons sustaining new vertebral deformity </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000227.pub4/references#CD000227-fig-0033">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000227.pub4/media/CDSR/CD000227/image_n/nCD000227-CMP-009.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000227-fig-0034"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000227.pub4/media/CDSR/CD000227/urn:x-wiley:14651858:media:CD000227:CD000227-CMP-010.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 10: Calcitriol [1,25(OH)2D3] plus vitamin D plus calcium versus vitamin D plus calcium, Outcome 1: Persons sustaining new vertebral deformity" data-id="CD000227-fig-0034" src="/cdsr/doi/10.1002/14651858.CD000227.pub4/media/CDSR/CD000227/image_n/nCD000227-CMP-010.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000227.pub4/media/CDSR/CD000227/image_t/tCD000227-CMP-010.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 10.1</div> <div class="figure-caption"> <p>Comparison 10: Calcitriol [1,25(OH)<sub>2</sub>D3] plus vitamin D plus calcium versus vitamin D plus calcium, Outcome 1: Persons sustaining new vertebral deformity </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000227.pub4/references#CD000227-fig-0034">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000227.pub4/media/CDSR/CD000227/image_n/nCD000227-CMP-010.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000227-fig-0035"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000227.pub4/media/CDSR/CD000227/urn:x-wiley:14651858:media:CD000227:CD000227-CMP-011.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 11: Calcitriol [1,25(OH)2D3] versus calcium, Outcome 1: Persons sustaining new non‐vertebral fracture" data-id="CD000227-fig-0035" src="/cdsr/doi/10.1002/14651858.CD000227.pub4/media/CDSR/CD000227/image_n/nCD000227-CMP-011.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000227.pub4/media/CDSR/CD000227/image_t/tCD000227-CMP-011.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 11.1</div> <div class="figure-caption"> <p>Comparison 11: Calcitriol [1,25(OH)<sub>2</sub>D3] versus calcium, Outcome 1: Persons sustaining new non‐vertebral fracture </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000227.pub4/references#CD000227-fig-0035">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000227.pub4/media/CDSR/CD000227/image_n/nCD000227-CMP-011.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000227-fig-0036"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000227.pub4/media/CDSR/CD000227/urn:x-wiley:14651858:media:CD000227:CD000227-CMP-011.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 11: Calcitriol [1,25(OH)2D3] versus calcium, Outcome 2: Persons sustaining new vertebral deformity" data-id="CD000227-fig-0036" src="/cdsr/doi/10.1002/14651858.CD000227.pub4/media/CDSR/CD000227/image_n/nCD000227-CMP-011.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000227.pub4/media/CDSR/CD000227/image_t/tCD000227-CMP-011.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 11.2</div> <div class="figure-caption"> <p>Comparison 11: Calcitriol [1,25(OH)<sub>2</sub>D3] versus calcium, Outcome 2: Persons sustaining new vertebral deformity </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000227.pub4/references#CD000227-fig-0036">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000227.pub4/media/CDSR/CD000227/image_n/nCD000227-CMP-011.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000227-fig-0037"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000227.pub4/media/CDSR/CD000227/urn:x-wiley:14651858:media:CD000227:CD000227-CMP-011.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 11: Calcitriol [1,25(OH)2D3] versus calcium, Outcome 3: Persons sustaining new vertebral deformity in Tilyard study" data-id="CD000227-fig-0037" src="/cdsr/doi/10.1002/14651858.CD000227.pub4/media/CDSR/CD000227/image_n/nCD000227-CMP-011.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000227.pub4/media/CDSR/CD000227/image_t/tCD000227-CMP-011.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 11.3</div> <div class="figure-caption"> <p>Comparison 11: Calcitriol [1,25(OH)<sub>2</sub>D3] versus calcium, Outcome 3: Persons sustaining new vertebral deformity in Tilyard study </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000227.pub4/references#CD000227-fig-0037">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000227.pub4/media/CDSR/CD000227/image_n/nCD000227-CMP-011.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000227-fig-0038"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000227.pub4/media/CDSR/CD000227/urn:x-wiley:14651858:media:CD000227:CD000227-CMP-012.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 12: Calcitriol [1,25(OH)2D3] versus vitamin D (with or without calcium in each group), Outcome 1: Persons sustaining new non‐vertebral fracture" data-id="CD000227-fig-0038" src="/cdsr/doi/10.1002/14651858.CD000227.pub4/media/CDSR/CD000227/image_n/nCD000227-CMP-012.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000227.pub4/media/CDSR/CD000227/image_t/tCD000227-CMP-012.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 12.1</div> <div class="figure-caption"> <p>Comparison 12: Calcitriol [1,25(OH)<sub>2</sub>D3] versus vitamin D (with or without calcium in each group), Outcome 1: Persons sustaining new non‐vertebral fracture </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000227.pub4/references#CD000227-fig-0038">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000227.pub4/media/CDSR/CD000227/image_n/nCD000227-CMP-012.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000227-fig-0039"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000227.pub4/media/CDSR/CD000227/urn:x-wiley:14651858:media:CD000227:CD000227-CMP-012.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 12: Calcitriol [1,25(OH)2D3] versus vitamin D (with or without calcium in each group), Outcome 2: Persons sustaining new vertebral deformity" data-id="CD000227-fig-0039" src="/cdsr/doi/10.1002/14651858.CD000227.pub4/media/CDSR/CD000227/image_n/nCD000227-CMP-012.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000227.pub4/media/CDSR/CD000227/image_t/tCD000227-CMP-012.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 12.2</div> <div class="figure-caption"> <p>Comparison 12: Calcitriol [1,25(OH)<sub>2</sub>D3] versus vitamin D (with or without calcium in each group), Outcome 2: Persons sustaining new vertebral deformity </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000227.pub4/references#CD000227-fig-0039">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000227.pub4/media/CDSR/CD000227/image_n/nCD000227-CMP-012.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000227-fig-0040"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000227.pub4/media/CDSR/CD000227/urn:x-wiley:14651858:media:CD000227:CD000227-CMP-013.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 13: Vitamin D [D2, D3 or 25(OH)D] or any analogue with/without calcium: adverse effects, Outcome 1: Deaths" data-id="CD000227-fig-0040" src="/cdsr/doi/10.1002/14651858.CD000227.pub4/media/CDSR/CD000227/image_n/nCD000227-CMP-013.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000227.pub4/media/CDSR/CD000227/image_t/tCD000227-CMP-013.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 13.1</div> <div class="figure-caption"> <p>Comparison 13: Vitamin D [D2, D3 or 25(OH)D] or any analogue with/without calcium: adverse effects, Outcome 1: Deaths </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000227.pub4/references#CD000227-fig-0040">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000227.pub4/media/CDSR/CD000227/image_n/nCD000227-CMP-013.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000227-fig-0041"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000227.pub4/media/CDSR/CD000227/urn:x-wiley:14651858:media:CD000227:CD000227-CMP-013.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 13: Vitamin D [D2, D3 or 25(OH)D] or any analogue with/without calcium: adverse effects, Outcome 2: Persons with hypercalcaemia" data-id="CD000227-fig-0041" src="/cdsr/doi/10.1002/14651858.CD000227.pub4/media/CDSR/CD000227/image_n/nCD000227-CMP-013.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000227.pub4/media/CDSR/CD000227/image_t/tCD000227-CMP-013.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 13.2</div> <div class="figure-caption"> <p>Comparison 13: Vitamin D [D2, D3 or 25(OH)D] or any analogue with/without calcium: adverse effects, Outcome 2: Persons with hypercalcaemia </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000227.pub4/references#CD000227-fig-0041">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000227.pub4/media/CDSR/CD000227/image_n/nCD000227-CMP-013.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000227-fig-0042"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000227.pub4/media/CDSR/CD000227/urn:x-wiley:14651858:media:CD000227:CD000227-CMP-013.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 13: Vitamin D [D2, D3 or 25(OH)D] or any analogue with/without calcium: adverse effects, Outcome 3: Persons with gastrointestinal effects" data-id="CD000227-fig-0042" src="/cdsr/doi/10.1002/14651858.CD000227.pub4/media/CDSR/CD000227/image_n/nCD000227-CMP-013.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000227.pub4/media/CDSR/CD000227/image_t/tCD000227-CMP-013.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 13.3</div> <div class="figure-caption"> <p>Comparison 13: Vitamin D [D2, D3 or 25(OH)D] or any analogue with/without calcium: adverse effects, Outcome 3: Persons with gastrointestinal effects </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000227.pub4/references#CD000227-fig-0042">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000227.pub4/media/CDSR/CD000227/image_n/nCD000227-CMP-013.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000227-fig-0043"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000227.pub4/media/CDSR/CD000227/urn:x-wiley:14651858:media:CD000227:CD000227-CMP-013.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 13: Vitamin D [D2, D3 or 25(OH)D] or any analogue with/without calcium: adverse effects, Outcome 4: Persons with renal disease (calculi or insufficiency)" data-id="CD000227-fig-0043" src="/cdsr/doi/10.1002/14651858.CD000227.pub4/media/CDSR/CD000227/image_n/nCD000227-CMP-013.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000227.pub4/media/CDSR/CD000227/image_t/tCD000227-CMP-013.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 13.4</div> <div class="figure-caption"> <p>Comparison 13: Vitamin D [D2, D3 or 25(OH)D] or any analogue with/without calcium: adverse effects, Outcome 4: Persons with renal disease (calculi or insufficiency) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000227.pub4/references#CD000227-fig-0043">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000227.pub4/media/CDSR/CD000227/image_n/nCD000227-CMP-013.04.svg" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD000227-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Vitamin D [D2, D3 or 25(OH)D] plus calcium compared with control or placebo for preventing fractures in older people</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Vitamin D (D2, D3 or 25(OH)D) plus calcium compared with control or placebo for preventing fractures in older people</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> post‐menopausal women and older people at risk of osteoporotic fractures </p> <p><b>Settings:</b> community or institutional </p> <p><b>Intervention:</b> vitamin D (D2, D3 or 25(OH)D) plus calcium </p> <p><b>Comparison:</b> control or placebo </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>No of Participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Quality of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Comments</b> </p> <p><b>Notes on assessment of the quality</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Assumed risk</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Corresponding risk</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>No vitamin D plus calcium</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Vitamin D plus calcium</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Persons sustaining new hip fracture</b> </p> <p>(1 year estimate)<sup>1</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Lower risk population</b><sup>2</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 0.84</b> (0.74 to 0.96) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>49,853 participants<br/>(9 trials) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊕⊕<br/><b>high</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>8 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>7 per 1000</b><br/>(6 to 8) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>High risk population</b><sup>3</sup> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>54 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>45 per 1000</b><br/>(40 to 52) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Persons sustaining new non‐vertebral fracture</b> </p> <p>(1 year estimate)<sup>1</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Overall population</b><sup>4</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR</b> <b>0.86</b> </p> <p>(0.78 to 0.96)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>10,380 participants</p> <p>(8 trials)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊕<br/><b>high</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>39 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>34 per 1000</b><br/>(30 to 37) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Persons sustaining new vertebral fracture or deformity</b> </p> <p>(1 year estimate)<sup>1</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Overall population</b><sup>5</sup> (see notes) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR</b> <b>0.89</b> </p> <p>(0.74 to 1.09)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>42,185 participants</p> <p>(4 trials)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/><b>moderate</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Variation and difficulties in the diagnosis and definition of vertebral fractures means that estimates of control risk are likely to be very provisional (and probably underestimates). This also reduces the quality of this evidence, downgraded to moderate evidence </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>2 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>2 per 1000</b><br/>(1 to 2) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Persons sustaining any new fracture</b> </p> <p>(1 year estimate)<sup>1</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Lower risk population</b><sup>6</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 0.95</b> </p> <p>(0.90 to 0.99)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>49,976</p> <p>participants</p> <p>(10 trials)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊕⊕<br/><b>high</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>26 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>25 per 1000</b><br/>(23 to 26) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>High risk population</b><sup>7</sup> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>75 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>71 per 1000</b><br/>(68 to 74) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Persons with hypercalcaemia ‐ Vitamin D (D2, D3 or 25(OH)D) plus calcium</b> </p> <p>(1 year estimate)<sup>1</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Overall population</b><sup>8</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 3.29</b> </p> <p>(0.37 to 29.14)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>3853 participants</p> <p>(2 trials)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/><b>low</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Downgraded for imprecision: confidence interval (0.37 to 29.14) crosses line of no effect </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>4 per 10,000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>13 per 10,000</b> </p> <p>(1 to 117)</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Persons with renal disease (calculi or insufficiency) ‐ Vitamin D (D2, D3 or 25(OH)D) plus calcium</b> </p> <p>(1 year estimate)<sup>1</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Overall population</b><sup>9</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 1.17</b> </p> <p>(1.03 to 1.34)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>39,552 participants<br/>(2 trials) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊕<br/><b>high</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>These data are dominated by the WHI 2006 trial, which had a 7 year follow‐up. As noted, the risk of some complications are unlikely to be uniform over time </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>8 per 10,000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>9 per 10,000</b><br/>(8 to 11) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Deaths ‐ Vitamin D (D2, D3, 25(OH)D) plus calcium</b> </p> <p>(1 year estimate)<sup>1</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Overall population</b><sup>10</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 0.94</b><br/>(0.87 to 1.02) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>46,794 participants<br/>(6 trials) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊕<br/><b>high</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>A similar overall result was found when data were pooled from 29 trials</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>57 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>54 per 1000</b><br/>(50 to 58) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in the footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><b>CI:</b> Confidence interval; <b>RR:</b> Risk Ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/><b>High quality:</b> further research is very unlikely to change our confidence in the estimate of effect<br/><b>Moderate quality:</b> further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate<br/><b>Low quality:</b> further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate<br/><b>Very low quality:</b> we are very uncertain about the estimate </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p>1. The included studies had different follow‐ups. All estimates are calculated for 1 year follow‐up. However, the risk of some outcomes may not be uniform over time </p> <p>2. Control group risk derived from median control group data across community residence studies testing vitamin D [D2, D3 or 25(OH)D] plus calcium; plus data from community studies reported in the Gillespie 2010 Cochrane review: Gillespie WJ, Gillespie LD, Parker MJ. Hip protectors for preventing hip fractures in older people. Cochrane Database of Systematic Reviews 2010, Issue 10. Art. No.: CD001255. DOI: 10.1002/14651858.CD001255.pub4 </p> <p>3. Control group risk derived from median control group data across institutional residence studies testing vitamin D [D2, D3 or 25(OH)D] plus calcium; plus data from institutional studies reported in Gillespie 2010 </p> <p>4. Control group risk derived from median control group across studies testing vitamin D [D2, D3 or 25(OH)D] alone and trials testing vitamin D [D2, D3 or 25(OH)D] plus calcium </p> <p>5. Control group risk derived from median control group across studies testing vitamin D [D2, D3 or 25(OH)D] plus calcium </p> <p>6. Control group risk derived from median control group data across community residence studies testing vitamin D [D2, D3 or 25(OH)D] plus calcium </p> <p>7. Control group risk derived from median control group data across institutional residence studies testing vitamin D [D2, D3 or 25(OH)D] plus calcium </p> <p>8. Control group risk derived from median control group across studies testing vitamin D [D2, D3 or 25(OH)D] alone. Five of 10 trials in this group and the two trials (Chapuy 1992 and Chapuy 2002) reporting on hypercalcaemia, reported no events in the control group </p> <p>9. Control group risk derived from median control group across studies testing vitamin D [D2, D3 or 25(OH)D] alone and trials testing vitamin D [D2, D3 or 25(OH)D] plus calcium </p> <p>10. Control group risk derived from median control group across studies testing vitamin D [D2, D3 or 25(OH)D] alone and trials testing vitamin D [D2, D3 or 25(OH)D] plus calcium </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Vitamin D [D2, D3 or 25(OH)D] plus calcium compared with control or placebo for preventing fractures in older people</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD000227.pub4/full#CD000227-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD000227-tbl-0002"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Vitamin D nomenclature, synonyms and abbreviations</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Vitamin D</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Synonyms</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Graph abbreviations</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Vitamin D: two forms are vitamin D2 and vitamin D3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Vitamin D2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Ergocalciferol</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>D2</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Vitamin D3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Cholecalciferol</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>D3</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>25‐hydroxy vitamin D: vitamin D with one hydroxyl group added equivalent to liver activation </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Calcidiol</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>25(OH)D</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1‐alphahydroxyvitamin D3*: vitamin D with one hydroxyl group added equivalent to renal activation </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Alfacalcidol</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1‐alpha(OH)D3</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1,25‐dihydroxyvitamin D3*: vitamin D with two hydroxyl groups added equivalent to both liver and renal activation </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Calcitriol</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1,25(OH)<sub>2</sub>D3 </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>24R,25(OH)<sub>2</sub> vitamin D3*: vitamin D with two hydroxyl groups added equivalent to both liver and renal activation </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> </tbody> <tfoot> <tr> <td colspan="3"> <div class="table-footnote"> <p>* denotes analogues/derivatives<br/>Ca: abbreviation for calcium in graphs </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Vitamin D nomenclature, synonyms and abbreviations</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD000227.pub4/full#CD000227-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD000227-tbl-0003"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Quality assessment items and possible scores</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Items</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Scores</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Item B</b><br/>Were the outcomes of participants who withdrew or were excluded after allocation described and included in an "intention‐to‐treat" analysis? </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Score 2</b> if adequate detail of withdrawals and exclusions after randomisation exists, and an intention‐to‐treat analysis has been, or can be carried out<br/><br/><b>Score 1</b> if number and reasons for withdrawal are mentioned but intention to treat analysis is not possible<br/><br/><b>Score 0</b> if inadequate detail exists to allow the author to check or carry out an intention to treat analysis, or obvious differences with no adjustment </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Item C</b><br/>Were the outcome assessors blind to assignment status? </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Score 2</b> if blinding of all possible outcome assessors is clearly established<br/><br/><b>Score 1</b> if there is a small or moderate chance of unblinding of assessors, or some but not other assessors who could have been blinded were blinded<br/><br/><b>Score 0</b> if no attempt to blind assessors to the assignment of treatment is reported </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Item D</b><br/>Were the treatment and control group comparable at entry? </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Score 2</b> if groups are demonstrably comparable in respect of potential confounding factors on inspection of the characteristics on entry (means with some expression of the variation e.g. SD, SE, confidence intervals are required), or differences between groups adjusted for in the analysis (stratification, Mantel‐Haenszel technique, logistic regression, multiple regression, multivariable techniques)<br/><br/><b>Score 1</b> if confounding appears small: although noted, adjustment has not been made<br/><br/><b>Score 0</b> if description of the treatment groups at baseline, either in text or table, is inadequate to confirm comparability for all plausibly important confounders, or statistically significant differences between the groups are present but no adjustment has been made in the analysis </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Item E</b><br/>Were the subjects blind to assignment status following allocation? </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Score 2</b> if effective action has been taken to blind participants to assignment<br/><br/><b>Score 1</b> if in a drug study, or in a study comparing a physical modality with a control, it is unclear whether participants were made aware, or could have become aware, of their assignment prior to measurement of outcomes, or the nature of the trial intervention is such that it is unlikely that they will have effects which allow identification of assignment (e.g. calcium supplements versus placebo)<br/><br/><b>Score 0</b> if in a drug study, no treatment rather than a placebo is used, or in a placebo‐controlled drug study or in a study of comparable physical modalities, participants became aware of their allocation before outcome assessment and analysis </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Item F</b><br/>Were the providers of care blind to assignment status? </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Score 2</b> if the study is clearly double or triple blind<br/><br/><b>Score 1</b> if it is unclear whether the treatment providers were blinded to the allocation<br/><br/><b>Score 0</b> if in a placebo controlled drug trial, the providers of care were informed of the treatment allocation before outcome assessment and analysis, or a physical modality was used in one or more arms of the trial </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Item G</b><br/>Were the care programmes, other than the trial options, identical? </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Score 2</b> if it is clear that the care programmes other than the trial interventions were identical<br/><br/><b>Score 1</b> if differences between the programmes are trivial </p> <p><b>Score 0</b> if the nature of the care programmes other than the trial interventions is unclear, or there are important differences between the programmes offered, other than the trial interventions </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Item H</b><br/>Were the inclusion and exclusion criteria for entry clearly defined? </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Score 2</b> if the inclusion and exclusion criteria are clearly defined and indicate that individuals currently exposed to a trial intervention were excluded e.g. vitamin D analogue, hormone replacement therapy<br/><br/><b>Score 1</b> if the inclusion and exclusion criteria as described allow the possibility that individuals may have entered the study currently exposed to a trial intervention, or description of the inclusion and exclusion criteria is inadequate to determine how the sample was made up<br/><br/><b>Score 0</b> if no description, other than age and gender, of inclusion and exclusion criteria was provided </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Item J</b><br/>Was the ascertainment of fractures and other outcomes active and of clinically appropriate duration? </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Score 2</b> if some form of concurrent collection of data about fracture e.g. subjects given postcards to mail back etc., with confirmation by interview, and by radiograph if positive, or, for vertebral fracture, routine confirmation by radiograph<br/><br/><b>Score 1</b> if contact was made on a regular basis e.g. 6‐monthly phone call to establish if fracture had occurred or not, with confirmation by radiograph if positive<br/><br/><b>Score 0</b> if fracture was registered as an outcome without confirmation by radiograph </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="2"> <div class="table-footnote"> <p>Item A, which considered allocation concealment, was removed as this now forms part of the risk of bias assessment </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Quality assessment items and possible scores</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD000227.pub4/full#CD000227-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD000227-tbl-0004"> <div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Characteristics of studies in comparisons 1 to 4</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Comparison 1: Vitamin D [D2, D3 or 25(OH)D] versus control or placebo</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Trial name in decreasing order of size</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Number recruited</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Setting</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Previous fracture Y/N</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Male or female?</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Mean/median age</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD000227-bbs2-0046" title="AndersonFH , SmithHE , RaphaelHM , CooperC . Intramuscular vitamin D increased serum 1,25-dihydroxycholecalciferol but did not affect 25-hydroxy-cholecalciferol levels in health older adults [abstract]. Journal of Bone and Mineral Research2000;15(Suppl 1):S315. AndersonFH , SmithHE , RaphaelHM , CrozierSR , CooperC . Effect of annual intramuscular vitamin D3 supplementation on fracture risk in 9440 community-living older people: the Wessex fracture prevention trial [abstract]. Journal of Bone and Mineral Research2004;19(Suppl 1):S57. ArdenNK , CrozierS , SmithH , AndersonF , EdwardsC , RaphaelH , et al. Knee pain, knee osteoarthritis, and the risk of fracture. Arthritis and Rheumatism2006;55(4):610-5. CooperC , CrozierS . Personal communication 23 February 2005. RaphaelH , SmithH , AndersonF , CooperC . Tackling the problems of trial management in primary care - experience from the Wessex research network fracture prevention study of annual vitamin D injection in older people [abstract]. Osteoporosis International2000;11(Suppl 1):S63-4. SmithH , AndersonF , RaphaelH , CooperC . The Wessex research network fracture prevention study - a large pragmatic trial of annual vitamin D injection in older people [abstract]. Osteoporosis International2000;11(Suppl 1):S64. SmithH , AndersonF , RaphaelH , CrozierS , CooperC . Effect of annual intramuscular vitamin D supplementation on fracture risk: population-based, randomised, double-blind, placebo-controlled trial [abstract]. Osteoporosis International2004;15(Suppl 1):S8. SmithH , AndersonF , RaphaelH , MaslinP , CrozierS , CooperC . Effect of annual intramuscular vitamin D on fracture risk in elderly men and women--a population-based, randomized, double-blind, placebo-controlled trial. Rheumatology2007;46(12):1852-7. ">Smith 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9440</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Multicentre general practice study in 111 sites, UK</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N</p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Both (4354 women, 5086 men)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>79</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000227-bbs2-0044" title="AndersonFH , GrantAM , AvenellA , CampbellMK , CooperC , DonaldsonC , et al. The RECORD Trial: an evaluation of calcium and/or vitamin D in the secondary prevention of osteoporotic fractures. Bone2005;36(Suppl 2):S122-3. FrancisRM , Grant AM and the RECORD trial group. The RECORD trial: a randomised double-blind study of calcium and/or vitamin D in the secondary prevention of low trauma fractures. Age Ageing2005;34(Suppl 2):ii15. GrantA , on behalf of the RECORD Trial Group. Prevention of low-trauma fractures in older people [author reply]. Lancet2005;366(9485):543-4. GrantAM , AndersonFH , for the RECORD Trial Group. The Medical Research Council RECORD Trial: an evaluation of calcium and/or vitamin D in the secondary prevention of osteoporotic fractures. Osteoporosis International2004;15(Suppl 2):S13. GrantAM , AndersonFH . The RECORD trial: an evaluation of calcium and/or vitamin D in the secondary prevention of osteoporotic fractures. Osteoporosis International2005;16(Suppl 3):S4-5. GrantAM , AvenellA , CampbellMK , McDonaldAM , MacLennanGS , McPhersonGC , et al. Oral vitamin D3 and calcium for secondary prevention of low-trauma fractures in elderly people (Randomised Evaluation of Calcium Or vitamin D, RECORD): a randomised placebo-controlled trial [comment in: Lancet 2005;366(9485):543]. Lancet2005;365(9471):1621-8. GrantAM . Personal communication 11 March 2004. ">RECORD 2005</a> </p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5292</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Community‐based study, UK</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p>Both (4481 women, 811 men)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>77</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD000227-bbs2-0028" title="LawM , MorrisJ , WithersH . Cholecalciferol, not ergocalciferol, should be used for vitamin D supplementation [author reply]. Age and Ageing2006;35(6):645. [MEDLINE: 16982666]LawM , MorrisJ , WithersH . Vitamin D supplementation and the prevention of fractures and falls. Reply. Age and Ageing2007;36(2):233. LawM , MorrisJ , WithersH . Vitamin D supplementation and the prevention of fractures and falls [author reply]. Age and Ageing2007;36(2):233. [MEDLINE: 17255084]LawM , WithersH , MorrisJ , AndersonF . Vitamin D supplementation and the prevention of fractures and falls: results of a randomised trial in elderly people in residential accommodation [comment in: Age and Ageing 2006;35(6):645 and Age and Ageing 2007;36(2):232-3]. Age and Ageing2006;35(5):482-6. ">Law 2006</a> </p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3717</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Clusters of participants in 30 bedded units in care homes or entire care home if small, UK </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N</p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Both (2825 women, 892 men)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>85</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD000227-bbs2-0030" title="JohansenA , LyonsRA , StoneM , BrophyS , NewcombeRG , PhillipsCJ , et al. Preventing fractures among older people living in institutional care: a randomised double blind placebo controlled trial of vitamin D supplementation [abstract]. Age and Ageing2006;35(Suppl 3):i41. LyonsRA , JohansenA , BrophyS , NewcombeRG , PhillipsCJ , LervyB , et al. Preventing fractures among older people living in institutional care: a pragmatic randomised double blind placebo controlled trial of vitamin D supplementation. Osteoporosis International2007;18(6):811-8. LyonsRA , JohansenA , StoneMD , BrophyS , NewcombeRG , PhilipsCJ , et al. Preventing fractures among older people living in institutional care: a randomised double blind placebo controlled trial of vitamin D supplementation [abstract]. Osteoporosis International2006;17(Suppl 3):372. ">Lyons 2007</a> </p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3440</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Residential homes (38%), nursing or dual‐registered home (55%), sheltered accommodation (7%), Wales </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N</p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Both (2624 women, 816 men)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>84</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD000227-bbs2-0048" title="TrivediDP , DollR , KhawKT . Effect of four monthly oral vitamin D3 (cholecalciferol) supplementation on fractures and mortality in men and women living in the community: randomised double blind controlled trial. BMJ2003;326:469. ">Trivedi 2003</a> </p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2686</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Community‐based study, UK</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N</p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Both (2037 men and 649 women)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>75</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD000227-bbs2-0029" title="GraafmansWC , OomsME , HofsteeHMA , BezemerPD , BouterLM , LipsP . Falls in the elderly: a prospective study of risk factors and risk profiles. American Journal of Epidemiology1996;143(11):1129-36. LipsP , GraafmansWC , OomsME , BezemerPD , BouterLM . The effect of vitamin D supplementation on the incidence of hip fractures in elderly people. Journal of Bone and Mineral Research1994;9 Suppl 1:S148. LipsP , GraafmansWC , OomsME , BezemerPD , BouterLM . Vitamin D supplementation and fracture incidence in elderly persons. Annals of Internal Medicine1996;124:400-6. [MEDLINE: 1996151943]">Lips 1996</a> </p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2578</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Community‐based study, The Netherlands</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N</p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Both (1916 women and 662 men)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>80</p> <p> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD000227-bbs2-0050" title="SandersK , DuqueG , EbelingP , McCorquodaleT , HerrmannM , Shore-LorentiC , et al. The efficacy of high-does oral vitamin D3 administered once a year: increased fracture risk is associated with 1,25 vitamin D level at 3-months post dose. In: ASBMR Annual Meeting; 2012 Oct 12-15; Minneapolis, Minnesota. http://www.asbmr.org/Meetings/AnnualMeeting/AbstractDetail.aspx?aid=6beb2500-4b8e-472b-8b38-d881cadb80e3. 2012. SandersK , StuartA , WilliamsonE , SimpsonJ , KotowiczM , NicholsonG . The efficacy of high-dose oral vitamin D3 administered once a year: a randomised, double-blind, placebo-controlled trial (Vital D study) for falls and fractures in older women. Osteoporosis International2011;22(Suppl 1):S104-5. SandersKM , DuqueG , McCorquodaleT , StuartAL , WilliamsonEJ , KotowiczMA , et al. Annual high-dose oral vitamin D3: is the increased risk of falls attributable to changes in muscle strength?Osteoporosis International2011;22(Suppl 4):S552. SandersKM , EbelingPR , StuartAL , WilliamsonEJ , KotowiczMA , NicholsonGC . Annual high-dose oral vitamin D3: is increased risk of fractures attributable to changes in bone turnover markers?Osteoporosis International2011;22(Suppl 4):S589. SandersKM , HaylesAL , KotowiczMA , NicholsonGC . Does vitamin D explain the lower fracture rate in rural communities?Bone2007;40(6 Suppl 2):S195. SandersKM , HaylesAL , KotowiczMA , NicholsonGC . The possible role of vitamin D and falls in relation to lower fracture rates in rural communities. Osteoporosis International2007;18(Suppl 1):S120-1. SandersKM , StuartAL , KotowiczMA , NicholsonGC . Annual feedback is an effective tool for a sustained increase in calcium intake among older women. Nutrients2010;2:1018-25. SandersKM , StuartAL , MerrimanEN , ReadML , KotowiczMA , YoungD , et al. Trials and tribulations of recruiting 2,000 older women onto a clinical trial investigating falls and fractures: Vital D study. BMC Medical Research Methodology2009;9:78. SandersKM , StuartAL , NicholsonGC . High-dose oral vitamin D supplementation and risk of falls in older women. JAMA2010;304(8):856-7. SandersKM , StuartAL , WilliamsonEJ , JackaFN , DoddS , NicholsonG , et al. Annual high-dose vitamin D3 and mental well-being: randomised controlled trial. British Journal of Psychiatry2011;198:357-64. SandersKM , StuartAL , WilliamsonEJ , SimpsonJA , KotowiczMA , NicholsonGC . Annual high-dose oral vitamin D for falls and fractures in elderly women: a randomised, double-blind, placebo-controlled trial (Vital D study). Osteoporosis International2010;21(Suppl 1):S30. SandersKM , StuartAL , WilliamsonEJ , SimpsonJA , KotowiczMA , YoungD , et al. Annual high-dose oral vitamin D and falls and fractures in older women. A randomized controlled trial. JAMA2010;303(18):1815-22. Sanders KM et al. Incorrect data. JAMA2010;303(23):2357. ">Vital D</a> </p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2258</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Community‐dwelling women in southern Victoria, Australia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Some</p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Women only</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>76</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD000227-bbs2-0032" title="MeyerHE , FalchJA , KvaavikE , SmedshaugGB , TverdalA , PedersenJI . Can vitamin D supplementation reduce the risk of fracture in the elderly? A randomised controlled trial. Osteoporosis International2000;11(Suppl 2):S114-5. MeyerHE , SmedshaugGB , KvaavikE , FalchJA , TverdalA , PedersenJI . Can vitamin D supplementation reduce the risk of fracture in the elderly? A randomized controlled trial. Journal of Bone and Mineral Research2002;17(4):709-15. SmedshaugGB , PedersenJI , MeyerHE . Can vitamin D supplementation improve grip strength in elderly nursing home residents? A double-blinded controlled trial. Scandinavian Journal of Food and Nutrition2007;51(2):74-8. ">Meyer 2002</a> </p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1144</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Nursing homes, Norway</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N</p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Both (868 women, 276 men)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>85</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD000227-bbs2-0020" title="GlendenningP , ZhuK , InderjeethC , HowatP , LewisJR , PrinceRL . Effects of three-monthly oral 150,000 IU cholecalciferol supplementation on falls, mobility, and muscle strength in older postmenopausal women: a randomized controlled trial. Journal of Bone and Mineral Research2012;27(1):170-6. ">Glendenning 2012</a> </p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>686</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Community living (from general practice or electoral role), Perth, Australia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N</p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Women only</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>77</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD000227-bbs2-0039" title="PeacockM , LiuG , CareyM , McClintockR , AmbrosiusW , HuiS , et al. Effect of calcium or 25OH vitamin D3 dietary supplementation on bone loss at the hip in men and women over the age of 60. Journal of Clinical Endocrinology and Metabolism2000;85:3011-9. ">Peacock 2000</a> </p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>438</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Community study, USA</p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N</p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Both (316 women, 122 men)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean age women 74 years, men 76 years</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD000227-bbs2-0053" title="WithamM . Can high-dose vitamin D supplementation reduce blood pressure and markers of cardiovascular risk in older people with isolated systolic hypertension? A randomised, double-blind, parallel group placebo controlled trial. http://www.controlled-trials.com/ISRCTN92186858/ (accessed 3 December 2013). WithamMD , PriceRJ , StruthersAD , DonnanPT , MessowM , FordI , et al. Vitamin D supplementation to reduce blood pressure in older patients with isolated systolic hypertension (VitDISH) - a randomised controlled trial. Personal communication ahead of publication 15 January 2013. ">Witham 2013</a> </p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>159</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Participants recruited from primary care, secondary care and the press, Scotland, UK </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N</p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Both (82 men, 77 women)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>77</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD000227-bbs2-0022" title="HarwoodRH , SahotaO , GaynorK , MasudT , HoskingD . A randomised, controlled comparison of different calcium and vitamin D supplementation regimens in elderly women after hip fracture: The Nottingham Neck of Femur (NoNOF) Study. Age and Ageing2004;33:45-51. [14695863]HarwoodRW . Personal communication 24 January 2003. SahotaO , HarwoodRH , GaynorK , MasudT , HoskingDJ . A randomised, controlled comparison of different calcium and vitamin D regimes: the NoNOF (Nottingham Neck of Femur) study. Osteoporosis International2003;14(Suppl 4):S10-11. ">Harwood 2004</a> </p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>150</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Community‐based study, UK</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Women only</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>81</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD000227-bbs2-0003" title="AvenellA , GrantAM , McGeeM , McPhersonG , CampbellMK , McGee MA for the RECORD Trial Management Group. The effects of an open design on trial participant recruitment, compliance and retention - a randomized controlled trial comparison with a blinded, placebo-controlled design. Clinical Trials Journal2004;1:490-8. AvenellA . Personal communication2005. ">Avenell 2004</a> </p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>134</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Community‐based study, UK</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Both (111 women, 23 men)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>78</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD000227-bbs2-0052" title="WithamMD , CrightonLJ , GillespieND , StruthersAD , McMurdoME . The effects of vitamin D supplementation on physical function and quality of life in older patients with heart failure. A randomized controlled trial. Circulation: Heart Failure2010;3:195-201. ">Witham 2010</a> </p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>105</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Participants recruited from primary and secondary care, Scotland, UK</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N</p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Both (69 men, 36 women)</p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>80</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD000227-bbs2-0033" title="MitriJ , Dawson-HughesB , HuFB , PittasAG . Effects of vitamin D and calcium supplementation on pancreatic β cell function, insulin sensitivity, and glycemia in adults at high risk of diabetes: the Calcium and Vitamin D for Diabetes Mellitus (CaDDM) randomized controlled trial. American Journal of Clinical Nutrition2011;94:486-94. ">Mitri 2011</a> </p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>92</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Community recruitment, Boston, USA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N</p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Both (47 women, 45 men)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>57</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Comparison 2: Vitamin D [D2, D3 or 25(OH)D] and calcium versus calcium</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Trial name in decreasing order of size</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Number recruited</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Setting</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Previous fracture Y/N</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Male or female?</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Mean/median age</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD000227-bbs2-0018" title="Garay LilloJ , ParrenoJ , GonzálezY , GonzálezJA . Geminis: a prospective, multicentric, randomised study to evaluate the effect of tricalcium phosphate versus tricalcium phosphate plus 25(OH) Vitamin D on the risk of fractures in older women [Géminis: Estudio prospectivo, multicéntrico y aleatori para valorar el efecto del Fosfato Tricálcico versus Fosfato Tricálcico + 25(OH) Vitamina D sobre el riesgo de fracturas en mujerioes ancianas.]. Geriátrika1997;13(6):24-8. ">Garay Lillo 1997</a> </p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6945</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Community‐based study, Spain</p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>N</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Women only</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not available</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD000227-bbs2-0044" title="AndersonFH , GrantAM , AvenellA , CampbellMK , CooperC , DonaldsonC , et al. The RECORD Trial: an evaluation of calcium and/or vitamin D in the secondary prevention of osteoporotic fractures. Bone2005;36(Suppl 2):S122-3. FrancisRM , Grant AM and the RECORD trial group. The RECORD trial: a randomised double-blind study of calcium and/or vitamin D in the secondary prevention of low trauma fractures. Age Ageing2005;34(Suppl 2):ii15. GrantA , on behalf of the RECORD Trial Group. Prevention of low-trauma fractures in older people [author reply]. Lancet2005;366(9485):543-4. GrantAM , AndersonFH , for the RECORD Trial Group. The Medical Research Council RECORD Trial: an evaluation of calcium and/or vitamin D in the secondary prevention of osteoporotic fractures. Osteoporosis International2004;15(Suppl 2):S13. GrantAM , AndersonFH . The RECORD trial: an evaluation of calcium and/or vitamin D in the secondary prevention of osteoporotic fractures. Osteoporosis International2005;16(Suppl 3):S4-5. GrantAM , AvenellA , CampbellMK , McDonaldAM , MacLennanGS , McPhersonGC , et al. Oral vitamin D3 and calcium for secondary prevention of low-trauma fractures in elderly people (Randomised Evaluation of Calcium Or vitamin D, RECORD): a randomised placebo-controlled trial [comment in: Lancet 2005;366(9485):543]. Lancet2005;365(9471):1621-8. GrantAM . Personal communication 11 March 2004. ">RECORD 2005</a> </p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5292</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Community‐based study, UK</p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Both (4481 women, 811 men)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>77</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD000227-bbs2-0014" title="FlickerL , MacInnisR , SteinM , SchererS , MeadK , NowsonC , et al. Should all older people in residential care receive vitamin D to prevent falls? Results of a randomised trial [abstract]. Journal of Bone and Mineral Research2004;19(Suppl 1):S99. FlickerL , MacInnisRJ , SteinMS , SchererSC , MeadKE , et al. Response letter to Dr. Gau et al. Journal of the American Geriatrics Society2006;54:1021-2. FlickerL , MacInnisRJ , SteinMS , SchererSC , MeadKE , NowsonCA , et al. Erratum. Journal of the American Geriatrics Society2012;60:1599. FlickerL , MacInnisRJ , SteinMS , SchererSC , MeadKE , NowsonCA , et al. Should older people in residential care receive vitamin D to prevent falls? Results of a randomized trial. Journal of the American Geriatrics Society2005;53(11):1881-8. FlickerL , MacInnisRJ , SteinMS , SchererSC , MeadKE , NowsonCA . Should all older people in residential care receive vitamin D to prevent falls? Results of a randomised trial. Journal of Bone and Mineral Research2004;19(Suppl 1):S99. FlickerL . Personal communication 7 January 2008. ">Flicker 2005</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>693</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>60 assisted living facilities and 89 nursing homes, Australia</p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>N</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Both (594 women, 31 men)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>83</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD000227-bbs2-0043" title="PrinceRL , AustinN , DevineA , DickIM , BruceD , ZhuK . Effects of ergocalciferol added to calcium on the risk of falls in elderly high-risk women. Archives of Internal Medicine2008;168(1):103-8. ZhuK , BruceD , AustinN , DevineA , EbelingPR , PrinceRL . Randomized controlled trial of the effects of calcium with or without vitamin D on bone structure and bone-related chemistry in elderly women with vitamin D insufficiency. Journal of Bone and Mineral Research2008;23(8):1343-8. ZhuK , DevineA , DickIM , WilsonSG , PrinceRL . Effects of calcium and vitamin D supplementation on hip bone mineral density and calcium-related analytes in elderly ambulatory Australian women: a five-year randomized controlled trial. Journal of Clinical Endocrinology and Metabolism2008;93(3):743-9. ">Prince 2008</a> </p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>302</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Community‐based study, Australia</p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>N</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Women only</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>77</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD000227-bbs2-0041" title="BollandMJ , GreyA . Different outcomes of meta-analyses and data inconsistency:response to comments by Pfeifer. Archives of Osteoporosis2015;10:43. BollandMJ , GreyA . Inconsistent data in text and tables. Osteoporosis International2015;26:2713. MinneHW , DobnigH , PfeiferM , SuppanK . Effects of vitamin D and calcium supplementation on falls and parameters of muscle function: a prospective, randomized, double-blind multicenter study [abstract]. Osteoporosis International2006;17(Suppl 2):S212. MinneHW , DobnigH , PfeiferM , SuppanK . Effects of vitamin D and calcium supplementation on falls and parameters of muscle-function - a prospective, randomized, double-blind multi-center study [abstract]. Osteoporosis International2006;17(Suppl 1):S21. PfeiferM , BegerowB , MinneHW , SuppanK , Fahrleitner-PammerA , DobnigH . Effects of a long-term vitamin D and calcium supplementation on falls and parameters of muscle function in community-dwelling older individuals. Osteoporosis International2009;20:315-22. PfeiferM , DobnigH , BegerowB , SuppanK . Effects of vitamin D and calcium supplementation on falls and parameters of muscle function: a prospective randomized, double-blind multi-centre study [abstract]. Journal of Bone and Mineral Research2004;19(Suppl 1):S58. PfeiferM , DobnigH , MinneHW , SuppanK . Effects of vitamin D and calcium supplementation on falls and parameters of muscle function - a prospective, randomized, double-blind multi-center study [abstract]. Osteoporosis International2005;16(Suppl 3):S45. PfeiferM . Different outcomes of meta-analyses and data inconsistency. Osteoporosis International2015;26:2715–2716. PfeiferM . Randomized controlled clinical trials and meta-analyses. Archives of Osteoporosis2015;10:42. ">Pfeifer 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>242</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Community‐based study, Austria and Germany</p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>N</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Both (181 women, 61 men)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>77</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD000227-bbs2-0006" title="BurleighE , McCollJ , PotterJ . Does vitamin D stop inpatients falling? A randomised controlled trial. Age and Ageing2007;36(5):507-13. ">Burleigh 2007</a> </p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>205</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Acute geriatric unit, Glasgow, Scotland, UK</p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>N</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Both (121 women, 84 men)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>83</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD000227-bbs2-0027" title="KomulainenM , KrogerH , TuppurainenMT , HeikkinenAM , AlhavaE , HonkanenR , et al. Prevention of femoral and lumbar bone loss with hormone replacement therapy and Vitamin D3 in early postmenopausal women: a population based 5-year randomized trial. Journal of Clinical Endocrinology and Metabolism1999;84(2):546-52. KomulainenM , KrogerH , TuppurainenMT , Keikkinen A-M, HonkanenR , SaarikoskiS , et al. Identification of early postmenopausal women with no bone response to HRT: results of a five-year clinical trial. Osteoporosis International2000;11:211-8. KomulainenMH , KrogerH , TuppurainenMT , Heikkinen A-M, AlhavaE , HonkanenR , et al. HRT and Vit D in prevention of non-vertebral fractures in postmenopausal women; a 5 year randomized trial. Maturitas1998;31(1):45-54. KomulainenMH . Personal communication 11 November 2004. ">Komulainen 1998</a> </p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>232</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Community‐based study, Finland</p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>N</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Women only</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>53</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD000227-bbs2-0040" title="MinneHW , PfeiferM , BegerowB , NachtigallD , HansenC . Vitamin D and calcium supplementation reduces falls in elderly women via improvement of body sway and normalisation of blood pressure; a prospective, randomized, and double-blind study. Osteoporosis International2000;11(Suppl 2):S115. PfeiferM , BegerowB , MinneHW , AbramsC , NachtigallD , HansenC . Effects of a short-term vitamin D and calcium supplementation on body sway and secondary hyperparathyroidism in elderly women. Journal of Bone and Mineral Research2000;15(6):1113-8. PfeiferM , BegerowB , NachtigallD , HansenC . Prevention of falls-related fractures: vitamin D reduces body sway in the elderly - a prospective, randomized, double blind study [abstract]. Bone1998;23(5 Suppl 1):1110. ">Pfeifer 2000</a> </p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>148</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Osteology clinic, Germany</p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>N</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Women only</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>75</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD000227-bbs2-0003" title="AvenellA , GrantAM , McGeeM , McPhersonG , CampbellMK , McGee MA for the RECORD Trial Management Group. The effects of an open design on trial participant recruitment, compliance and retention - a randomized controlled trial comparison with a blinded, placebo-controlled design. Clinical Trials Journal2004;1:490-8. AvenellA . Personal communication2005. ">Avenell 2004</a> </p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>134</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Community‐based study, UK</p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Both (111 women, 23 men)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>78</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD000227-bbs2-0004" title="Bischoff-FerrariHA , ConzelmannM , StahelinHB , DickW , CarpenterMG , AdkinAL , et al. Is fall prevention by vitamin D mediated by a change in postural or dynamic balance?Osteoporosis International2006;17(5):656-63. BischoffHA , StahelinHB , DickW , AkosR , KnechtM , SalisC , et al. Effects of vitamin D and calcium supplementation on falls: a randomized controlled trial. Journal of Bone and Mineral Research2003;18(2):343-51. [MEDLINE: 12568412]BischoffHA . Personal communication 13 July 2003. BischoffHA . Vitamin D deficiency in the elderly. Journal of Bone and Mineral Research2003;18(7):1343. [MEDLINE: 12854846]HeaneyR . Vitamin D depletion and effective calcium absorption. Journal of Bone and Mineral Research2003;18(7):1342. ">Bischoff 2003</a> </p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>122</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Two long‐stay geriatric care units, Switzerland</p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>N</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Women only</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>85</p> <p> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD000227-bbs2-0026" title="JanssenHC , SamsonMM , VerhaarHJ . Muscle strength and mobility in vitamin D-insufficient female geriatric patients: a randomized controlled trial on vitamin D and calcium supplementation. Aging Clinical and Experimental Research2010;22(1):78-84. ">Janssen 2010</a> </p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>70</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Outpatient clinic of the Department of Geriatric Medicine at the University Medical Centre, Utrecht, The Netherlands </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>N</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Women only</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>81</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Comparison 3: Vitamin D [D2, D3 or 25(OH)D] versus calcium</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Trial name in decreasing order of size</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Number recruited</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Setting</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Previous fracture Y/N</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Male or female?</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Mean/median age</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD000227-bbs2-0044" title="AndersonFH , GrantAM , AvenellA , CampbellMK , CooperC , DonaldsonC , et al. The RECORD Trial: an evaluation of calcium and/or vitamin D in the secondary prevention of osteoporotic fractures. Bone2005;36(Suppl 2):S122-3. FrancisRM , Grant AM and the RECORD trial group. The RECORD trial: a randomised double-blind study of calcium and/or vitamin D in the secondary prevention of low trauma fractures. Age Ageing2005;34(Suppl 2):ii15. GrantA , on behalf of the RECORD Trial Group. Prevention of low-trauma fractures in older people [author reply]. Lancet2005;366(9485):543-4. GrantAM , AndersonFH , for the RECORD Trial Group. The Medical Research Council RECORD Trial: an evaluation of calcium and/or vitamin D in the secondary prevention of osteoporotic fractures. Osteoporosis International2004;15(Suppl 2):S13. GrantAM , AndersonFH . The RECORD trial: an evaluation of calcium and/or vitamin D in the secondary prevention of osteoporotic fractures. Osteoporosis International2005;16(Suppl 3):S4-5. GrantAM , AvenellA , CampbellMK , McDonaldAM , MacLennanGS , McPhersonGC , et al. Oral vitamin D3 and calcium for secondary prevention of low-trauma fractures in elderly people (Randomised Evaluation of Calcium Or vitamin D, RECORD): a randomised placebo-controlled trial [comment in: Lancet 2005;366(9485):543]. Lancet2005;365(9471):1621-8. GrantAM . Personal communication 11 March 2004. ">RECORD 2005</a> </p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5292</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Community‐based study, UK</p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Both (4481 women, 811 men)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>77</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD000227-bbs2-0039" title="PeacockM , LiuG , CareyM , McClintockR , AmbrosiusW , HuiS , et al. Effect of calcium or 25OH vitamin D3 dietary supplementation on bone loss at the hip in men and women over the age of 60. Journal of Clinical Endocrinology and Metabolism2000;85:3011-9. ">Peacock 2000</a> </p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>438</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Community‐based study, USA</p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>N</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Both (316 women, 122 men)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean age women 74 years, men 76 years</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD000227-bbs2-0003" title="AvenellA , GrantAM , McGeeM , McPhersonG , CampbellMK , McGee MA for the RECORD Trial Management Group. The effects of an open design on trial participant recruitment, compliance and retention - a randomized controlled trial comparison with a blinded, placebo-controlled design. Clinical Trials Journal2004;1:490-8. AvenellA . Personal communication2005. ">Avenell 2004</a> </p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>134</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Community‐based study, UK</p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Both (111 women, 23 men)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>78</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD000227-bbs2-0033" title="MitriJ , Dawson-HughesB , HuFB , PittasAG . Effects of vitamin D and calcium supplementation on pancreatic β cell function, insulin sensitivity, and glycemia in adults at high risk of diabetes: the Calcium and Vitamin D for Diabetes Mellitus (CaDDM) randomized controlled trial. American Journal of Clinical Nutrition2011;94:486-94. ">Mitri 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>92</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Community‐based study, USA</p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>N</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Both (47 women, 45 men)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>57</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Comparison 4: Vitamin D [D2, D3 or 25(OH)D] and calcium versus control or placebo</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Trial name in decreasing order of size</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Number recruited</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Setting</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Previous fracture Y/N</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Male or female?</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Mean/median age</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD000227-bbs2-0051" title="CauleyJ , Wactawski-WendeJ , RobbinsJ , RodaboughR , ChenZ , JohnsonK , et al. The Women's Health Initiative (WHI) calcium and vitamin D supplementation trial: health outcomes 5 years after trial completion. ASBMR Annual Meeting; 2012 Oct 12-15; Minneapolis, Minnesota. http://www.asbmr.org/Meetings/AnnualMeeting/AbstractDetail.aspx?aid=6450bf3e-c670-4dc0-814c-8842e23cd80e (accessed 27 December 2012). CauleyJA , LaCroixA , WuL , LeeJ , HorowitzM , BauerD , et al. Serum 25 hydroxy vitamin D 25(OH) and the risk of hip fracture: the Women's Health Initiative (WHI). Journal of Bone and Mineral Research2007;22(Suppl 1):S57. ChenZ , BeckTJ , WrightNC , LaCroixAZ , CauleyJA , LewisCE , et al. The effect of calcium plus vitamin D supplement on hip geometric structures: results from the Women's Health Initiative CaD trial. Journal of Bone and Mineral Research2007;22(Suppl 1):S59. JacksonRD , LaCroixAZ , CauleyJA , McGowanJ . The Women's Health Initiative Calcium-Vitamin D Trial: overview and baseline characteristics of participants. Annals of Epidemiology2003;13:S98-106. JacksonRD , LaCroixAZ , GassM , WallaceRB , RobbinsJ , LewisCE , et al. Calcium plus vitamin D supplementation and the risk of fractures [erratum appears in New England Journal of Medicine 9 March 2006;354(10):1102]. New England Journal of Medicine2006;354(7):669-83. JacksonRD , WrightNC , BeckTJ , SherrillD , CauleyJA , LewisCE , et al. Calcium plus vitamin D supplementation has limited effects on femoral geometric strength in older postmenopausal women: the Women's Health Initiative. Calcified Tissue International2011;88:198-208. McGowanJA , JacksonRD , CauleyJA , LaCroixAZ . Calcium and vitamin D in the prevention of hip and other fractures: an update on the Women's Health Initiative CaD Trial. Journal of Bone and Mineral Research2002;17(Suppl 1):S477. The Women's Health Initiative Study Group. Design of the Women's Health Initiative clinical trial and observational study. Controlled Clinical Trials1998;19(1):61-109. ">WHI 2006</a> </p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>36,282</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Community based women, USA</p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>N</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Women only</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>62</p> <p> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000227-bbs2-0044" title="AndersonFH , GrantAM , AvenellA , CampbellMK , CooperC , DonaldsonC , et al. The RECORD Trial: an evaluation of calcium and/or vitamin D in the secondary prevention of osteoporotic fractures. Bone2005;36(Suppl 2):S122-3. FrancisRM , Grant AM and the RECORD trial group. The RECORD trial: a randomised double-blind study of calcium and/or vitamin D in the secondary prevention of low trauma fractures. Age Ageing2005;34(Suppl 2):ii15. GrantA , on behalf of the RECORD Trial Group. Prevention of low-trauma fractures in older people [author reply]. Lancet2005;366(9485):543-4. GrantAM , AndersonFH , for the RECORD Trial Group. The Medical Research Council RECORD Trial: an evaluation of calcium and/or vitamin D in the secondary prevention of osteoporotic fractures. Osteoporosis International2004;15(Suppl 2):S13. GrantAM , AndersonFH . The RECORD trial: an evaluation of calcium and/or vitamin D in the secondary prevention of osteoporotic fractures. Osteoporosis International2005;16(Suppl 3):S4-5. GrantAM , AvenellA , CampbellMK , McDonaldAM , MacLennanGS , McPhersonGC , et al. Oral vitamin D3 and calcium for secondary prevention of low-trauma fractures in elderly people (Randomised Evaluation of Calcium Or vitamin D, RECORD): a randomised placebo-controlled trial [comment in: Lancet 2005;366(9485):543]. Lancet2005;365(9471):1621-8. GrantAM . Personal communication 11 March 2004. ">RECORD 2005</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5292</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Community‐based study, UK</p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Both (4481 women, 811 men)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>77</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD000227-bbs2-0037" title="KarkkainenM , TuppurainenM , RikkonenT , SalovaaraK , SirolaJ , HonkanenR , et al. Vitamin-D 800IU/day + calcium 1000mg supplementation decreases the risk of recurrent falling among postmenopausal ambulatory women - a population-based, randomized, 3-year study (OSTPRE-FPS). Osteoporosis International2008;19(Suppl 1):S17-18. KarkkainenM , TuppurainenM , RikkonenT , SalovaaraK , SirolaJ , HonkanenR , et al. Vitamin-D 800IU/day + calcium supplementation decreases the risk of falling among postmenopausal ambulatory women - a population-based, randomized 3-year study (OSTPRE-FPS) [abstract]. Journal of Bone and Mineral Research2007;22(Suppl 1):S131. KarkkainenM , TuppurainenM , SalovaaraK , SandiniL , RikkonenT , SirolaJ , et al. Effect of calcium and vitamin D supplementation on bone mineral density in women aged 65-71 years: a 3-year randomized population-based trial (OSTPRE-FPS). Osteoporosis International2010;21:2047-55. KarkkainenMK , TuppurainenM , SalovaaraM , SandiniL , RikkonenT , SirolaJ , et al. Does daily vitamin D 800 IU and calcium 1000 mg supplementation decrease the risk of falling in ambulatory women aged 65-71 years? A 3-year randomized population-based trial (OSTPRE-FPS). Maturitas2010;65:359-65. KrogerHP , TuppurainenM . OSTPRE-FPS Prevention of Fractures and Falls in Postmenopausal Women With Calcium and Vitamin-D Supplementation - a Randomised Study. http://www.controlled-trials.com/mrct/trial/405493/OSTPRE. SalovaaraK , TuppurainenM , KarkkainenM , RikkonenT , SandiniL , SirolaJ , et al. Effect of vitamin D3 and calcium on fracture risk in 65- to 71-year-old women: a population-based 3-year randomized, controlled trial - the OSTPRE-FPS. Journal of Bone and Mineral Research2010;25(7):1487-95. SalovaaraKT , TuppurainenM , RikkonenT , KarkkainenM , SirolaJ , HonkanenR , et al. Effect of vitamin-D3 and calcium on fracture risk in 65-71 year old women in a 3-year randomized clinical trial - preliminary results from the OSTPRE-Fracture Prevention Study. Calcified Tissue International2008;82:545-6. SalovaaraKT , TuppurainenM , RikkonenT , KarkkainenM , SirolaJ , HonkanenR , et al. Effect of vitamin-D3 and calcium on fracture risk in 65-71 year old women in a 3-year randomized clinical trial - preliminary results of the OSTPRE-Fracture Prevention Study. Journal of Bone and Mineral Research2007;22(Suppl 1):S76. ">OSTPRE‐FPS 2007</a> </p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3195</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Population‐based sample, recruited by post, northern Savonia, Finland</p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>N</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Women only</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>67</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD000227-bbs2-0042" title="DumvilleJC , MilesJN , PorthouseJ , CockayneES , SaxonL , KingC , et al. Can vitamin D supplementation prevent seasonal affective disorder? A randomised trial among older women. Osteoporosis International2004;15:S42-3. PorthouseJ , CockayneS , KingC , SaxonL , SteeleE , AsprayT , et al. Randomised controlled trial of calcium and supplementation with cholecalciferol (vitamin D3) for prevention of fractures in primary care. BMJ2005;330(7498):1003-6. PorthouseJ , CockayneS , KingC , SaxonL , SteeleE , AsprayT , et al. Randomised controlled trial of calcium and vitamin D supplementation for fracture prevention in primary care. Osteoporosis International2004;15(Suppl 2):S13. PorthouseJ , CockayneS , KingC , SaxonL , SteeleE , AsprayT , et al. Randomised controlled trial of calcium and vitamin D supplementation for fracture prevention in primary care. Osteoporosis International2005;16:S27. PufferS . Calcium and vitamin D in primary care: adherence results from a randomised controlled trial [abstract 6.9.3]. In: RCN International Nursing Conference; 2004 Mar 21-31; Cambridge (UK). London: Royal College of Nursing, 2004. S Puffer, on behalf of the Calcium and Vitamin D Trial. Calcium and vitamin D in primary care. Compliance results from a randomised controlled trial. Osteoporosis International2003;14(Suppl 4):S8. TorgersonD , on behalf of the trial group. Calcium and vitamin D in preventing fractures [author reply]. BMJ2005;331(7508):109. TorgersonDJ . Personal communication 9-16 February 2005. ">Porthouse 2005</a> </p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3314</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Multicentre general practice study, UK</p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Some</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Women only</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>77</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD000227-bbs2-0008" title="ChapuyMC , ArlotM , et al. Prevention of non vertebral fractures and cortical bone loss in elderly women: a prospective controlled trial using calcium and vitamin D3 supplements [abstract]. Osteoporosis International1993;3 Suppl 1:258. ChapuyMC , ArlotME , DelmasPD , MeunierPJ . Effect of calcium and cholecalciferol treatment for three years on hip fractures in elderly women. BMJ1994;308:1081-2. ChapuyMC , ArlotME , DuboeufF , BrunJ , CrouzetB , ArnaudS , et al. Vitamin D3 and calcium to prevent hip fractures in elderly women. New England Journal of Medicine1992;327:1637-42. MeunierPJ , PamphileR , ChapuyMC , SchultenJ , ArlotM , LilluH . A calcium-vitamin D3 combined supplementation is cost-saving for preventing hip fractures in institutionalised elderly women: an economic evaluation from the perspective of seven European countries (Belgium, France, Germany, The Netherlands, Spain, Sweden, United Kingdom). Osteoporosis International2002;13(Suppl 1):S14. ">Chapuy 1992</a> </p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3270</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Residents of nursing homes or apartment houses for elderly people, France</p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>N</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Women only</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>84</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD000227-bbs2-0009" title="BosworthC , deBoerIH , TargherG , KendrickJ , SmitsG , ChoncholM . The effect of combined calcium and cholecalciferol supplementation on bone mineral density in elderly women with moderate chronic kidney disease. Clinical Nephrology2012;77(5):358-65. ChapuyMC , PamphileR , ParisE , KempfC , SchlichtingM , ArnaudS , et al. Combined calcium and vitamin D3 supplementation in elderly women: confirmation of reversal of secondary hyperparathyroidism and hip fracture risk: the Decalyos II study. Osteoporosis International2002;13(3):257-64. [MEDLINE: 11991447]ChapuyMC , PamphileR , ParisE , KempfC , SchlichtingM , ArnaudS , et al. Combined calcium and vitamin D3 supplementation to prevent hip fracture in elderly women. A confirmatory study: Decalyos II. Osteoporosis International2002;13(Suppl 1):S25. MeunierPJ . Personal communication 28 February 2005. ">Chapuy 2002</a> </p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>583</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Residents of 55 apartment houses for elderly people, France</p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>N</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Women only</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>85</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD000227-bbs2-0010" title="Bischoff-FerrariHA , OravEJ , Dawson-HughesB . Additive effect of higher testosterone levels and vitamin D plus calcium supplementation in regard to fall risk reduction among older men and women. Osteoporosis International2008;19:1307-14. Bischoff-FerrariHA , OravEJ , Dawson-HughesB . Effect of cholecalciferol plus calcium on falling in ambulatory older men and women: a 3-year randomized controlled trial. Archives of Internal Medicine2006;166(4):424-30. Bischoff-FerrariHA , OravEJ , Dawson-HughesB . Effect of vitamin D3 plus calcium on fall risk in older men and women: a 3-year randomized controlled trial. Journal of Bone and Mineral Research2004;19(Suppl 1):S57. Dawson-HughesB , HarrisSS , KrallEA , DallalGE . Effect of calcium and vitamin D supplementation on bone density in men and women 65 years of age or older. New England Journal of Medicine1997;337(10):670-6. Dawson-HughesB , HarrisSS , KrallEA , DallalGE . Effect of withdrawal of calcium and vitamin D supplements on bone mass in elderly men and women. American Journal of Clinical Nutrition2000;72(3):745-50. Dawson-HughesB , HarrisSS . Calcium intake influences the association of protein intake with rates of bone loss in elderly men and women. American Journal of Clinical Nutrition2002;75(4):773-9. KrallEA , RandallC , HarrisSS , GarciaRI , Dawson-HughesB . Calcium and vitamin D supplements reduce tooth loss in the elderly. Journal of Bone and Mineral Research2000;15(Suppl 1):S191. KrallEA , WehlerC , GarciaRI , HarrisSS , Dawson-HughesB . Calcium and vitamin D supplements reduce tooth loss in the elderly. American Journal of Medicine2001;111(6):452-6. NiramitmahapanyaS , HarrisSS , Dawson-HughesB . Type of dietary fat is associated with the 25-hydroxyvitamin D3 increment in response to vitamin D supplementation. Journal of Clinical Endocrinology and Metabolism2011;96(10):3170-4. ">Dawson‐Hughes 1997</a> </p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>445</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Community‐based study, USA</p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>N</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Both (199 men, 246 women</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>71</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD000227-bbs2-0022" title="HarwoodRH , SahotaO , GaynorK , MasudT , HoskingD . A randomised, controlled comparison of different calcium and vitamin D supplementation regimens in elderly women after hip fracture: The Nottingham Neck of Femur (NoNOF) Study. Age and Ageing2004;33:45-51. [14695863]HarwoodRW . Personal communication 24 January 2003. SahotaO , HarwoodRH , GaynorK , MasudT , HoskingDJ . A randomised, controlled comparison of different calcium and vitamin D regimes: the NoNOF (Nottingham Neck of Femur) study. Osteoporosis International2003;14(Suppl 4):S10-11. ">Harwood 2004</a> </p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>150</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Community‐based study, UK</p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Women only</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>81</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD000227-bbs2-0003" title="AvenellA , GrantAM , McGeeM , McPhersonG , CampbellMK , McGee MA for the RECORD Trial Management Group. The effects of an open design on trial participant recruitment, compliance and retention - a randomized controlled trial comparison with a blinded, placebo-controlled design. Clinical Trials Journal2004;1:490-8. AvenellA . Personal communication2005. ">Avenell 2004</a> </p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>134</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Community‐based study, UK</p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Both (111 women, 23 men)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>78</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Characteristics of studies in comparisons 1 to 4</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD000227.pub4/full#CD000227-tbl-0004">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD000227-tbl-0005"> <div class="table-heading"><span class="table-label">Table 4.</span> <span class="table-title">Baseline 25‐hydroxy vitamin D in intervention and control groups</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Study ID</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>25(OH)D nmol/L</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000227-bbs2-0001" title="AloiaJF , VaswaniA , YehJK , EllisK , YasumuraS , CohnSH . Calcitriol in the treatment of postmenopausal osteoporosis. American Journal of Medicine1988;84(3 Pt 1):401-8. AloiaJF . Role of calcitriol in the treatment of postmenopausal osteoporosis. Metabolism1990;39(4 Suppl 1):35-8. GallagherJC . Personal communication 21 February 1995. ">Aloia 1988</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Intervention 54.8 (SD 17.8); Control 66.5 (SD 29.3)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000227-bbs2-0002" title="ArthurRS , PirainoB , CandibD , CoopersteinL , ChenT , WestC , et al. Effect of low-dose calcitriol and calcium therapy on bone histomorphometry and urinary calcium excretion in osteopenic women. Mineral and Electrolyte Metabolism1990;16(6):385-90. [MEDLINE: 1991211662]">Arthur 1990</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Intervention 30 (SD 7.5); Control 52.5 (SD 22.5)* (Considerable difference between intervention and control) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000227-bbs2-0003" title="AvenellA , GrantAM , McGeeM , McPhersonG , CampbellMK , McGee MA for the RECORD Trial Management Group. The effects of an open design on trial participant recruitment, compliance and retention - a randomized controlled trial comparison with a blinded, placebo-controlled design. Clinical Trials Journal2004;1:490-8. AvenellA . Personal communication2005. ">Avenell 2004</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N/A</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000227-bbs2-0004" title="Bischoff-FerrariHA , ConzelmannM , StahelinHB , DickW , CarpenterMG , AdkinAL , et al. Is fall prevention by vitamin D mediated by a change in postural or dynamic balance?Osteoporosis International2006;17(5):656-63. BischoffHA , StahelinHB , DickW , AkosR , KnechtM , SalisC , et al. Effects of vitamin D and calcium supplementation on falls: a randomized controlled trial. Journal of Bone and Mineral Research2003;18(2):343-51. [MEDLINE: 12568412]BischoffHA . Personal communication 13 July 2003. BischoffHA . Vitamin D deficiency in the elderly. Journal of Bone and Mineral Research2003;18(7):1343. [MEDLINE: 12854846]HeaneyR . Vitamin D depletion and effective calcium absorption. Journal of Bone and Mineral Research2003;18(7):1342. ">Bischoff 2003</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Intervention 30.8 (interquartile range 23‐55); Control 29 (interquartile range 23‐55)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000227-bbs2-0005" title="Bolton-SmithC , McMurdoME , PatersonCR , MolePA , HarveyJM , FentonST , et al. Two-year randomized controlled trial of vitamin K1 (phylloquinone) and vitamin D3 plus calcium on bone health of older women. Journal of Bone and Mineral Research2007;22(4):509-19. McMurdoME . Personal communication 1 October 2007. ">Bolton‐Smith 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Intervention 62.5 (SD 15.5); Control 57 (15.3)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000227-bbs2-0006" title="BurleighE , McCollJ , PotterJ . Does vitamin D stop inpatients falling? A randomised controlled trial. Age and Ageing2007;36(5):507-13. ">Burleigh 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Intervention 21.7 (SD 7.1); Control 24.7 (SD 10.0)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000227-bbs2-0007" title="CaniggiaA , DellingG , NutiR , LoreF , VattimoA . Clinical, biochemical and histological results of a double-blind trial with 1,25-dihydroxyvitamin D3, estradiol and placebo in post-menopausal osteoporosis. Acta Vitaminologica et Enzymologica1984;6(2):117-28. ">Caniggia 1984</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N/A</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000227-bbs2-0008" title="ChapuyMC , ArlotM , et al. Prevention of non vertebral fractures and cortical bone loss in elderly women: a prospective controlled trial using calcium and vitamin D3 supplements [abstract]. Osteoporosis International1993;3 Suppl 1:258. ChapuyMC , ArlotME , DelmasPD , MeunierPJ . Effect of calcium and cholecalciferol treatment for three years on hip fractures in elderly women. BMJ1994;308:1081-2. ChapuyMC , ArlotME , DuboeufF , BrunJ , CrouzetB , ArnaudS , et al. Vitamin D3 and calcium to prevent hip fractures in elderly women. New England Journal of Medicine1992;327:1637-42. MeunierPJ , PamphileR , ChapuyMC , SchultenJ , ArlotM , LilluH . A calcium-vitamin D3 combined supplementation is cost-saving for preventing hip fractures in institutionalised elderly women: an economic evaluation from the perspective of seven European countries (Belgium, France, Germany, The Netherlands, Spain, Sweden, United Kingdom). Osteoporosis International2002;13(Suppl 1):S14. ">Chapuy 1992</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Intervention 40.0 (SD 27.5); Control 32.5 (SD 22.5) subgroups</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000227-bbs2-0009" title="BosworthC , deBoerIH , TargherG , KendrickJ , SmitsG , ChoncholM . The effect of combined calcium and cholecalciferol supplementation on bone mineral density in elderly women with moderate chronic kidney disease. Clinical Nephrology2012;77(5):358-65. ChapuyMC , PamphileR , ParisE , KempfC , SchlichtingM , ArnaudS , et al. Combined calcium and vitamin D3 supplementation in elderly women: confirmation of reversal of secondary hyperparathyroidism and hip fracture risk: the Decalyos II study. Osteoporosis International2002;13(3):257-64. [MEDLINE: 11991447]ChapuyMC , PamphileR , ParisE , KempfC , SchlichtingM , ArnaudS , et al. Combined calcium and vitamin D3 supplementation to prevent hip fracture in elderly women. A confirmatory study: Decalyos II. Osteoporosis International2002;13(Suppl 1):S25. MeunierPJ . Personal communication 28 February 2005. ">Chapuy 2002</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Intervention 21.3 (SD 13.3), 22.5 (SD 16.5); Control 22.8 (SD 17.3)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000227-bbs2-0010" title="Bischoff-FerrariHA , OravEJ , Dawson-HughesB . Additive effect of higher testosterone levels and vitamin D plus calcium supplementation in regard to fall risk reduction among older men and women. Osteoporosis International2008;19:1307-14. Bischoff-FerrariHA , OravEJ , Dawson-HughesB . Effect of cholecalciferol plus calcium on falling in ambulatory older men and women: a 3-year randomized controlled trial. Archives of Internal Medicine2006;166(4):424-30. Bischoff-FerrariHA , OravEJ , Dawson-HughesB . Effect of vitamin D3 plus calcium on fall risk in older men and women: a 3-year randomized controlled trial. Journal of Bone and Mineral Research2004;19(Suppl 1):S57. Dawson-HughesB , HarrisSS , KrallEA , DallalGE . Effect of calcium and vitamin D supplementation on bone density in men and women 65 years of age or older. New England Journal of Medicine1997;337(10):670-6. Dawson-HughesB , HarrisSS , KrallEA , DallalGE . Effect of withdrawal of calcium and vitamin D supplements on bone mass in elderly men and women. American Journal of Clinical Nutrition2000;72(3):745-50. Dawson-HughesB , HarrisSS . Calcium intake influences the association of protein intake with rates of bone loss in elderly men and women. American Journal of Clinical Nutrition2002;75(4):773-9. KrallEA , RandallC , HarrisSS , GarciaRI , Dawson-HughesB . Calcium and vitamin D supplements reduce tooth loss in the elderly. Journal of Bone and Mineral Research2000;15(Suppl 1):S191. KrallEA , WehlerC , GarciaRI , HarrisSS , Dawson-HughesB . Calcium and vitamin D supplements reduce tooth loss in the elderly. American Journal of Medicine2001;111(6):452-6. NiramitmahapanyaS , HarrisSS , Dawson-HughesB . Type of dietary fat is associated with the 25-hydroxyvitamin D3 increment in response to vitamin D supplementation. Journal of Clinical Endocrinology and Metabolism2011;96(10):3170-4. ">Dawson‐Hughes 1997</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Intervention 82.5 (SD 40.8) men, 71.8 (SD 33.3) women; Control 84.0 (SD 31.8) men, 61.3 (SD 25.8) women </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000227-bbs2-0011" title="DukasL , BischoffHA , LindpaintnerLS , SchachtE , Birkner-BinderD , DammTN , et al. Alfacalcidol reduces the number of fallers in a community-dwelling elderly population with a minimum calcium intake of more than 500 mg daily. Journal of the American Geriatrics Society2004;52(2):230-6. DukasL , BischoffHA , LindpaintnerLS , SchachtE , Birkner-BinderD , ThalmanB , et al. Alfacalcidol reduces the number of fallers and falls in community-dwelling elderly provided a minimum total daily intake of 500mg calcium [abstract]. Calcified Tissue International2003;72:371. DukasL , SchachtE , MazorZ , StahelinHB . Treatment with alfacalcidol in elderly people significantly decreases the high risk of falls associated with a low creatinine clearance of &lt;65 ml/min. Osteoporosis International2005;16(2):198-203. DukasL , SchachtE , StahelinHB . A significant independent new risk factor for falls in the elderly: a low creatinine clearance of less than 65ml/min. Osteoporosis International2003;14(Suppl 7):S33. DukasL , SchachtE , StahelinHB . High risk of falls related to low D-hormone syndrome and its treatment with alfacalcidol. Osteoporosis International2004;15(Suppl 1):S8-9. DukasL , SchachtE , StahelinHB . Reduction of falls and fallers in high risk patients by D-hormone analogs. Osteoporosis International2004;15(Suppl 1):S144-5. DukasL , SchachtE , StahelinHB . Treatment with alfacalcidol significantly decreases the high incidence of fallers and the high risk of falls associated with low creatinine clearance (&lt;65ml/min) in elderly community-dwelling men and women. Osteoporosis International2003;14(Suppl 7):S33. DukasL , SchachtE . Reduction of falls and fallers using D-hormone analogs. Osteoporosis International2006;17(Suppl 1):S122-3. DukasLC , SchachtE , MazorZ , StahelinHB . The low creatinine clearance associated high risk of falls can significantly be treated with alfacalcidol. Journal of Bone and Mineral Research2004;19(Suppl 1):S95. DukasLC . Personal communication 19 July 2004. ">Dukas 2004</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Intervention 98.8 (SD 30.0); Control 97.8 (SD 27.3)*</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000227-bbs2-0012" title="EbelingPR , WarkJD , YeungS , PoonC , SalehiN , NicholsonGC , et al. Effects of calcitriol or calcium on bone mineral density, bone turnover, and fractures in men with primary osteoporosis: a two-year randomized, double-blind, double placebo study. Journal of Clinical Endocrinology and Metabolism2001;86(9):4098-103. EbelingPR . Personal communication 15 February 2005. ">Ebeling 2001</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Intervention 91 (SD 42); Control 86 (27)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000227-bbs2-0013" title="FalchJA , OdegaardOR , FinnangerAM , MathesonI . Postmenopausal osteoporosis: no effect of three years treatment with 1,25-dihydroxycholecalciferol. Acta Medica Scandinavica1987;221(2):199-204. [MEDLINE: 1987237893]FalchJA , OdegaardOR , FinnangerAM . 3 years treatment with 1.25(OH)2 Vitamin D3 does not reduce bone loss or fracture rate in postmenopausal women with fracture of the distal forearm. In: NormanAW , SchaeferK , Grigoleit H-G, v HerrathD , editors(s). Vitamin D : chemical, biochemical, and clinical update: proceedings of the Sixth Workshop on Vitamin D, Merano, Italy, March 1985. Berlin: de Gruyter, 1985:1004-5. FalchJA . Personal communication1999. ">Falch 1987</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N/A</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000227-bbs2-0014" title="FlickerL , MacInnisR , SteinM , SchererS , MeadK , NowsonC , et al. Should all older people in residential care receive vitamin D to prevent falls? Results of a randomised trial [abstract]. Journal of Bone and Mineral Research2004;19(Suppl 1):S99. FlickerL , MacInnisRJ , SteinMS , SchererSC , MeadKE , et al. Response letter to Dr. Gau et al. Journal of the American Geriatrics Society2006;54:1021-2. FlickerL , MacInnisRJ , SteinMS , SchererSC , MeadKE , NowsonCA , et al. Erratum. Journal of the American Geriatrics Society2012;60:1599. FlickerL , MacInnisRJ , SteinMS , SchererSC , MeadKE , NowsonCA , et al. Should older people in residential care receive vitamin D to prevent falls? Results of a randomized trial. Journal of the American Geriatrics Society2005;53(11):1881-8. FlickerL , MacInnisRJ , SteinMS , SchererSC , MeadKE , NowsonCA . Should all older people in residential care receive vitamin D to prevent falls? Results of a randomised trial. Journal of Bone and Mineral Research2004;19(Suppl 1):S99. FlickerL . Personal communication 7 January 2008. ">Flicker 2005</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Intervention 61% in 25‐40 range; Control 54% in 25‐40 range</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000227-bbs2-0015" title="GallagherJC , RiggsBL , ReckerRR , GoldgarD . The effect of calcitriol on patients with postmenopausal osteoporosis with special reference to fracture frequency. Proceedings of the Society for Experimental Biology and Medicine1989;191(3):287-92. [MEDLINE: 1989296988]">Gallagher 1989</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N/A</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000227-bbs2-0016" title="GallagherJC , GoldgarD . Treatment of postmenopausal osteoporosis with high doses of synthetic calcitriol. A randomized controlled study. Annals of Internal Medicine1990;113(9):649-55. [MEDLINE: 1991023790]GallagherJC . Metabolic effects of synthetic calcitriol (Rocaltrol) in the treatment of postmenopausal osteoporosis. Metabolism: Clinical &amp; Experimental1990;39(4 Suppl 1):27-9. [MEDLINE: 2112606]GallagherJC . Personal communication 21 February 1995. ">Gallagher 1990</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N/A</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000227-bbs2-0017" title="GallagherJC , FowlerS . Effect of estrogen, calcitriol and a combination of estrogen and calcitriol on bone mineral density and fractures in elderly women. Journal of Bone and Mineral Research1999;14(Suppl 1):S209. GallagherJC , FowlerSE , DetterJR , ShermanSS . Combination treatment with estrogen and calcitriol in the prevention of age-related bone loss. Journal of Clinical Endocrinology and Metabolism2001;86(8):3618-28. GallagherJC , HaynatskiG , FowlerS . Calcitriol therapy reduces falls and fractures in elderly women. Calcified Tissue International2003;72:334. GallagherJC , HaynatzkiG , FowlerS . Effect of estrogen, calcitriol or the combination of both on falls and non vertebral fractures in elderly women. Journal of Bone and Mineral Research2001;17(Suppl 1):S210. GallagherJC , RapuriPB , HaynatzkiG , DetterJR . Effect of discontinuation of estrogen, calcitriol, and the combination of both on bone density and bone markers. Journal of Clinical Endocrinology and Metabolism2002;87(11):4914-23. [12414850]GallagherJC , RapuriPB , HaynatzkiG . A comparison of estrogen, calcitriol or both therapies on the relationship between serum parathyroid hormone and 25 hydroxy vitamin. Journal of Bone and MIneral Research2004;19(Suppl 1):S440. GallagherJC . Personal communication 21 February 2005. GallagherJC . The effects of calcitriol on falls and fractures and physical performance tests. Journal of Steroid Biochemistry and Molecular Biology2004;89-90(1-5):497-501. ">Gallagher 2001</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Intervention 78.0 (SD 21.6); Control 80.5 (SD 27.4)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000227-bbs2-0018" title="Garay LilloJ , ParrenoJ , GonzálezY , GonzálezJA . Geminis: a prospective, multicentric, randomised study to evaluate the effect of tricalcium phosphate versus tricalcium phosphate plus 25(OH) Vitamin D on the risk of fractures in older women [Géminis: Estudio prospectivo, multicéntrico y aleatori para valorar el efecto del Fosfato Tricálcico versus Fosfato Tricálcico + 25(OH) Vitamina D sobre el riesgo de fracturas en mujerioes ancianas.]. Geriátrika1997;13(6):24-8. ">Garay Lillo 1997</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Intervention 58.3 (SD 46.3); Control 64.8 (SD 51.3) subgroups</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000227-bbs2-0019" title="GeusensP , DequekerJ . Long-term effect of nandrolone decanoate, 1 alpha-hydroxyvitamin D3 or intermittent calcium infusion therapy on bone mineral content, bone remodeling and fracture rate in symptomatic osteoporosis: a double-blind controlled study. Bone and Mineral1986;1(4):347-57. ">Geusens 1986</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N/A</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000227-bbs2-0020" title="GlendenningP , ZhuK , InderjeethC , HowatP , LewisJR , PrinceRL . Effects of three-monthly oral 150,000 IU cholecalciferol supplementation on falls, mobility, and muscle strength in older postmenopausal women: a randomized controlled trial. Journal of Bone and Mineral Research2012;27(1):170-6. ">Glendenning 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>65.8 (SD 22.7) combined intervention and control subgroup</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000227-bbs2-0021" title="GoraiI , ChakiO , TaguchiY , NakayamaM , OsadaH , SuzukiN , et al. Early postmenopausal bone loss is prevented by estrogen and partially by 1alpha-OH-vitamin D3: therapeutic effects of estrogen and/or 1alpha-OH-vitamin D3. Calcified Tissue International1999;65:16-22. ">Gorai 1999</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N/A</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000227-bbs2-0022" title="HarwoodRH , SahotaO , GaynorK , MasudT , HoskingD . A randomised, controlled comparison of different calcium and vitamin D supplementation regimens in elderly women after hip fracture: The Nottingham Neck of Femur (NoNOF) Study. Age and Ageing2004;33:45-51. [14695863]HarwoodRW . Personal communication 24 January 2003. SahotaO , HarwoodRH , GaynorK , MasudT , HoskingDJ . A randomised, controlled comparison of different calcium and vitamin D regimes: the NoNOF (Nottingham Neck of Femur) study. Osteoporosis International2003;14(Suppl 4):S10-11. ">Harwood 2004</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Intervention 28 (range 10‐67), 30 (range 12‐85), 29 (range 6‐75); Control 30 (range 12‐64) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000227-bbs2-0023" title="HayashiY , FujitaT , InoueT . A multi-center study on efficacy of 1 alpha-hydroxy vitamin D3 in preventing spinal fracture of patients with osteoporosis (abstract). Journal of Bone and Mineral Research1989;4 Suppl 1:Si84. HayashiY , FujitaT , InoueT . Decrease of vertebral fracture in osteoporotics by administration of 1alpha-hydroxy-vitamin D3. Journal of Bone and Mineral Metabolism1992;10(2):50-4. ">Hayashi 1992</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N/A</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000227-bbs2-0024" title="InkovaaraJ , GothoniG , HalttulaR , HeikinheimoR , TokolaO . Calcium, vitamin D and anabolic steroids in treatment of aged bones: double-blind placebo-controlled long-term clinical trial. Age and Ageing1983;12:124-30. ">Inkovaara 1983</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N/A</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000227-bbs2-0025" title="AlpertJS . Concerns about the integrity of Ishida Y, Kawai S. Am J Med. 2004;117:549-555: the reply. American Journal of Medicine2020;133:e315. AvenellA , GreyA , GambleGD , BollandMJ . Concerns about the integrity of the Yamaguchi Osteoporosis Prevention Study (YOPS) report, Am J Med. 2004;117:549-555. American Journal of Medicine2020;133:e311-4. IshidaY , KawaiS . A two-year randomized controlled trial of hormone replacement therapy, etidronate, calcitonin, vitamin D, or vitamin K, in women with postmenopausal osteoporosis. Journal of Bone and Mineral Research2002;17(Suppl 1):S478. IshidaY , KawaiS . Comparative efficacy of hormone replacement therapy, bisphosphonates, calcitonin, vitamin D and vitamin K in postmenopausal women with osteoporosis. Journal of Bone and Mineral Research2003;18(Suppl 2):S158. IshidaY , KawaiS . Comparative efficacy of hormone replacement therapy, etidronate, calcitonin, alfacalcidol, and vitamin K in postmenopausal women with osteoporosis: the Yamaguchi osteoporosis prevention study. American Journal of Medicine2004;117:549-55. IshidaY , KawaiS . Comparative efficacy of hormone replacement therapy, etidronate, calcitonin, vitamin D and vitamin K in postmenopausal osteoporosis. Bone2003;33(5 Suppl1):S220. IshidaY , SohH , OgawaS , KawaharaS , MurataH . A one-year randomized controlled trial of hormone replacement therapy, bisphosphonate, calcitonin, vitamin D, and vitamin K, in women with postmenopausal osteoporosis. Journal of Bone and Mineral Research2000;15(Suppl 1):S310. IshidaY , SohH , TsuchidaS , KawaharaS , MurataH , KawaiS . Effectiveness of hormone replacement therapy, etidronate, calcitonin, vitamin D, and vitamin K in postmenopausal women with osteoporosis [abstract]. Bone2002;30(3 Suppl 1):50S. IshidaY . Personal communication 21 February 2005. ">Ishida 2004 (retracted)</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N/A</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000227-bbs2-0026" title="JanssenHC , SamsonMM , VerhaarHJ . Muscle strength and mobility in vitamin D-insufficient female geriatric patients: a randomized controlled trial on vitamin D and calcium supplementation. Aging Clinical and Experimental Research2010;22(1):78-84. ">Janssen 2010</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Vitamin D and calcium 32.6 (SD 11.6); Placebo and calcium 34.3 (SD 11.5)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000227-bbs2-0027" title="KomulainenM , KrogerH , TuppurainenMT , HeikkinenAM , AlhavaE , HonkanenR , et al. Prevention of femoral and lumbar bone loss with hormone replacement therapy and Vitamin D3 in early postmenopausal women: a population based 5-year randomized trial. Journal of Clinical Endocrinology and Metabolism1999;84(2):546-52. KomulainenM , KrogerH , TuppurainenMT , Keikkinen A-M, HonkanenR , SaarikoskiS , et al. Identification of early postmenopausal women with no bone response to HRT: results of a five-year clinical trial. Osteoporosis International2000;11:211-8. KomulainenMH , KrogerH , TuppurainenMT , Heikkinen A-M, AlhavaE , HonkanenR , et al. HRT and Vit D in prevention of non-vertebral fractures in postmenopausal women; a 5 year randomized trial. Maturitas1998;31(1):45-54. KomulainenMH . Personal communication 11 November 2004. ">Komulainen 1998</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N/A</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000227-bbs2-0028" title="LawM , MorrisJ , WithersH . Cholecalciferol, not ergocalciferol, should be used for vitamin D supplementation [author reply]. Age and Ageing2006;35(6):645. [MEDLINE: 16982666]LawM , MorrisJ , WithersH . Vitamin D supplementation and the prevention of fractures and falls. Reply. Age and Ageing2007;36(2):233. LawM , MorrisJ , WithersH . Vitamin D supplementation and the prevention of fractures and falls [author reply]. Age and Ageing2007;36(2):233. [MEDLINE: 17255084]LawM , WithersH , MorrisJ , AndersonF . Vitamin D supplementation and the prevention of fractures and falls: results of a randomised trial in elderly people in residential accommodation [comment in: Age and Ageing 2006;35(6):645 and Age and Ageing 2007;36(2):232-3]. Age and Ageing2006;35(5):482-6. ">Law 2006</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Intervention 47 median (35‐102, 90th centile range) subgroup; no data for control group </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000227-bbs2-0029" title="GraafmansWC , OomsME , HofsteeHMA , BezemerPD , BouterLM , LipsP . Falls in the elderly: a prospective study of risk factors and risk profiles. American Journal of Epidemiology1996;143(11):1129-36. LipsP , GraafmansWC , OomsME , BezemerPD , BouterLM . The effect of vitamin D supplementation on the incidence of hip fractures in elderly people. Journal of Bone and Mineral Research1994;9 Suppl 1:S148. LipsP , GraafmansWC , OomsME , BezemerPD , BouterLM . Vitamin D supplementation and fracture incidence in elderly persons. Annals of Internal Medicine1996;124:400-6. [MEDLINE: 1996151943]">Lips 1996</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Intervention 27 (25th‐75th centile 19‐36); Control 26 (25th‐75th centile 19‐37) subgroups</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000227-bbs2-0030" title="JohansenA , LyonsRA , StoneM , BrophyS , NewcombeRG , PhillipsCJ , et al. Preventing fractures among older people living in institutional care: a randomised double blind placebo controlled trial of vitamin D supplementation [abstract]. Age and Ageing2006;35(Suppl 3):i41. LyonsRA , JohansenA , BrophyS , NewcombeRG , PhillipsCJ , LervyB , et al. Preventing fractures among older people living in institutional care: a pragmatic randomised double blind placebo controlled trial of vitamin D supplementation. Osteoporosis International2007;18(6):811-8. LyonsRA , JohansenA , StoneMD , BrophyS , NewcombeRG , PhilipsCJ , et al. Preventing fractures among older people living in institutional care: a randomised double blind placebo controlled trial of vitamin D supplementation [abstract]. Osteoporosis International2006;17(Suppl 3):372. ">Lyons 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N/A</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000227-bbs2-0031" title="MenczelJ , FoldesJ , SteinbergR , LeichterI , ShalitaB , Bjolah-AbramT , et al. Alfacalcidol (Alpha D3) and calcium in osteoporosis. Clinical Orthopaedics and Related Research1994;(300):241-7. ">Menczel 1994</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N/A</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000227-bbs2-0032" title="MeyerHE , FalchJA , KvaavikE , SmedshaugGB , TverdalA , PedersenJI . Can vitamin D supplementation reduce the risk of fracture in the elderly? A randomised controlled trial. Osteoporosis International2000;11(Suppl 2):S114-5. MeyerHE , SmedshaugGB , KvaavikE , FalchJA , TverdalA , PedersenJI . Can vitamin D supplementation reduce the risk of fracture in the elderly? A randomized controlled trial. Journal of Bone and Mineral Research2002;17(4):709-15. SmedshaugGB , PedersenJI , MeyerHE . Can vitamin D supplementation improve grip strength in elderly nursing home residents? A double-blinded controlled trial. Scandinavian Journal of Food and Nutrition2007;51(2):74-8. ">Meyer 2002</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Intervention 47 (SD 26); Control 51 (SD 33) subgroups</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000227-bbs2-0033" title="MitriJ , Dawson-HughesB , HuFB , PittasAG . Effects of vitamin D and calcium supplementation on pancreatic β cell function, insulin sensitivity, and glycemia in adults at high risk of diabetes: the Calcium and Vitamin D for Diabetes Mellitus (CaDDM) randomized controlled trial. American Journal of Clinical Nutrition2011;94:486-94. ">Mitri 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Vitamin D and calcium 56 (SE 4), Vitamin D and placebo 66 (SE 4), Calcium and placebo 63 (SE 5), Placebos 61 (SE 3) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000227-bbs2-0034" title="NakatsukaK , InabaM , ArataniH , IbaK , SatoT , KoikeT , et al. Effects of long-term administration of alfacalcidol on bone mass and bone metabolism in patients with primary osteoporosis - comparison with calcium preparations [Japanese]. Nippon Ronen Igakkai Zasshi - Japanese Journal of Geriatrics1997;34(7):569-76. ">Nakatsuka 1997</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Intervention 58.4 (SD 24.5); Control 69.8 (SD 28.5)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000227-bbs2-0035" title="OnesK , SchachtE , DukasL , CaglarN . Effects of combined treatment with alendronate and alfacalcidol on bone mineral density and bone turnover in postmenopausal osteoporosis: a two-years, randomized, multiarm, controlled trial. Internet Journal of Epidemiology2007;4(1):DOI: 10.5580/1523. ">Ones 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N/A</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000227-bbs2-0036" title="OrimoH , ShirakiM , HayashiY , HoshinoT , OnayaT , MiyazakiS , et al. Effects of 1-alpha-hydroxyvitamin D3 on lumbar bone mineral density and vertebral fractures in patients with postmenopausal osteoporosis. Calcified Tissue International1994;54:370-6. ">Orimo 1994</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Intervention 58.0 (SD 22.5); Control 50.3 (SD 16.3)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000227-bbs2-0037" title="KarkkainenM , TuppurainenM , RikkonenT , SalovaaraK , SirolaJ , HonkanenR , et al. Vitamin-D 800IU/day + calcium 1000mg supplementation decreases the risk of recurrent falling among postmenopausal ambulatory women - a population-based, randomized, 3-year study (OSTPRE-FPS). Osteoporosis International2008;19(Suppl 1):S17-18. KarkkainenM , TuppurainenM , RikkonenT , SalovaaraK , SirolaJ , HonkanenR , et al. Vitamin-D 800IU/day + calcium supplementation decreases the risk of falling among postmenopausal ambulatory women - a population-based, randomized 3-year study (OSTPRE-FPS) [abstract]. Journal of Bone and Mineral Research2007;22(Suppl 1):S131. KarkkainenM , TuppurainenM , SalovaaraK , SandiniL , RikkonenT , SirolaJ , et al. Effect of calcium and vitamin D supplementation on bone mineral density in women aged 65-71 years: a 3-year randomized population-based trial (OSTPRE-FPS). Osteoporosis International2010;21:2047-55. KarkkainenMK , TuppurainenM , SalovaaraM , SandiniL , RikkonenT , SirolaJ , et al. Does daily vitamin D 800 IU and calcium 1000 mg supplementation decrease the risk of falling in ambulatory women aged 65-71 years? A 3-year randomized population-based trial (OSTPRE-FPS). Maturitas2010;65:359-65. KrogerHP , TuppurainenM . OSTPRE-FPS Prevention of Fractures and Falls in Postmenopausal Women With Calcium and Vitamin-D Supplementation - a Randomised Study. http://www.controlled-trials.com/mrct/trial/405493/OSTPRE. SalovaaraK , TuppurainenM , KarkkainenM , RikkonenT , SandiniL , SirolaJ , et al. Effect of vitamin D3 and calcium on fracture risk in 65- to 71-year-old women: a population-based 3-year randomized, controlled trial - the OSTPRE-FPS. Journal of Bone and Mineral Research2010;25(7):1487-95. SalovaaraKT , TuppurainenM , RikkonenT , KarkkainenM , SirolaJ , HonkanenR , et al. Effect of vitamin-D3 and calcium on fracture risk in 65-71 year old women in a 3-year randomized clinical trial - preliminary results from the OSTPRE-Fracture Prevention Study. Calcified Tissue International2008;82:545-6. SalovaaraKT , TuppurainenM , RikkonenT , KarkkainenM , SirolaJ , HonkanenR , et al. Effect of vitamin-D3 and calcium on fracture risk in 65-71 year old women in a 3-year randomized clinical trial - preliminary results of the OSTPRE-Fracture Prevention Study. Journal of Bone and Mineral Research2007;22(Suppl 1):S76. ">OSTPRE‐FPS 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Intervention 50.0 (SD 18.7); Control 49.1 (SD 17.7) subgroups</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000227-bbs2-0038" title="OttSM , ChesnutCH . Calcitriol treatment is not effective in postmenopausal osteoporosis: see comments. Annals of Internal Medicine1989;110:267-74. ">Ott 1989</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Intervention 66.8 (SD 31.5); Control 65.8 (SD 39.3)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000227-bbs2-0039" title="PeacockM , LiuG , CareyM , McClintockR , AmbrosiusW , HuiS , et al. Effect of calcium or 25OH vitamin D3 dietary supplementation on bone loss at the hip in men and women over the age of 60. Journal of Clinical Endocrinology and Metabolism2000;85:3011-9. ">Peacock 2000</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Intervention 65.0 (SD 25) men, 57.5 (SD 33) women; Control 65.0 (SD 30) men, 60.0 (SD 30) women </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000227-bbs2-0040" title="MinneHW , PfeiferM , BegerowB , NachtigallD , HansenC . Vitamin D and calcium supplementation reduces falls in elderly women via improvement of body sway and normalisation of blood pressure; a prospective, randomized, and double-blind study. Osteoporosis International2000;11(Suppl 2):S115. PfeiferM , BegerowB , MinneHW , AbramsC , NachtigallD , HansenC . Effects of a short-term vitamin D and calcium supplementation on body sway and secondary hyperparathyroidism in elderly women. Journal of Bone and Mineral Research2000;15(6):1113-8. PfeiferM , BegerowB , NachtigallD , HansenC . Prevention of falls-related fractures: vitamin D reduces body sway in the elderly - a prospective, randomized, double blind study [abstract]. Bone1998;23(5 Suppl 1):1110. ">Pfeifer 2000</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Interventiion 25.7 (SD 13.6); Control 24.6 (SD 12.1)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000227-bbs2-0041" title="BollandMJ , GreyA . Different outcomes of meta-analyses and data inconsistency:response to comments by Pfeifer. Archives of Osteoporosis2015;10:43. BollandMJ , GreyA . Inconsistent data in text and tables. Osteoporosis International2015;26:2713. MinneHW , DobnigH , PfeiferM , SuppanK . Effects of vitamin D and calcium supplementation on falls and parameters of muscle function: a prospective, randomized, double-blind multicenter study [abstract]. Osteoporosis International2006;17(Suppl 2):S212. MinneHW , DobnigH , PfeiferM , SuppanK . Effects of vitamin D and calcium supplementation on falls and parameters of muscle-function - a prospective, randomized, double-blind multi-center study [abstract]. Osteoporosis International2006;17(Suppl 1):S21. PfeiferM , BegerowB , MinneHW , SuppanK , Fahrleitner-PammerA , DobnigH . Effects of a long-term vitamin D and calcium supplementation on falls and parameters of muscle function in community-dwelling older individuals. Osteoporosis International2009;20:315-22. PfeiferM , DobnigH , BegerowB , SuppanK . Effects of vitamin D and calcium supplementation on falls and parameters of muscle function: a prospective randomized, double-blind multi-centre study [abstract]. Journal of Bone and Mineral Research2004;19(Suppl 1):S58. PfeiferM , DobnigH , MinneHW , SuppanK . Effects of vitamin D and calcium supplementation on falls and parameters of muscle function - a prospective, randomized, double-blind multi-center study [abstract]. Osteoporosis International2005;16(Suppl 3):S45. PfeiferM . Different outcomes of meta-analyses and data inconsistency. Osteoporosis International2015;26:2715–2716. PfeiferM . Randomized controlled clinical trials and meta-analyses. Archives of Osteoporosis2015;10:42. ">Pfeifer 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Vitamin D and calcium 55 (SD 18); Calcium 54 (SD 18)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000227-bbs2-0042" title="DumvilleJC , MilesJN , PorthouseJ , CockayneES , SaxonL , KingC , et al. Can vitamin D supplementation prevent seasonal affective disorder? A randomised trial among older women. Osteoporosis International2004;15:S42-3. PorthouseJ , CockayneS , KingC , SaxonL , SteeleE , AsprayT , et al. Randomised controlled trial of calcium and supplementation with cholecalciferol (vitamin D3) for prevention of fractures in primary care. BMJ2005;330(7498):1003-6. PorthouseJ , CockayneS , KingC , SaxonL , SteeleE , AsprayT , et al. Randomised controlled trial of calcium and vitamin D supplementation for fracture prevention in primary care. Osteoporosis International2004;15(Suppl 2):S13. PorthouseJ , CockayneS , KingC , SaxonL , SteeleE , AsprayT , et al. Randomised controlled trial of calcium and vitamin D supplementation for fracture prevention in primary care. Osteoporosis International2005;16:S27. PufferS . Calcium and vitamin D in primary care: adherence results from a randomised controlled trial [abstract 6.9.3]. In: RCN International Nursing Conference; 2004 Mar 21-31; Cambridge (UK). London: Royal College of Nursing, 2004. S Puffer, on behalf of the Calcium and Vitamin D Trial. Calcium and vitamin D in primary care. Compliance results from a randomised controlled trial. Osteoporosis International2003;14(Suppl 4):S8. TorgersonD , on behalf of the trial group. Calcium and vitamin D in preventing fractures [author reply]. BMJ2005;331(7508):109. TorgersonDJ . Personal communication 9-16 February 2005. ">Porthouse 2005</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N/A</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000227-bbs2-0043" title="PrinceRL , AustinN , DevineA , DickIM , BruceD , ZhuK . Effects of ergocalciferol added to calcium on the risk of falls in elderly high-risk women. Archives of Internal Medicine2008;168(1):103-8. ZhuK , BruceD , AustinN , DevineA , EbelingPR , PrinceRL . Randomized controlled trial of the effects of calcium with or without vitamin D on bone structure and bone-related chemistry in elderly women with vitamin D insufficiency. Journal of Bone and Mineral Research2008;23(8):1343-8. ZhuK , DevineA , DickIM , WilsonSG , PrinceRL . Effects of calcium and vitamin D supplementation on hip bone mineral density and calcium-related analytes in elderly ambulatory Australian women: a five-year randomized controlled trial. Journal of Clinical Endocrinology and Metabolism2008;93(3):743-9. ">Prince 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Intervention 45.2 (SD 12.5); Control 44.3 (SD 12.7)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000227-bbs2-0044" title="AndersonFH , GrantAM , AvenellA , CampbellMK , CooperC , DonaldsonC , et al. The RECORD Trial: an evaluation of calcium and/or vitamin D in the secondary prevention of osteoporotic fractures. Bone2005;36(Suppl 2):S122-3. FrancisRM , Grant AM and the RECORD trial group. The RECORD trial: a randomised double-blind study of calcium and/or vitamin D in the secondary prevention of low trauma fractures. Age Ageing2005;34(Suppl 2):ii15. GrantA , on behalf of the RECORD Trial Group. Prevention of low-trauma fractures in older people [author reply]. Lancet2005;366(9485):543-4. GrantAM , AndersonFH , for the RECORD Trial Group. The Medical Research Council RECORD Trial: an evaluation of calcium and/or vitamin D in the secondary prevention of osteoporotic fractures. Osteoporosis International2004;15(Suppl 2):S13. GrantAM , AndersonFH . The RECORD trial: an evaluation of calcium and/or vitamin D in the secondary prevention of osteoporotic fractures. Osteoporosis International2005;16(Suppl 3):S4-5. GrantAM , AvenellA , CampbellMK , McDonaldAM , MacLennanGS , McPhersonGC , et al. Oral vitamin D3 and calcium for secondary prevention of low-trauma fractures in elderly people (Randomised Evaluation of Calcium Or vitamin D, RECORD): a randomised placebo-controlled trial [comment in: Lancet 2005;366(9485):543]. Lancet2005;365(9471):1621-8. GrantAM . Personal communication 11 March 2004. ">RECORD 2005</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Intervention 38.0 (SD 16.3); Control 39.5 (SD 14.8) subgroups*</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000227-bbs2-0045" title="ShirakiM , KushidaK , YamazakiK , NagaiT , InoueT , OrimoH . Effects of 2 years' treatment of osteoporosis with 1alpha-hydroxy vitamin D3 on bone mineral density and incidence of fracture: a placebo-controlled, double-blind prospective study. Endocrine Journal1996;43(2):211-20. ">Shiraki 1996</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N/A</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000227-bbs2-0046" title="AndersonFH , SmithHE , RaphaelHM , CooperC . Intramuscular vitamin D increased serum 1,25-dihydroxycholecalciferol but did not affect 25-hydroxy-cholecalciferol levels in health older adults [abstract]. Journal of Bone and Mineral Research2000;15(Suppl 1):S315. AndersonFH , SmithHE , RaphaelHM , CrozierSR , CooperC . Effect of annual intramuscular vitamin D3 supplementation on fracture risk in 9440 community-living older people: the Wessex fracture prevention trial [abstract]. Journal of Bone and Mineral Research2004;19(Suppl 1):S57. ArdenNK , CrozierS , SmithH , AndersonF , EdwardsC , RaphaelH , et al. Knee pain, knee osteoarthritis, and the risk of fracture. Arthritis and Rheumatism2006;55(4):610-5. CooperC , CrozierS . Personal communication 23 February 2005. RaphaelH , SmithH , AndersonF , CooperC . Tackling the problems of trial management in primary care - experience from the Wessex research network fracture prevention study of annual vitamin D injection in older people [abstract]. Osteoporosis International2000;11(Suppl 1):S63-4. SmithH , AndersonF , RaphaelH , CooperC . The Wessex research network fracture prevention study - a large pragmatic trial of annual vitamin D injection in older people [abstract]. Osteoporosis International2000;11(Suppl 1):S64. SmithH , AndersonF , RaphaelH , CrozierS , CooperC . Effect of annual intramuscular vitamin D supplementation on fracture risk: population-based, randomised, double-blind, placebo-controlled trial [abstract]. Osteoporosis International2004;15(Suppl 1):S8. SmithH , AndersonF , RaphaelH , MaslinP , CrozierS , CooperC . Effect of annual intramuscular vitamin D on fracture risk in elderly men and women--a population-based, randomized, double-blind, placebo-controlled trial. Rheumatology2007;46(12):1852-7. ">Smith 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Intervention 56.5; Control 62.2 subgroups</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000227-bbs2-0047" title="MorrisonNA , GeorgePM , VaughanT , TilyardMW , FramptonCM , GilchristNL . Vitamin D receptor genotypes influence the success of calcitriol therapy for recurrent vertebral fracture in osteoporosis. Pharmacogenetics and Genomics2005;15(2):127-35. TilyardM . Low-dose calcitriol versus calcium in established postmenopausal osteoporosis. Metabolism: Clinical &amp; Experimental1990;39(4 Suppl 1):50-2. TilyardMW , SpearsGF , ThomsonJ , DoveyS . Treatment of postmenopausal osteoporosis with calcitriol or calcium. New England Journal of Medicine1992;326(6):357-62. TilyardMW , SpearsGFS , ThomsonJ , DoveyS . Calcitriol or calcium for postmenopausal osteoporosis. New England Journal of Medicine1992;327:284. TilyardMW . 1,25-dihydroxyvitamin D3 (calcitriol) in the treatment of postmenopausal osteoporosis. Aktuelle Rheumatologie1994;19(Suppl 1):23-6. ">Tilyard 1992</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N/A</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000227-bbs2-0048" title="TrivediDP , DollR , KhawKT . Effect of four monthly oral vitamin D3 (cholecalciferol) supplementation on fractures and mortality in men and women living in the community: randomised double blind controlled trial. BMJ2003;326:469. ">Trivedi 2003</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N/A</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000227-bbs2-0049" title="UshiroyamaT , IkedaA , SakaiM , HigashiyamaT , UekiM . Effects of the combined use of calcitonin and 1alpha-hydroxycholecalciferol on vertebral bone loss and bone turnover in women with postmenopausal osteopenia and osteoporosis: a prospective study of long-term and continuous administration with low dose calcitonin. Maturitas2001;40:229-38. ">Ushiroyama 2001</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N/A</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000227-bbs2-0050" title="SandersK , DuqueG , EbelingP , McCorquodaleT , HerrmannM , Shore-LorentiC , et al. The efficacy of high-does oral vitamin D3 administered once a year: increased fracture risk is associated with 1,25 vitamin D level at 3-months post dose. In: ASBMR Annual Meeting; 2012 Oct 12-15; Minneapolis, Minnesota. http://www.asbmr.org/Meetings/AnnualMeeting/AbstractDetail.aspx?aid=6beb2500-4b8e-472b-8b38-d881cadb80e3. 2012. SandersK , StuartA , WilliamsonE , SimpsonJ , KotowiczM , NicholsonG . The efficacy of high-dose oral vitamin D3 administered once a year: a randomised, double-blind, placebo-controlled trial (Vital D study) for falls and fractures in older women. Osteoporosis International2011;22(Suppl 1):S104-5. SandersKM , DuqueG , McCorquodaleT , StuartAL , WilliamsonEJ , KotowiczMA , et al. Annual high-dose oral vitamin D3: is the increased risk of falls attributable to changes in muscle strength?Osteoporosis International2011;22(Suppl 4):S552. SandersKM , EbelingPR , StuartAL , WilliamsonEJ , KotowiczMA , NicholsonGC . Annual high-dose oral vitamin D3: is increased risk of fractures attributable to changes in bone turnover markers?Osteoporosis International2011;22(Suppl 4):S589. SandersKM , HaylesAL , KotowiczMA , NicholsonGC . Does vitamin D explain the lower fracture rate in rural communities?Bone2007;40(6 Suppl 2):S195. SandersKM , HaylesAL , KotowiczMA , NicholsonGC . The possible role of vitamin D and falls in relation to lower fracture rates in rural communities. Osteoporosis International2007;18(Suppl 1):S120-1. SandersKM , StuartAL , KotowiczMA , NicholsonGC . Annual feedback is an effective tool for a sustained increase in calcium intake among older women. Nutrients2010;2:1018-25. SandersKM , StuartAL , MerrimanEN , ReadML , KotowiczMA , YoungD , et al. Trials and tribulations of recruiting 2,000 older women onto a clinical trial investigating falls and fractures: Vital D study. BMC Medical Research Methodology2009;9:78. SandersKM , StuartAL , NicholsonGC . High-dose oral vitamin D supplementation and risk of falls in older women. JAMA2010;304(8):856-7. SandersKM , StuartAL , WilliamsonEJ , JackaFN , DoddS , NicholsonG , et al. Annual high-dose vitamin D3 and mental well-being: randomised controlled trial. British Journal of Psychiatry2011;198:357-64. SandersKM , StuartAL , WilliamsonEJ , SimpsonJA , KotowiczMA , NicholsonGC . Annual high-dose oral vitamin D for falls and fractures in elderly women: a randomised, double-blind, placebo-controlled trial (Vital D study). Osteoporosis International2010;21(Suppl 1):S30. SandersKM , StuartAL , WilliamsonEJ , SimpsonJA , KotowiczMA , YoungD , et al. Annual high-dose oral vitamin D and falls and fractures in older women. A randomized controlled trial. JAMA2010;303(18):1815-22. Sanders KM et al. Incorrect data. JAMA2010;303(23):2357. ">Vital D</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Intervention 53 (interquartile range 40‐65); Control 45 (interquartile range 40‐57) subgroups </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000227-bbs2-0051" title="CauleyJ , Wactawski-WendeJ , RobbinsJ , RodaboughR , ChenZ , JohnsonK , et al. The Women's Health Initiative (WHI) calcium and vitamin D supplementation trial: health outcomes 5 years after trial completion. ASBMR Annual Meeting; 2012 Oct 12-15; Minneapolis, Minnesota. http://www.asbmr.org/Meetings/AnnualMeeting/AbstractDetail.aspx?aid=6450bf3e-c670-4dc0-814c-8842e23cd80e (accessed 27 December 2012). CauleyJA , LaCroixA , WuL , LeeJ , HorowitzM , BauerD , et al. Serum 25 hydroxy vitamin D 25(OH) and the risk of hip fracture: the Women's Health Initiative (WHI). Journal of Bone and Mineral Research2007;22(Suppl 1):S57. ChenZ , BeckTJ , WrightNC , LaCroixAZ , CauleyJA , LewisCE , et al. The effect of calcium plus vitamin D supplement on hip geometric structures: results from the Women's Health Initiative CaD trial. Journal of Bone and Mineral Research2007;22(Suppl 1):S59. JacksonRD , LaCroixAZ , CauleyJA , McGowanJ . The Women's Health Initiative Calcium-Vitamin D Trial: overview and baseline characteristics of participants. Annals of Epidemiology2003;13:S98-106. JacksonRD , LaCroixAZ , GassM , WallaceRB , RobbinsJ , LewisCE , et al. Calcium plus vitamin D supplementation and the risk of fractures [erratum appears in New England Journal of Medicine 9 March 2006;354(10):1102]. New England Journal of Medicine2006;354(7):669-83. JacksonRD , WrightNC , BeckTJ , SherrillD , CauleyJA , LewisCE , et al. Calcium plus vitamin D supplementation has limited effects on femoral geometric strength in older postmenopausal women: the Women's Health Initiative. Calcified Tissue International2011;88:198-208. McGowanJA , JacksonRD , CauleyJA , LaCroixAZ . Calcium and vitamin D in the prevention of hip and other fractures: an update on the Women's Health Initiative CaD Trial. Journal of Bone and Mineral Research2002;17(Suppl 1):S477. The Women's Health Initiative Study Group. Design of the Women's Health Initiative clinical trial and observational study. Controlled Clinical Trials1998;19(1):61-109. ">WHI 2006</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>46.0 (SD 22.6) subsequent hip fracture, 48.4 (SD 23.5) Controls, subgroups</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000227-bbs2-0052" title="WithamMD , CrightonLJ , GillespieND , StruthersAD , McMurdoME . The effects of vitamin D supplementation on physical function and quality of life in older patients with heart failure. A randomized controlled trial. Circulation: Heart Failure2010;3:195-201. ">Witham 2010</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Intervention 20.5 (SD 8.9); Control 23.7 (SD 10.0)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000227-bbs2-0053" title="WithamM . Can high-dose vitamin D supplementation reduce blood pressure and markers of cardiovascular risk in older people with isolated systolic hypertension? A randomised, double-blind, parallel group placebo controlled trial. http://www.controlled-trials.com/ISRCTN92186858/ (accessed 3 December 2013). WithamMD , PriceRJ , StruthersAD , DonnanPT , MessowM , FordI , et al. Vitamin D supplementation to reduce blood pressure in older patients with isolated systolic hypertension (VitDISH) - a randomised controlled trial. Personal communication ahead of publication 15 January 2013. ">Witham 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Intervention 44(SD 16); Control 45(SD 15)</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="2"> <div class="table-footnote"> <p>* reported as D3<br/>N/A: not available </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 4.</span> <span class="table-title">Baseline 25‐hydroxy vitamin D in intervention and control groups</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD000227.pub4/full#CD000227-tbl-0005">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD000227-tbl-0006"> <div class="table-heading"><span class="table-label">Table 5.</span> <span class="table-title">Selected adverse effects reported in excluded trials</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Excluded study ID</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Adverse effects</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000227-bbs2-0056" title="AloiaJF , TalwarSA , PollackS , YehJ . A randomized controlled trial of vitamin D3 supplementation in African American women. Archives of Internal Medicine2005;165(14):1618-23. TalwarSA , AloiaJF , PollackS , YehJ . Oral vitamin D3 supplementation in postmenopausal African American women. Calcified Tissue International2004;74(Suppl 1):S102. TalwarSA , AloiaJF , PollackS , YehJ . Oral vitamin D3 supplementation in postmenopausal African American women. Journal of Bone and Mineral Research2004;19(Suppl 1):S324. ">Aloia 2005</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Death, renal stone, hypercalcaemia</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000227-bbs2-0059" title="BinkleyN , ReckerR , HolstA , WalliserJ , LipsP , PfeiferM . Treatment effects of vitamin D3 8400IU once weekly on elderly subjects with vitamin D insufficiency. Osteoporosis International2007;18(Suppl 1):S118. ">Binkley 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Renal insufficiency, hypercalcaemia</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000227-bbs2-0060" title="BrazierM , GradosF , KamelS , MathieuM , MorelA , MaamerM , et al. Clinical and laboratory safety of one year's use of a combination calcium + vitamin D tablet in ambulatory elderly women with vitamin D insufficiency: results of a multicenter, randomized, double-blind, placebo-controlled study. Clinical Therapeutics2005;27(12):1885-93. ">Brazier 2005</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Death, gastrointestinal event, hypercalcaemia</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000227-bbs2-0061" title="BroeKE , ChenTC , WeinbergJ , Bischoff-FerrariHA , HolickMF , KielDP . A higher dose of vitamin D reduces the risk of falls in nursing home residents: a randomized, multiple-dose study. Journal of the American Geriatrics Society2007;55(2):234-9. KielDP , BroeKE , ChenTC , CupplesLA , Bischoff-FerrariH , HolickMF . A higher dose of vitamin D reduces the risk of falls in nursing home residents: a randomized, placebo-controlled, multiple dose study. Journal of Bone and Mineral Research2004;19(Suppl 1):S462-3. ">Broe 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Death</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000227-bbs2-0063" title="ChenJT , ShirakiM , HasumiK , TanakaN , KataseK , KatoT , et al. 1-alpha-hydroxyvitamin D3 treatment decreases bone turnover and modulates calcium-regulating hormones in early postmenopausal women. Bone1997;20:557-62. ">Chen 1997</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Gastrointestinal event, hypercalcaemia</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000227-bbs2-0066" title="CorlessD , DawsonE , FraserF , EllisM , EvansSJW , PerryJD , et al. Do vitamin D supplements improve the physical capabilities of elderly hospital patients?Age and Ageing1985;14:76-84. ">Corless 1985</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Death, hypercalcaemia</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000227-bbs2-0067" title="DalyRM , BassS , NowsonC . Long-term effects of calcium-vitamin-D3-fortified milk on bone geometry and strength in older men. Bone2006;39(4):946-53. DalyRM , BrownM , BassS , KukuljanS , NowsonC . Calcium and vitamin D3 fortified milk reduces bone loss at clinically relevant skeletal sites in older men: a 2-year randomised controlled trial. Journal of Bone and Mineral Research2005;20(Suppl 1):S97. DalyRM , BrownM , BassS , KukuljanS , NowsonC . Calcium- and vitamin D3-fortified milk reduces bone loss at clinically relevant skeletal sites in older men: a 2-year randomized controlled trial. Journal of Bone and Mineral Research2006;21(3):397-405. KukuljanS , DalyRM , BassSL , SandersK , NicholsonGC , TurnerCH , et al. Does calcium-vitamin D3 fortified milk enhance the effects of exercise on BMD in older men: an 18 month randomised controlled trial. Journal of Bone and Mineral Research2006;21(Suppl 1):S184. ">Daly 2006</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Gastrointestinal event</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000227-bbs2-0068" title="Dawson-HughesB , DallalGE , KrallEA , HarrisS , SokollLJ , FalconerG . Effect of vitamin D supplementation on wintertime and overall bone loss in healthy postmenopausal women. Annals of Internal Medicine1991;115:505-12. ">Dawson‐Hughes 1991</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Renal insufficiency and renal stone, hypercalcaemia</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000227-bbs2-0073" title="DoetschAM , FaberJ , LynnerupN , WatjenI , BliddalH , Danneskiold-SamsoeB . The effect of calcium and vitamin D3 supplementation on the healing of the proximal humerus fracture: a randomized placebo-controlled study. Calcified Tissue International2004;75:183-8. ">Doetsch 2004</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Death</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000227-bbs2-0079" title="GradyD , HalloranB , CummingsS , LeveilleS , WellsL , BlackD , et al. 1,25 dihydroxy vitamin D3 and muscle strength in the elderly: a randomized clinical trial. Journal of Clinical Endocrinology and Metabolism1991;73:1111-7. ">Grady 1991</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Death, renal insufficiency</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000227-bbs2-0088" title="JensenC , HollowayL , BlockG , SpillerG , GildengorinG , GundersonE , et al. Long-term effects of nutrient intervention on markers of bone remodeling and calciotropic hormones in late-postmenopausal women. American Journal of Clinical Nutrition2002;75:1114-20. [MEDLINE: 12036821]JensenGF , ChristiansenC , TransbolI . Treatment of post menopausal osteoporosis. A controlled therapeutic trial comparing oestrogen/gestagen, 1,25-dihydroxy-vitamin D3 and calcium. Clinical Endocrinology1982;16:515-24. ">Jensen 1982</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Hypercalcaemia</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000227-bbs2-0091" title="JohnsonKR , JobberJ , StonawskiBJ . Prophylactic vitamin D in the elderly. Age and Ageing1980;9:121-7. ">Johnson 1980</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Hypercalcaemia</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000227-bbs2-0092" title="KeaneEM , HealyM , O'MooreR , CoakleyD , WalshJB . Vitamin D-fortified liquid milk: benefits for the elderly community-based population. Calcified Tissue International1998;62:300-2. ">Keane 1998</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Death</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000227-bbs2-0095" title="LarsenER , MosekildeL , FoldspangA . Determinants of acceptance of a community-based program for the prevention of falls and fractures among the elderly. Preventive Medicine2001;33(2 Pt 1):115-9. LarsenER , MosekildeL , FoldspangA . Vitamin D and calcium supplementation prevents osteoporotic fractures in elderly community dwelling residents: a pragmatic population-based 3-year intervention study. Journal of Bone and Mineral Research2004;19(3):370-8. LarsenER , MosekildeL , FoldspangA . Vitamin D and calcium supplementation prevents severe falls in elderly community-dwelling women: a pragmatic population-based 3-year intervention study. Aging Clinical and Experimental Research2005;17(2):125-32. LarsenER , MosekildeL , FoldspangA . Vitamin D and calcium treatment and environmental adjustment in the prevention of falls and osteoporotic fractures among elderly Danish community residents. Journal of Bone and Mineral Research2002;17(Suppl 1):S157. ">Larsen 2004</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Death</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000227-bbs2-0096" title="LathamNK , AndersonCS , LeeA , BennettDA , MoseleyA , CameronID . A randomized, controlled trial of quadriceps resistance exercise and vitamin D in frail older people: the Frailty Interventions Trial in Elderly Subjects. Journal of the American Geriatrics Society2003;51:291-9. ">Latham 2003</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Death</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000227-bbs2-0097" title="MeierC , WoitgeHW , WitteK , LemmerB , SeibelMJ . Supplementation with oral vitamin D3 and calcium during winter season prevents seasonal bone loss: a randomized controlled open-label prospective trial. Journal of Bone and Mineral Research2004;19:1221-30. ">Meier 2004</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Death</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000227-bbs2-0098" title="MoschonisG , ManiosY . Skeletal site-dependent response of bone mineral density and quantitative ultrasound parameters following a 12-month dietary intervention using dairy products fortified with calcium and vitamin D: the Postmenopausal Health Study. British Journal of Nutrition2006;96(6):1140-8. ">Moschonis 2006</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Gastrointestinal event</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000227-bbs2-0100" title="OngphiphadhanakulB , PiaseuN , Sae TungS , ChailurkitL , RajatanavinR . Prevention of postmenopausal bone loss by low and conventional doses of calcitriol or conjugated equine estrogen. Maturitas2000;34:179-84. ">Ongphiphadhanakul 2000</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Hypercalcaemia</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000227-bbs2-0102" title="OrimoH , NakamuraT , FukunagaM , OhtaH , HosoiT , UemuraY , et al. Effects of alendronate plus alfacalcidol in osteoporosis patients with a high risk of fracture: the Japanese Osteoporosis Intervention Trial (JOINT) - 02. Current Medical Research and Opinion2011;27(6):1273-84. ">Orimo 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Gastrointestinal event, hypercalcaemia</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 5.</span> <span class="table-title">Selected adverse effects reported in excluded trials</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD000227.pub4/full#CD000227-tbl-0006">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD000227-tbl-0007"> <div class="table-heading"><span class="table-label">Table 6.</span> <span class="table-title">Quality assessment scores</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Study</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Item B</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Item C</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Item D</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Item E</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Item F</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Item G</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Item H</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Item J</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000227-bbs2-0001" title="AloiaJF , VaswaniA , YehJK , EllisK , YasumuraS , CohnSH . Calcitriol in the treatment of postmenopausal osteoporosis. American Journal of Medicine1988;84(3 Pt 1):401-8. AloiaJF . Role of calcitriol in the treatment of postmenopausal osteoporosis. Metabolism1990;39(4 Suppl 1):35-8. GallagherJC . Personal communication 21 February 1995. ">Aloia 1988</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000227-bbs2-0002" title="ArthurRS , PirainoB , CandibD , CoopersteinL , ChenT , WestC , et al. Effect of low-dose calcitriol and calcium therapy on bone histomorphometry and urinary calcium excretion in osteopenic women. Mineral and Electrolyte Metabolism1990;16(6):385-90. [MEDLINE: 1991211662]">Arthur 1990</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000227-bbs2-0003" title="AvenellA , GrantAM , McGeeM , McPhersonG , CampbellMK , McGee MA for the RECORD Trial Management Group. The effects of an open design on trial participant recruitment, compliance and retention - a randomized controlled trial comparison with a blinded, placebo-controlled design. Clinical Trials Journal2004;1:490-8. AvenellA . Personal communication2005. ">Avenell 2004</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000227-bbs2-0004" title="Bischoff-FerrariHA , ConzelmannM , StahelinHB , DickW , CarpenterMG , AdkinAL , et al. Is fall prevention by vitamin D mediated by a change in postural or dynamic balance?Osteoporosis International2006;17(5):656-63. BischoffHA , StahelinHB , DickW , AkosR , KnechtM , SalisC , et al. Effects of vitamin D and calcium supplementation on falls: a randomized controlled trial. Journal of Bone and Mineral Research2003;18(2):343-51. [MEDLINE: 12568412]BischoffHA . Personal communication 13 July 2003. BischoffHA . Vitamin D deficiency in the elderly. Journal of Bone and Mineral Research2003;18(7):1343. [MEDLINE: 12854846]HeaneyR . Vitamin D depletion and effective calcium absorption. Journal of Bone and Mineral Research2003;18(7):1342. ">Bischoff 2003</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000227-bbs2-0005" title="Bolton-SmithC , McMurdoME , PatersonCR , MolePA , HarveyJM , FentonST , et al. Two-year randomized controlled trial of vitamin K1 (phylloquinone) and vitamin D3 plus calcium on bone health of older women. Journal of Bone and Mineral Research2007;22(4):509-19. McMurdoME . Personal communication 1 October 2007. ">Bolton‐Smith 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000227-bbs2-0006" title="BurleighE , McCollJ , PotterJ . Does vitamin D stop inpatients falling? A randomised controlled trial. Age and Ageing2007;36(5):507-13. ">Burleigh 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000227-bbs2-0007" title="CaniggiaA , DellingG , NutiR , LoreF , VattimoA . Clinical, biochemical and histological results of a double-blind trial with 1,25-dihydroxyvitamin D3, estradiol and placebo in post-menopausal osteoporosis. Acta Vitaminologica et Enzymologica1984;6(2):117-28. ">Caniggia 1984</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000227-bbs2-0008" title="ChapuyMC , ArlotM , et al. Prevention of non vertebral fractures and cortical bone loss in elderly women: a prospective controlled trial using calcium and vitamin D3 supplements [abstract]. Osteoporosis International1993;3 Suppl 1:258. ChapuyMC , ArlotME , DelmasPD , MeunierPJ . Effect of calcium and cholecalciferol treatment for three years on hip fractures in elderly women. BMJ1994;308:1081-2. ChapuyMC , ArlotME , DuboeufF , BrunJ , CrouzetB , ArnaudS , et al. Vitamin D3 and calcium to prevent hip fractures in elderly women. New England Journal of Medicine1992;327:1637-42. MeunierPJ , PamphileR , ChapuyMC , SchultenJ , ArlotM , LilluH . A calcium-vitamin D3 combined supplementation is cost-saving for preventing hip fractures in institutionalised elderly women: an economic evaluation from the perspective of seven European countries (Belgium, France, Germany, The Netherlands, Spain, Sweden, United Kingdom). Osteoporosis International2002;13(Suppl 1):S14. ">Chapuy 1992</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000227-bbs2-0009" title="BosworthC , deBoerIH , TargherG , KendrickJ , SmitsG , ChoncholM . The effect of combined calcium and cholecalciferol supplementation on bone mineral density in elderly women with moderate chronic kidney disease. Clinical Nephrology2012;77(5):358-65. ChapuyMC , PamphileR , ParisE , KempfC , SchlichtingM , ArnaudS , et al. Combined calcium and vitamin D3 supplementation in elderly women: confirmation of reversal of secondary hyperparathyroidism and hip fracture risk: the Decalyos II study. Osteoporosis International2002;13(3):257-64. [MEDLINE: 11991447]ChapuyMC , PamphileR , ParisE , KempfC , SchlichtingM , ArnaudS , et al. Combined calcium and vitamin D3 supplementation to prevent hip fracture in elderly women. A confirmatory study: Decalyos II. Osteoporosis International2002;13(Suppl 1):S25. MeunierPJ . Personal communication 28 February 2005. ">Chapuy 2002</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000227-bbs2-0010" title="Bischoff-FerrariHA , OravEJ , Dawson-HughesB . Additive effect of higher testosterone levels and vitamin D plus calcium supplementation in regard to fall risk reduction among older men and women. Osteoporosis International2008;19:1307-14. Bischoff-FerrariHA , OravEJ , Dawson-HughesB . Effect of cholecalciferol plus calcium on falling in ambulatory older men and women: a 3-year randomized controlled trial. Archives of Internal Medicine2006;166(4):424-30. Bischoff-FerrariHA , OravEJ , Dawson-HughesB . Effect of vitamin D3 plus calcium on fall risk in older men and women: a 3-year randomized controlled trial. Journal of Bone and Mineral Research2004;19(Suppl 1):S57. Dawson-HughesB , HarrisSS , KrallEA , DallalGE . Effect of calcium and vitamin D supplementation on bone density in men and women 65 years of age or older. New England Journal of Medicine1997;337(10):670-6. Dawson-HughesB , HarrisSS , KrallEA , DallalGE . Effect of withdrawal of calcium and vitamin D supplements on bone mass in elderly men and women. American Journal of Clinical Nutrition2000;72(3):745-50. Dawson-HughesB , HarrisSS . Calcium intake influences the association of protein intake with rates of bone loss in elderly men and women. American Journal of Clinical Nutrition2002;75(4):773-9. KrallEA , RandallC , HarrisSS , GarciaRI , Dawson-HughesB . Calcium and vitamin D supplements reduce tooth loss in the elderly. Journal of Bone and Mineral Research2000;15(Suppl 1):S191. KrallEA , WehlerC , GarciaRI , HarrisSS , Dawson-HughesB . Calcium and vitamin D supplements reduce tooth loss in the elderly. American Journal of Medicine2001;111(6):452-6. NiramitmahapanyaS , HarrisSS , Dawson-HughesB . Type of dietary fat is associated with the 25-hydroxyvitamin D3 increment in response to vitamin D supplementation. Journal of Clinical Endocrinology and Metabolism2011;96(10):3170-4. ">Dawson‐Hughes 1997</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000227-bbs2-0011" title="DukasL , BischoffHA , LindpaintnerLS , SchachtE , Birkner-BinderD , DammTN , et al. Alfacalcidol reduces the number of fallers in a community-dwelling elderly population with a minimum calcium intake of more than 500 mg daily. Journal of the American Geriatrics Society2004;52(2):230-6. DukasL , BischoffHA , LindpaintnerLS , SchachtE , Birkner-BinderD , ThalmanB , et al. Alfacalcidol reduces the number of fallers and falls in community-dwelling elderly provided a minimum total daily intake of 500mg calcium [abstract]. Calcified Tissue International2003;72:371. DukasL , SchachtE , MazorZ , StahelinHB . Treatment with alfacalcidol in elderly people significantly decreases the high risk of falls associated with a low creatinine clearance of &lt;65 ml/min. Osteoporosis International2005;16(2):198-203. DukasL , SchachtE , StahelinHB . A significant independent new risk factor for falls in the elderly: a low creatinine clearance of less than 65ml/min. Osteoporosis International2003;14(Suppl 7):S33. DukasL , SchachtE , StahelinHB . High risk of falls related to low D-hormone syndrome and its treatment with alfacalcidol. Osteoporosis International2004;15(Suppl 1):S8-9. DukasL , SchachtE , StahelinHB . Reduction of falls and fallers in high risk patients by D-hormone analogs. Osteoporosis International2004;15(Suppl 1):S144-5. DukasL , SchachtE , StahelinHB . Treatment with alfacalcidol significantly decreases the high incidence of fallers and the high risk of falls associated with low creatinine clearance (&lt;65ml/min) in elderly community-dwelling men and women. Osteoporosis International2003;14(Suppl 7):S33. DukasL , SchachtE . Reduction of falls and fallers using D-hormone analogs. Osteoporosis International2006;17(Suppl 1):S122-3. DukasLC , SchachtE , MazorZ , StahelinHB . The low creatinine clearance associated high risk of falls can significantly be treated with alfacalcidol. Journal of Bone and Mineral Research2004;19(Suppl 1):S95. DukasLC . Personal communication 19 July 2004. ">Dukas 2004</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000227-bbs2-0012" title="EbelingPR , WarkJD , YeungS , PoonC , SalehiN , NicholsonGC , et al. Effects of calcitriol or calcium on bone mineral density, bone turnover, and fractures in men with primary osteoporosis: a two-year randomized, double-blind, double placebo study. Journal of Clinical Endocrinology and Metabolism2001;86(9):4098-103. EbelingPR . Personal communication 15 February 2005. ">Ebeling 2001</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000227-bbs2-0013" title="FalchJA , OdegaardOR , FinnangerAM , MathesonI . Postmenopausal osteoporosis: no effect of three years treatment with 1,25-dihydroxycholecalciferol. Acta Medica Scandinavica1987;221(2):199-204. [MEDLINE: 1987237893]FalchJA , OdegaardOR , FinnangerAM . 3 years treatment with 1.25(OH)2 Vitamin D3 does not reduce bone loss or fracture rate in postmenopausal women with fracture of the distal forearm. In: NormanAW , SchaeferK , Grigoleit H-G, v HerrathD , editors(s). Vitamin D : chemical, biochemical, and clinical update: proceedings of the Sixth Workshop on Vitamin D, Merano, Italy, March 1985. Berlin: de Gruyter, 1985:1004-5. FalchJA . Personal communication1999. ">Falch 1987</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000227-bbs2-0014" title="FlickerL , MacInnisR , SteinM , SchererS , MeadK , NowsonC , et al. Should all older people in residential care receive vitamin D to prevent falls? Results of a randomised trial [abstract]. Journal of Bone and Mineral Research2004;19(Suppl 1):S99. FlickerL , MacInnisRJ , SteinMS , SchererSC , MeadKE , et al. Response letter to Dr. Gau et al. Journal of the American Geriatrics Society2006;54:1021-2. FlickerL , MacInnisRJ , SteinMS , SchererSC , MeadKE , NowsonCA , et al. Erratum. Journal of the American Geriatrics Society2012;60:1599. FlickerL , MacInnisRJ , SteinMS , SchererSC , MeadKE , NowsonCA , et al. Should older people in residential care receive vitamin D to prevent falls? Results of a randomized trial. Journal of the American Geriatrics Society2005;53(11):1881-8. FlickerL , MacInnisRJ , SteinMS , SchererSC , MeadKE , NowsonCA . Should all older people in residential care receive vitamin D to prevent falls? Results of a randomised trial. Journal of Bone and Mineral Research2004;19(Suppl 1):S99. FlickerL . Personal communication 7 January 2008. ">Flicker 2005</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000227-bbs2-0015" title="GallagherJC , RiggsBL , ReckerRR , GoldgarD . The effect of calcitriol on patients with postmenopausal osteoporosis with special reference to fracture frequency. Proceedings of the Society for Experimental Biology and Medicine1989;191(3):287-92. [MEDLINE: 1989296988]">Gallagher 1989</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000227-bbs2-0016" title="GallagherJC , GoldgarD . Treatment of postmenopausal osteoporosis with high doses of synthetic calcitriol. A randomized controlled study. Annals of Internal Medicine1990;113(9):649-55. [MEDLINE: 1991023790]GallagherJC . Metabolic effects of synthetic calcitriol (Rocaltrol) in the treatment of postmenopausal osteoporosis. Metabolism: Clinical &amp; Experimental1990;39(4 Suppl 1):27-9. [MEDLINE: 2112606]GallagherJC . Personal communication 21 February 1995. ">Gallagher 1990</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000227-bbs2-0017" title="GallagherJC , FowlerS . Effect of estrogen, calcitriol and a combination of estrogen and calcitriol on bone mineral density and fractures in elderly women. Journal of Bone and Mineral Research1999;14(Suppl 1):S209. GallagherJC , FowlerSE , DetterJR , ShermanSS . Combination treatment with estrogen and calcitriol in the prevention of age-related bone loss. Journal of Clinical Endocrinology and Metabolism2001;86(8):3618-28. GallagherJC , HaynatskiG , FowlerS . Calcitriol therapy reduces falls and fractures in elderly women. Calcified Tissue International2003;72:334. GallagherJC , HaynatzkiG , FowlerS . Effect of estrogen, calcitriol or the combination of both on falls and non vertebral fractures in elderly women. Journal of Bone and Mineral Research2001;17(Suppl 1):S210. GallagherJC , RapuriPB , HaynatzkiG , DetterJR . Effect of discontinuation of estrogen, calcitriol, and the combination of both on bone density and bone markers. Journal of Clinical Endocrinology and Metabolism2002;87(11):4914-23. [12414850]GallagherJC , RapuriPB , HaynatzkiG . A comparison of estrogen, calcitriol or both therapies on the relationship between serum parathyroid hormone and 25 hydroxy vitamin. Journal of Bone and MIneral Research2004;19(Suppl 1):S440. GallagherJC . Personal communication 21 February 2005. GallagherJC . The effects of calcitriol on falls and fractures and physical performance tests. Journal of Steroid Biochemistry and Molecular Biology2004;89-90(1-5):497-501. ">Gallagher 2001</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000227-bbs2-0018" title="Garay LilloJ , ParrenoJ , GonzálezY , GonzálezJA . Geminis: a prospective, multicentric, randomised study to evaluate the effect of tricalcium phosphate versus tricalcium phosphate plus 25(OH) Vitamin D on the risk of fractures in older women [Géminis: Estudio prospectivo, multicéntrico y aleatori para valorar el efecto del Fosfato Tricálcico versus Fosfato Tricálcico + 25(OH) Vitamina D sobre el riesgo de fracturas en mujerioes ancianas.]. Geriátrika1997;13(6):24-8. ">Garay Lillo 1997</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000227-bbs2-0019" title="GeusensP , DequekerJ . Long-term effect of nandrolone decanoate, 1 alpha-hydroxyvitamin D3 or intermittent calcium infusion therapy on bone mineral content, bone remodeling and fracture rate in symptomatic osteoporosis: a double-blind controlled study. Bone and Mineral1986;1(4):347-57. ">Geusens 1986</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000227-bbs2-0020" title="GlendenningP , ZhuK , InderjeethC , HowatP , LewisJR , PrinceRL . Effects of three-monthly oral 150,000 IU cholecalciferol supplementation on falls, mobility, and muscle strength in older postmenopausal women: a randomized controlled trial. Journal of Bone and Mineral Research2012;27(1):170-6. ">Glendenning 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000227-bbs2-0021" title="GoraiI , ChakiO , TaguchiY , NakayamaM , OsadaH , SuzukiN , et al. Early postmenopausal bone loss is prevented by estrogen and partially by 1alpha-OH-vitamin D3: therapeutic effects of estrogen and/or 1alpha-OH-vitamin D3. Calcified Tissue International1999;65:16-22. ">Gorai 1999</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000227-bbs2-0022" title="HarwoodRH , SahotaO , GaynorK , MasudT , HoskingD . A randomised, controlled comparison of different calcium and vitamin D supplementation regimens in elderly women after hip fracture: The Nottingham Neck of Femur (NoNOF) Study. Age and Ageing2004;33:45-51. [14695863]HarwoodRW . Personal communication 24 January 2003. SahotaO , HarwoodRH , GaynorK , MasudT , HoskingDJ . A randomised, controlled comparison of different calcium and vitamin D regimes: the NoNOF (Nottingham Neck of Femur) study. Osteoporosis International2003;14(Suppl 4):S10-11. ">Harwood 2004</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000227-bbs2-0023" title="HayashiY , FujitaT , InoueT . A multi-center study on efficacy of 1 alpha-hydroxy vitamin D3 in preventing spinal fracture of patients with osteoporosis (abstract). Journal of Bone and Mineral Research1989;4 Suppl 1:Si84. HayashiY , FujitaT , InoueT . Decrease of vertebral fracture in osteoporotics by administration of 1alpha-hydroxy-vitamin D3. Journal of Bone and Mineral Metabolism1992;10(2):50-4. ">Hayashi 1992</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000227-bbs2-0024" title="InkovaaraJ , GothoniG , HalttulaR , HeikinheimoR , TokolaO . Calcium, vitamin D and anabolic steroids in treatment of aged bones: double-blind placebo-controlled long-term clinical trial. Age and Ageing1983;12:124-30. ">Inkovaara 1983</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000227-bbs2-0025" title="AlpertJS . Concerns about the integrity of Ishida Y, Kawai S. Am J Med. 2004;117:549-555: the reply. American Journal of Medicine2020;133:e315. AvenellA , GreyA , GambleGD , BollandMJ . Concerns about the integrity of the Yamaguchi Osteoporosis Prevention Study (YOPS) report, Am J Med. 2004;117:549-555. American Journal of Medicine2020;133:e311-4. IshidaY , KawaiS . A two-year randomized controlled trial of hormone replacement therapy, etidronate, calcitonin, vitamin D, or vitamin K, in women with postmenopausal osteoporosis. Journal of Bone and Mineral Research2002;17(Suppl 1):S478. IshidaY , KawaiS . Comparative efficacy of hormone replacement therapy, bisphosphonates, calcitonin, vitamin D and vitamin K in postmenopausal women with osteoporosis. Journal of Bone and Mineral Research2003;18(Suppl 2):S158. IshidaY , KawaiS . Comparative efficacy of hormone replacement therapy, etidronate, calcitonin, alfacalcidol, and vitamin K in postmenopausal women with osteoporosis: the Yamaguchi osteoporosis prevention study. American Journal of Medicine2004;117:549-55. IshidaY , KawaiS . Comparative efficacy of hormone replacement therapy, etidronate, calcitonin, vitamin D and vitamin K in postmenopausal osteoporosis. Bone2003;33(5 Suppl1):S220. IshidaY , SohH , OgawaS , KawaharaS , MurataH . A one-year randomized controlled trial of hormone replacement therapy, bisphosphonate, calcitonin, vitamin D, and vitamin K, in women with postmenopausal osteoporosis. Journal of Bone and Mineral Research2000;15(Suppl 1):S310. IshidaY , SohH , TsuchidaS , KawaharaS , MurataH , KawaiS . Effectiveness of hormone replacement therapy, etidronate, calcitonin, vitamin D, and vitamin K in postmenopausal women with osteoporosis [abstract]. Bone2002;30(3 Suppl 1):50S. IshidaY . Personal communication 21 February 2005. ">Ishida 2004 (retracted)</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000227-bbs2-0026" title="JanssenHC , SamsonMM , VerhaarHJ . Muscle strength and mobility in vitamin D-insufficient female geriatric patients: a randomized controlled trial on vitamin D and calcium supplementation. Aging Clinical and Experimental Research2010;22(1):78-84. ">Janssen 2010</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000227-bbs2-0027" title="KomulainenM , KrogerH , TuppurainenMT , HeikkinenAM , AlhavaE , HonkanenR , et al. Prevention of femoral and lumbar bone loss with hormone replacement therapy and Vitamin D3 in early postmenopausal women: a population based 5-year randomized trial. Journal of Clinical Endocrinology and Metabolism1999;84(2):546-52. KomulainenM , KrogerH , TuppurainenMT , Keikkinen A-M, HonkanenR , SaarikoskiS , et al. Identification of early postmenopausal women with no bone response to HRT: results of a five-year clinical trial. Osteoporosis International2000;11:211-8. KomulainenMH , KrogerH , TuppurainenMT , Heikkinen A-M, AlhavaE , HonkanenR , et al. HRT and Vit D in prevention of non-vertebral fractures in postmenopausal women; a 5 year randomized trial. Maturitas1998;31(1):45-54. KomulainenMH . Personal communication 11 November 2004. ">Komulainen 1998</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000227-bbs2-0028" title="LawM , MorrisJ , WithersH . Cholecalciferol, not ergocalciferol, should be used for vitamin D supplementation [author reply]. Age and Ageing2006;35(6):645. [MEDLINE: 16982666]LawM , MorrisJ , WithersH . Vitamin D supplementation and the prevention of fractures and falls. Reply. Age and Ageing2007;36(2):233. LawM , MorrisJ , WithersH . Vitamin D supplementation and the prevention of fractures and falls [author reply]. Age and Ageing2007;36(2):233. [MEDLINE: 17255084]LawM , WithersH , MorrisJ , AndersonF . Vitamin D supplementation and the prevention of fractures and falls: results of a randomised trial in elderly people in residential accommodation [comment in: Age and Ageing 2006;35(6):645 and Age and Ageing 2007;36(2):232-3]. Age and Ageing2006;35(5):482-6. ">Law 2006</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000227-bbs2-0029" title="GraafmansWC , OomsME , HofsteeHMA , BezemerPD , BouterLM , LipsP . Falls in the elderly: a prospective study of risk factors and risk profiles. American Journal of Epidemiology1996;143(11):1129-36. LipsP , GraafmansWC , OomsME , BezemerPD , BouterLM . The effect of vitamin D supplementation on the incidence of hip fractures in elderly people. Journal of Bone and Mineral Research1994;9 Suppl 1:S148. LipsP , GraafmansWC , OomsME , BezemerPD , BouterLM . Vitamin D supplementation and fracture incidence in elderly persons. Annals of Internal Medicine1996;124:400-6. [MEDLINE: 1996151943]">Lips 1996</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000227-bbs2-0030" title="JohansenA , LyonsRA , StoneM , BrophyS , NewcombeRG , PhillipsCJ , et al. Preventing fractures among older people living in institutional care: a randomised double blind placebo controlled trial of vitamin D supplementation [abstract]. Age and Ageing2006;35(Suppl 3):i41. LyonsRA , JohansenA , BrophyS , NewcombeRG , PhillipsCJ , LervyB , et al. Preventing fractures among older people living in institutional care: a pragmatic randomised double blind placebo controlled trial of vitamin D supplementation. Osteoporosis International2007;18(6):811-8. LyonsRA , JohansenA , StoneMD , BrophyS , NewcombeRG , PhilipsCJ , et al. Preventing fractures among older people living in institutional care: a randomised double blind placebo controlled trial of vitamin D supplementation [abstract]. Osteoporosis International2006;17(Suppl 3):372. ">Lyons 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000227-bbs2-0031" title="MenczelJ , FoldesJ , SteinbergR , LeichterI , ShalitaB , Bjolah-AbramT , et al. Alfacalcidol (Alpha D3) and calcium in osteoporosis. Clinical Orthopaedics and Related Research1994;(300):241-7. ">Menczel 1994</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000227-bbs2-0032" title="MeyerHE , FalchJA , KvaavikE , SmedshaugGB , TverdalA , PedersenJI . Can vitamin D supplementation reduce the risk of fracture in the elderly? A randomised controlled trial. Osteoporosis International2000;11(Suppl 2):S114-5. MeyerHE , SmedshaugGB , KvaavikE , FalchJA , TverdalA , PedersenJI . Can vitamin D supplementation reduce the risk of fracture in the elderly? A randomized controlled trial. Journal of Bone and Mineral Research2002;17(4):709-15. SmedshaugGB , PedersenJI , MeyerHE . Can vitamin D supplementation improve grip strength in elderly nursing home residents? A double-blinded controlled trial. Scandinavian Journal of Food and Nutrition2007;51(2):74-8. ">Meyer 2002</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000227-bbs2-0033" title="MitriJ , Dawson-HughesB , HuFB , PittasAG . Effects of vitamin D and calcium supplementation on pancreatic β cell function, insulin sensitivity, and glycemia in adults at high risk of diabetes: the Calcium and Vitamin D for Diabetes Mellitus (CaDDM) randomized controlled trial. American Journal of Clinical Nutrition2011;94:486-94. ">Mitri 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000227-bbs2-0034" title="NakatsukaK , InabaM , ArataniH , IbaK , SatoT , KoikeT , et al. Effects of long-term administration of alfacalcidol on bone mass and bone metabolism in patients with primary osteoporosis - comparison with calcium preparations [Japanese]. Nippon Ronen Igakkai Zasshi - Japanese Journal of Geriatrics1997;34(7):569-76. ">Nakatsuka 1997</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000227-bbs2-0035" title="OnesK , SchachtE , DukasL , CaglarN . Effects of combined treatment with alendronate and alfacalcidol on bone mineral density and bone turnover in postmenopausal osteoporosis: a two-years, randomized, multiarm, controlled trial. Internet Journal of Epidemiology2007;4(1):DOI: 10.5580/1523. ">Ones 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000227-bbs2-0036" title="OrimoH , ShirakiM , HayashiY , HoshinoT , OnayaT , MiyazakiS , et al. Effects of 1-alpha-hydroxyvitamin D3 on lumbar bone mineral density and vertebral fractures in patients with postmenopausal osteoporosis. Calcified Tissue International1994;54:370-6. ">Orimo 1994</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000227-bbs2-0037" title="KarkkainenM , TuppurainenM , RikkonenT , SalovaaraK , SirolaJ , HonkanenR , et al. Vitamin-D 800IU/day + calcium 1000mg supplementation decreases the risk of recurrent falling among postmenopausal ambulatory women - a population-based, randomized, 3-year study (OSTPRE-FPS). Osteoporosis International2008;19(Suppl 1):S17-18. KarkkainenM , TuppurainenM , RikkonenT , SalovaaraK , SirolaJ , HonkanenR , et al. Vitamin-D 800IU/day + calcium supplementation decreases the risk of falling among postmenopausal ambulatory women - a population-based, randomized 3-year study (OSTPRE-FPS) [abstract]. Journal of Bone and Mineral Research2007;22(Suppl 1):S131. KarkkainenM , TuppurainenM , SalovaaraK , SandiniL , RikkonenT , SirolaJ , et al. Effect of calcium and vitamin D supplementation on bone mineral density in women aged 65-71 years: a 3-year randomized population-based trial (OSTPRE-FPS). Osteoporosis International2010;21:2047-55. KarkkainenMK , TuppurainenM , SalovaaraM , SandiniL , RikkonenT , SirolaJ , et al. Does daily vitamin D 800 IU and calcium 1000 mg supplementation decrease the risk of falling in ambulatory women aged 65-71 years? A 3-year randomized population-based trial (OSTPRE-FPS). Maturitas2010;65:359-65. KrogerHP , TuppurainenM . OSTPRE-FPS Prevention of Fractures and Falls in Postmenopausal Women With Calcium and Vitamin-D Supplementation - a Randomised Study. http://www.controlled-trials.com/mrct/trial/405493/OSTPRE. SalovaaraK , TuppurainenM , KarkkainenM , RikkonenT , SandiniL , SirolaJ , et al. Effect of vitamin D3 and calcium on fracture risk in 65- to 71-year-old women: a population-based 3-year randomized, controlled trial - the OSTPRE-FPS. Journal of Bone and Mineral Research2010;25(7):1487-95. SalovaaraKT , TuppurainenM , RikkonenT , KarkkainenM , SirolaJ , HonkanenR , et al. Effect of vitamin-D3 and calcium on fracture risk in 65-71 year old women in a 3-year randomized clinical trial - preliminary results from the OSTPRE-Fracture Prevention Study. Calcified Tissue International2008;82:545-6. SalovaaraKT , TuppurainenM , RikkonenT , KarkkainenM , SirolaJ , HonkanenR , et al. Effect of vitamin-D3 and calcium on fracture risk in 65-71 year old women in a 3-year randomized clinical trial - preliminary results of the OSTPRE-Fracture Prevention Study. Journal of Bone and Mineral Research2007;22(Suppl 1):S76. ">OSTPRE‐FPS 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000227-bbs2-0038" title="OttSM , ChesnutCH . Calcitriol treatment is not effective in postmenopausal osteoporosis: see comments. Annals of Internal Medicine1989;110:267-74. ">Ott 1989</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000227-bbs2-0039" title="PeacockM , LiuG , CareyM , McClintockR , AmbrosiusW , HuiS , et al. Effect of calcium or 25OH vitamin D3 dietary supplementation on bone loss at the hip in men and women over the age of 60. Journal of Clinical Endocrinology and Metabolism2000;85:3011-9. ">Peacock 2000</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000227-bbs2-0040" title="MinneHW , PfeiferM , BegerowB , NachtigallD , HansenC . Vitamin D and calcium supplementation reduces falls in elderly women via improvement of body sway and normalisation of blood pressure; a prospective, randomized, and double-blind study. Osteoporosis International2000;11(Suppl 2):S115. PfeiferM , BegerowB , MinneHW , AbramsC , NachtigallD , HansenC . Effects of a short-term vitamin D and calcium supplementation on body sway and secondary hyperparathyroidism in elderly women. Journal of Bone and Mineral Research2000;15(6):1113-8. PfeiferM , BegerowB , NachtigallD , HansenC . Prevention of falls-related fractures: vitamin D reduces body sway in the elderly - a prospective, randomized, double blind study [abstract]. Bone1998;23(5 Suppl 1):1110. ">Pfeifer 2000</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000227-bbs2-0041" title="BollandMJ , GreyA . Different outcomes of meta-analyses and data inconsistency:response to comments by Pfeifer. Archives of Osteoporosis2015;10:43. BollandMJ , GreyA . Inconsistent data in text and tables. Osteoporosis International2015;26:2713. MinneHW , DobnigH , PfeiferM , SuppanK . Effects of vitamin D and calcium supplementation on falls and parameters of muscle function: a prospective, randomized, double-blind multicenter study [abstract]. Osteoporosis International2006;17(Suppl 2):S212. MinneHW , DobnigH , PfeiferM , SuppanK . Effects of vitamin D and calcium supplementation on falls and parameters of muscle-function - a prospective, randomized, double-blind multi-center study [abstract]. Osteoporosis International2006;17(Suppl 1):S21. PfeiferM , BegerowB , MinneHW , SuppanK , Fahrleitner-PammerA , DobnigH . Effects of a long-term vitamin D and calcium supplementation on falls and parameters of muscle function in community-dwelling older individuals. Osteoporosis International2009;20:315-22. PfeiferM , DobnigH , BegerowB , SuppanK . Effects of vitamin D and calcium supplementation on falls and parameters of muscle function: a prospective randomized, double-blind multi-centre study [abstract]. Journal of Bone and Mineral Research2004;19(Suppl 1):S58. PfeiferM , DobnigH , MinneHW , SuppanK . Effects of vitamin D and calcium supplementation on falls and parameters of muscle function - a prospective, randomized, double-blind multi-center study [abstract]. Osteoporosis International2005;16(Suppl 3):S45. PfeiferM . Different outcomes of meta-analyses and data inconsistency. Osteoporosis International2015;26:2715–2716. PfeiferM . Randomized controlled clinical trials and meta-analyses. Archives of Osteoporosis2015;10:42. ">Pfeifer 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000227-bbs2-0042" title="DumvilleJC , MilesJN , PorthouseJ , CockayneES , SaxonL , KingC , et al. Can vitamin D supplementation prevent seasonal affective disorder? A randomised trial among older women. Osteoporosis International2004;15:S42-3. PorthouseJ , CockayneS , KingC , SaxonL , SteeleE , AsprayT , et al. Randomised controlled trial of calcium and supplementation with cholecalciferol (vitamin D3) for prevention of fractures in primary care. BMJ2005;330(7498):1003-6. PorthouseJ , CockayneS , KingC , SaxonL , SteeleE , AsprayT , et al. Randomised controlled trial of calcium and vitamin D supplementation for fracture prevention in primary care. Osteoporosis International2004;15(Suppl 2):S13. PorthouseJ , CockayneS , KingC , SaxonL , SteeleE , AsprayT , et al. Randomised controlled trial of calcium and vitamin D supplementation for fracture prevention in primary care. Osteoporosis International2005;16:S27. PufferS . Calcium and vitamin D in primary care: adherence results from a randomised controlled trial [abstract 6.9.3]. In: RCN International Nursing Conference; 2004 Mar 21-31; Cambridge (UK). London: Royal College of Nursing, 2004. S Puffer, on behalf of the Calcium and Vitamin D Trial. Calcium and vitamin D in primary care. Compliance results from a randomised controlled trial. Osteoporosis International2003;14(Suppl 4):S8. TorgersonD , on behalf of the trial group. Calcium and vitamin D in preventing fractures [author reply]. BMJ2005;331(7508):109. TorgersonDJ . Personal communication 9-16 February 2005. ">Porthouse 2005</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000227-bbs2-0043" title="PrinceRL , AustinN , DevineA , DickIM , BruceD , ZhuK . Effects of ergocalciferol added to calcium on the risk of falls in elderly high-risk women. Archives of Internal Medicine2008;168(1):103-8. ZhuK , BruceD , AustinN , DevineA , EbelingPR , PrinceRL . Randomized controlled trial of the effects of calcium with or without vitamin D on bone structure and bone-related chemistry in elderly women with vitamin D insufficiency. Journal of Bone and Mineral Research2008;23(8):1343-8. ZhuK , DevineA , DickIM , WilsonSG , PrinceRL . Effects of calcium and vitamin D supplementation on hip bone mineral density and calcium-related analytes in elderly ambulatory Australian women: a five-year randomized controlled trial. Journal of Clinical Endocrinology and Metabolism2008;93(3):743-9. ">Prince 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000227-bbs2-0044" title="AndersonFH , GrantAM , AvenellA , CampbellMK , CooperC , DonaldsonC , et al. The RECORD Trial: an evaluation of calcium and/or vitamin D in the secondary prevention of osteoporotic fractures. Bone2005;36(Suppl 2):S122-3. FrancisRM , Grant AM and the RECORD trial group. The RECORD trial: a randomised double-blind study of calcium and/or vitamin D in the secondary prevention of low trauma fractures. Age Ageing2005;34(Suppl 2):ii15. GrantA , on behalf of the RECORD Trial Group. Prevention of low-trauma fractures in older people [author reply]. Lancet2005;366(9485):543-4. GrantAM , AndersonFH , for the RECORD Trial Group. The Medical Research Council RECORD Trial: an evaluation of calcium and/or vitamin D in the secondary prevention of osteoporotic fractures. Osteoporosis International2004;15(Suppl 2):S13. GrantAM , AndersonFH . The RECORD trial: an evaluation of calcium and/or vitamin D in the secondary prevention of osteoporotic fractures. Osteoporosis International2005;16(Suppl 3):S4-5. GrantAM , AvenellA , CampbellMK , McDonaldAM , MacLennanGS , McPhersonGC , et al. Oral vitamin D3 and calcium for secondary prevention of low-trauma fractures in elderly people (Randomised Evaluation of Calcium Or vitamin D, RECORD): a randomised placebo-controlled trial [comment in: Lancet 2005;366(9485):543]. Lancet2005;365(9471):1621-8. GrantAM . Personal communication 11 March 2004. ">RECORD 2005</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000227-bbs2-0045" title="ShirakiM , KushidaK , YamazakiK , NagaiT , InoueT , OrimoH . Effects of 2 years' treatment of osteoporosis with 1alpha-hydroxy vitamin D3 on bone mineral density and incidence of fracture: a placebo-controlled, double-blind prospective study. Endocrine Journal1996;43(2):211-20. ">Shiraki 1996</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000227-bbs2-0046" title="AndersonFH , SmithHE , RaphaelHM , CooperC . Intramuscular vitamin D increased serum 1,25-dihydroxycholecalciferol but did not affect 25-hydroxy-cholecalciferol levels in health older adults [abstract]. Journal of Bone and Mineral Research2000;15(Suppl 1):S315. AndersonFH , SmithHE , RaphaelHM , CrozierSR , CooperC . Effect of annual intramuscular vitamin D3 supplementation on fracture risk in 9440 community-living older people: the Wessex fracture prevention trial [abstract]. Journal of Bone and Mineral Research2004;19(Suppl 1):S57. ArdenNK , CrozierS , SmithH , AndersonF , EdwardsC , RaphaelH , et al. Knee pain, knee osteoarthritis, and the risk of fracture. Arthritis and Rheumatism2006;55(4):610-5. CooperC , CrozierS . Personal communication 23 February 2005. RaphaelH , SmithH , AndersonF , CooperC . Tackling the problems of trial management in primary care - experience from the Wessex research network fracture prevention study of annual vitamin D injection in older people [abstract]. Osteoporosis International2000;11(Suppl 1):S63-4. SmithH , AndersonF , RaphaelH , CooperC . The Wessex research network fracture prevention study - a large pragmatic trial of annual vitamin D injection in older people [abstract]. Osteoporosis International2000;11(Suppl 1):S64. SmithH , AndersonF , RaphaelH , CrozierS , CooperC . Effect of annual intramuscular vitamin D supplementation on fracture risk: population-based, randomised, double-blind, placebo-controlled trial [abstract]. Osteoporosis International2004;15(Suppl 1):S8. SmithH , AndersonF , RaphaelH , MaslinP , CrozierS , CooperC . Effect of annual intramuscular vitamin D on fracture risk in elderly men and women--a population-based, randomized, double-blind, placebo-controlled trial. Rheumatology2007;46(12):1852-7. ">Smith 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000227-bbs2-0047" title="MorrisonNA , GeorgePM , VaughanT , TilyardMW , FramptonCM , GilchristNL . Vitamin D receptor genotypes influence the success of calcitriol therapy for recurrent vertebral fracture in osteoporosis. Pharmacogenetics and Genomics2005;15(2):127-35. TilyardM . Low-dose calcitriol versus calcium in established postmenopausal osteoporosis. Metabolism: Clinical &amp; Experimental1990;39(4 Suppl 1):50-2. TilyardMW , SpearsGF , ThomsonJ , DoveyS . Treatment of postmenopausal osteoporosis with calcitriol or calcium. New England Journal of Medicine1992;326(6):357-62. TilyardMW , SpearsGFS , ThomsonJ , DoveyS . Calcitriol or calcium for postmenopausal osteoporosis. New England Journal of Medicine1992;327:284. TilyardMW . 1,25-dihydroxyvitamin D3 (calcitriol) in the treatment of postmenopausal osteoporosis. Aktuelle Rheumatologie1994;19(Suppl 1):23-6. ">Tilyard 1992</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000227-bbs2-0048" title="TrivediDP , DollR , KhawKT . Effect of four monthly oral vitamin D3 (cholecalciferol) supplementation on fractures and mortality in men and women living in the community: randomised double blind controlled trial. BMJ2003;326:469. ">Trivedi 2003</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000227-bbs2-0049" title="UshiroyamaT , IkedaA , SakaiM , HigashiyamaT , UekiM . Effects of the combined use of calcitonin and 1alpha-hydroxycholecalciferol on vertebral bone loss and bone turnover in women with postmenopausal osteopenia and osteoporosis: a prospective study of long-term and continuous administration with low dose calcitonin. Maturitas2001;40:229-38. ">Ushiroyama 2001</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000227-bbs2-0050" title="SandersK , DuqueG , EbelingP , McCorquodaleT , HerrmannM , Shore-LorentiC , et al. The efficacy of high-does oral vitamin D3 administered once a year: increased fracture risk is associated with 1,25 vitamin D level at 3-months post dose. In: ASBMR Annual Meeting; 2012 Oct 12-15; Minneapolis, Minnesota. http://www.asbmr.org/Meetings/AnnualMeeting/AbstractDetail.aspx?aid=6beb2500-4b8e-472b-8b38-d881cadb80e3. 2012. SandersK , StuartA , WilliamsonE , SimpsonJ , KotowiczM , NicholsonG . The efficacy of high-dose oral vitamin D3 administered once a year: a randomised, double-blind, placebo-controlled trial (Vital D study) for falls and fractures in older women. Osteoporosis International2011;22(Suppl 1):S104-5. SandersKM , DuqueG , McCorquodaleT , StuartAL , WilliamsonEJ , KotowiczMA , et al. Annual high-dose oral vitamin D3: is the increased risk of falls attributable to changes in muscle strength?Osteoporosis International2011;22(Suppl 4):S552. SandersKM , EbelingPR , StuartAL , WilliamsonEJ , KotowiczMA , NicholsonGC . Annual high-dose oral vitamin D3: is increased risk of fractures attributable to changes in bone turnover markers?Osteoporosis International2011;22(Suppl 4):S589. SandersKM , HaylesAL , KotowiczMA , NicholsonGC . Does vitamin D explain the lower fracture rate in rural communities?Bone2007;40(6 Suppl 2):S195. SandersKM , HaylesAL , KotowiczMA , NicholsonGC . The possible role of vitamin D and falls in relation to lower fracture rates in rural communities. Osteoporosis International2007;18(Suppl 1):S120-1. SandersKM , StuartAL , KotowiczMA , NicholsonGC . Annual feedback is an effective tool for a sustained increase in calcium intake among older women. Nutrients2010;2:1018-25. SandersKM , StuartAL , MerrimanEN , ReadML , KotowiczMA , YoungD , et al. Trials and tribulations of recruiting 2,000 older women onto a clinical trial investigating falls and fractures: Vital D study. BMC Medical Research Methodology2009;9:78. SandersKM , StuartAL , NicholsonGC . High-dose oral vitamin D supplementation and risk of falls in older women. JAMA2010;304(8):856-7. SandersKM , StuartAL , WilliamsonEJ , JackaFN , DoddS , NicholsonG , et al. Annual high-dose vitamin D3 and mental well-being: randomised controlled trial. British Journal of Psychiatry2011;198:357-64. SandersKM , StuartAL , WilliamsonEJ , SimpsonJA , KotowiczMA , NicholsonGC . Annual high-dose oral vitamin D for falls and fractures in elderly women: a randomised, double-blind, placebo-controlled trial (Vital D study). Osteoporosis International2010;21(Suppl 1):S30. SandersKM , StuartAL , WilliamsonEJ , SimpsonJA , KotowiczMA , YoungD , et al. Annual high-dose oral vitamin D and falls and fractures in older women. A randomized controlled trial. JAMA2010;303(18):1815-22. Sanders KM et al. Incorrect data. JAMA2010;303(23):2357. ">Vital D</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000227-bbs2-0051" title="CauleyJ , Wactawski-WendeJ , RobbinsJ , RodaboughR , ChenZ , JohnsonK , et al. The Women's Health Initiative (WHI) calcium and vitamin D supplementation trial: health outcomes 5 years after trial completion. ASBMR Annual Meeting; 2012 Oct 12-15; Minneapolis, Minnesota. http://www.asbmr.org/Meetings/AnnualMeeting/AbstractDetail.aspx?aid=6450bf3e-c670-4dc0-814c-8842e23cd80e (accessed 27 December 2012). CauleyJA , LaCroixA , WuL , LeeJ , HorowitzM , BauerD , et al. Serum 25 hydroxy vitamin D 25(OH) and the risk of hip fracture: the Women's Health Initiative (WHI). Journal of Bone and Mineral Research2007;22(Suppl 1):S57. ChenZ , BeckTJ , WrightNC , LaCroixAZ , CauleyJA , LewisCE , et al. The effect of calcium plus vitamin D supplement on hip geometric structures: results from the Women's Health Initiative CaD trial. Journal of Bone and Mineral Research2007;22(Suppl 1):S59. JacksonRD , LaCroixAZ , CauleyJA , McGowanJ . The Women's Health Initiative Calcium-Vitamin D Trial: overview and baseline characteristics of participants. Annals of Epidemiology2003;13:S98-106. JacksonRD , LaCroixAZ , GassM , WallaceRB , RobbinsJ , LewisCE , et al. Calcium plus vitamin D supplementation and the risk of fractures [erratum appears in New England Journal of Medicine 9 March 2006;354(10):1102]. New England Journal of Medicine2006;354(7):669-83. JacksonRD , WrightNC , BeckTJ , SherrillD , CauleyJA , LewisCE , et al. Calcium plus vitamin D supplementation has limited effects on femoral geometric strength in older postmenopausal women: the Women's Health Initiative. Calcified Tissue International2011;88:198-208. McGowanJA , JacksonRD , CauleyJA , LaCroixAZ . Calcium and vitamin D in the prevention of hip and other fractures: an update on the Women's Health Initiative CaD Trial. Journal of Bone and Mineral Research2002;17(Suppl 1):S477. The Women's Health Initiative Study Group. Design of the Women's Health Initiative clinical trial and observational study. Controlled Clinical Trials1998;19(1):61-109. ">WHI 2006</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000227-bbs2-0052" title="WithamMD , CrightonLJ , GillespieND , StruthersAD , McMurdoME . The effects of vitamin D supplementation on physical function and quality of life in older patients with heart failure. A randomized controlled trial. Circulation: Heart Failure2010;3:195-201. ">Witham 2010</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000227-bbs2-0053" title="WithamM . Can high-dose vitamin D supplementation reduce blood pressure and markers of cardiovascular risk in older people with isolated systolic hypertension? A randomised, double-blind, parallel group placebo controlled trial. http://www.controlled-trials.com/ISRCTN92186858/ (accessed 3 December 2013). WithamMD , PriceRJ , StruthersAD , DonnanPT , MessowM , FordI , et al. Vitamin D supplementation to reduce blood pressure in older patients with isolated systolic hypertension (VitDISH) - a randomised controlled trial. Personal communication ahead of publication 15 January 2013. ">Witham 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 6.</span> <span class="table-title">Quality assessment scores</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD000227.pub4/full#CD000227-tbl-0007">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD000227-tbl-0008"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Vitamin D [D2, D3 or 25(OH)D] versus control or placebo</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.1 Persons sustaining new hip fracture <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>27693</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.12 [0.98, 1.29]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1.1 Not selected on the basis of previous osteoporotic fracture</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>24873</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.12 [0.97, 1.30]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1.2 Selected on the basis of previous osteoporotic fracture</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2820</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.08 [0.72, 1.62]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.2 Persons sustaining new non‐vertebral fracture <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>22930</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.05 [0.96, 1.14]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2.1 Not selected on the basis of previous osteoporotic fracture</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>20185</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.06 [0.96, 1.16]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2.2 Selected on the basis of previous osteoporotic fracture</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2745</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.02 [0.85, 1.24]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.3 Persons sustaining new vertebral fracture or deformity <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>11396</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.03 [0.76, 1.39]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3.1 Not selected on the basis of previous osteoporotic fracture</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>8651</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.00 [0.74, 1.36]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3.2 Selected on the basis of previous osteoporotic fracture</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2745</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.79 [0.38, 8.37]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.4 Persons sustaining any new fracture <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>28271</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.03 [0.96, 1.11]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.4.1 Not selected on the basis of previous osteoporotic fracture</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>25451</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.03 [0.95, 1.12]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.4.2 Selected on the basis of previous osteoporotic fracture</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2820</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.01 [0.84, 1.21]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Vitamin D [D2, D3 or 25(OH)D] versus control or placebo</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD000227.pub4/references#CD000227-tbl-0008">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD000227-tbl-0009"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Vitamin D [D2, D3 or 25(OH)D] plus calcium versus calcium</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.1 Persons sustaining new hip fracture <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>7411</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.84 [0.63, 1.13]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1.1 Not selected on the basis of previous osteoporotic fracture</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4730</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.71 [0.45, 1.12]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1.2 Selected on the basis of previous osteoporotic fracture</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2681</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.96 [0.65, 1.41]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.2 Persons sustaining new non‐vertebral fracture <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3336</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.96 [0.79, 1.16]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2.1 Not selected on the basis of previous osteoporotic fracture</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>655</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.67 [0.37, 1.22]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2.2 Selected on the basis of previous osteoporotic fracture</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2681</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.00 [0.82, 1.22]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.3 Persons sustaining new vertebral fracture <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.3.1 Selected on the basis of previous osteoporotic fracture</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2681</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.14 [0.01, 2.77]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.4 Persons sustaining any new fracture <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>8812</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.87 [0.74, 1.02]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.4.1 Not selected on the basis of previous osteoporotic fracture</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>6131</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.70 [0.53, 0.92]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.4.2 Selected on the basis of previous osteoporotic fracture</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2681</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.98 [0.80, 1.20]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Vitamin D [D2, D3 or 25(OH)D] plus calcium versus calcium</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD000227.pub4/references#CD000227-tbl-0009">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD000227-tbl-0010"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Vitamin D [D2, D3 or 25(OH)D] versus calcium</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.1 Persons sustaining new hip fracture <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1.1 Selected on the basis of previous osteoporotic fracture</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2718</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.90 [0.61, 1.32]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.2 Persons sustaining new non‐vertebral fracture <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3021</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.10 [0.91, 1.33]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2.1 Not selected on the basis of previous osteoporotic fracture</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>303</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.29 [0.62, 2.66]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2.2 Selected on the basis of previous osteoporotic fracture</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2718</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.09 [0.90, 1.32]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.3 Persons sustaining new vertebral fracture or deformity <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2976</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.21 [1.08, 4.53]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.3.1 Not selected on the basis of previous osteoporotic fracture</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>258</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.59 [1.13, 5.95]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.3.2 Selected on the basis of previous osteoporotic fracture</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2718</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.30 [0.29, 5.80]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.4 Persons sustaining any new fracture <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3021</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.11 [0.92, 1.33]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.4.1 Not selected on the basis of previous osteoporotic fracture</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>303</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.29 [0.62, 2.66]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.4.2 Selected on the basis of previous osteoporotic fracture</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2718</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.09 [0.90, 1.33]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Vitamin D [D2, D3 or 25(OH)D] versus calcium</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD000227.pub4/references#CD000227-tbl-0010">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD000227-tbl-0011"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">Vitamin D [D2, D3 or 25(OH)D] plus calcium versus control or placebo</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.1 Persons sustaining new hip fracture <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>49853</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.84 [0.74, 0.96]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1.1 Not selected on the basis of previous osteoporotic fracture</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>43719</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.82 [0.71, 0.94]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1.2 Selected on the basis of previous osteoporotic fracture</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>6134</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.02 [0.71, 1.47]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.2 Persons sustaining new hip fracture: subgroup analysis by residential status (institution vs community) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>49853</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.84 [0.74, 0.96]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2.1 Resident in institution (nursing home, residential care etc)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3853</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.75 [0.62, 0.92]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2.2 Community dwelling</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>46000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.91 [0.77, 1.09]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.3 Persons sustaining new non‐vertebral fracture <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>10380</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.86 [0.78, 0.96]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.3.1 Not selected on the basis of previous osteoporotic fracture</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>7560</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.84 [0.74, 0.95]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.3.2 Selected on the basis of previous osteoporotic fracture</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2820</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.93 [0.77, 1.13]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.4 Persons sustaining new vertebral fracture <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>42185</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.89 [0.74, 1.09]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.4.1 Not selected on the basis of previous osteoporotic fracture</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>39477</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.90 [0.74, 1.10]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.4.2 Selected on the basis of previous osteoporotic fracture</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2708</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.34 [0.04, 3.20]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.5 Persons sustaining any new fracture <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>49976</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.95 [0.90, 0.99]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.5.1 Not selected on the basis of previous osteoporotic fracture</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>43842</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.95 [0.90, 1.00]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.5.2 Selected on the basis of previous osteoporotic fracture</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>6134</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.93 [0.79, 1.10]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.6 Persons sustaining any new fracture: subgroup analysis by residential status (institution vs community) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>49976</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.95 [0.90, 0.99]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.6.1 Resident in institution (nursing home, residential care etc)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3853</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.85 [0.74, 0.98]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.6.2 Community dwelling</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>46123</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.96 [0.91, 1.01]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">Vitamin D [D2, D3 or 25(OH)D] plus calcium versus control or placebo</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD000227.pub4/references#CD000227-tbl-0011">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD000227-tbl-0012"> <div class="table-heading"><span class="table-label">Comparison 5.</span> <span class="table-title">Alfacalcidol [1‐alpha(OH)D3] versus control or placebo</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.1 Persons sustaining new non‐vertebral fracture <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>526</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.97 [0.25, 3.82]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1.1 Not selected on the basis of previous osteoporotic fracture</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>380</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.97 [0.25, 3.82]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1.2 Selected on the basis of previous osteoporotic fracture</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>146</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.2 Persons sustaining new vertebral fracture <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.2.1 Selected on the basis of previous osteoporotic fracture</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>740</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.56 [0.48, 0.65]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 5.</span> <span class="table-title">Alfacalcidol [1‐alpha(OH)D3] versus control or placebo</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD000227.pub4/references#CD000227-tbl-0012">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD000227-tbl-0013"> <div class="table-heading"><span class="table-label">Comparison 6.</span> <span class="table-title">Alfacalcidol [1‐alpha(OH)D3] plus calcium versus calcium</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6.1 Persons sustaining new hip fracture <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.1.1 Selected on the basis of previous osteoporotic fracture</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>113</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.20 [0.01, 4.00]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6.2 Persons sustaining new vertebral deformity <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>390</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.44 [0.21, 0.96]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.2.1 Selected on the basis of previous osteoporotic fracture</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>357</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.53 [0.23, 1.24]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.2.2 Not selected on the basis of previous osteoporotic fracture</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>33</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.19 [0.02, 1.44]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 6.</span> <span class="table-title">Alfacalcidol [1‐alpha(OH)D3] plus calcium versus calcium</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD000227.pub4/references#CD000227-tbl-0013">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD000227-tbl-0014"> <div class="table-heading"><span class="table-label">Comparison 7.</span> <span class="table-title">Alfacalcidol [1‐alpha(OH)D3] versus calcium</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7.1 Persons sustaining new vertebral deformity <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.1.1 Selected on the basis of previous osteoporotic fracture</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>23</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.95 [0.52, 1.74]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 7.</span> <span class="table-title">Alfacalcidol [1‐alpha(OH)D3] versus calcium</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD000227.pub4/references#CD000227-tbl-0014">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD000227-tbl-0015"> <div class="table-heading"><span class="table-label">Comparison 8.</span> <span class="table-title">Calcitriol [1,25(OH)2D3] versus control or placebo</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8.1 Persons sustaining new hip fracture <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.1.1 Not selected on the basis of previous osteoporotic fracture</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>246</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.33 [0.01, 8.10]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8.2 Persons sustaining new non‐vertebral fracture <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.2.1 Not selected on the basis of previous osteoporotic fracture</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>246</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.42 [0.15, 1.15]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8.3 Persons sustaining new vertebral deformity <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>327</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.75 [0.40, 1.41]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.3.1 Not selected on the basis of previous osteoporotic fracture</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>246</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>4.00 [0.45, 35.28]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.3.2 Selected on the basis of previous osteoporotic fracture</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>81</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.55 [0.28, 1.10]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 8.</span> <span class="table-title">Calcitriol [1,25(OH)2D3] versus control or placebo</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD000227.pub4/references#CD000227-tbl-0015">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD000227-tbl-0016"> <div class="table-heading"><span class="table-label">Comparison 9.</span> <span class="table-title">Calcitriol [1,25(OH)2D3] plus calcium versus calcium</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9.1 Persons sustaining new non‐vertebral fracture <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>86</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.50 [0.51, 12.19]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.1.1 Selected on the basis of previous osteoporotic fracture</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>86</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.50 [0.51, 12.19]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9.2 Persons sustaining new vertebral deformity <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.2.1 Selected on the basis of previous osteoporotic fracture</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>86</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.50 [0.58, 3.85]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 9.</span> <span class="table-title">Calcitriol [1,25(OH)2D3] plus calcium versus calcium</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD000227.pub4/references#CD000227-tbl-0016">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD000227-tbl-0017"> <div class="table-heading"><span class="table-label">Comparison 10.</span> <span class="table-title">Calcitriol [1,25(OH)2D3] plus vitamin D plus calcium versus vitamin D plus calcium</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">10.1 Persons sustaining new vertebral deformity <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.1.1 Selected on the basis of previous osteoporotic fracture</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>84</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.79 [0.41, 1.52]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 10.</span> <span class="table-title">Calcitriol [1,25(OH)2D3] plus vitamin D plus calcium versus vitamin D plus calcium</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD000227.pub4/references#CD000227-tbl-0017">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD000227-tbl-0018"> <div class="table-heading"><span class="table-label">Comparison 11.</span> <span class="table-title">Calcitriol [1,25(OH)2D3] versus calcium</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">11.1 Persons sustaining new non‐vertebral fracture <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.1.1 Selected on the basis of previous osteoporotic fracture</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>663</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.23 [0.10, 14.78]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">11.2 Persons sustaining new vertebral deformity <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.2.1 Selected on the basis of previous osteoporotic fracture</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>556</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.69 [0.25, 11.28]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">11.3 Persons sustaining new vertebral deformity in Tilyard study <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.3.1 Year 1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>515</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.80 [0.40, 1.58]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.3.2 Year 2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>476</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.47 [0.26, 0.87]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.3.3 Year 3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>432</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.28 [0.15, 0.52]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 11.</span> <span class="table-title">Calcitriol [1,25(OH)2D3] versus calcium</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD000227.pub4/references#CD000227-tbl-0018">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD000227-tbl-0019"> <div class="table-heading"><span class="table-label">Comparison 12.</span> <span class="table-title">Calcitriol [1,25(OH)2D3] versus vitamin D (with or without calcium in each group)</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">12.1 Persons sustaining new non‐vertebral fracture <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.1.1 Selected on the basis of previous osteoporotic fracture</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>86</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.16 [0.40, 3.37]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">12.2 Persons sustaining new vertebral deformity <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.2.1 Selected on the basis of previous osteoporotic fracture</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>96</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.38 [0.55, 3.47]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 12.</span> <span class="table-title">Calcitriol [1,25(OH)2D3] versus vitamin D (with or without calcium in each group)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD000227.pub4/references#CD000227-tbl-0019">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD000227-tbl-0020"> <div class="table-heading"><span class="table-label">Comparison 13.</span> <span class="table-title">Vitamin D [D2, D3 or 25(OH)D] or any analogue with/without calcium: adverse effects</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">13.1 Deaths <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>29</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>71032</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.97 [0.93, 1.01]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>13.1.1 Vitamin D [D2, D3, 25(OH)D]</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>18</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>22854</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.99 [0.94, 1.03]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>13.1.2 Vitamin D [D2, D3 or 25(OH)D] plus calcium</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>46794</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.94 [0.87, 1.02]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>13.1.3 Alfacalcidol [1‐alpha(OH)D3]</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>380</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.97 [0.06, 15.38]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>13.1.4 Calcitriol [1,25(OH)2D3]</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1004</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.13 [0.41, 3.09]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">13.2 Persons with hypercalcaemia <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>21</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>17124</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.28 [1.57, 3.31]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>13.2.1 Vitamin D [D2, D3 or 25(OH)D]</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>11611</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.57 [0.80, 3.05]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>13.2.2 Vitamin D [D2, D3 or 25(OH)D] plus calcium</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3853</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.29 [0.37, 29.14]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>13.2.3 Alfacalcidol [1‐alpha(OH)D3]</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>672</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.52 [0.85, 2.72]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>13.2.4 Calcitriol [1,25(OH)2D3]</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>988</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>4.41 [2.14, 9.09]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">13.3 Persons with gastrointestinal effects <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>47761</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.04 [1.00, 1.08]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>13.3.1 Vitamin D [D2, D3 or 25(OH)D]</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>6230</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.95 [0.79, 1.14]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>13.3.2 Vitamin D [D2, D3 or 25(OH)D] plus calcium</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>40524</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.05 [1.01, 1.09]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>13.3.3 Alfacalcidol [1‐alpha(OH)D3]</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>98</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>13.3.4 Calcitriol [1,25(OH)2D3]</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>909</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.02 [0.66, 1.58]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">13.4 Persons with renal disease (calculi or insufficiency) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>46548</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.16 [1.02, 1.33]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>13.4.1 Vitamin D [D2, D3, 25(OH)D]</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>5978</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.59 [0.24, 1.42]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>13.4.2 Vitamin D [D2, D3 or 25(OH)D] plus calcium</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>39552</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.17 [1.03, 1.34]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>13.4.3 Alfacalcidol [1‐alpha(OH)D3]</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>66</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>13.4.4 Calcitriol [1,25(OH)2D3]</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>952</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.59 [0.61, 10.96]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 13.</span> <span class="table-title">Vitamin D [D2, D3 or 25(OH)D] or any analogue with/without calcium: adverse effects</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD000227.pub4/references#CD000227-tbl-0020">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD000227.pub4&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="de#CD000227-note-0009">Deutsch</a> </li> <li class="section-language"> <a class="" href="es#CD000227-note-0020">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD000227-note-0017">فارسی</a> </li> <li class="section-language"> <a class="" href="hr#CD000227-note-0016">Hrvatski</a> </li> <li class="section-language"> <a class="" href="ja#CD000227-note-0015">日本語</a> </li> <li class="section-language"> <a class="" href="ko#CD000227-note-0013">한국어</a> </li> <li class="section-language"> <a class="" href="ms#CD000227-note-0014">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="pl#CD000227-note-0018">Polski</a> </li> <li class="section-language"> <a class="" href="ru#CD000227-note-0012">Русский</a> </li> <li class="section-language"> <a class="" href="ta#CD000227-note-0019">தமிழ்</a> </li> <li class="section-language"> <a class="" href="zh_HANS#CD000227-note-0010">简体中文</a> </li> <li class="section-language"> <a class="" href="zh_HANT#CD000227-note-0011">繁體中文</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738734064000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738734064000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772746000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD000227\x2epub4\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD000227\x2epub4\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD000227\x2epub4\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD000227\x2epub4"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD000227\x2epub4\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD000227\x2epub4\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD000227\x2epub4\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD000227\x2epub4\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD000227\x2epub4\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD000227\x2epub4"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD000227\x2epub4\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD000227\x2epub4\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD000227\x2epub4\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD000227\x2epub4"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD000227\x2epub4\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD000227\x2epub4\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD000227\x2epub4\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD000227\x2epub4"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=z6k50IFd&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD000227.pub4&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD000227.pub4';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD000227.pub4/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD000227.pub4/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD000227.pub4%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740714872417"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD000227.pub4/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740714872421"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD000227.pub4/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918d7940dd2c9368',t:'MTc0MDcxNDg3Mi4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 